---
document_datetime: 2024-07-12 14:26:24
document_pages: 268
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/remsima-h-c-002576-ii-0133-g-epar-assessment-report-variation_en.pdf
document_name: remsima-h-c-002576-ii-0133-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 247.640243
conversion_datetime: 2025-12-25 03:11:09.838588
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

30 May 2024 EMA/281845/2024 Committee for Medicinal Products for Human Use (CHMP)

## Type II group of variations assessment report

Invented name: Remsima

International non-proprietary name: infliximab

Procedure No. EMEA/H/C/002576/II/0133/G

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 4                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| 2. Overall conclusion and impact on the benefit/risk balance.....................                                          | 4                                                                                                                 |
| 3. Recommendations.................................................................................                        | 10                                                                                                                |
| 4. EPAR changes .......................................................................................                    | 11                                                                                                                |
| 5. Introduction..........................................................................................                  | 13                                                                                                                |
| 6. Clinical Pharmacology aspects ..............................................................                            | 18                                                                                                                |
| 6.1. Methods - analysis of data submitted                                                                                  | ..................................................................18                                              |
| 6.1.1. Bioanalytical methods.....................................................................................18        |                                                                                                                   |
| 6.1.2. Population PK modelling..................................................................................23         |                                                                                                                   |
| 6.1.3. Population PK-PD modelling.............................................................................27           |                                                                                                                   |
| 6.2. Results............................................................................................................29 |                                                                                                                   |
| 6.2.1. Observed pharmacokinetics                                                                                           | .............................................................................29                                   |
| 6.2.2. Population PK modelling and simulations                                                                             | ...........................................................32                                                     |
| 6.2.3. Population PK-PD modelling and simulations                                                                          | ......................................................51                                                          |
| 6.3. Discussion                                                                                                            | .......................................................................................................67         |
| aspects                                                                                                                    | ........................................................................ 69                                       |
| 7. Clinical Efficacy 7.1.1.                                                                                                | Methods........................................................................................................74 |
| 7.1.2. Results                                                                                                             | .........................................................................................................81       |
| 7.2. Study CT-P13 3.8                                                                                                      | .............................................................................................95                   |
| 7.2.1. Study design                                                                                                        | .................................................................................................95               |
| 7.2.2. Methods........................................................................................................97   |                                                                                                                   |
| 7.2.3. Results                                                                                                             | .......................................................................................................103        |
| 7.2.4. Usability                                                                                                           | .....................................................................................................117          |
| 7.3. REMSWITCH...................................................................................................120       |                                                                                                                   |
| 7.4. Discussion                                                                                                            | .....................................................................................................127          |
| 7.4.1. Conclusions.................................................................................................131     |                                                                                                                   |
| 8. Clinical Safety aspects.........................................................................                        | 132                                                                                                               |
| 8.1. Methods - analysis of data submitted                                                                                  | ................................................................132                                               |
| 8.2. Results..........................................................................................................134  |                                                                                                                   |
| 8.2.1. Patient exposure..........................................................................................134       |                                                                                                                   |
| 8.2.2. Adverse events............................................................................................138       |                                                                                                                   |
| 8.2.3. TEAEs during maintenance phase                                                                                      | ...................................................................141                                            |
| 8.2.4. Immunogenicity...........................................................................................170        |                                                                                                                   |
| 8.2.5. Comparison of Safety Results Across Studies                                                                         | ...................................................179                                                            |
| 8.2.6. REMSWITCH study/safety..............................................................................181             |                                                                                                                   |
| 8.3. Discussion                                                                                                            | .....................................................................................................181          |
| 9. PRAC advice ........................................................................................                    | 186                                                                                                               |
| 10. Risk management plan......................................................................                             | 186                                                                                                               |

<div style=\"page-break-after: always\"></div>

| 11. Changes to the Product Information .................................................                                                                                              | 187   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| 12. Request for supplementary information............................................                                                                                                 | 187   |
| 12.1. Major objections ...........................................................................................187                                                                 |       |
| 12.2. Other concerns .............................................................................................188                                                                 |       |
| 13. Assessment of the responses to the request for supplementary information .............................................................................................            | 188   |
| 13.1. Major objections ...........................................................................................188                                                                 |       |
| 13.2. Other concerns .............................................................................................193                                                                 |       |
| 14. 2 nd request for supplementary information .......................................                                                                                                | 251   |
| 14.1. Major objections ...........................................................................................251                                                                 |       |
| 14.2. Other concerns .............................................................................................251                                                                 |       |
| 15. Assessment of the responses to the 2 nd request for supplementary information .............................................................................................       | 251   |
| 15.1. Major objections ...........................................................................................251                                                                 |       |
| 15.2. Other concerns .............................................................................................252                                                                 |       |
| 16. 3 rd request for supplementary information........................................                                                                                                | 264   |
| 16.1. Major objections ...........................................................................................264                                                                 |       |
| 16.2. Other concerns .............................................................................................264                                                                 |       |
| 17. Assessment of the responses to the 3 rd request for supplementary information .............................................................................................       | 264   |
| 17.1. Major obections ............................................................................................264                                                                 |       |
| 17.2. Other concerns .............................................................................................266                                                                 |       |
| 18. 4 th request for supplementary information........................................                                                                                                | 267   |
| 18.1. Major objections ...........................................................................................267                                                                 |       |
| 19. Assessment of the early responses to the 4 th request for supplementary information ............................................................................................. | 267   |
| 19.1. Major Objections...........................................................................................267                                                                  |       |
| 20. Attachments......................................................................................                                                                                 | 268   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Celltrion Healthcare Hungary Kft. submitted to the European Medicines Agency on 30 June 2023 an application for a group of variations.

The following changes were proposed:

| Variations requested   | Variations requested                                                                                              | Type    | Annexes affected   |
|------------------------|-------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.4                  | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | Type II | I, IIIA and IIIB   |
| C.I.4                  | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | Type II | I, IIIA and IIIB   |
| C.I.4                  | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | Type II | I, IIIA and IIIB   |

Grouped application comprising three type II variations (C.I.4) as follows:

- Update of section 4.2, 4.8 and 5.1 of the SmPC in order to add 3-IV induction dosing regimen and dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response and update efficacy and safety information based on Week 54 data from studies CTP13 3.7 (ulcerative colitis) and CT-P13 3.8 (Crohn's disease), listed as a category 3 study in the RMP; Study CT-P13 3.7 is a Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis and study CT-P13 3.8 is a Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13  (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease.
- Update of section 4.2 and 5.2 of the SmPC in order to add subcutaneous induction posology and pharmacokinetic information based on Population PK and PK-PD Modelling and Simulation.
- Update of section 4.2 of the SmPC in order to switch from high-dose IV maintenance (&gt; 5 mg/kg) to subcutaneous maintenance dose of 120 mg Q2W based on data from REMSWITCH study (Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study).

The RMP version 16.1 has also been submitted. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to introduce minor updates to the PI.

The requested group of variations proposed amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

After the first RSI the two latter variations were withdrawn. The first variation remained but the proposal for dose escalation in UC patients was withdrawn.

## 2. Overall conclusion and impact on the benefit/risk balance

Remsima (CT-P13, infliximab) was initially developed for intravenous (IV) infusion and was approved in the European Union (EU) in 2013 as a biosimilar product to Remicade for the treatment of rheumatoid arthritis (RA), adult Crohn's disease (CD), paediatric CD, ulcerative colitis (UC), paediatric UC, ankylosing spondylitis (AS), psoriatic arthritis (PsA) and psoriasis (Ps). The subcutaneous (SC) formulation of Remsima was later approved in the EU for the RA indication and adult CD, UC, AS, PsA and Ps indications. The originator Remicade is not available as an SC formulation. Therefore, Remsima SC is not bound by any originator's product information.

<div style=\"page-break-after: always\"></div>

This grouped variation application initially concerned 3 Type II variations, as outlined in section 1. After the first assessment round several proposed amendments were withdrawn and only the following proposed updates of  the  SmPC  for  CD  and  UC indications remained:

1. Addition  of  a  3-IV  induction  dosing  regimen  (5  mg/kg  at  Weeks  0,  2  and  6)  followed  by  SC maintenance treatment (120 mg Q2W) in addition to the approved 2-IV regimen (5 mg/kg at Weeks 0 and 2).
2. The possibility for dose adjustment from SC 120 mg (currently approved dose) to SC 240 mg for patients with loss of response in patients with CD.
3. Description of the two new phase 3 studies (in CD- and UC-patients)

Two new clinical studies (Studies CT-P13 3.7 and CT-P13 3.8 conducted in UC and CD patients, respectively) were introduced to the CT-P13 SC clinical development programme and results from these studies have been  proposed  to  be  included  in  the  SmPC.  Notably,  in  the  current  submission  the  overall  B/R  of induction/maintenance treatments was not questioned, as those have already been approved and included in the SmPC of IV and SC Remsima. It was evaluated if these new phase 3 studies provide statistically and clinically significant, robust and valuable information for the prescriber, enough to be placed into the SmPC 5.1 and to replace the earlier data from the previous smaller studies in CD and UC.

## Proposed changes to the SmPC

## Primary efficacy results in CD patients (Study CT-P13 3.8)

Out 396 CD patients who were enrolled and treated with CT-P13 5 mg/kg IV during induction, 343 patients were  responders  and  were  randomly  assigned  to  study  treatment  and  initiated  the  double-blind maintenance phase at Week 10 (231 and 112 patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively).

The co-primary endpoints were clinical remission based on Crohn's Disease Activity Index (CDAI) at Week 54 and endoscopic response based on central Simplified Endoscopic Activity Score for Crohn's Disease (SESCD)  at  Week  54.  Patients  who  received  an  open-label  dose  escalation  (to  240  mg)  after  W22  were automatically classified as non-responders although some of them did not lose response and some of the patients who lost response did not receive a dose escalation.

The proportion of patients who achieved clinical remission by CDAI at Week 54 was higher in the CT-P13 SC 120 mg group than Placebo SC group (144 [62.3%] and 36 [32.1%], respectively). The proportion of patients who achieved endoscopic response (defined as a 50% decrease in SES-CD score) at Week 54 was 118 [51.1%] and 20 [17.9%] in CT-P13 SC 120 mg and Placebo SC groups, respectively.

The intercurrent event of loss of response (LoR) was handled differently for different patients without any clear plan for the different handling in the protocol and this flaw in the study design could skew the results of  the  primary  outcome.  Moreover,  some  protocol  violations  occurred  where  patients  received  a  dose escalation despite not meeting LoR criteria. However, the number of patients receiving dose escalation despite  not  meeting  LoR  criteria  was  small,  the  difference  in  the  proportion  of  remitters  is  considered clinically meaningful and the magnitude of the difference sufficiently large to be relevant for the prescriber. Hence, inclusion of study Study CT-P13 3.8 results in SmPC 5.1 is considered acceptable even if there was some bias involved.

The open label extension phase of Study CT-P13 3.8 showed that the proportion of patients who achieved clinical remission was more or less maintained at Week 102 compared to Week 54. Of note, among patients originally  randomised  to  placebo  27/112  (24%)  were  in  clinical  remission  two  years  after  a  successful induction treatment with infliximab IV despite no active treatment after week 10.

<div style=\"page-break-after: always\"></div>

## Primary efficacy results UC patients (Study CT-P13 3.7)

Out of 548 UC patients who were enrolled and treated with CT-P13 5 mg/kg IV during induction, 438 patients  were  responders  at  week  10  and  initiated  the  double-blind  maintenance  phase  (294  and  144 patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively). According to the presented results the proportion of patients who achieved a clinical remission by modified Mayo score at Week 54 was higher in the CT-P13 SC 120 mg treatment group (127 [43.2%]) than in the Placebo SC treatment group (30 [20.8%]). Of note, this outcome does not accurately reflect results for the prespecified primary endpoint.

However, in study 3.7, 81 [27.6%] and 70 [48.6%] UC patients in the CT-P13 SC and Placebo groups, respectively received an open-label dose adjustment to CT-P13 SC 240mg after week 22. The possibility to dose adjust is significantly intertwined in the primary endpoint as only patients who did not escalate the dose had a possibility to be responders at week 54. Moreover, the intercurrent event of loss of response was handled differently for different patients and this flaw in the study design could skew the results of the primary outcome. Some patients who lost response were dose adjusted and others were not, but these different pathways were neither randomised nor based on any predefined characteristics. Therefore, week 54 results cannot be presented in the SmPC without mentioning the possibility to dose adjust. However, describing the dose adjustment would be promoting an off-label posology, which is not acceptable.

Upon CHMP's repeated request for more detailed information, the MAH provided results which illustrated the consequence of inappropriate planning of the estimand, misalignment of dose escalation requirements and the schedule of assessments (SoA), and revealed poor adherence to the protocol:

One  of  the  criteria  for  being  a  non-remitter/non-responder  at  W54  was  based  on  having  had  doseescalation.  While it could have been acceptable to include 'any LoR before W54' in the non-remitter/nonresponder definition, the primary endpoint estimand was obviously inappropriate because the definition of LoR, prerequisites for dose escalation/no dose escalation and the SoA were not appropriately standardized in the protocol nor the conditions in the protocol consistently followed. According to the protocol definition, it was not possible to detect a LoR between W22 and 54 because no endoscopy was performed.

The intention of the study protocol was to reflect a treatment policy situation where a patient in case of loss of response could be taken off the treatment or continue in hope of better days to come. This approach led to a situation where some patients with LoR were immediately established as being treatment failures, while others, were considered non-responders only if they remained non-responders also at week 54. The criteria for continuing on randomised treatment despite LoR were never defined in the protocol. Moreover, in a real-world setting, an evaluation whether to continue treatment despite LoR would normally not last for several months. This issue, however, does not have a major impact on the interpretation of the W54 results as the number of patients continuing despite LoR is small.

However, some patients were switched to active treatment/dose escalated though not meeting the LoR criteria, i.e., 'put on rescue therapy'. In study 3.7 such physician decisions were abundant (35% of all dose escalations) and done off protocol, without prespecified criteria or any post hoc explanation. Therefore, the outcome does not reflect the prespecified primary endpoint, as the protocol defined all dose escalations to be consequences of LoR.

The reason for the high number of this type of protocol violations may be related to the definition of LoR. In the protocol, the LoR criteria were based on modified Mayo score (including the endoscopic subscore): 'an increase in modified Mayo score of ≥ 2 points and ≥ 30% from the Week 10 modified Mayo score with actual value of ≥ 5 points, and endoscopic subscore of ≥ 2 points.' However, the modified Mayo score was only recorded at weeks 10, 22 and 54. Hence, according to protocol it was not even possible to detect a

LoR between W22 and 54. Therefore, if not done on W22, the decisions to escalate the dose were probably

<div style=\"page-break-after: always\"></div>

based on partial Mayo score (excluding the endoscopic subscore), which was recorded at every visit. The problem is that a patient who meets the hitherto undefined criteria for LoR by partial Mayo, would not necessarily be a non-responder according to the modified Mayo, which defines the primary endpoint. This issue could have been reflected in the SoA for example by ad hoc endoscopy if clinically indicated, but no such effort was done.

Ultimately, a total of 35% (50/144) of patients who received a dose adjustment did not meet LoR criteria and 10% of all patients in the SC 120mg group and 15% of the placebo group were classified as nonremitter/non-responder only due to dose escalation, not due to per protocol LoR. Hence, classifying patients with dose escalation as non-responders as if they were all patients who lost response after W22 is simply not reflecting reality nor the intended primary objective of the study as per protocol.

The  definition  of  non-remitter/non-responder  is  equally  relevant  for  the  interpretation  of  the  primary outcome as the definition of a 'responder'. Out of all non-responders at W54, only 5.5% were classified as non-responders based on clinical criteria, with no difference between treatment groups, while the rest of the non-responders were due to intercurrent events, mainly dose adjustment, which did not equal LoR.

To conclude, the off-label dose escalation after W22 meaningfully affects the interpretation of the results at W54 and the true impact of Remsima SC maintenance regimen cannot be estimated based on the results of this study. 35% of the dose escalations were not according to protocol, which introduces a major bias and puts the whole planning and conduct of the study into question. Therefore, the W54 results from study 3.7 are invalid for inclusion in the SPC.

While there is no doubt that Remsima SC is in fact more effective than placebo in the treatment of UC, the numerical magnitude of the treatment effect cannot be accurately estimated. The UC indication is already granted for both induction and maintenance therapy and it is not put into question, but no new useful information for the prescriber has been presented with this application.

## New proposed 3-IV induction regimen

The new induction regimen proposed for Remsima SC in UC, CD and fistulising CD was used in studies 3.7 and 3.8 and it is identical to the induction regimens currently approved with IV Remsima for all above indications.  Due  to  a  shorter  interval  between  the  last  IV  dose  and  the  first  SC  dose  than  previously approved, the new induction regimen will lead to somewhat higher exposure (AUC but not Cmax) during weeks 10-14. Based on the previously established positive benefit-risk  balance  for  very  similar  dosing regimens with Remsima SC, introduction of the 3-IV induction dosing regimen is acceptable (5 mg/kg at Weeks 0, 2 and 6) followed by SC maintenance treatment (120 mg Q2W from week 10).

## Proposed dose escalation

Studies 3.7 and 3.8 were provided in support of a dose escalation from SC 120 mg to 240 mg for patients with loss of response. However, the study designs were not adequate to answer the question whether dose escalation is more effective (and sufficiently safe) compared to continuing treatment with SC 120 mg.

As  there  was  no  randomised  treatment  arm  where  patients  with  a  loss  of  response  continued  on  the previously assigned SC 120mg treatment, it is difficult to know how the disease would have progressed without the dose escalation. As UC and CD are fluctuating refractory diseases with sometimes long symptom free periods, some patients could have achieved remission again by week 54 after loss of response, even without dose escalation. Furthermore, as dose escalation was not mandatory for all patients who fulfilled the loss of response criteria, there is a potential for selection bias.

<div style=\"page-break-after: always\"></div>

After the first RSI, the MAH withdrew this proposal for dose escalation for patients with UC. Therefore, the discussion below pertains only to study 3.8.

## Efficacy of a dose increase in CD patients

A total of 41 patients in the CT-P13 SC 120 mg group and 48 patients in the placebo group experienced LoR prior to Week 54. Among these patients, 34/41 (82.9%) in CT-P13 SC 120 mg group and 41/48 (85.4%) in placebo group received adjusted dose while 7 patients in each group remained on the initially assigned treatment.  A few patients received adjusted dose despite not being eligible for the dose adjustment, 5/182 (2.7%) in CT-P13 SC 120 mg group and 4/57 (7.0%) in placebo group. This protocol violation seems to be driven by the clinicians' desire to improve the treatment for poor responders but exposes poor adherence to GCP. However, the frequency of these protocol violations is small enough not to pursue the issue further.

Among the 34 patients with dose adjustment in the CT-P13 SC 120 mg group 17 (50%) patients achieved clinical remission by CDAI and 7 (20.6%) patients achieved endoscopic response at Week 54. On the other hand, in the 7 patients who experienced a LoR but did not receive a dose adjustment but continued on the initial CT-P13 SC 120 mg, regain of clinical remission occurred in 1/7 (14.3%) and endoscopic response reemerged in 3 (42.9%) patients. Regain of CDAI response occurred in 21/34 (61.8%) patients with a dose escalation while patients who lost response but remained on active treatment had a renewed CDAI response in 2 (28.6%) cases. Spontaneous regain of CDAI response and CDAI remission was also seen in patients who remained on placebo (3 and 1 patients, respectively).

Although the numbers are small, and the subgroups are not comparable due to a lack of randomisation, it can be concluded that spontaneous regain of response is not negligible but regain of response according to CDAI is more common and the improvement in absolute CDAI score is more pronounced in patients with a dose adjustment than in those who remained on initial treatment despite a LoR. Some patients did not respond at all to the dose adjustment and some lost response again after a brief improvement but overall, a majority of patients in the active treatment arm who received an escalated dose had a positive outcome 16 weeks after dose adjustment.

A clear difference between patients who experienced LoR and those who did not is seen in terms of serum drug concentration before LoR. This finding supports the theory of loss of response being associated with suboptimal drug concentrations. As also mean anti-drug antibody (ADA) titres were substantially higher among patients who lost response compared to those who did not, it is reasonable to assume a causal relationship between loss of response, high ADA titres and decreased drug concentrations.

It has not been clarified how drug concentrations developed among those with a dose increase and for how long patients with high ADA titres at dose adjustment could maintain a potential benefit from a higher dose. However, as these are not issues which could affect the wording in SPC, they will not be pursued further. Due to the high ADA titres the mean drug concentrations are not expected to be twice as high as normal after a dose increase among patients who lost response. In study 3.8 satisfactory response rates were maintained for at least 16 weeks after dose adjustment.

The benefit of a dose escalation from infliximab 120mg SC Q2W to infliximab 240mg SC Q2W in case of a loss of response has been sufficiently demonstrated in CD patients.

## Safety of a dose increase in CD patients.

The submitted safety results on subgroups administered the 120 mg and 240 mg dose show no dosedependently  increased  risk  for  infection,  serious  adverse  reactions,  or  systemic  and  localised  injection reaction rates. The MAH had originally not described in detail the populations for the comparison between placebo and CT-P13 SC and between the 120 mg and 240 mg doses and how exposure time for each dose was accounted for in the analyses. Upon request, the MAH provided comparative safety analyses performed for the events that occurred on or after the first administration of each treatment of CT-P13 SC 120 mg or

<div style=\"page-break-after: always\"></div>

240 mg for pooled data from all studies with either or both of these doses for all approved indications. Furthermore, analyses on events occurring prior to dose adjustment (CT-P13 SC 120 mg) vs. after dose adjustment (240 mg SC) and within the CT-P13 SC group and treatment-emergent adverse events (TEAEs) occurring prior to dose adjustment (placebo) vs after dose adjustment (from placebo to CT-P13 SC 240 mg) within the placebo group were submitted 1) for pooled population of all studies allowing dose escalation (Studies CT-P13 3.7, CT-P13 3.8 and CT-P13 1.6 Part 2) and 2) separately for study CT-P13 3.8 in Crohn's disease (but not for study CT-P13 3.7, since dose escalation is no more applied for ulcerative colitis). The data were calculated per 100 patient years and showed that the safety profile of higher dose of CT-P13 SC 240 mg is comparable to the approved dose of CT-P13 SC 120 mg (see section 13.2 of this AR). In study CT-P13 3.8, the mean and median duration for patients who received CT-P13 SC 240 mg were 58.9 weeks and 68.1 weeks, respectively, and 73 patients received CT-P13 SC 240 mg as maintenance treatment for at least 44 weeks. Hence, the long-term safety profile of CT-P13 SC 240 mg in subjects with CD is deemed to have been sufficiently demonstrated.

## Conclusion

The CHMP concluded that the benefit-risk balance of Remsima remains positive.

New information was added to the SmPC, section 4.2, regarding the induction regimen in the treatment of CD and UC. The possibility for a dose adjustment to Remsima SC 240 mg has been added for CD patients with loss of response. Sections 5.1 and 4.8 of the SmPC were updated with the description of a new phase 3 study in CD-patients.

<div style=\"page-break-after: always\"></div>

## 3. Recommendations

This application originally concerned the following changes:

| Variations requested   | Variations requested                                                                                              | Type    | Annexes affected   |
|------------------------|-------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.4                  | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | Type II | I, IIIA and IIIB   |
| C.I.4                  | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | Type II | I, IIIA and IIIB   |
| C.I.4                  | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | Type II | I, IIIA and IIIB   |

Grouped application comprising three type II variations (C.I.4) as follows:

- Update of section 4.2, 4.8 and 5.1 of the SmPC in order to add 3-IV induction dosing regimen and dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response and update efficacy and safety information based on Week 54 data from studies CTP13 3.7 (ulcerative colitis) and CT-P13 3.8 (Crohn's disease), listed as a category 3 study in the RMP; Study CT-P13 3.7 is a Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of  the  Subcutaneous Injection  of  CT-P13  (CT-P13  SC)  as  Maintenance  Therapy  in  Patients  with Moderately to Severely Active Ulcerative Colitis and study CT-P13 3.8 is a Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease.
-  Update  of  section  4.2  and  5.2  of  the  SmPC  in  order  to  add  subcutaneous  induction  posology  and pharmacokinetic information based on Population PK and PK-PD Modelling and Simulation.
- Update of section 4.2 of the SmPC in order to switch from high-dose IV maintenance (&gt; 5 mg/kg) to subcutaneous maintenance dose of 120 mg Q2W based on data from REMSWITCH study (Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study).

The RMP version 16.1 has also been submitted. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to introduce minor updates to the PI.

- Following the assessment of the submitted data and the consequent proposals for PI update, the following changes in the variation group were found not to be acceptable and were consequently withdrawn :
- Update of section 4.2 and 5.1 of the SmPC in order to add dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response and update efficacy and safety information based on Week 54 data from study CT-P13 3.7. Study CT-P13 3.7 is a Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis.
- In addition, the following proposed changes were withdrawn:
-  Update  of  section  4.2  and  5.2  of  the  SmPC  in  order  to  add  subcutaneous  induction  posology  and pharmacokinetic information based on Population PK and PK-PD Modelling and Simulation.
- Update of section 4.2 of the SmPC in order to switch from high-dose IV maintenance (&gt; 5 mg/kg) to subcutaneous maintenance dose of 120 mg Q2W based on data from REMSWITCH study (Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study).
- The following changes are recommended for approval:

<div style=\"page-break-after: always\"></div>

- -Addition  of  a  3-IV  induction  dosing  regimen  (5  mg/kg  at  Weeks  0,  2  and  6)  followed  by  SC maintenance treatment (120 mg Q2W) in CD and UC patients;
- -The possibility for dose adjustment from CT-P13 SC 120 mg to 240 mg for CD patients with loss of response;
- -SmPC updates in sections 4.2, 4.8 and 5.1 regarding all of the above, including description of the phase 3 study 3.8 in CD patients.

This application concerns the following agreed changes:

| Variation agreed   | Variation agreed                                                                                                  | Type    | Annexes affected   |
|--------------------|-------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.4              | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | Type II | I, IIIA and IIIB   |

Update of section 4.2, 4.8 and 5.1 of the SmPC in order to add 3-IV induction dosing regimen based on Week 54 data from studies CT-P13 3.7 (ulcerative colitis) and CT-P13 3.8 (Crohn's disease), listed as a category 3 study in the RMP.

Study CT-P13 3.7 is a Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis and study CT-P13 3.8 is a Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13  (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease.

The RMP version 16.2 was agreed. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to introduce minor updates to the PI.

## Amendments to the marketing authorisation

In view of the data submitted with the group of variations, amendments to Annexes I, IIIA and IIIB and to the Risk Management Plan are recommended.

## 4. EPAR changes

The table in Module 8b of the EPAR will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Remsima-H-C-2576-II-0133.

For more information, please refer to the Summary of Product Characteristics.

<div style=\"page-break-after: always\"></div>

## Annex: Assessment comments on the type II variation

<div style=\"page-break-after: always\"></div>

## 5. Introduction

Remsima  (CT-P13, infliximab)  was  initially  developed  for  intravenous  (IV) infusion  (hereafter referred to as CT-P13 IV) and was approved in the European Union (EU) in September 2013 as a biosimilar product to EU-approved Remicade for the treatment of rheumatoid arthritis (RA), adult Crohn's disease (CD), paediatric  CD,  ulcerative  colitis  (UC),  paediatric  UC,  ankylosing spondylitis (AS), psoriatic arthritis (PsA) and psoriasis (Ps). The subcutaneous (SC) formulation of  Remsima  (hereafter  referred  to  as  CTP13 SC) was also approved in the EU for the RA indication (EMEA/H/C/002576/X/0062) on 22 November 2019,  and  adult  CD,  UC,  AS,  PsA  and  Ps  indications  (EMEA/H/C/002576/II/0082)  on  27  July  2020. Additionally, SC induction posology for RA indication (EMEA/H/C/002576/II/0095) was also approved on 30 April 2021.

According to the currently approved Summary of product characteristics (SmPC) for Remsima SC formulation (CT-P13 SC), two IV infusions of infliximab 5 mg/kg should be given 2 weeks apart prior  to  the  initiation of  maintenance  therapy  with  Remsima  SC  for  IBD  indications.  The  first treatment with Remsima SC should be initiated as maintenance therapy 4 weeks after the second intravenous administration.

In this grouped Type II variation application, the Marketing Authorisation Holder (MAH) initially proposed several updates of the SmPC for CD and UC indications:

1. Addition  of  a  3-IV induction dosing regimen (5 mg/kg at Weeks  0, 2 and 6) followed by SC maintenance treatment (120 mg Q2W);
2. The possibility for dose adjustment from CT-P13 SC 120 mg to 240 mg for patients with loss of response;
3. Addition of a subcutaneous induction dosing regimen (240 mg at Week 0 followed by 120 mg at Weeks 1, 2, 3 and 4) followed by SC maintenance treatment (120 mg Q2W);
4. The possibility to switch  from  high-dose  (&gt;  5  mg/kg)  IV  maintenance  to  subcutaneous maintenance treatment
5. Major SmPC-updates on all of the above, including description of the two new phase 3 studies (CD and UC) in sections 5.1 and 4.8.

According to the MAH, introduction of a 3-IV induction option would allow greater treatment options for patients and healthcare professionals but the benefits of this option were not further discussed.

The possibility of a dose increase after loss of response would give another chance to show clinical response.

The benefits of subcutaneous induction without the need for IV loading is justified by improved subject convenience, reduced pharmacy preparation times and optimisation of medical resources.

Two clinical studies (Studies CT-P13 3.7 and CT-P13 3.8 conducted in UC and CD patients, respectively) are  newly  introduced  to  the  CT-P13  SC  clinical  development  programme  and  are  used  to  support  the changes. However, the proposed SC induction dosing regimen for CD and UC indications is only supported by population pharmacokinetic (PK) Modelling and Simulation analyses. Detailed information about the two clinical studies is summarized below in Table 2.

The switch from high-dose IV maintenance to subcutaneous maintenance treatment is supported by an observational study (REMSWITCH study in CD and UC patients), described in a peer reviewed journal, but with no CSR.

The proposed posology changes and supporting evidence are summarised in Table 1.

In  addition  to  the  tabulated  changes,  a  new  time  point  for  decision  making  regarding  maintenance treatment has been introduced for Crohn's disease. No justification was provided for this change.

There has been no scientific advice held regarding the changes proposed in this submission.

<div style=\"page-break-after: always\"></div>

After the first RSI, the Applicant withdrew several parts of the grouped variation application. Discussion on the initially proposed changes is kept here for transparency.

In this assessment report, the product is referred to as CT-P13 SC or Remsima SC.

<div style=\"page-break-after: always\"></div>

Table 2. Proposed Posology Changes and Supporting Evidences Included in This Submission

| #   | Proposed Change                                          | Indications   | Proposed Update to SmPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Proposed Update to SmPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Supporting Evidence                                                                              | Related Sections          |
|-----|----------------------------------------------------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------|
|     |                                                          |               | Before Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | After Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                  |                           |
| 1   | 3-IV induction dosing regimen                            | CD, UC        | Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. If a patient does not respond after 2 doses of intravenous infusions, no additional treatment with infliximab should be given. Available data do not support further infliximab treatment, in patients not responding within 6 weeks of the initial infusion. | Treatment with Remsima subcutaneous formulation should be initiated with loading doses of infliximab which may be intravenous or subcutaneous. When subcutaneous loading is used, Remsima 240 mg (double injection of Remsima 120 mg) should be given as a subcutaneous injection followed by additional subcutaneous injections of Remsima 120 mg at 1, 2, 3 and 4 weeks after the first injection, then every 2 weeks thereafter. If intravenous loading doses of infliximab are given to initiate treatment, 2 intravenous infusions of infliximab 5 mg/kg should be given at 2 weeks apart, and an additional intravenous infusion of infliximab 5 mg/kg may be given 4 weeks after the second infusion. The first treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of intravenous infusions. The recommended maintenance dose for Remsima subcutaneous formulation is 120 mgonce every 2 weeks. Limited data in patients who initially responded to induction regimen with | PK, efficacy, safety and immunogenicity results from Studies CT-P13 3.7 (UC) and CT-P13 3.8 (CD) | 2.7.2.2.1 2.7.3.2 2.7.4.2 |
| 2   | Dose adjustment for patients with loss of response (LoR) | CD, UC        | Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. If a patient does not respond after 2 doses of intravenous infusions, no additional treatment with infliximab should be given. Available data do not support further infliximab treatment, in patients not responding within 6 weeks of the initial infusion. | Treatment with Remsima subcutaneous formulation should be initiated with loading doses of infliximab which may be intravenous or subcutaneous. When subcutaneous loading is used, Remsima 240 mg (double injection of Remsima 120 mg) should be given as a subcutaneous injection followed by additional subcutaneous injections of Remsima 120 mg at 1, 2, 3 and 4 weeks after the first injection, then every 2 weeks thereafter. If intravenous loading doses of infliximab are given to initiate treatment, 2 intravenous infusions of infliximab 5 mg/kg should be given at 2 weeks apart, and an additional intravenous infusion of infliximab 5 mg/kg may be given 4 weeks after the second infusion. The first treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of intravenous infusions. The recommended maintenance dose for Remsima subcutaneous formulation is 120 mgonce every 2 weeks. Limited data in patients who initially responded to induction regimen with | PK, efficacy, safety and immunogenicity results from Studies CT-P13 3.7 (UC) and CT-P13 3.8 (CD) | 2.7.2.2.1 2.7.3.2 2.7.4.2 |
| 3   | SCinduction posology                                     | CD, UC        | Treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of two intravenous infusions of infliximab 5 mg/kg given 2 weeks apart. The recommended dose for Remsima subcutaneous formulation is 120 mg once every 2 weeks. If a patient does not respond after 2 doses of intravenous infusions, no additional treatment with infliximab should be given. Available data do not support further infliximab treatment, in patients not responding within 6 weeks of the initial infusion. | Treatment with Remsima subcutaneous formulation should be initiated with loading doses of infliximab which may be intravenous or subcutaneous. When subcutaneous loading is used, Remsima 240 mg (double injection of Remsima 120 mg) should be given as a subcutaneous injection followed by additional subcutaneous injections of Remsima 120 mg at 1, 2, 3 and 4 weeks after the first injection, then every 2 weeks thereafter. If intravenous loading doses of infliximab are given to initiate treatment, 2 intravenous infusions of infliximab 5 mg/kg should be given at 2 weeks apart, and an additional intravenous infusion of infliximab 5 mg/kg may be given 4 weeks after the second infusion. The first treatment with Remsima administered subcutaneously should be initiated as maintenance therapy 4 weeks after the last administration of intravenous infusions. The recommended maintenance dose for Remsima subcutaneous formulation is 120 mgonce every 2 weeks. Limited data in patients who initially responded to induction regimen with | Population PK and PK- PD Modelling and Simulation                                                | 2.7.2.3.3                 |
|     |                                                          |               | with dose Continued reconsidered of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | that some patients may regain response escalation (see section 5.1). therapy should be carefully in patients who show no evidence therapeutic benefit after dose adjustment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                  |                           |

<div style=\"page-break-after: always\"></div>

| 4   | Switch from high-dose (> 5 mg/kg) IV maintenance to SCmaintenance   | CD   | There is insufficient information regarding the switching of patients who received the intravenous infusions of infliximab higher than 3 mg/kg for rheumatoid arthritis or 5 mg/kg for Crohn's disease every 8 weeks to the subcutaneous formulation of There is insufficient information regarding the switching of patients who received the intravenous infusions of infliximab higher than 3 mg/kg for rheumatoid arthritis every 8 weeks to the subcutaneous formulation of Remsima. PK, efficacy, safety and immunogenicity results from REMSWITCH study   | 2.7.2.3.5 2.7.3.4.4 2.7.4.6.3   |
|-----|---------------------------------------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|

<div style=\"page-break-after: always\"></div>

Table 3. Overview of Clinical Development Program of CT-P13 SC

| Protocol No.   | Population                                                            | Design                                                                                                                                                                                                                                  | Objective(s)                                                                                                                                                                                                                                                     | Study Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Status   |
|----------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| CT-P13 3.7     | UC Enrolled: 548 Randomized (W10): 438 CT-P13 SC: 294 Placebo SC: 144 | Randomized, placebo- controlled, double- blind, multicentre, parallel-group Phase 3 study to evaluate the efficacy, PK, PD and safety of CT-P13 SCas maintenance therapy in patients with moderately to severely active UC              | Primary Objective:  To demonstrate superiority of CT-P13 SC over Placebo SC based on clinical remission at Week 54 Secondary Objective:  To evaluate additional efficacy, PK, PD and overall safety including immunogenicity                                   | <Induction phase> - Week 0 to 10 Three doses of CT-P13 IV 5 mg/kg at Weeks 0, 2 and 6 for all patients <Maintenance phase> - Week 10 to 54 Arm 1: CT-P13 SC 120 mg via PFS at Week 10 and then every 2 weeks up to Week 54 Arm 2: Placebo SC (matching volume to CT- P13 SC 120 mg) via PFS at Week 10 and then every 2 weeks up to Week 54 <Extension phase> - Week 56 to 102 CT-P13 SC 120 mg via PFS at Week 56 and then every 2 weeks up to Week 102             | Ongoing  |
| CT-P13 3.8     | CD Enrolled: 396 Randomized (W10): 343 CT-P13 SC: 231 Placebo SC: 112 | Randomized, placebo- controlled, double- blind, multicentre, parallel-group, Phase 3 study to evaluate the efficacy, PK, PD, usability and safety of CT-P13 SC as maintenance therapy in patients with moderately to severely active CD | Primary Objective:  To demonstrate superiority of CT-P13 SCover Placebo SC based on clinical remission and endoscopic response at Week 54 Secondary Objective:  To evaluate additional efficacy, PK, PD, usability and overall safety including immunogenicity | <Induction phase> - Week 0 to 10 Three doses of CT-P13 IV (5 mg/kg) at Weeks 0, 2 and 6 for all patients <Maintenance phase> - Week 10 to 54  Arm 1: CT-P13 SC 120 mg via PFS at Week 10 and then every 2 weeks up to Week 54  Arm 2: Placebo SC (matching volume to CT- P13 SC 120 mg) via PFS at Week 10 and then every 2 weeks up to Week 54 <Extension phase> - Week 56 to 102 CT-P13 SC 120 mg via PFS or AI at Week 56 and then every 2 weeks up to Week 102 | Ongoing  |

Abbreviations: AI, Auto-injector; CD, Crohn's disease; IBD, Inflammatory bowel disease; IV, Intravenous; PD, Pharmacodynamics; PFS, Pre-filled syringe; PK, Pharmacokinetics; SC, Subcutaneous; UC, Ulcerative colitis

<div style=\"page-break-after: always\"></div>

## 6. Clinical Pharmacology aspects

## 6.1. Methods - analysis of data submitted

## 6.1.1. Bioanalytical methods

Bioanalytical methods applied in CT-P13 clinical program included the assays for quantifying human plasma concentration of CT-P13 and detecting anti-drug antibody (ADA) and neutralising antibody (NAb) after IV (Study CT-P13 3.7) and SC (Study CT-P13 3.8) injections. The fecal calprotectin (FC) and C-reactive protein (CRP) were also monitored as pharmacodynamic (PD) parameters in Studies CT-P13 3.7 and CT-P13 3.8. Table 3 provides an overview of the bioanalytical methods used in the clinical program for pharmacokinetics and immunogenicity testing. The reports in blue font are included in this Type II/133/G variation and are further discussed and assessed in this current AR whereas the reports in black font have been assessed and discussed in the context of previous regulatory submissions for this finished drug product.

Table 4. Overview of bioanalytical methods used in CT-P13 clinical studies.

| Category   | MethodPlatform   | Validation Report                                                                         | RelerantSequence                                        |
|------------|------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------|
| PK         | MSD ECL          | RBPQ7 (Original) RBPQ8（Addendum3) RBPQ8(Addendum 5) RBPQ8 (Addendum 7) RBPQ14(Addendum 6) | Section2.7.1ofSN0133 Section2.7.1ofSN0171 Section 1.2.1 |
| ADA        | MSDECLACE        | RLBH6 (Original) RLBH6 (Amendment 1) RLBH8(Addendum1) RLBH10 (Addendum 2)                 | Section2.7.2.4ofSN0171 Section 1.2.2.1                  |
| NAb        | NewIMSDECLACE    | RMLA10 (Original)                                                                         | Section1.2.2.2                                          |

Abbreviations:ACE,AffinityCaptureElution;ADA,Anti-drugantibody,ECL,Electrochemiluminescence;

MSD,MesoScaleDiscovery;NAb,Neutralisingantibody;PK,Pharmacokinetics;SC,Subcutaneous

## Detection of ADA in human serum by ECL-MSD based method

At the early phase of sample analysis for Study CT-P13 3.8, the ADA-assay showed poor performance with high run failure rate in reagent qualification runs. Positive controls failed to meet pre-defined acceptance criteria  and  negative  controls  showed  large  variance  in  response  between  wells.  The  root  cause  was identified in a thorough investigation as the quality of Pierce TM  Streptavidin coated high capacity (SA) plates. Pierce TM  SA plate was then replaced with SA plate manufactured by Roche, and additional method validation was performed by PPD Laboratory to confirm assay performance after the change of SA plate. The detailed validation report (RLBH10, Addendum 2) was provided in the submission and the summary of the validation results is presented in the Table 4.

<div style=\"page-break-after: always\"></div>

Table 5. Validation summary of ADA detection assay (partial validation after change of SA plate)

<!-- image -->

| Aspect                                          | PerformanceParameters                                                                                                                                                                                                                                                   | PerformanceParameters                                                                                                                                                                                                                                                   | PerformanceParameters                                                                                                                                                                                                                                                   | PerformanceParameters                                                                                                                                                                                                                                                   |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Project Code                                    | RLBH10                                                                                                                                                                                                                                                                  | RLBH10                                                                                                                                                                                                                                                                  | RLBH10                                                                                                                                                                                                                                                                  | RLBH10                                                                                                                                                                                                                                                                  |
| PC Characteristics                              | HCA233（Humanmonoclonalanti-infliximabantibodyinhumanserum)                                                                                                                                                                                                              | HCA233（Humanmonoclonalanti-infliximabantibodyinhumanserum)                                                                                                                                                                                                              | HCA233（Humanmonoclonalanti-infliximabantibodyinhumanserum)                                                                                                                                                                                                              | HCA233（Humanmonoclonalanti-infliximabantibodyinhumanserum)                                                                                                                                                                                                              |
| PC Concentrations                               | 2.80, 5.00,10.0, 100, and 1000 ng/mL                                                                                                                                                                                                                                    | 2.80, 5.00,10.0, 100, and 1000 ng/mL                                                                                                                                                                                                                                    | 2.80, 5.00,10.0, 100, and 1000 ng/mL                                                                                                                                                                                                                                    | 2.80, 5.00,10.0, 100, and 1000 ng/mL                                                                                                                                                                                                                                    |
| Screening Assay Cut Point (Mean Plate NC x CPV) | CPV=1.06(Normal human serum)                                                                                                                                                                                                                                            | CPV=1.06(Normal human serum)                                                                                                                                                                                                                                            | CPV=1.06(Normal human serum)                                                                                                                                                                                                                                            | CPV=1.06(Normal human serum)                                                                                                                                                                                                                                            |
| Specificity/Confirmatory Assay Cut Point        | %Signal Inhibition =22.2%(Normal human serum)                                                                                                                                                                                                                           | %Signal Inhibition =22.2%(Normal human serum)                                                                                                                                                                                                                           | %Signal Inhibition =22.2%(Normal human serum)                                                                                                                                                                                                                           | %Signal Inhibition =22.2%(Normal human serum)                                                                                                                                                                                                                           |
| TitreAssayCutPoint (MeanPlateNCxCPV)            | CPV=1.13(Normalhumanserum)                                                                                                                                                                                                                                              | CPV=1.13(Normalhumanserum)                                                                                                                                                                                                                                              | CPV=1.13(Normalhumanserum)                                                                                                                                                                                                                                              | CPV=1.13(Normalhumanserum)                                                                                                                                                                                                                                              |
| Sensitivity                                     | Screening=1.33ng/mL,Confirmatory=2.35ng/mLfornormalhumanserum                                                                                                                                                                                                           | Screening=1.33ng/mL,Confirmatory=2.35ng/mLfornormalhumanserum                                                                                                                                                                                                           | Screening=1.33ng/mL,Confirmatory=2.35ng/mLfornormalhumanserum                                                                                                                                                                                                           | Screening=1.33ng/mL,Confirmatory=2.35ng/mLfornormalhumanserum                                                                                                                                                                                                           |
| LPCDetermination                                | 5.00 ng/mL The lower limits for run acceptance LPCs were determined to be 1.23SNR for the screening assay and 30.7% for the confirmatory assay.                                                                                                                         | 5.00 ng/mL The lower limits for run acceptance LPCs were determined to be 1.23SNR for the screening assay and 30.7% for the confirmatory assay.                                                                                                                         | 5.00 ng/mL The lower limits for run acceptance LPCs were determined to be 1.23SNR for the screening assay and 30.7% for the confirmatory assay.                                                                                                                         | 5.00 ng/mL The lower limits for run acceptance LPCs were determined to be 1.23SNR for the screening assay and 30.7% for the confirmatory assay.                                                                                                                         |
| Titre Precision                                 | Acceptable with All the titres of 24 curves were within ± 1 dilution of the median titre (1:8 dilution).                                                                                                                                                                | Acceptable with All the titres of 24 curves were within ± 1 dilution of the median titre (1:8 dilution).                                                                                                                                                                | Acceptable with All the titres of 24 curves were within ± 1 dilution of the median titre (1:8 dilution).                                                                                                                                                                | Acceptable with All the titres of 24 curves were within ± 1 dilution of the median titre (1:8 dilution).                                                                                                                                                                |
| Intra-assayStatistics- RLU                      | Level                                                                                                                                                                                                                                                                   | Conc. (ng/mL)                                                                                                                                                                                                                                                           | Precision (%CV)                                                                                                                                                                                                                                                         | Precision (%CV)                                                                                                                                                                                                                                                         |
| Intra-assayStatistics- RLU                      | Level                                                                                                                                                                                                                                                                   | Conc. (ng/mL)                                                                                                                                                                                                                                                           | Screening                                                                                                                                                                                                                                                               | Confirmatory %oInhibitory                                                                                                                                                                                                                                               |
| Intra-assayStatistics- RLU                      | NC LPC MPC HPC                                                                                                                                                                                                                                                          | N/A 2.80 100 1,000                                                                                                                                                                                                                                                      | 1.23% 1.30% 6.54% 4.52%                                                                                                                                                                                                                                                 | 38.9%* 7.55% 0.651% 0.0578%                                                                                                                                                                                                                                             |
| Intra-assayStatistics- RLU                      | * Since all replicate results for the inhibited NC confirmed negative, the assay performed as expected and intra-assay precision for the NC %inhibition was consideredacceptable.                                                                                       | * Since all replicate results for the inhibited NC confirmed negative, the assay performed as expected and intra-assay precision for the NC %inhibition was consideredacceptable.                                                                                       | * Since all replicate results for the inhibited NC confirmed negative, the assay performed as expected and intra-assay precision for the NC %inhibition was consideredacceptable.                                                                                       | * Since all replicate results for the inhibited NC confirmed negative, the assay performed as expected and intra-assay precision for the NC %inhibition was consideredacceptable.                                                                                       |
| Inter-assayStatistics- RLU or SNR               | Level                                                                                                                                                                                                                                                                   | Conc. (ng/mL)                                                                                                                                                                                                                                                           | Precision (%o CV)                                                                                                                                                                                                                                                       | Precision (%o CV)                                                                                                                                                                                                                                                       |
| Inter-assayStatistics- RLU or SNR               | Level                                                                                                                                                                                                                                                                   | Conc. (ng/mL)                                                                                                                                                                                                                                                           | Screening                                                                                                                                                                                                                                                               | Confirmatory %oInhibitory                                                                                                                                                                                                                                               |
| Inter-assayStatistics- RLU or SNR               | NC LPC LPC MPC HPC                                                                                                                                                                                                                                                      | N/A 2.80 5.00 100 1,000                                                                                                                                                                                                                                                 | 10.1% (RLU) 6.23% (SNR) 6.92% (SNR) 17.2% (SNR) 15.9% (SNR)                                                                                                                                                                                                             | 70.8%** 18.3% 11.6% 1.60% 0.171%                                                                                                                                                                                                                                        |
| Inter-assayStatistics- RLU or SNR               | ** Since the replicate results for the inhibited NCs consistently confirmed negative and the mean % inhibition for the NC was 9.9% (below the CCP of 22.2%),the assay performed as expected and inter-assay precision for the NC %inhibition was considered acceptable. | ** Since the replicate results for the inhibited NCs consistently confirmed negative and the mean % inhibition for the NC was 9.9% (below the CCP of 22.2%),the assay performed as expected and inter-assay precision for the NC %inhibition was considered acceptable. | ** Since the replicate results for the inhibited NCs consistently confirmed negative and the mean % inhibition for the NC was 9.9% (below the CCP of 22.2%),the assay performed as expected and inter-assay precision for the NC %inhibition was considered acceptable. | ** Since the replicate results for the inhibited NCs consistently confirmed negative and the mean % inhibition for the NC was 9.9% (below the CCP of 22.2%),the assay performed as expected and inter-assay precision for the NC %inhibition was considered acceptable. |
| Drug Tolerance                                  | ≥25.0ng/mLantibodydetectedin thepresenceof 120μg/mLCT-P13SCand CT-P13 IV                                                                                                                                                                                                | ≥25.0ng/mLantibodydetectedin thepresenceof 120μg/mLCT-P13SCand CT-P13 IV                                                                                                                                                                                                | ≥25.0ng/mLantibodydetectedin thepresenceof 120μg/mLCT-P13SCand CT-P13 IV                                                                                                                                                                                                | ≥25.0ng/mLantibodydetectedin thepresenceof 120μg/mLCT-P13SCand CT-P13 IV                                                                                                                                                                                                |
| ProzoneorHookEffect                             | AhookeffectwasobservedatADAconcentrationsabove6,250ng/mLdueto decreasesintheRLUsrelativetoincreasingADAconcentrations. However, ADA concentrations up to 25,000 ng/mL screened potential positive and confirmed positive.                                               | AhookeffectwasobservedatADAconcentrationsabove6,250ng/mLdueto decreasesintheRLUsrelativetoincreasingADAconcentrations. However, ADA concentrations up to 25,000 ng/mL screened potential positive and confirmed positive.                                               | AhookeffectwasobservedatADAconcentrationsabove6,250ng/mLdueto decreasesintheRLUsrelativetoincreasingADAconcentrations. However, ADA concentrations up to 25,000 ng/mL screened potential positive and confirmed positive.                                               | AhookeffectwasobservedatADAconcentrationsabove6,250ng/mLdueto decreasesintheRLUsrelativetoincreasingADAconcentrations. However, ADA concentrations up to 25,000 ng/mL screened potential positive and confirmed positive.                                               |

Source:RLBH10

Abbreviations: ACE,Affinity capture elution; ADA,Anti-drug antibody;Conc.,Concentration;CCP, Confirmatory cut point; CPV,Cut point value;%CV,Percent coefficient of variation; ECL, Electrochemiluminescence; HPC, High positive control; IV, Intravenous; LPC, Low positive control; MPC, Medium positive control; MSD, Meso Scale Discovery; NC, Negative control; PC, Positive control; RLU, Relativelightunit;SC,Subcutaneous;SNR,Signal tonoiseratio

## Detection of NAb in human serum by MSD ECL assay

Prior to Studies CT-P13 3.7 and CT-P13 3.8, the MSD ECL ACE based immunoassay containing acid sample treatment was tested in qualification runs to assure the appropriate assay performance. The results showed large well-to-well variance in negative and positive control responses, thus failing to meet the pre-defined acceptance  criteria.  Therefore,  the  new  MSD  ECL  ACE  method  was  developed  and  validated  by  PPD Laboratory. The new method utilises TNF α and Sulfo-tag CT-P13 as second capture and detection reagents on MSD plate respectively, whereas in old method the corresponding reagents are biotinylated CT-P13 and Sulfo-tag TNF α ( Figure 1). A full validation report of new NAb-assay was provided in the submission and the results are summarized in Table 5.

<div style=\"page-break-after: always\"></div>

Figure 1. Schematic diagram of the new MSD ECL ACE method for NAb detection in serum

<!-- image -->

Abbreviations: ACE, Affinity capture elution; ECL, Electrochemiluminescence; MSD, Meso Scale Discovery; NAb, neutralising antibody; ST, Sulfo-tag; TNFa, Tumor Necrosis Factor α

<div style=\"page-break-after: always\"></div>

Table 6. Summary of the validation of the novel NAb detection method in healthy human serum.

<!-- image -->

| Species/Matrix                     | Human Serum                                                                                                                                                                                                                                         | Human Serum                                                                                                                                                                                                                                         | Human Serum                                                                                                                                                                                                                                         |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AnalysisMethod                     | new MSD ECL ACE                                                                                                                                                                                                                                     | new MSD ECL ACE                                                                                                                                                                                                                                     | new MSD ECL ACE                                                                                                                                                                                                                                     |
| Screening Assay Cut point          | CPVforHealthy=0.889SNR CPVforUC=0.861 SNR CPVforCD=0.884SNR                                                                                                                                                                                         | CPVforHealthy=0.889SNR CPVforUC=0.861 SNR CPVforCD=0.884SNR                                                                                                                                                                                         | CPVforHealthy=0.889SNR CPVforUC=0.861 SNR CPVforCD=0.884SNR                                                                                                                                                                                         |
| Titration Assay Cut point          | CPVforHealthy=0.850SNR CPVforUC=0.823SNR CPVforCD=0.849SNR                                                                                                                                                                                          | CPVforHealthy=0.850SNR CPVforUC=0.823SNR CPVforCD=0.849SNR                                                                                                                                                                                          | CPVforHealthy=0.850SNR CPVforUC=0.823SNR CPVforCD=0.849SNR                                                                                                                                                                                          |
| MRD                                | 1:10.7                                                                                                                                                                                                                                              | 1:10.7                                                                                                                                                                                                                                              | 1:10.7                                                                                                                                                                                                                                              |
| Sensitivity                        | 58.7 ng/mL                                                                                                                                                                                                                                          | 58.7 ng/mL                                                                                                                                                                                                                                          | 58.7 ng/mL                                                                                                                                                                                                                                          |
| PCCharacteristics                  | Humanmonoclonalanti-infliximabantibodyHCA213,purchasedfromBioRad                                                                                                                                                                                    | Humanmonoclonalanti-infliximabantibodyHCA213,purchasedfromBioRad                                                                                                                                                                                    | Humanmonoclonalanti-infliximabantibodyHCA213,purchasedfromBioRad                                                                                                                                                                                    |
| PCConcentrations                   | 119,687and1.000ng/mL                                                                                                                                                                                                                                | 119,687and1.000ng/mL                                                                                                                                                                                                                                | 119,687and1.000ng/mL                                                                                                                                                                                                                                |
| Control Intra-assay Statistics-SNR | Level                                                                                                                                                                                                                                               | Conc. (μg/mL)                                                                                                                                                                                                                                       | Precision (%CV)                                                                                                                                                                                                                                     |
| Control Intra-assay Statistics-SNR | NC LPC                                                                                                                                                                                                                                              | N/A 119 687                                                                                                                                                                                                                                         | 4.01 6.17 6.58                                                                                                                                                                                                                                      |
| Control Intra-assay Statistics-SNR | MPC HPC                                                                                                                                                                                                                                             | 1000                                                                                                                                                                                                                                                | 9.28                                                                                                                                                                                                                                                |
| Control Inter-assay Statistics-RLU | Level                                                                                                                                                                                                                                               | Conc. (μg/mL)                                                                                                                                                                                                                                       | Precision (%oCV)                                                                                                                                                                                                                                    |
| Control Inter-assay Statistics-RLU | NC                                                                                                                                                                                                                                                  | N/A                                                                                                                                                                                                                                                 | 12.9                                                                                                                                                                                                                                                |
| Control Inter-assay Statistics-RLU | LPC                                                                                                                                                                                                                                                 | 119                                                                                                                                                                                                                                                 | 12.8                                                                                                                                                                                                                                                |
| Control Inter-assay Statistics-RLU | MPC                                                                                                                                                                                                                                                 | 687                                                                                                                                                                                                                                                 | 12.1                                                                                                                                                                                                                                                |
| Control Inter-assay Statistics-RLU | HPC                                                                                                                                                                                                                                                 | 1000                                                                                                                                                                                                                                                | 14.2                                                                                                                                                                                                                                                |
| TitrePrecision                     | Acceptable with ·All the titres of24 curveswere within ±1 dilution of the median titre (1:8dilution)                                                                                                                                                | Acceptable with ·All the titres of24 curveswere within ±1 dilution of the median titre (1:8dilution)                                                                                                                                                | Acceptable with ·All the titres of24 curveswere within ±1 dilution of the median titre (1:8dilution)                                                                                                                                                |
| Matrix Interference; Healthy       | Acceptable with ·10/10unitsmeetingthe acceptancecriteriawhenanalysedunfortifiedserums · 10/10 units meeting the acceptance criteria when fortified at the LPC level · 10/10 units meeting the acceptance criteria when fortified at the HPC level   | Acceptable with ·10/10unitsmeetingthe acceptancecriteriawhenanalysedunfortifiedserums · 10/10 units meeting the acceptance criteria when fortified at the LPC level · 10/10 units meeting the acceptance criteria when fortified at the HPC level   | Acceptable with ·10/10unitsmeetingthe acceptancecriteriawhenanalysedunfortifiedserums · 10/10 units meeting the acceptance criteria when fortified at the LPC level · 10/10 units meeting the acceptance criteria when fortified at the HPC level   |
| Matrix Interference; UC            | Acceptablewith · 10/10 units meeting the acceptance criteria when analysed unfortified serums · 10/10 units meeting the acceptance criteria when fortified at the LPC level ·10/10unitsmeeting the acceptance criteria whenfortified at theHPC1evel | Acceptablewith · 10/10 units meeting the acceptance criteria when analysed unfortified serums · 10/10 units meeting the acceptance criteria when fortified at the LPC level ·10/10unitsmeeting the acceptance criteria whenfortified at theHPC1evel | Acceptablewith · 10/10 units meeting the acceptance criteria when analysed unfortified serums · 10/10 units meeting the acceptance criteria when fortified at the LPC level ·10/10unitsmeeting the acceptance criteria whenfortified at theHPC1evel |
| Matrix Interference; CD            | Acceptable with ·10/10unitsmeeting the acceptance criteria when analysedunfortifiedserums ·10/10unitsmeetingthe acceptance criteriawhenfortified at theLPClevel ·10/10unitsmeeting the acceptance criteriawhenfortified at theHPC1evel              | Acceptable with ·10/10unitsmeeting the acceptance criteria when analysedunfortifiedserums ·10/10unitsmeetingthe acceptance criteriawhenfortified at theLPClevel ·10/10unitsmeeting the acceptance criteriawhenfortified at theHPC1evel              | Acceptable with ·10/10unitsmeeting the acceptance criteria when analysedunfortifiedserums ·10/10unitsmeetingthe acceptance criteriawhenfortified at theLPClevel ·10/10unitsmeeting the acceptance criteriawhenfortified at theHPC1evel              |
| DrugTolerance                      | ·500 and 1000 ng/mL antibody detectedin the presence ofup to 40μg/mL drug ·119ng/mLantibodydetectedin thepresenceofup to30pg/mLdrug                                                                                                                 | ·500 and 1000 ng/mL antibody detectedin the presence ofup to 40μg/mL drug ·119ng/mLantibodydetectedin thepresenceofup to30pg/mLdrug                                                                                                                 | ·500 and 1000 ng/mL antibody detectedin the presence ofup to 40μg/mL drug ·119ng/mLantibodydetectedin thepresenceofup to30pg/mLdrug                                                                                                                 |
| Hemolysis&Lipenia                  | · No apparent effect from hemolysis on the detection of anti-CT-P13 neutralising antibodies · No apparent effect from lipemia on the detection of anti-CT-P13 neutralising antibodies                                                               | · No apparent effect from hemolysis on the detection of anti-CT-P13 neutralising antibodies · No apparent effect from lipemia on the detection of anti-CT-P13 neutralising antibodies                                                               | · No apparent effect from hemolysis on the detection of anti-CT-P13 neutralising antibodies · No apparent effect from lipemia on the detection of anti-CT-P13 neutralising antibodies                                                               |
| Targetinterference                 | No target interference was observed up to 2000 pg/mL of TNFa                                                                                                                                                                                        | No target interference was observed up to 2000 pg/mL of TNFa                                                                                                                                                                                        | No target interference was observed up to 2000 pg/mL of TNFa                                                                                                                                                                                        |
| Prozone(Hook)Effect                | No apparent prozone effect observed at concentrations up to 25.o00 ng/mL                                                                                                                                                                            | No apparent prozone effect observed at concentrations up to 25.o00 ng/mL                                                                                                                                                                            | No apparent prozone effect observed at concentrations up to 25.o00 ng/mL                                                                                                                                                                            |
| Thawed Matrix Stability (Hours)    | 28hoursatroomtemperature                                                                                                                                                                                                                            | 28hoursatroomtemperature                                                                                                                                                                                                                            | 28hoursatroomtemperature                                                                                                                                                                                                                            |
| Freeze/TharStability (Cycles)      | Sixcyclesthawedatroom temperature                                                                                                                                                                                                                   | Sixcyclesthawedatroom temperature                                                                                                                                                                                                                   | Sixcyclesthawedatroom temperature                                                                                                                                                                                                                   |

Source:RMLA10

Abbreviations: ACE, Affinity capture elution; CD, Crohn's disease; CPV, Cut point value; %CV, Percent coefficient of variation;ECL,Electrochemiluminescence; HPC,High positive control; LPC, Low positive control; MPC, Medium positive control; MRD, Minimum required dilution; MSD, Meso Scale Discovery: Tumornecrosisfactoralpha;SNR,Signal-to-noiseratio;UC,Ulcerative colitis

## CHMP comments (bioanalytical methods)

The Type II/133/G variation contains two clinical studies CT-P13 3.7 (with ulcerative colitis patients) and 3.8 (with Crohn's disease patients). The bioanalysis of clinical study samples included quantification of CTP13  plasma  concentration  and  PD  markers  as  well  as  ADA  and  NAb  detection  in  plasma.  The  plasma concentration and PD marker quantification methods are the same as used in earlier development and have been  assessed  and  discussed  within  the  context  of  previous  regulatory  submission.  Therefore,  these methods are left out of this assessment.

<div style=\"page-break-after: always\"></div>

However, ADA and NAb detection methods both of which are MSD ECL based immunocapture assays showed at the early phase of sample analysis/reagent testing high run failure rate mainly due to large variation in controls, thus not meeting the pre-defined acceptance criteria. Therefore, both methods were modified and either partially or fully validated. In general, the validation of these modified methods has been done in accordance with the relevant EMA guideline and are shortly discussed below.

## Determination of ADA in human serum

MAH informs that according to extensive investigation the Pierce TM  streptavidin coated high capacity (SA) plates were the reason for poor performance of ADA method. Therefore, Pierce TM  SA plates were changed to corresponding SA plates provided by Roche. Partial validation (RLBH10, Addendum 2) with new plates was performed. This is considered acceptable since otherwise, the method was not changed.

The partial validation with new SA plates provided by Roche was performed only in healthy human serum. Since the clinical studies are performed with ulcerative colitis and Crohn's disease patients, the MAH is requested to evaluate matrix interference of corresponding disease serum unless otherwise justified. The screening, confirmatory and tier cut points were determined in acceptable manner being relatively close to cut points in old method with Pierce TM  SA plates. The intra- and inter-assay precision for screening and confirmation and titer precision met the acceptance criteria. Only the confirmatory precision of negative controls did not meet the acceptance criteria. However, this is considered acceptable since all replicate results for the inhibited negative controls were confirmed negative. The method with Roche SA plates was slightly less sensitive than the method with Pierce TM  SA plates: screening sensitivity 1.33 ng/mL vs. 0.54 ng/mL and confirmatory sensitivity 2.35 ng/mL vs. 1.61 ng/mL. Also, drug tolerance of the method with Roche plates was slightly weaker: 25 ng/mL vs. 6.25 ng/mL of ADA in the presence of 120 µg/mL of CTP13.  However,  the  difference  in  sensitivity  and  drug  tolerance  is  not  considerable  since  the  ADA concentrations in the clinical samples are high. The stability was assessed for 6 freeze/thaw cycles and storage at room temperature for 28 hours.

## NAb detection in human serum

The Applicant modified NAb detection method (see principle of the method in Figure 6.1.1.1) by changing second  capture  and  detection  reagents  as  follows:    TNF α and  Sulfo-tag  CT-P13  for  new  method  and biotinylated  CT-P13  and  Sulfo-tag  TNF α for  old  method.  The  new  method  was  fully  validated  by  PPD Laboratory in healthy and diseased (ulcerative colitis and Crohn's disease) serum, see validation report RMLA10. The screening and titration cut points and sensitivity were evaluated both in healthy and disease serum in acceptable manner. No hook effect nor target/matrix (=hemolysis, lipidemia and healthy/diseased serum) interference was observed. The drug tolerance of NAb-method was 119 ng/mL of NAbs detected in the presence of 40 µg/mL CT-P13. Overall, the method validation followed the current guidance and was considered acceptable.

## The bioanalytical reports of clinical samples

The quantification of CT-P13 plasma concentration was reliable within the given accuracy and precision ranges and the performance of calibration curves was acceptable. The reasons for repeat analysis were presented and the required criteria for incurred method analysis was met. However, it should be noted that ISR analysis of clinical samples is still on-going. At this stage, the Applicant had re-assayed 9.87% of the samples and informs that approximately 10% of the clinical samples will be reflected in the final report. The MAH is requested to provide full ISR data once available.

Detection of ADA and NAb in clinical samples was reliable and the negative and positive controls met the acceptance criteria.

<div style=\"page-break-after: always\"></div>

## Updated comments (RSI AR)

The Applicant has performed matrix interference studies with the serum of ulcerative colitis and Crohn's disease patients. No interference was observed. Issue is considered resolved.

The full ISR data has been provided and is considered acceptable.

## 6.1.2. Population PK modelling

The objectives of population PK and PK-PD modelling and simulation (M&amp;S) analyses were to update the previously developed population PK model of CT-P13, PK-PD model of CDAI scores, and PK-PD model of partial Mayo scores via inclusion of newly available PK and clinical efficacy data and to perform PK and PKPD simulations in support of CT-P13 SC induction posology in patients with CD and UC.

## CHMP comments

The variation of Remsima (aka CT-P13) SC induction posology in patients with CD and UC is supported only by population PK and PK-PD modelling and simulation analyses. There are no observed data with the proposed dosing regimen. The approved posology for Remsima SC in CD and UC is maintenance therapy (120 mg SC Q2W, starting at Week 6) after initial therapy with infliximab IV (5 mg/kg, infused at Week 0 and Week 2).

Considering the scope of the variation and the proposed and approved dosing regimens, the most critical M&amp;S results are related to PK over the first 6 weeks of therapy.

N.B.  The  MAH's  justifications  for  dose  recommendation  for  SC  induction  regimen  in  treatment  of moderately  to  severely  active  Crohn's  disease,  fistulising  active  Crohn's  disease,  and  moderately  to severely active ulcerative colitis, which are presented in Section 3.3 of Module 2.7.2, are based only on population PK modelling and simulations. PK-PD modelling and simulations were also conducted by the MAH; the pharmacometrics assessor's conclusion is that the PK-PD models are not appropriate to support the SC induction posology.

## Updated comments (RSI AR)

The Applicant initially applied for SC induction dosing regimen in treatment of CD and UC, which was based only on population PK(/PD) modelling and simulations. The initial documentation and assessment (CHMP comments) are presented below.

The Applicant withdrew this part of the grouped variation application after the first RSI and corresponding changes are no longer proposed to the PI. Consequently, the related questions are no longer relevant.

A summary of the 12 clinical studies included in the population PK analysis is presented in Table 6. Eight studies (1.4, 1.1, 3.1, 3.4, 1.5, 3.5, 1.6, and 1.9) were included in a prior population PK model, which was assessed in variation II/95.

Table 7. Summary of studies included in the population PK analysis.

| Study               | Study Design                                                                                  | Pop                 | Doses                                                                                      | PKSampling Time Points                                                                                                    |
|---------------------|-----------------------------------------------------------------------------------------------|---------------------|--------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| IV formulation only | IV formulation only                                                                           | IV formulation only | IV formulation only                                                                        | IV formulation only                                                                                                       |
| CT-P13 1.4*         | Randomized, double- blind, 3- arm, parallel-group, single-dose, PK, safety and immunogenicity | HV                  | Test: 5 mg/kg CT-P13 IV Reference: A) 5 mg/kg Remicade (EU) IV B) 5 mg/kg Remicade (US) IV | Pre-dose, EOI, 1 hour after EOI and then at 6, 12, 24, 48 and 72 h after SOI and on Day 8, 15, 29, 43 and 57 (after SOI). |

<div style=\"page-break-after: always\"></div>

| Study                                      | Study Design                                                                                                          | Pop                                        | Doses                                                                                                                                                                                                                                                                                                                              | PKSampling Time Points                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-P13 1.1*                                | Randomized, double-blind, multicenter, multiple-dose, 2- arm, parallel-group, efficacy, PK and safety                 | AS                                         | Test: 5 mg/kg CT-P13 IV at Weeks 0, 2, 6, then every 8 weeks to Week54 Reference: 5 mg/kg Remicade (EU) IV at Weeks 0, 2, 6, then every 8 weeks to Week 54                                                                                                                                                                         | On dosing days samples were collected pre-dose, 15 minutes and 1h after EOI. Between dose 5 and 6 samples were also collected at 3, 8, 24, 192, 360, 696 and 1032 h after SOI.                                                                                                                                                                                                                                                                                                                 |
| CT-P13 3.1*                                | Randomized, double-blind, multicenter, multiple-dose, 2- arm, parallel-group, efficacy, PK, PD and safety             | RA                                         | Test: 3 mg/kg CT-P13 IV at Weeks 0, 2, 6, then every 8 weeks up to Week54(+MTX12.5 to 25 mg/week) Reference: 3 mg/kg Remicade (EU) IV at Weeks 0, 2, 6, then every 8 weeks up to Week54                                                                                                                                            | On dosing days samples were collected pre-dose, 15 minutes and 1h after EOI.                                                                                                                                                                                                                                                                                                                                                                                                                   |
| CT-P13 3.4*                                | Randomized, double-blind, multicenter, 4-arm, parallel- group study comparing efficacy, safety, PK and immunogenicity | CD                                         | 1: CT- P13→ CT-P13 at Week 30 2: CT- P13→ Remicade at Week 30 3: Remicade→ Remicade at Week 30 4: Remicade →CT -P13 at Week 30 CT-P13 and Remicade dose: 5 mg/kg IV at Weeks 0, 2, 6 then                                                                                                                                          | On dosing days samples were collected pre-dose and within 15 minutes after EOI up to dose 5. At Week 22 (dose 5), samples were collected only pre-dose.                                                                                                                                                                                                                                                                                                                                        |
| every 8 weeks up to Week 54 SC formulation | every 8 weeks up to Week 54 SC formulation                                                                            | every 8 weeks up to Week 54 SC formulation | every 8 weeks up to Week 54 SC formulation                                                                                                                                                                                                                                                                                         | every 8 weeks up to Week 54 SC formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| CT-P13 1.5*                                | Open-label, dose escalating, single- dose, safety, and PK                                                             | HV                                         | Test: 120, 180 or 240 mgCT-P13 SC Reference: 3 or 5 mg/kg CT-P13 IV                                                                                                                                                                                                                                                                | SC formulation: Pre-dose, 2, 3, 6, 12, 24, 48, 72 h and 7, 14, 28, 42, 56 and 84 days post-injection. IV formulation: Pre-dose, EOI, 3, 6, 12, 24, 48, 72 h and 7, 14, 28, 42, 56 and 84 days after SOI.                                                                                                                                                                                                                                                                                       |
| CT-P13 3.5                                 | Part 1: Open-label, randomized, multicenter, 4-arm, parallel- group, PK, efficacy and safety                          | RA                                         | Test: Initial 3 mg/kg CT-P13 IV at Weeks 0, 2 then 90, 120 or 180 mg CT-P13 SC at Week 6 and every other week up to Week 54 (+MTX 12.5 to 25 mg/week) Reference: 3 mg/kg CT-P13 IV at Weeks 0, 2, 6, then every 8 weeks up to Week54(+MTX12.5 to 25 mg/week)                                                                       | Cohort 1 (IV): On dosing days samples were collected pre-dose on all dosing days. At Week 22 samples were collected pre- dose, EOI, 3, 8, 24, 48, 96, 168 h and 14, 28 and 42 days after SOI. Cohorts 2-4 (SC): On dosing days samples were collected pre-dose at Weeks 0, 2, 6, 14, 22, 30, 38, 46 and 54. At Week 22, 24, 26 and 28 samples were collected alternatively for group Aand B at 24, 48, 96, 168, 216 and 264 h or at 168 h post injection, and 14 days after Week 28 injection. |
| CT-P13 3.5                                 | Part 2: Double- blind, randomized, multicenter, parallel- group, PK, efficacy, PD and safety                          | RA                                         | Test: Initial 3 mg/kg CT-P13 IV at Weeks 0, 2 then 120 mg CT-P13 SC atWeek6 and every other Weekup toWeek54 (+MTX12.5 to 25 mg/week) Reference: 3 mg/kg CT-P13 IV at Weeks 0, 2, 6, then every 8 weeks and switched to CT-P13 SC 120 mg at Week 30. Further doses with CT-P13 SC were given up to Week 54 (+MTX12.5 to 25 mg/week) | On dosing days samples were collected pre-dose; Group A-D: at Week 22 samples were collected pre-dose, EOA and 1 after EOA for all groups and at 8, 24, 48, 96 h and 7, 9, 14 (pre-dose at Week 24), and 42 (pre-dose at Week 28) days after SOI, and pre-dose at Week 26 and 30. Samples were also obtained pre- dose at Weeks 38, 46 and 54.                                                                                                                                                 |
| CT-P13 1.6                                 | Part 1: Open-label, randomized, multicenter, 4-arm, parallel- group, PK,                                              | CD                                         | Test: Initial 5 mg/kg CT-P13 IV at weeks 0, 2 then 120, 180 or 240 mg CT-P13 SC at Week 6 and every other Week up to Week 54                                                                                                                                                                                                       | Cohort 1 (IV):On dosing days samples were collected pre-dose on all dosing days. At Week 22 samples were also collected EOI, 3, 8, 24, 48, 96, 168 h and 14, 28, 42                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Study                      | Study Design                                                                                 | Pop    | Doses                                                                                                                                                                                                                                                                                                                                                                                        | PKSampling Time Points                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------------------|----------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | efficacy and safety                                                                          |        | Reference: 5 mg/kg CT-P13 IV at Weeks 0, 2, 6, then every 8 weeks up to Week 54                                                                                                                                                                                                                                                                                                              | days after SOI. Cohorts 2-4 (SC):On dosing days samples were collected pre-dose at Weeks 0, 2, 6, 8, 10, 14, 22, 30, 38, 46 and 54. At Week 22, 24, 26 and 28 samples were also collected alternatively for group Aand Bat 24, 48, 96, 168, 216 and 264 h or at 168 h post injection and 14 days after Week 28 injection.                                                                                                                                                                                                                                    |
|                            | Part 2: Open-label, randomized, multicenter, parallel- group, PK, efficacy and safety        | CD, UC | Test: Initial 5 mg/kg CT-P13 IV at Weeks 0, 2 then 120 mg (< 80 kg) or 240 mg (≥ 80 kg) CT -P13 SC at Week 6 and every other Week up to Week 54 Reference: 5 mg/kg CT-P13 IV at Weeks 0, 2, 6, then every 8 weeks up to Week 54                                                                                                                                                              | Arm 1 (IV):On dosing days samples were collected pre-dose on all dosing days. At Week 22 samples were collected pre-dose, EOI, 1, 8, 24, 48, 168 h and 14, 28, 42 days after SOI. Arm 2 (SC):On dosing days samples were collected pre-dose at Weeks 0, 2, 6, 14, 22, 30, 38, 46 and 54. At Week 22 samples were collected pre-dose in all groups. Samples were collected pre-dose, 24, 48, 72, 96, 120, 144, 168, 216, and 264 h at Week 22, 24, 26 and 28 in Group A, B,C and D, respectively. Samples were also obtained pre-dose at Weeks 38, 46 and 54. |
| CT-P13 1.9*                | Open-label, randomized, 2-arm, parallel-group, single-dose, PK and safety                    | HV     | Test: 120 mg CT-P13 SC via auto- injector Reference: 120 mg CT-P13 SC via pre- filled syringe                                                                                                                                                                                                                                                                                                | Pre-dose, 2, 6, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 192, 216, 240, 288, 336, 672, 1008, 1344 and 2016 (Day 84) after the SOI.                                                                                                                                                                                                                                                                                                                                                                                                                      |
| CT-P13 3.7 (up to week 54) | Randomized, placebo controlled, double blind, 2-arm parallel group, PK, efficacy and safety. | UC     | Test: CT-P13 5 mg/kg IV at Weeks 0, 2 and 6, then CT-P13 120 mg SC every other week from Week 10, up to Week 102. CT- P13 240mg SC every other week from Week 22, if loss of response. Reference: CT-P13 5 mg/kg IV at Weeks 0, 2 and 6, then placebo SC every other week from Week 10, up to Week 54. CT-P13 240mg SC every other week from Week 22, if                                     | Pre-dose at Weeks 0, 2, 6, 10, 14, 22 and within 15 minutes after EOI of Week 6. In addition, samples were collected any time between 48 hours and 72 hours after study drug administration of Week 22, any time between 120 hours and 168 hours after study drug administration of Week 22, and pre-dose of Week 24. AdditionalPK sample at time of dose adjustment                                                                                                                                                                                         |
| CT-P13 3.8 (up to week 54) | Randomized, placebo controlled, double blind, 2-arm parallel group, PK, efficacy and safety. | CD     | loss of response. Test: CT-P13 5 mg/kg IV at Weeks 0, 2 and 6, then CT-P13 120 mg SC every other week from Week 10, up to Week 102. CT- P13 240mg SC every other week from Week 22, if loss of response. Reference: CT-P13 5 mg/kg IV at Weeks 0, 2 and 6, then placebo SC every other week from Week 10, up to Week 54. CT-P13 240mg SC every other week from Week 22, if loss of response. | Pre-dose at Weeks 0, 2, 6, 10, 14, 22 and within 15 minutes after EOI of Week 6. In addition, samples were collected any time between 48 hours and 72 hours after study drug administration of Week 22, any time between 120 hours and 168 hours after study drug administration of Week 22, and pre-dose of Week 24. AdditionalPK sample at time of dose adjustment.                                                                                                                                                                                        |
| CT-P13 1.10                | Open-label, randomized, 2-arm, parallel-group, single-dose, PK and safety                    | HV     | CT-P13 120 mg SC or CT-P13 240 mg SC                                                                                                                                                                                                                                                                                                                                                         | Pre-dose, 2, 6, 24,48, 72, 96, 108, 120, 132, 144, 156, 168, 192, 216, 240, 288, 336, 672, 1008, 1344 and 2016 h after the SOI.                                                                                                                                                                                                                                                                                                                                                                                                                              |
| CT-P13 1.11                | Open-label, randomized, 2-arm,                                                               | HV     | Test: CT-P13 SC 120 mg via auto-injector                                                                                                                                                                                                                                                                                                                                                     | Pre-dose, 2, 6, 24,48, 72, 96, 108, 120, 132, 144, 156, 168, 192, 216, 240, 288, 336, 672,                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Study   | Study Design                               | Pop   | Doses                                              | PKSampling Time Points               |
|---------|--------------------------------------------|-------|----------------------------------------------------|--------------------------------------|
|         | parallel-group, single-dose, PK and safety |       | Reference: CT-P13 SC 120 mg via pre-filled syringe | 1008, 1344 and 2016 h after the SOI. |

HV =healthy volunteers; IV =intravenous, MTX =methotrexate; RA =rheumatoid arthritis; SC =subcutaneous;

SOI =start of infusion; UC =ulcerative colitis.

The data from studies CT-P13 3.7 and CT-P13 3.8 (up to 31 st  May 2022) were initially provided for modelling in  a  blinded  form  and  the  treatment  of  each  subject  was  tentatively  identified  from  the  observed concentration versus time data. The blinded data were used to develop the current PK model. Subsequently, complete unblinded data (including treatment assignment) of patients who had completed week 54 were provided; these data superseded the prior blinded data. The developed PK model was re-run with the updated unblinded dataset.

PK Model development : A total of 52113 PK measurements obtained from 3114 subjects were available to educate development of the population PK model. As in prior population PK analyses, a total of 170 measurements from 12 subjects were excluded from the analysis as they were recruited into a fraudulent site (7 subjects from Study CT-P13 1.1) or due to scientific misconduct of the site (5 subjects from Study CT-P13 3.5), leaving 51943 measurements available. A summary of those measurements that were further excluded from the model development process is presented in Table 7. Overall, 43148 PK measurements from 2998 subjects were included in the population PK model development.

Table 8. Summary of Records Excluded from PK Model Development.

| Description                                                                               | Number of Observation Records                                         |   NumberofRemaining Observation Records |
|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------|
| Total Number of Available Observations in the Dataset                                     | Total Number of Available Observations in the Dataset                 |                                   51943 |
| Observation records from non-evaluable subjects (a)                                       | 43                                                                    |                                   51900 |
| Observation records with missing concentration value                                      | 82                                                                    |                                   51818 |
| Observation records missing an associated dosing record                                   | 4                                                                     |                                   51814 |
| Pre-first dose samples                                                                    | 3069                                                                  |                                   48745 |
| Outlier (b)                                                                               | 1                                                                     |                                   48744 |
| Observation records below the limit of quantification                                     | 5023                                                                  |                                   43721 |
| |CWRES| > 6 (c)                                                                           | 191                                                                   |                                   43530 |
| Observation records from subjects with treatment unassigned (CT-P13 3.7 | CT-P13 3.8) (d) | 382                                                                   |                                   43148 |
| Total Number of Available Observations Employed for Model Development                     | Total Number of Available Observations Employed for Model Development |                                   43148 |

## CHMP comments

According to Section 5.1.1.1 of the population PK/PD report, PK measurements from 3114 subjects were available for PK model development and after exclusions PK measurements from 2998 subjects were included in the population PK model development. According to Table 13 and Table 14 of the report (Summary of continuous and categorical covariates, respectively), 3017 subjects were included in the

<div style=\"page-break-after: always\"></div>

population PK model development. Please clarify the discrepancy. In addition, please provide summaries of continuous and categorical covariates for the final unblinded dataset.

## Updated comments (RSI AR)

The Applicant withdrew this part of the grouped variation application after the first RSI and corresponding changes are no longer proposed to the PI. The question above is no longer relevant.

PK  Model  update :  A  total  of  53744  unblinded  PK  measurements  obtained  from  3253  subjects  were available  to  educate  update  of  the  population  PK  model.  As  previously,  a  total  of  170  measurements obtained from 12 subjects were excluded from the analysis as they were recruited into a fraudulent site (7 subjects from Study CT-P13 1.1) or due to scientific misconduct of the site (5 subjects from Study CT-P13 3.5),  leaving  53574  measurements  available.  A  summary  of  those  measurements  that  were  further excluded from the model update is presented in Table 8. Overall, 44779 PK measurements from 3198 subjects were included in the updated population PK analysis.

Table 9. Summary of Records Excluded from PK Model Update.

| Description                                                           | Number of Observation Records                                         |   NumberofRemaining Observation Records |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------|
| Total Number of Available Observations in the Dataset                 | Total Number of Available Observations in the Dataset                 |                                   53574 |
| Observation records from non-evaluable subjects (a)                   | 72                                                                    |                                   53502 |
| Observation records with missing concentration value                  | 82                                                                    |                                   53420 |
| Observation records missing an associated dosing record               | 4                                                                     |                                   53416 |
| Pre-first dose samples                                                | 3179                                                                  |                                   50237 |
| Outlier (b)                                                           | 1                                                                     |                                   50236 |
| Observation records below the limit of quantification                 | 5259                                                                  |                                   44977 |
| |CWRES| > 6 (c)                                                       | 198                                                                   |                                   44779 |
| Total Number of Available Observations Employed for Model Development | Total Number of Available Observations Employed for Model Development |                                   44779 |

NONMEM® version 7.4.3 was used for population PK and PK-PD modelling. Xpose, PsN and R were used for  model  diagnostics,  graphical  analysis,  facilitation  of  NONMEM  tasks,  simulations,  and  statistical summaries. The FOCE-I method was initially used during PK model development. However, the estimation algorithm repeatedly failed to minimize successfully. Subsequently, a stochastic approximation expectationmaximization (SAEM) estimation algorithm to obtain all parameter estimates, followed sequentially by an Importance Sampling to obtain Objective Function and standard errors, was employed for all the population PK analyses.

## 6.1.3. Population PK-PD modelling

The Applicant had previously developed population PK-PD models to describe the effect of CT-P13 on the reduction of CDAI scores (patients with Crohn's disease) and partial Mayo scores (patients with ulcerative colitis). As with population PK analyses, data from studies CT-P13 3.7 and CT-P13 3.8 (up to 31 st  May 2022) were initially provided for modelling in a blinded form and the treatment of each subject was tentatively identified.  The  blinded  data  were  used  to  develop  the  current  PK-PD  models.  Subsequently,  complete unblinded data (including treatment assignment) of patients who had completed week 54 in studies CT-

<div style=\"page-break-after: always\"></div>

P13 3.7 and CT-P13 3.8 were provided; these data superseded the prior blinded data. The developed PKPD models were re-run with the updated unblinded dataset. The first-order conditional estimation method with interaction (FOCE-I) in NONMEM was used for PK-PD analyses.

## PK-PD model for CDAI score (Crohn's disease)

Model development : CDAI scores and PK data were available from studies CT-P13 3.4, CT-P13 1.6 Part 1 and Part 2, and CT-P13 3.8 (see Table 6.1.2.1). A total of 4737 quantifiable CDAI scores from 656 subjects were initially available. Subsequently, 62 observations were excluded from the analysis for study CT-P13 3.8 visits after nominal week 54. In addition, 57 CDAI scores obtained after Week 30 from Study CT-P13 1.6 Part 2 Arm 1, in which subjects switched from IV dosing to SC maintenance dosing at Week 30, were excluded. Then, 29 negative observations were noted. The anticipated lower bound of potential CDAI scores was 0. These anomalous observations were excluded. In addition, 266 CDAI scores were excluded from subjects whose treatment could not be identified because the data from study CT-P13 3.8 were blinded. Following these exclusions, 4323 remaining CDAI scores from 624 subjects were employed during model development: 641 scores from 97 subjects from Study CT-P13 1.6, 1064 scores from 220 subjects from Study CT-P13 3.4 and 2618 scores from 307 subjects Study CT-P13 3.8.

Model update : A total of 5287 quantifiable CDAI scores from 708 subjects were available for model update. Of these CDAI scores, 71 observations were for study 3.8 visits after nominal week 54 and they were excluded. In addition, 57 CDAI scores, obtained after Week 30 from Study CT-P13 1.6 Part 2 Arm 1, were excluded.  Then,  28  negative  observations  were  noted  and  excluded.  Following  these  exclusions,  5131 remaining CDAI scores from 708 subjects were employed during the model update: 641 scores from 97 subjects from Study CT-P13 1.6, 1064 scores from 220 subjects from Study CT-P13 3.4 and 3426 scores from 391 subjects Study CT-P13 3.8.

## PK-PD model for partial Mayo score (ulcerative colitis)

Model development : Partial Mayo score and PK data were available from studies CT-P13 1.6 Part 2 and CT-P13 3.7 (see Table 6.1.2.1). A total of 4476 quantifiable partial Mayo scores from 544 subjects were initially available. Of these, 1 partial Mayo score was excluded because the stop time of the IV was missing. Then, 107 partial Mayo scores were excluded from subjects whose treatment could not be identified because the data from study CT-P13 3.7 were blinded. Subsequently, 103 observations were excluded from the analysis for study 3.7 visits after nominal week 54. In addition, 104 partial Mayo scores, obtained after Week 30 from Study CT-P13 1.6 Part 2 Arm 1, in which subjects switched from IV dosing to SC maintenance dosing at Week 30, were excluded. Finally, 112 partial Mayo scores were excluded from subjects without PK information, resulting in 4049 partial Mayo scores from 516 subjects remaining for model development: 563 scores from 78 subjects from Study CT-P13 1.6 Part 2 and 3486 scores from 438 subjects from Study CT-P13 3.7.

Model update : A total of 5235 quantifiable partial Mayo scores from 616 subjects were available for model update.  Of  these,  1  partial  Mayo  score  was  excluded  because  the  stop  time  of  the  IV  was  missing. Subsequently, 102 observations were excluded from the analysis for study 3.7 visits after nominal week 54. In addition, 104 partial Mayo scores, obtained after Week 30 from Study CT-P13 1.6 Part 2 Arm 1 were excluded, resulting in 5028 partial Mayo scores from 616 subjects remaining for inclusion in the model update: 563 scores from 78 subjects from Study CT-P13 1.6 and 4465 scores from 538 subjects from Study CT-P13 3.7.

<div style=\"page-break-after: always\"></div>

## 6.2. Results

## 6.2.1. Observed pharmacokinetics

Summary statistics  for  observed  infliximab  Ctrough  and  Cmax  in  studies  CT-P13  3.7  and  CT-P13  3.8  are presented in Tables 6.2.1.1 and 6.2.1.2, respectively.

<div style=\"page-break-after: always\"></div>

Table 10. Descriptive Statistics of Serum PK Parameters in Study CT-P13 3.7.

| Parameter Visit Statistics    | Parameter Visit Statistics   | CT-P13 SC 120 mg N=286   | Placebo N=140         |
|-------------------------------|------------------------------|--------------------------|-----------------------|
| C trough ( μ g/mL)            |                              |                          |                       |
| Week 0 (Pre-dose at Week 2)   | n                            | 286                      | 139                   |
| Week 0 (Pre-dose at Week 2)   | Mean ± SD                    | 23.93 ± 11.35            | 23.80 ± 8.24          |
| Week 0 (Pre-dose at Week 2)   | CV%                          | 47.4                     | 34.6                  |
| Week 0 (Pre-dose at Week 2)   | Median (Min, Max)            | 23.95 (0.10, 132.00)     | 23.40 (3.85, 57.20)   |
| Week 2 (Pre-dose at Week 6)   | n                            | 284                      | 140                   |
| Week 2 (Pre-dose at Week 6)   | Mean ± SD                    | 13.87 ± 7.69             | 14.79 ± 12.75         |
| Week 2 (Pre-dose at Week 6)   | CV%                          | 55.4                     | 86.2                  |
| Week 2 (Pre-dose at Week 6)   | Median (Min, Max)            | 14.00 (0.10, 54.40)      | 14.05 (0.10, 115.00)  |
| Week 6 (Pre-dose at Week 10)  | n                            | 282                      | 139                   |
| Week 6 (Pre-dose at Week 10)  | Mean ± SD                    | 13.17 ± 6.72             | 12.88 ± 7.34          |
| Week 6 (Pre-dose at Week 10)  | CV%                          | 51.0                     | 57.0                  |
| Week 6 (Pre-dose at Week 10)  | Median (Min, Max)            | 13.30 (0.10, 36.00)      | 13.00 (0.10, 43.20)   |
| Week 12                       | n                            | 280                      | 138                   |
| (Pre-Dose at Week 14)         | Mean ± SD                    | 15.43 ± 7.16             | 3.15 ± 2.60           |
| (Pre-Dose at Week 14)         | CV%                          | 46.4                     | 82.5                  |
| (Pre-Dose at Week 14)         | Median (Min, Max)            | 15.55 (0.10, 36.10)      | 2.59 (0.10, 12.90)    |
| Week 20 (Pre-Dose at Week 22) | n                            | 267                      | 135                   |
| Week 20 (Pre-Dose at Week 22) | Mean ± SD                    | 14.64 ± 7.83             | 0.21 ± 0.27           |
| Week 20 (Pre-Dose at Week 22) | CV%                          | 53.4                     | 130.4                 |
| Week 20 (Pre-Dose at Week 22) | Median (Min, Max)            | 14.60 (0.10, 42.20)      | 0.10 (0.10, 2.06)     |
| Week 28 (Pre-Dose at Week 30) | n                            | 197                      | 76                    |
| Week 28 (Pre-Dose at Week 30) | Mean ± SD                    | 16.25 ± 9.24             | 0.32 ± 1.77           |
| Week 28 (Pre-Dose at Week 30) | CV%                          | 56.8                     | 546.8                 |
| Week 28 (Pre-Dose at Week 30) | Median (Min, Max)            | 16.10 (0.10, 45.10)      | 0.10 (0.10, 15.50)    |
| Week 36 (Pre-Dose at Week 38) | n                            | 186                      | 66                    |
| Week 36 (Pre-Dose at Week 38) | Mean ± SD                    | 15.13 ± 9.07             | 0.12 ± 0.13           |
| Week 36 (Pre-Dose at Week 38) | CV%                          | 59.9                     | 108.2                 |
| Week 36 (Pre-Dose at Week 38) | Median (Min, Max)            | 14.50 (0.10, 52.80)      | 0.10 (0.10, 1.11)     |
| Week 44 (Pre-Dose at Week 46) | n                            | 181                      | 59                    |
| Week 44 (Pre-Dose at Week 46) | Mean ± SD                    | 15.34 ± 9.12             | 0.27 ± 1.00           |
| Week 44 (Pre-Dose at Week 46) | CV%                          | 59.4                     | 369.8                 |
| Week 44 (Pre-Dose at Week 46) | Median (Min, Max)            | 14.80 (0.10, 52.20)      | 0.10 (0.10, 7.26)     |
| Week 52 (Pre-Dose at Week 54) | n                            | 181                      | 58                    |
| Week 52 (Pre-Dose at Week 54) | Mean ± SD                    | 15.13 ± 9.33             | 0.39 ± 2.14           |
| Week 52 (Pre-Dose at Week 54) | CV%                          | 61.7                     | 546.8                 |
| Week 52 (Pre-Dose at Week 54) | Median (Min, Max)            | 14.20 (0.10, 52.80)      | 0.10 (0.10, 16.40)    |
| C max ( μ g/mL)               |                              |                          |                       |
| Week 6                        | n                            | 281                      | 138                   |
| Week 6                        | Mean ± SD                    | 116.80 ± 44.78           | 117.96 ± 45.93        |
| Week 6                        | CV%                          | 38.3                     | 38.9                  |
| Week 6                        | Median (Min, Max)            | 122.00 (0.10, 286.00)    | 120.00 (1.59, 233.00) |

Note: Patients in 'Placebo' group were administered CT-P13 5 mg/kg IV at Weeks 0, 2, and 6.  All below the LLoQs after the first administration were set to LLoQ. For patients with dose adjustment, data collected before initiation of dose adjustment for both treatment groups were included in this summary.

Cmax , Maximum serum concentration; Ctrough , Trough serum concentration; CV% , Percent coefficient of variation; LLoQ , Lower limit of quantification; Max , Maximum; Min , Minimum; PK , Pharmacokinetics; SC , Subcutaneous; SD , Standard deviation

<div style=\"page-break-after: always\"></div>

Table 11. Descriptive Statistics of Serum PK Parameters in Study CT-P13 3.8.

| Parameter Visit Statistics    | Parameter Visit Statistics   | CT-P13 SC 120 mg (N=226)   | Placebo (N=108)       |
|-------------------------------|------------------------------|----------------------------|-----------------------|
| C trough (µg/mL)              |                              |                            |                       |
| Week 0 (Pre-dose at Week 2)   | n                            | 225                        | 107                   |
| Week 0 (Pre-dose at Week 2)   | Mean ± SD                    | 22.26 ± 8.56               | 21.04 ± 8.60          |
| Week 0 (Pre-dose at Week 2)   | CV%                          | 38.4                       | 40.9                  |
| Week 0 (Pre-dose at Week 2)   | Median (Min, Max)            | 22.40 (0.10, 49.40)        | 21.10 (0.10, 39.40)   |
| Week 2 (Pre-dose at Week 6)   | n                            | 225                        | 105                   |
| Week 2 (Pre-dose at Week 6)   | Mean ± SD                    | 13.22 ± 7.88               | 13.52 ± 7.47          |
| Week 2 (Pre-dose at Week 6)   | CV%                          | 59.6                       | 55.2                  |
| Week 2 (Pre-dose at Week 6)   | Median (Min, Max)            | 12.70 (0.10, 47.80)        | 13.80 (0.10, 27.90)   |
| Week 6 (Pre-dose at Week 10)  | n                            | 222                        | 107                   |
| Week 6 (Pre-dose at Week 10)  | Mean ± SD                    | 12.53 ± 7.34               | 14.14 ± 8.08          |
| Week 6 (Pre-dose at Week 10)  | CV%                          | 58.6                       | 57.1                  |
| Week 6 (Pre-dose at Week 10)  | Median (Min, Max)            | 12.50 (0.10, 41.30)        | 14.30 (0.10, 46.40)   |
| Week 12                       | n                            | 220                        | 106                   |
| (Pre-Dose at Week 14)         | Mean ± SD                    | 14.65 ± 6.93               | 3.92 ± 3.35           |
| (Pre-Dose at Week 14)         | CV%                          | 47.3                       | 85.5                  |
| (Pre-Dose at Week 14)         | Median (Min, Max)            | 14.05 (0.10, 35.20)        | 3.32 (0.10, 15.30)    |
| Week 20 (Pre-Dose at Week 22) | n                            | 215                        | 104                   |
| Week 20 (Pre-Dose at Week 22) | Mean ± SD                    | 14.60 ± 8.90               | 0.49 ± 1.46           |
| Week 20 (Pre-Dose at Week 22) | CV%                          | 60.9                       | 295.0                 |
| Week 20 (Pre-Dose at Week 22) | Median (Min, Max)            | 14.30 (0.10, 52.50)        | 0.10 (0.10, 11.00)    |
| Week 28 (Pre-Dose at Week 30) | n                            | 191                        | 68                    |
| Week 28 (Pre-Dose at Week 30) | Mean ± SD                    | 14.80 ± 9.23               | 0.12 ± 0.09           |
| Week 28 (Pre-Dose at Week 30) | CV%                          | 62.3                       | 77.7                  |
| Week 28 (Pre-Dose at Week 30) | Median (Min, Max)            | 14.80 (0.10, 55.80)        | 0.10 (0.10, 0.81)     |
| Week 36 (Pre-Dose at Week 38) | n                            | 177                        | 58                    |
| Week 36 (Pre-Dose at Week 38) | Mean ± SD                    | 13.35 ± 8.41               | 0.10 ± 0.00           |
| Week 36 (Pre-Dose at Week 38) | CV%                          | 63.0                       | 5.0                   |
| Week 36 (Pre-Dose at Week 38) | Median (Min, Max)            | 13.40 (0.10, 39.40)        | 0.10 (0.10, 0.14)     |
| Week 44 (Pre-Dose at Week 46) | n                            | 168                        | 56                    |
| Week 44 (Pre-Dose at Week 46) | Mean ± SD                    | 13.62 ± 8.14               | 0.13 ± 0.20           |
| Week 44 (Pre-Dose at Week 46) | CV%                          | 59.8                       | 155.6                 |
| Week 44 (Pre-Dose at Week 46) | Median (Min, Max)            | 14.40 (0.10, 29.10)        | 0.10 (0.10, 1.57)     |
| Week 52 (Pre-Dose at Week 54) | n                            | 161                        | 50                    |
| Week 52 (Pre-Dose at Week 54) | Mean ± SD                    | 13.28 ± 8.83               | 0.29 ± 1.15           |
| Week 52 (Pre-Dose at Week 54) | CV%                          | 66.5                       | 404.3                 |
| Week 52 (Pre-Dose at Week 54) | Median (Min, Max)            | 13.30 (0.10, 48.70)        | 0.10 (0.10, 8.22)     |
| C max (µg/mL)                 |                              |                            |                       |
| Week 6                        | n                            | 220                        | 101                   |
| Week 6                        | Mean ± SD                    | 118.33 ± 51.87             | 110.31 ± 50.28        |
| Week 6                        | CV%                          | 43.8                       | 45.6                  |
| Week 6                        | Median (Min, Max)            | 125.00 (0.10, 273.00)      | 121.00 (0.10, 187.00) |

Note: Patients in 'Placebo' group were administered CT-P13 5 mg/kg IV at Weeks 0, 2, and 6. All below the LLoQs after the first administration were set to LLoQ. For patients with dose adjustment, data collected before initiation of dose adjustment for both treatment groups were included in this summary.

Cmax , Maximum serum concentration; Ctrough , Trough serum concentration; CV% , Percent coefficient of variation; LLoQ , Lower limit of quantification; Max , Maximum; Min , Minimum; PK , Pharmacokinetics; SC , Subcutaneous; SD , Standard deviation

<div style=\"page-break-after: always\"></div>

## 6.2.2. Population PK modelling and simulations

## PK model development

As explained above, the population PK model was developed using partially blinded data. A previously developed population PK model developed following IV and SC administration to healthy volunteers and AS, CD, RA and UC patients was employed as the base PK model. It was a 2-compartment IV infusion model  with  linear  first  order  elimination  from  the  central  compartment  (V1),  and  an  additional  depot compartment with a first-order SC absorption rate constant term linked to the central compartment. Both types of clearance (CL and Q) and volume of distribution parameters (V1 and V3) were allometrically scaled as  part  of  the  structural  model  using  estimated  allometric  exponents.  In  addition,  covariate  effects  to describe the emergence of an immunogenic response [NAb status (yes/no) combined with ADA titre values, in a linear form), and its effect on CL, in a time-dependent manner, were included in the base structural model. Immunogenicity (ADA titre and NAb status) was set as 'unknown' for patients in the older studies 1.1, 1.4, 1.5, 1.9, 3.1, and 3.4. The base model employed for subsequent covariate model development (Run5050) is summarized in Table 11.

Table 12. Parameter Estimates: Base model for model development (Run5050)

| Parameter                           | Paraineter Estinate   | Paraineter Estinate   | Paraineter Estinate   |
|-------------------------------------|-----------------------|-----------------------|-----------------------|
|                                     | Typical Value         | RSE (%) (b)           | Shrinkage (%)         |
| F                                   | 0.643                 | n/a                   | n/a                   |
| Ka (hr'l)                           | 0.00808               | n/a                   | n/a                   |
| (/1)  D                             | 0.0109                | n/a                   | n/a                   |
| CLim kng. (L/h)                     | 0.0134                | n/a                   | n/a                   |
| CLNAh+ (proportional)               | 1.25                  | n/a                   | n/a                   |
| ADAslop (linear)                    | 0.00927               | n/a                   | n/a                   |
| Q (L/h)                             | 0.00188               | n/a                   | n/a                   |
| V1 (L)                              | 3.38                  | n/a                   | n/a                   |
| V3 (L)                              | 0.712                 | n/a                   | n/a                   |
| Allometric exponent on CL I Q       | 0.727                 | n/a                   | n/a                   |
| Allometric exponent on V1V3         | 0.605                 | n/a                   | n/a                   |
| IIV CL [VAR (CV%)]                  | 0.137 (38.4)          | n/a                   | 6.3                   |
| IIV V1 [VAR (CV%)]                  | 0.145 (39.5)          | n/a                   | 14.4                  |
| Proportional residual error (SD) () | 0.375                 | n/a                   | n/a                   |

() Additive residual error of the log transformed data. ) RSE unavailable as covariance step was unsuccessful. ADA;lp=slope of linear effect of positive ADA titre on CL; CLimm umkuwn=typical value of clearance in all studies where immunogenicity data is unavailable; CLimm kownneg-typical value of clearance in all studies where immunogenicity data is available; CLNAb+=proportional effect of positive NAb status on clearance; CV=coefficient of vaniation; ETA=individual random effects; F=bioavailability SC administration; IIV=inter-individual variability; KA=absorption rate constant, n/a=not applicable; Q=intercompartmental CL; RSE=relative standard error; SD=standard deviation; V1=central volume of distribution: V3=peripheral volume of distribution; VAR=variance

CV%=V(exp(∞²)-1)*100

The tested pre-specified covariates are summarized in Table 6.2.2.2. Insufficient data were available to explore  the  effects  of  pre-specified  covariates  fecal  calprotectin,  baseline  CDAI  or  partial  Mayo  score, coadministration  of  azathioprine,  6-mercaptopurine  or  'prior  exposure  to  biologic  therapy  and/or  JAK inhibitor' on the PK of CT-P13.

<div style=\"page-break-after: always\"></div>

Table 13. . Tested covariates in population PK model

| Covariate                                                                                                           |                                                   |
|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|
| Age at screening (years)                                                                                            | CL, V1                                            |
| Creatinine clearance (mL/min), according to the Cockroft-Gault formula                                              | CL                                                |
| Albumin at baseline (g/L)                                                                                           | CL, V1                                            |
| CRP at baseline (nmol/L)                                                                                            | CL, V1                                            |
| Gender                                                                                                              | CL, V1                                            |
| Race                                                                                                                | CL, V1                                            |
| Methotrexate coadministration (Binary variable if subject received the co-medication at any point during the study) | CL, V1                                            |
| Disease duration (years)                                                                                            | CL, V1                                            |
| Indication (disease state or healthy volunteer)                                                                     | CL, V1                                            |
| Immunogenic response (NAb statusandADA titer)                                                                       | CL                                                |
| CL =clearance; V1 =central volume of distribution                                                                   | CL =clearance; V1 =central volume of distribution |

Covariates on CL and/or V1 were tested one at the time. A total of four covariates were associated with OFV  decrease  of  more  than  10.84  (corresponding  to  p&lt;0.001;  Chi-Square  test,  df=1)  but  were  not considered by the MAH to have a meaningful impact on the parameter and, hence, were not added to the model (Table 13).

Table 14. Summary of statistically significant rejected covariate models.

| Description                                               |   Δ OFV | MAH's comment                                                                                                                                                                                                                                                      |
|-----------------------------------------------------------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Including CRCL as a covariate of CL                       |   -13.4 | Approximately 5% change in CL at the 5 th and 95 th percentiles of the covariate. Small reduction in OFV. Negligible reduction in ETA variance. Overall, no justification for retention.                                                                           |
| Including Gender as a covariate of CL                     |   -31.1 | Small (~9%) difference in CL across genders (well within 0.8-1.25 boundaries). Moderate reduction in OFV. Negligible reduction in ETA variance. No indication in exploratory plots that the covariate effect is required. Overall, no justification for retention. |
| Including Race (White vs Non- White) as a covariate of CL |   -11.4 | Small (~6%) change in CL between white and non-white. Small reduction in OFV. Negligible reduction in ETA variance. No indication in exploratory plots that the covariate effect is required. Overall, no justification for retention.                             |
| Including Indication as a covariate of V1                 |  -148.3 | Large reduction in OFV. Differences in V1 tend to zero; or are contained within 0.8-1.25 boundaries. Small reduction in ETA variance. No indication in exploratory plots that the covariate effect is required. Overall, no justification for retention.           |

Finally, inclusion of a partial OMEGA block (including covariance between the unexplained IIV of CL and V1) was explored (Run5055) and resulted in a statistically significant reduction in the OFV in comparison with Run5050 ( Δ OFV -115.2). As such, Run5055 was declared the final model from the model development analysis  with  the  partially  blinded  dataset.  Parameter  estimates  and  model diagram  and  equations  are shown in Table 6.2.2.4 and Figure 6.2.2.1, respectively. Bootstrap analysis (1000 replicates) demonstrated close agreement with the parameter estimates from Run5055.

<div style=\"page-break-after: always\"></div>

Table 15. Parameter Estimates: Final PK Model from Model Development Analysis (Run5055)

| Parameter                           | Paraineter Estimate   | Paraineter Estimate   | Paraineter Estimate   |
|-------------------------------------|-----------------------|-----------------------|-----------------------|
|                                     | Typical Value         | RSE (%) (b)           | Shrinkage (%)         |
| F                                   | 0.644                 | 1.8                   | n/a                   |
| KA (h-t)                            | 0.00823               | 2.2                   | n/a                   |
| CLimm mlm (L/h)                     | 0.0113                | 1.2                   | n/a                   |
| CLimlmmg. (L/h)                     | 0.0132                | 2.6                   | n/a                   |
| CLNAb+ (proportional)               | 1.24                  | 3.0                   | n/a                   |
| ADA;op (linear)                     | 0.00872               | 35                    | n/a                   |
| Q (L/h)                             | 0.00187               | 11                    | n/a                   |
| V1 (L)                              | 3.36                  | 1.2                   | n/a                   |
| V3 (L)                              | 0.714                 | 4.6                   | n/a                   |
| Allometric exponent on CL | Q       | 0.729                 | 5.4                   | n/a                   |
| Allometric exponent on V1V3         | 0.628                 | 6.9                   | n/a                   |
| IIV CL [VAR (CV%)]                  | 0.149 (40.1)          | 5.0                   | 6                     |
| CL~V1 [Covariance (Correlation)]    | 0.0603 (0.397)        | 12                    | n/a                   |
| IIV V1 [VAR (CV%)]                  | 0.155 (40.9)          | 9.9                   | 14.3                  |
| Proportional residual error (SD) () | 0.374                 | 1.4                   | n/a                   |

CV% = V(exp(∞²)-1)*100

( Additive residual error of the log transformed data. 0) RSE of the IIV parameters relate to the untransformed parameter.

ADAslop=slope of linear effect of positive ADA titre on CL; CLumm umhuowntypical value of clearance in all studies where immunogemicity data is unavailable; CLimm knownmegtypical value of clearance in all studies where immunogenicity data is available; CLNAb+=proportional effect of positive NAb status on clearance;

CV=coefficient of variation; ETA=individual random effects; F=bioavailability SC administration;

IIV=inter-individual variability; KA=absorption rate constant; n/a=not applicable; Q=intercompartmental CL; RSE=relative standard error; SD=standard deviation; V1=central volume of distribution: V3=peripheral volume of distribution; VAR=variance

<div style=\"page-break-after: always\"></div>

Figure 2. . Final Population PK Model Obtained from Model Development (Run5055): Equations and Model Diagram

<!-- image -->

In studies CT-P13 1.6, CT-P13 1.10, CT-P13 1.11, CT-P13 3.5, CT-P13 3.7 &amp; CT-P13 3.8,

<!-- formula-not-decoded -->

In studies CT-P13 1.1, CT-P13 1.4, CT-P13 1.5, CT-P13 1.9, CT-P13 3.1 &amp; CT-P13 3.4,

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

Intravenous ( IV ) dose administration occurred directly into compartment 1. Subcutaneous ( SC ) dose administration occurred into depot compartment 0. Subcutaneous doses were subject to reduction commensurate with the absolute bioavailability of the SC dose ( F ). A(0) : Amount of drug in the SC depot compartment; A(1) : amount of drug in the central compartment; A(2) : Amount of drug in the peripheral compartment; KA : absorption rate constant; V1 : Central volume of distribution; V3 : peripheral volume of distribution; CL : clearance; Q : intercompartmental clearance; WGTBL : body weight at baseline; θ CL,exp : allometric scaling constant applied to clearance parameters; θ V,exp : allometric scaling constant applied to volume parameters; θ ADA.slope : slope of linear effect of positive ADA titre on CL; (1+ θ ADA.slope ∙ADA\\_titre) assumes a value of 1 when ADA\\_titre ≤ 0; θ CL,NAb+ : proportional effect of positive NAb status on CL; NAb\\_FLAG: binary (1/0) variable which assumes the value of 1 only when NAb status is positive (once positive, always positive); ( θ NAb+ ∙NAb\\_FLAG) assumes a value of 1 when NAb\\_FLAG = 0; t : time; η x : Inter-individual random effects for the x th  parameter.

The sensitivity of the parameter estimates to the CWRES outliers was assessed via re-execution of the population PK model but with the re-inclusion of all CWRES outliers (Run5056. In general, all structural model  parameters  were  subject  to  minimal  change  upon  inclusion  of  the  CWRES  outliers  (change  in parameter values &lt; 15 %), except for ADAslope which was subject to a moderate change of approximately 29% (consistent with the moderate RSE of ADAslope [~35%] in Run5055). As anticipated, the stochastic elements of the final model (IIV in V1 and the residual error component) also increased upon re-inclusion of the CWRES defined outliers. Overall, the model was not found to be sensitive to the re-inclusion of the CWRES outliers, giving confidence in the robustness of the parameter estimates obtained from the model.

<div style=\"page-break-after: always\"></div>

Goodness of fit (GOF) plots for Run5055, stratified by route of administration, are shown in Figures 3 and 4. The significant inflection in the CWRES versus Time Since Last Dose (Figure 4) was explained to be an artefact of very small number of datapoints. Specifically, a single iteration of |CWRES| &gt; 6 exclusion was performed.  Subsequently,  following  these  exclusions,  a  very  small  number  (~  0.3  %)  of  additional datapoints were then associated with |CWRES| &gt; 6, resulting in artefactual deviations in the CWRES plots. Selected prediction corrected VPC (pcVPC) plots are shown in Figure 5 and Figure 6. The MAH concluded that overall, the model description of the observed data was adequate.

Figure 3. Observed Versus Predicted Goodness of Fit Diagnostic Plots (Run5055)

<!-- image -->

Observeddataarepresented asblackopensymbols.Thelineofunity（theexpectation)isshowninthesolid black line. The blue line and associated grey area reflect a generalized additive smooth of the data, and associated 95%confidenceinterval.

SC=subcutaneous;IV=intravenous

<div style=\"page-break-after: always\"></div>

Figure 4. CWRES Goodness of Fit Diagnostic Plots (Run5055)

<!-- image -->

Observed data arepresented asblack open symbols. The horizontalline with y intercept =O (the expectation) is shown as a solid black line. The blue line and associated grey area reflect a generalized additive smooth of the data,andassociated95%confidenceinterval.

CWRES=conditionalweightedresidual;SC=subcutaneous;IV=intravenous

<div style=\"page-break-after: always\"></div>

Figure 5. pcVPC Plot: Time after Last Dose (Run5055; Individual Observations Omitted for Clarity)

<!-- image -->

The median prediction corrected observed concentrations are represented by a grey solid line. The 5th and 95th percentiles of the prediction corrected observed concentrations are represented by dashed grey lines. The dark blue shaded area represents the 95% confidence intervals of the median of the prediction corrected model predicted data. The light blue shaded areas represents the 95% confidence intervals of the 5th and 95th percentiles of the prediction corrected model predicted data. The pcVPC was obtained from the model including the residual error term. Negative prediction corrected concentrations, associated with the 5th percentile of the last bin, were not able to be fepresented on this logarithmic presentation.

<div style=\"page-break-after: always\"></div>

Figure 6. pcVPC Plot: Time after First Dose, Stratified by Route of Administration (Run5055; Individual Observations Omitted for Clarity)

<!-- image -->

The median prediction corrected observed concentrations are represented by a grey solid line. The 5th and 95th percentiles of the prediction corrected observed concentrations are represented by dashed grey lines. The dark blue shaded area represents the 95% confidence intervals of the median of the prediction corrected model predicted data. The light blue shaded areas represents the 95% confidence intervals of the 5th and 95th percentiles of the prediction corrected model predicted data. The pcVPC was obtained from the model including the residual error term.

IV=intravenous; SC=subcutaneous

## PK model update

As explained above, the population PK model that was developed using partially blinded data was updated when unblinded data were available. The PK model described in Figure 6.2.2.1 was re-run with the updated unblinded dataset (Run5102). Parameter estimates obtained from Run5102 (Table 6.2.2.5) were estimated with moderate to high precision and were in close agreement with the parameter estimates from Run5055). Bootstrap analysis demonstrated close agreement with the parameter estimates from Run5102.

<div style=\"page-break-after: always\"></div>

Table 16. Parameter Estimates: Updated Final Population PK Model (Run5102)

| Parameter                           | Paraneter Estimate   | Paraneter Estimate   | Paraneter Estimate   |
|-------------------------------------|----------------------|----------------------|----------------------|
|                                     | Typical Value        | RSE (%) (b)          | Shrinkage (%)        |
| F                                   | 0.667                | 1.3                  | n/a                  |
| KA (h-)                             | 0.00820              | 1.9                  | n/a                  |
| CLim  (L/h)                         | 0.0117               | 1.1                  | n/a                  |
| CLimm kwmng. (L/h)                  | 0.0134               | 0.98                 | n/a                  |
| CLNAb+ (proportional)               | 1.24                 | 2.5                  | n/a                  |
| ADA:lp (linear)                     | 0.00814              | 24                   | n/a                  |
| Q(L/h)                              | 0.00212              | 9.7                  | n/a                  |
| V1 (L)                              | 3.41                 | 0.92                 | n/a                  |
| V3 (L)                              | 0.737                | 4.4                  | n/a                  |
| Allometric exponent on CL | Q       | 0.730                | 5.2                  | n/a                  |
| Allometric exponent on V1V3         | 0.642                | 6.4                  | n/a                  |
| IIV CL [VAR (CV%)]                  | 0.154 (40.8)         | 4.3                  | 5.5                  |
| CL~V1 [Covariance (Correlation)]    | 0.0761 (0.494)       | 9.1                  | n/a                  |
| IIV V1 [VAR (CV%)]                  | 0.154 (40.8)         | 7.4                  | 14.7                 |
| Proportional residual error (SD) () | 0.375                | 1.3                  | n/a                  |

CV% = V(exp(∞²)-1)*100

ADA;lp=slope of linear effect of positive ADA titer on CL; CLimm ukwwtypical value of clearance in all studies where immunogenicity data is unavailable; CLimm knowmmg-typical value of clearance in all studies where immmogenicity data is available; CLNAb+=proportional effect of positive NAb status on clearance;

CV=coefficient of variation; ETA=individual random effects; F=bioavailability SC administration;

IIV=inter-individual variability; K;=absorption rate constant; n/a=not applicable; Q=intercompartmental CL;

RSE=relative standard error; SD=standard deviation; V1=central vohume of distribution: V3=peripheral volume of distribution; VAR=vaniance

GOF plots and selected pcVPC plots for Run5102 are shown in Figure 7 to Figure 10. The MAH concluded that overall, the model description of the observed data was adequate.

<div style=\"page-break-after: always\"></div>

Figure 7. Observed Versus Predicted Goodness of Fit Plots (Run5102)

<!-- image -->

Observed data are presented as black open symbols. The line of unity (the expectation) is shown in the solid black line. The blue line and associated grey area reflect a generalized additive smooth of the data, and associated 95% confidence interval

SO=subcutaneous;IV=intravenous

<div style=\"page-break-after: always\"></div>

Figure 8. CWRES Goodness of Fit Diagnostic Plots (Run5102)

<!-- image -->

Observed data are presented as black open symbols. The horizontal line with y intercept = O (the expectation)is shown as a solid black line. The blue line and associated grey area reflect a generalized additive smooth of the data, and associated 95% confidence interval.

CWRES=conditional weighted residual; SC=subcutaneous;IV=intravenous

<div style=\"page-break-after: always\"></div>

Figure 9. pcVPC Plot: Time after Last Dose (Run5102; Individual Observations Omitted for Clarity)

<!-- image -->

The median prediction corrected observed concentrations are represented by a grey solid line. The 5h and 95h percentiles of the prediction corrected observed concentrations are represented by dashed grey lines. The dark. blue shaded area represents the 95% confidence intervals of the median of the prediction corrected model predicted data. The light blue shaded areas represents the 95% confidence intervals of the 5 and 95 percentiles of the prediction corrected model predicted data. The pcVPC was obtained from the updated model, including the residual error term. Negative prediction corrected concentrations, associated with the 5* percentile of the last bin, were not able to be represented on this logarithmic presentation.

<div style=\"page-break-after: always\"></div>

Figure 10. pcVPC Plot: Time after First Dose, Stratified by Route of Administration (Run5102; Individual Observations Omitted for Clarity)

<!-- image -->

The median prediction corrected observed concentrations are represented by a grey solid line. The 5 and 95h percentiles of the prediction corrected observed concentrations are represented by dashed grey lines. The dark blue shaded area represents the 95% confidence intervals of the median of the prediction corrected model predicted data. The light blue shaded areas represents the 95% confidence intervals of the 5 and 95th percentiles of the prediction corrected model predicted data. The pc VPC was obtained from the updated model, including the residual eiror temm.

IV=intravenous; SC=subcutaneous

## CHMP comments

ADA and NAb were shown to have relevant impact on CL in prior population PK models for CT-P13 and this  was  confirmed  in  current  analyses.  MAH's  bioanalytical  methods  for  ADA  and  NAb  have  been amended over time and it is appropriate to set the ADA/NAb status for subjects in old studies as unknown. The MAH should confirm that immunogenicity samples (ADA and NAb) from studies CT-P13 1.6, 1.10, 1.11, 3.5, 3.7, and 3.8 were measured using the same methods, or if the methods were not the same that the results of the methods are comparable.

Pre-selected potential covariates were formally tested in univariate analyses during model development. Some of them were statistically significant (based on Δ OFV) but not included in the PK model. MAH's justifications  for  not  including  these  covariates  in  the  model  are  considered  acceptable.  The  partial OMEGA block  (CL  -  V1)  was  added  to  the  model  only  after  testing  the  covariates.  Generally,  it  is preferable to (re)test covariates after the structural model is finalised. However, it is considered unlikely that this would affect the conclusions of covariate testing and the issue is not pursued.

<div style=\"page-break-after: always\"></div>

As noted by the MAH, there is marked deviation in CWRES vs time since last dose plot driven by few data points after &gt; 10 weeks since last dose. A proportional plus additive residual error model might describe the data better than the proportional model.

The current population PK model appears to have significant model misspecifications according to the pcVPCs stratified by route of administration (Figure 6.2.2.9) which should be addressed by the Applicant. The below issues are considered critical in case a modelling and simulation approach is utilized to support a dosing regimen that has not been tested in clinical studies.

- a) The median profile for the observed data is not adequately described by the model predictions. Infliximab may have non-linear PK with respect to dose/concentration and/or time (i.e., targetmediated  drug  disposition)  which  is  not  accounted  for.  The  Applicant  should  address  this limitation by exploring model(s) for non-linear PK and update the final model as appropriate.
- b) The variability (i.e., outer percentiles) is over-predicted for the IV route and under-predicted for the SC route, which is problematic considering that the Applicant propose to use the PK model to support a new SC induction regimen. Potential differences in variability between IV and SC is an important aspect for assessing the new SC induction regimen. The SC dosing may display higher variability than IV due to variability in rate and extent of absorption from the subcutaneous injection site. The Applicant should resolve the misspecification in variability, for example by exploring  inter-individual  variability  in  KA  and/or  F  and  update  the  SC  induction  regimen predictions.

The provided pcVPC plots are not sufficient. The scope of the current variation application is to add induction regimen for Remsima SC in treatment of CD and UC, i.e., the MAH proposes a new dosing regimen for the first 6 weeks of treatment. Additional pcVPC plots should be provided for the final PK model with x-axis showing 6 weeks after the first dose and 6 weeks after the last dose. Binning should be  selected  carefully  to  avoid  artefacts  in  the  plots.  Plots  should  be  stratified  at  least  by  route  of administration,  SC  dose,  immunogenic  response  (unknown/no/yes),  and  separate  plots  should  be provided for patients with CD and UC (stratified by route of administration).

## Updated comments (RSI AR)

The Applicant withdrew this part of the grouped variation application after the first RSI and corresponding changes are no longer proposed to the PI. The questions above are no longer relevant.

## PK simulations

The aim of these simulations was to support the development of an SC induction posology in patients with UC and CD (i.e., SC dosing over the first 6 weeks of treatment).

Simulations were performed in virtual subjects of body weights 50 to 150 kg (in stratifications of 10 kg). A virtual  population  of  1000  patients  was  obtained  from  a  uniform  distribution  in  each  of  the  ten  10  kg categories, ranging from 50 kg to 150 kg (total number of virtual patients = 10,000). Simulations were performed  using  the  final  population  PK  model  assuming  perfect  adherence  to  the  planned  treatment regimen, for 14 weeks. All simulations included unexplained IIV but did not include parameter uncertainty or residual error.

Exposure to CT-P13 following administration of four Test SC induction regimens (Scenarios A - D; Table 6.2.2.6) was compared to that obtained following administration of the approved IV treatment regimen (Reference; Table 16). The analyses were stratified to explore the effect of body weight (in 10 kg strata) on exposure to CT-P13.

<div style=\"page-break-after: always\"></div>

Table 17. Simulated Test and Reference Dose Regimen Scenarios

| Scenario   | Week       | Week   | Week       | Week   | Week   | Week       | Week       |
|------------|------------|--------|------------|--------|--------|------------|------------|
| Scenario   | 0          | 1      | 2          | 3      | 4      | 6          | 8 to 14    |
| Scenario A | 240 mg     | -      | 240 mg     | -      | 240 mg | 120 mg     | 120 mg Q2W |
| Scenario B | 240 mg     | 120 mg | 120 mg     | 120 mg | 120 mg | 120 mg     | 120 mg Q2W |
| Scenario C | 240 mg     | 240 mg | 240 mg     | 120 mg | 120 mg | 120 mg     | 120 mg Q2W |
| Scenario D | 240 mg     | 240 mg | 240 mg     | 240 mg | 120 mg | 120 mg     | 120 mg Q2W |
| Reference  | 5 mg/kg IV | -      | 5 mg/kg IV | -      | -      | 5 mg/kg IV | -          |

Simulated concentration-time curves of CT-P13 for Weeks 0-6 following administration of each of the Test Scenarios, superimposed on the Reference, are presented in Figure 6.2.2.10 (weight range 50 to 150 kg, N=10,000). Summary statistics for PK parameters AUC, Ctrough, and Cmax for the Test Scenarios and the Reference are presented in Tables 6.2.2.7 to 6.2.2.9.

During the induction phase (weeks 0-6 of treatment) the median total exposure, as evidenced by AUCW0-2 and AUCW0-6, was significantly lower for each Test Scenario than for the IV Reference treatment (Table 17, Table 18). As shown in Figure 11, the median CT-P13 concentration for Scenario B was consistently lower compared with that of the Reference Regimen over the first four weeks of treatment, although the Ctrough levels at Week 2 and 4 are rather close to concentrations of the Reference regimen.

<div style=\"page-break-after: always\"></div>

Figure 11. Simulated Median (5 th  - 95 th  percentile) CT-P13 Concentration vs Time Profiles Following Administration of Test Scenario A, B, C, D and Reference Regimen for Weeks 0-6.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 18. . Summary Statistics [Median (5 th  - 95 th  Percentile)] of AUC Following Administration of Test Scenario and Reference Regimens.

| Treatment Regimen   | AUC ( μ g.h/mL)       | AUC ( μ g.h/mL)       | AUC ( μ g.h/mL)        | AUC ( μ g.h/mL)       |
|---------------------|-----------------------|-----------------------|------------------------|-----------------------|
| Treatment Regimen   | AUC W0-2              | AUC W0-6              | AUC W0-14              | AUC W6-14             |
| Scenario A          | 4840 (2610 - 9280)    | 21000 (11000 - 40900) | 42900 (21200 - 87200)  | 21800 (10100 - 47300) |
| Scenario B          | 5930 (3200 - 11400)   | 22200 (11500 - 43200) | 43000 (21200 - 87400)  | 20700 (9600 - 44900)  |
| Scenario C          | 7030 (3790 - 13600)   | 30000 (15600 - 58500) | 52300 (25700 - 107000) | 22000 (9930 - 49500)  |
| Scenario D          | 7030 (3790 - 13600)   | 33300 (17300 - 64900) | 56900 (28000 - 117000) | 23300 (10400 - 53200) |
| Reference           | 19200 (11100 - 33600) | 50700 (27700 - 91100) | 83100 (43400 - 158000) | 32200 (15700 - 68000) |

Scenario A : CT-P13 240 mg SC at Weeks 0, 2, and 4, followed by CT-P13 120 mg SC Q2W from Week 6

Scenario B : CT-P13 240 mg SC at Week 0, followed by CT-P13 120 mg SC at Weeks 1, 2 and 3, followed by CT-P13 120 mg SC Q2W from Week 4

Scenario C : CT-P13 240 mg SC at Weeks 0, 1, and 2, followed by CT-P13 120 mg SC at Week 3, followed by CT-P13 120 mg SC Q2W from Week 4

Scenario D : CT-P13 240 mg SC at Weeks 0, 1, 2 and 3, followed by CT-P13 120 mg SC Q2W from Week 4 Reference : CT-P13 5 mg/kg IV at Weeks 0, 2 and 6.

AUC : area under the concentration versus time curve; AUCW0-2 : AUC between Weeks 0 and 2; AUCW0-6 : AUC between Weeks 0 and 6; AUCW0-14 : AUC between Weeks 0 and 14; AUCW6-14 : AUC between Weeks 6 and 14.

IV : intravenous; SC : subcutaneous; Q2W : dosing every two weeks

Table 19. Summary Statistics [Median (5 th  - 95 th  Percentile)] of Ctrough Following Administration of Test Scenario and Reference Regimens.

| Treatment Regimen   | C trough ( μ g/mL)   | C trough ( μ g/mL)   | C trough ( μ g/mL)   | C trough ( μ g/mL)   | C trough ( μ g/mL)   | C trough ( μ g/mL)   |
|---------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Treatment Regimen   | C trough,W1          | C trough,W2          | C trough,W3          | C trough,W4          | C trough,W6          | C trough,W14         |
| Scenario A          | n/a                  | 12.9 (6.45 - 25.1)   | n/a                  | 17.5 (8.01 - 35.9)   | 19.2 (8.42 - 41.0)   | 10.7 (4.38 - 25.4)   |
| Scenario B          | 17.7 (9.51 - 34.0)   | 21.7 (11.5 - 41.7)   | 23.1 (11.7 - 45.2)   | 23.8 (11.8 - 47.4)   | 15.7 (6.35 - 35.4)   | 10.6 (4.36 - 25.1)   |
| Scenario C          | 17.7 (9.51 - 34.0)   | 30.6 (16.4 - 58.4)   | 38.3 (20.0 - 74.2)   | 34.1 (16.6 - 68.1)   | 19.4 (7.41 - 45.0)   | 10.8 (4.38 - 26.0)   |
| Scenario D          | 17.7 (9.51 - 34.0)   | 30.6 (16.4 - 58.4)   | 38.3 (20.0 - 74.2)   | 43.0 (21.9 - 84.4)   | 23.2 (8.97 - 53.2)   | 10.9 (4.40 - 26.6)   |
| Reference           | n/a                  | 25.5 (10.1 - 49.5)   | n/a                  | n/a                  | 11.5 (2.54 - 35.8)   | 2.00 (0.303 - 11.2)  |

Scenario A : CT-P13 240 mg SC at Weeks 0, 2, and 4, followed by CT-P13 120 mg SC Q2W from Week 6

Scenario B : CT-P13 240 mg SC at Week 0, followed by CT-P13 120 mg SC at Weeks 1, 2 and 3, followed by CT-P13 120 mg SC Q2W from Week 4

Scenario C : CT-P13 240 mg SC at Weeks 0, 1, and 2, followed by CT-P13 120 mg SC at Week 3, followed by CT-P13 120 mg SC Q2W from Week 4

Scenario D : CT-P13 240 mg SC at Weeks 0, 1, 2 and 3, followed by CT-P13 120 mg SC Q2W from Week 4 Reference : CT-P13 5 mg/kg IV at Weeks 0, 2 and 6.

Ctrough : trough concentration; Ctrough,W1 : Ctrough at Week 1; Ctrough,W2 : Ctrough at Week 2; Ctrough,W3 : Ctrough at Week 3; Ctrough,W4 :

Ctrough at Week 4; Ctrough,W6 : Ctrough at Week 6; Ctrough,W14 : Ctrough at Week 14.

IV : intravenous; SC : subcutaneous; Q2W : dosing every two weeks; n/a : not applicable

<div style=\"page-break-after: always\"></div>

Table 20. Summary Statistics [Median (5 th  - 95 th  Percentile)] of Cmax Following Administration of Test Scenario and Reference Regimens.

| Treatment Regimen   | C max ( μ g/mL)    | C max ( μ g/mL)    | C max ( μ g/mL)    | C max ( μ g/mL)    | C max ( μ g/mL)    | C max ( μ g/mL)    | C max ( μ g/mL)    |
|---------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| Treatment Regimen   | C max,W0           | C max,W1           | C max,W2           | C max,W3           | C max,W4           | C max,W6           | C max,W12          |
| Scenario A          | 18.0 (9.70 - 34.5) | n/a                | 26.4 (14.2 - 50.7) | n/a                | 29.7 (15.5 - 58.0) | 22.8 (11.1 - 46.9) | 16.7 (8.19 - 35.0) |
| Scenario B          | 17.8 (9.62 - 34.4) | 23.6 (12.8 - 45.2) | 25.7 (13.6 - 49.5) | 26.6 (13.8 - 52.0) | 27.3 (13.9 - 54.0) | 20.1 (9.62 - 42.0) | 16.6 (8.15 - 34.6) |
| Scenario C          | 17.8 (9.62 - 34.4) | 32.0 (17.3 - 61.4) | 41.4 (22.3 - 79.3) | 40.4 (21.0 - 78.4) | 35.9 (17.8 - 71.5) | 23.0 (10.5 - 49.7) | 16.8 (8.21 - 35.8) |
| Scenario D          | 17.8 (9.62 - 34.4) | 32.0 (17.3 - 61.4) | 41.4 (22.3 - 79.3) | 47.3 (24.9 - 91.6) | 44.5 (22.7 - 87.5) | 26.0 (11.7 - 56.9) | 17.0 (8.25 - 36.7) |
| Reference           | 113 (58.8 - 223)   | n/a                | 140 (78.6 - 258)   | n/a                | n/a                | 127 (71.0 - 241)   | n/a                |

Scenario A : CT-P13 240 mg SC at Weeks 0, 2, and 4, followed by CT-P13 120 mg SC Q2W from Week 6

Scenario B : CT-P13 240 mg SC at Week 0, followed by CT-P13 120 mg SC at Weeks 1, 2 and 3, followed by CT-P13 120 mg SC Q2W from Week 4

Scenario C : CT-P13 240 mg SC at Weeks 0, 1, and 2, followed by CT-P13 120 mg SC at Week 3, followed by CT-P13 120 mg SC Q2W from Week 4

Scenario D : CT-P13 240 mg SC at Weeks 0, 1, 2 and 3, followed by CT-P13 120 mg SC Q2W from Week 4 Reference : CT-P13 5 mg/kg IV at Weeks 0, 2 and 6.

Cmax : maximum concentration; Cmax,W0 : Cmax after dosing at Week 0; Cmax,W1 : Cmax after dosing at Week 1; Cmax,W2 : Cmax after dosing at Week 2; Cmax,W3 : Cmax after dosing at Week 3; Cmax,W4 : Cmax after dosing at Week 4; Cmax,W 6: Cmax after dosing at Week 6; Cmax,W12 : Cmax after dosing at Week 12.

IV : intravenous; SC : subcutaneous; Q2W : dosing every two weeks; n/a : not applicable

Figure 12. Median (5 th -95 th  Percentiles) Simulated CT-P13 Concentration vs Time Profiles Following Administration of Test Scenario B and Reference Regimens (Week 0-6), by 10 kg Weight Strata.

<!-- image -->

Test Scenario B (orange) : CT-P13 240 mg SC at Week 0, followed by CT-P13 120 mg SC at Weeks 1, 2 and 3, followed by CT-P13 120 mg SC Q2W from Week 4.

Reference (green) : CT-P13 5 mg/kg IV at Weeks 0, 2 and 6.

IV : intravenous; SC : subcutaneous; Q2W : dosing every two weeks.

<div style=\"page-break-after: always\"></div>

Table 21. Geometric Mean Ratio and Associated 90% Confidence Intervals of AUC: Scenario B Versus Reference Regimen, by Body Weight.

| Weight Strata              | Geometric Mean Ratio and Associated 90% Confidence Interval   | Geometric Mean Ratio and Associated 90% Confidence Interval   | Geometric Mean Ratio and Associated 90% Confidence Interval   | Geometric Mean Ratio and Associated 90% Confidence Interval   |
|----------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                            | AUC W0-2                                                      | AUC W0-6                                                      | AUC W0-14                                                     | AUC W6-14                                                     |
| All Patients (50 - 150 kg) | 0.311 (0.308 - 0.314)                                         | 0.439 (0.435 - 0.443)                                         | 0.518 (0.513 - 0.523)                                         | 0.641 (0.634 - 0.648)                                         |
| Patients (50 - 60 kg)      | 0.538 (0.525 - 0.551)                                         | 0.761 (0.742 - 0.780)                                         | 0.898 (0.874 - 0.923)                                         | 1.11 (1.08 - 1.15)                                            |
| Patients (60 - 70 kg)      | 0.456 (0.445 - 0.467)                                         | 0.645 (0.629 - 0.661)                                         | 0.761 (0.740 - 0.782)                                         | 0.940 (0.911 - 0.970)                                         |
| Patients (70 - 80 kg)      | 0.395 (0.386 - 0.405)                                         | 0.559 (0.545 - 0.573)                                         | 0.659 (0.642 - 0.678)                                         | 0.816 (0.791 - 0.842)                                         |
| Patients (80 - 90 kg)      | 0.349 (0.341 - 0.358)                                         | 0.494 (0.481 - 0.506)                                         | 0.582 (0.566 - 0.598)                                         | 0.720 (0.698 - 0.743)                                         |
| Patients (90 - 100 kg)     | 0.313 (0.306 - 0.320)                                         | 0.442 (0.431 - 0.453)                                         | 0.521 (0.507 - 0.536)                                         | 0.645 (0.625 - 0.666)                                         |
| Patients (100 - 110 kg)    | 0.283 (0.277 - 0.290)                                         | 0.400 (0.390 - 0.410)                                         | 0.472 (0.459 - 0.485)                                         | 0.584 (0.566 - 0.603)                                         |
| Patients (110 - 120 kg)    | 0.259 (0.253 - 0.265)                                         | 0.366 (0.356 - 0.375)                                         | 0.431 (0.419 - 0.443)                                         | 0.534 (0.517 - 0.551)                                         |
| Patients (120 - 130 kg)    | 0.239 (0.233 - 0.244)                                         | 0.336 (0.328 - 0.345)                                         | 0.396 (0.386 - 0.408)                                         | 0.491 (0.476 - 0.507)                                         |
| Patients (130 - 140 kg)    | 0.221 (0.216 - 0.226)                                         | 0.312 (0.304 - 0.320)                                         | 0.367 (0.357 - 0.377)                                         | 0.455 (0.441 - 0.470)                                         |
| Patients (140 - 150 kg)    | 0.206 (0.201 - 0.211)                                         | 0.290 (0.283 - 0.298)                                         | 0.342 (0.333 - 0.352)                                         | 0.424 (0.411 - 0.437)                                         |

Scenario B : CT-P13 240 mg SC at Week 0, followed by CT-P13 120 mg SC at Weeks 1, 2 and 3, followed by CT-P13 120 mg SC Q2W from Week 4. Reference : CT-P13 5 mg/kg IV at Weeks 0, 2 and 6.

AUC : area under the concentration versus time curve; AUCW0-2 : AUC between Weeks 0 and 2; AUCW0-6 : AUC between Weeks 0 and 6; AUCW0-14 : AUC between Weeks 0 and 14; AUCW6-14 : AUC between Weeks 6 and 14.

IV : intravenous; SC : subcutaneous; Q2W : dosing every two weeks

Table 22. Geometric Mean Ratio and Associated 90% Confidence Intervals of Ctrough: Scenario B Versus Reference Regimen, by Body Weight.

| Weight Strata              | Geometric Mean Ratio and Associated 90% Confidence Interval   | Geometric Mean Ratio and Associated 90% Confidence Interval   | Geometric Mean Ratio and Associated 90% Confidence Interval   |
|----------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                            | C trough,W2                                                   | C trough,W6                                                   | C trough,W14                                                  |
| All Patients (50 - 150 kg) | 0.898 (0.889 - 0.907)                                         | 1.43 (1.41 - 1.46)                                            | 5.41 (5.30 - 5.51)                                            |
| Patients (50 - 60 kg)      | 1.51 (1.47 - 1.56)                                            | 2.40 (2.29 - 2.52)                                            | 8.52 (8.01 - 9.06)                                            |
| Patients (60 - 70 kg)      | 1.29 (1.25 - 1.33)                                            | 2.05 (1.96 - 2.15)                                            | 7.42 (6.97 - 7.89)                                            |
| Patients (70 - 80 kg)      | 1.13 (1.09 - 1.16)                                            | 1.80 (1.71 - 1.89)                                            | 6.59 (6.20 - 7.01)                                            |
| Patients (80 - 90 kg)      | 1.00 (0.973 - 1.03)                                           | 1.60 (1.52 - 1.68)                                            | 5.95 (5.59 - 6.33)                                            |
| Patients (90 - 100 kg)     | 0.903 (0.876 - 0.931)                                         | 1.44 (1.37 - 1.51)                                            | 5.43 (5.10 - 5.78)                                            |
| Patients (100 - 110 kg)    | 0.822 (0.797 - 0.848)                                         | 1.31 (1.25 - 1.38)                                            | 5.00 (4.70 - 5.33)                                            |
| Patients (110 - 120 kg)    | 0.755 (0.732 - 0.778)                                         | 1.21 (1.15 - 1.27)                                            | 4.65 (4.36 - 4.95)                                            |
| Patients (120 - 130 kg)    | 0.698 (0.676 - 0.720)                                         | 1.12 (1.06 - 1.18)                                            | 4.34 (4.08 - 4.62)                                            |
| Patients (130 - 140 kg)    | 0.649 (0.629 - 0.670)                                         | 1.04 (0.991 - 1.09)                                           | 4.08 (3.83 - 4.34)                                            |
| Patients (140 - 150 kg)    | 0.607 (0.588 - 0.626)                                         | 0.975 (0.928 - 1.02)                                          | 3.85 (3.61 - 4.10)                                            |

Scenario B : CT-P13 240 mg SC at Week 0, followed by CT-P13 120 mg SC at Weeks 1, 2 and 3, followed by CT-P13 120 mg SC Q2W from Week 4. Reference : CT-P13 5 mg/kg IV at Weeks 0, 2 and 6.

Ctrough : trough concentration; Ctrough,W2 : Ctrough at Week 2; Ctrough,W6 : Ctrough at Week 6; Ctrough,W14 : Ctrough at Week 14. IV : intravenous; SC : subcutaneous; Q2W : dosing every two weeks

<div style=\"page-break-after: always\"></div>

Table 23. Geometric Mean Ratio and Associated 90% Confidence Intervals of Cmax: Scenario B Versus Reference Regimen, by Body Weight.

| Weight Strata              | Geometric Mean Ratio and Associated 90% Confidence Interval   | Geometric Mean Ratio and Associated 90% Confidence Interval   | Geometric Mean Ratio and Associated 90% Confidence Interval   |
|----------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                            | C max,W0                                                      | C max,W2                                                      | C max,W6/12                                                   |
| All Patients (50 - 150 kg) | 0.158 (0.156 - 0.159)                                         | 0.183 (0.181 - 0.185)                                         | 0.130 (0.128 - 0.131)                                         |
| Patients (50 - 60 kg)      | 0.279 (0.272 - 0.287)                                         | 0.325 (0.317 - 0.334)                                         | 0.233 (0.227 - 0.240)                                         |
| Patients (60 - 70 kg)      | 0.235 (0.229 - 0.241)                                         | 0.273 (0.267 - 0.280)                                         | 0.195 (0.190 - 0.201)                                         |
| Patients (70 - 80 kg)      | 0.202 (0.197 - 0.208)                                         | 0.236 (0.230 - 0.242)                                         | 0.168 (0.163 - 0.172)                                         |
| Patients (80 - 90 kg)      | 0.178 (0.173 - 0.183)                                         | 0.207 (0.202 - 0.212)                                         | 0.147 (0.143 - 0.151)                                         |
| Patients (90 - 100 kg)     | 0.159 (0.154 - 0.163)                                         | 0.184 (0.180 - 0.189)                                         | 0.131 (0.127 - 0.134)                                         |
| Patients (100 - 110 kg)    | 0.143 (0.139 - 0.147)                                         | 0.166 (0.162 - 0.170)                                         | 0.117 (0.114 - 0.121)                                         |
| Patients (110 - 120 kg)    | 0.130 (0.127 - 0.134)                                         | 0.151 (0.147 - 0.155)                                         | 0.107 (0.104 - 0.109)                                         |
| Patients (120 - 130 kg)    | 0.119 (0.116 - 0.123)                                         | 0.139 (0.135 - 0.142)                                         | 0.0975 (0.0949 - 0.100)                                       |
| Patients (130 - 140 kg)    | 0.110 (0.107 - 0.113)                                         | 0.128 (0.125 - 0.131)                                         | 0.0898 (0.0874 - 0.0923)                                      |
| Patients (140 - 150 kg)    | 0.102 (0.0997 - 0.105)                                        | 0.119 (0.116 - 0.122)                                         | 0.0833 (0.0811 - 0.0856)                                      |

Scenario B : CT-P13 240 mg SC at Week 0, followed by CT-P13 120 mg SC at Weeks 1, 2 and 3, followed by CT-P13 120 mg SC Q2W from Week 4. Reference : CT-P13 5 mg/kg IV at Weeks 0, 2 and 6.

Cmax : maximum concentration; Cmax,W0 : Cmax after dosing at Week 0; Cmax,W2 : Cmax after dosing at Week 2;

Cmax,W6/12 : Cmax after dosing at Week 6 (Reference regimen) in comparison with Week 12 (Test Regimen);

IV : intravenous; SC : subcutaneous; Q2W : dosing every two weeks

## CHMP comments

SC maintenance dosing (120 mg Q2W) starting at Week 6 is already approved for Remsima in treatment of CD and UC. Therefore, the main issue for the current variation application is whether the MAH can exclude the possibility of worsening of efficacy and safety during the first 6 weeks of treatment with the proposed SC induction dosing regimen (Scenario B: 240 mg SC at Week 0, followed by 120 mg SC at Weeks 1, 2 and 3, followed by 120 mg SC Q2W from Week 4).

As shown in Figure 6.2.2.10 and Tables 6.2.2.7 to 6.2.2.9, the simulated concentration-time profiles and exposure parameters (Ctrough, AUC, Cmax) over the first 6 weeks are markedly different between the approved IV dosing regimen and the proposed SC dosing regimen (Scenario B: 240 mg SC at Week 0, followed by 120 mg SC at Weeks 1, 2 and 3, followed by 120 mg SC Q2W from Week 4).

In addition, if there is a change from body weight based IV dose (5 mg/kg) to a flat SC dose (120 mg) patients with high body weight will have lower exposure than patients with low body weight (see Figure 6.2.2.11 and Tables 6.2.2.10 to 6.2.2.12).

## 6.2.3. Population PK-PD modelling and simulations

## PK-PD model for CDAI score

The observed CDAI scores, stratified by maintenance dosing regimen, are presented in Figure 14. The induction regimen (initial 2 or 3 doses) was administered intravenously in each study. The mean CDAI score decreased rapidly over the first 1 to 2 months (i.e., during the induction treatment with IV infliximab) and tended to plateau at approximately Week 14. However, individual CDAI scores fluctuated markedly over time (Figure 15).

<div style=\"page-break-after: always\"></div>

Figure 13. . Observed Individual and Mean (± SD) CDAI Score Versus Nominal Time Since First Dose Profiles, Stratified by Maintenance Dosing Regimen.

<!-- image -->

'Treatment' indicates the maintenance dosing regimen administered after the IV induction phase. Observed data are presented as a jitter plot for ease of visualization.

CDAI =Crohn's disease activity index; IV =intravenous (Q8W maintenance regimen);

SC =subcutaneous (Q2W maintenance regimen).

<div style=\"page-break-after: always\"></div>

Figure 14. Individual CDAI Scores Versus Actual Time Since First Dose Profiles (All Patients)

<!-- image -->

Model development : The CDAI score was characterized by an indirect response model wherein a probit transformed inhibitory Imax model was used to describe the suppressive effect of CT-P13 on the zeroorder rate constant of CDAI score production (kin) while the baseline CDAI score was defined as the ratio of kin to the first order rate constant of the amelioration of CDAI score (kout). Model structure is shown in Figure 15.

Figure 15. Equations and Model Diagram: Population PK-PD Model of CDAI Score.

<!-- image -->

<!-- formula-not-decoded -->

kn: apparent zero-order rate constant for production of the response; kour: first-order rate constant for the amelioration of response; Imax: maximum fractional ability of the drug to affect baseline CDAI score; ICs: drug concentration that produces 50% of maximum inhibition; Imaxi: Imx Value in the i individual; Φ: cumulative distribution fuction of the normal distribution; 0, typical value of the x parameter,  Inter-individual random effects for the x parameter.

<div style=\"page-break-after: always\"></div>

Initially, the model was applied to untransformed CDAI score data (Run6001). Data driven optimization of the random effects model was performed, resulting in model which included IIV for baseline CDAI score and in the probit transformed Imax, with correlation between the unexplained IIV in baseline CDAI score and Imax implemented via an off-diagonal element of the OMEGA block and an additive residual error (Run6011). However, VPCs indicated  that  the  candidate  model  Run6011  was  not  acceptable  (overprediction  of  the central tendency and underprediction at the 5 th  percentile).

The untransformed CDAI score data had a positively skewed distribution (Figure 16 A). To improve the description of the CDAI score data, the data was transformed. Initially, a log(x+1) transformation was applied, but problems with skewness (Figure 16 B) and model performance were not solved. Subsequently, the square root transformation of the CDAI score was used, which pushed the data closer to a normal distribution (Figure 6.2.3.4, C), albeit with a zero value inflation. The model was applied to the square root transformed CDAI score data with exclusion of the zero values (2.3 % of the data) and the random effects structure was optimized, resulting in a model with IIV in baseline CDAI score and Imax, and an additive residual  error  on  square  root  transformed  data  (Run6028).  Finally,  zero  values  were  reincluded  in  the analysis (Run6044), without affecting the estimated parameter values. Run6044 was declared the final base model. Parameter estimates obtained from Run6044 are summarized in Table 23. Bootstrap estimates were in close agreement with the final model parameter estimates.

<div style=\"page-break-after: always\"></div>

Figure 16. A Distribution of untransformed and transformed CDAI Scores.

<!-- image -->

A: untransformed data; B: log(x+1) transformed data; C: square root transformed data.

<div style=\"page-break-after: always\"></div>

Table 24. Parameter Estimates: Population PK-PD model of CDAI Score (Run6044)

| Parameter                                              | Parameter Value   |   RSE () (%) | Shrinkage (%)   | Parameter Value (Original Scale)   |
|--------------------------------------------------------|-------------------|--------------|-----------------|------------------------------------|
| Baseline CDAI Score                                    | 5.69              |        0.175 | n/a             | 296                                |
| kout (/hr)                                             | -6.30             |        1.5   | n/a             | 0.00184                            |
| Imas                                                   | 0.351             |        8.68  | n/a             | 0.637                              |
| ICso (μg/mL)                                           | -50.5             |       12.2   | n/a             | 1.17 x 10-22                       |
| Additive Residual Error (SD)                           | -2.74             |        2.15  | n/a             | 7.50                               |
| Unexplained IIV in Baseline CDAI Score [VAR (CV%)] (@) | 0.0106 (10.3)     |       44.6   | 60.4            | n/a                                |
| Unexplained IIV in Imax [VAR (CV%)] °)                 | 0.468 (68.4)      |        8.27  | 14              | n/a                                |

Parameter units are those associated with the original scale.

CV=coefficient of variation; IIV=interindividual variability; ICso=drug concentration that produces 50% of maximum inhibition; Imax=maximum fractional ability of the drug to affect baseline CDAI score; kou=firstorder rate constant for the amelioration of response; n/a=not applicable; RSE=relative standard error, SD=standard deviation; VAR=variance

Exploratory graphical analysis suggested no strong relationship between the potential covariates (baseline CDAI score, age, albumin, disease duration, gender, race, and concomitant treatment with 6-mercaptopurine, azathioprine, and methotrexate) and IIV in Imax. Subsequent model based assessment of selected covariate effects was conducted (Table 24); none of the covariates were considered clinically relevant by the MAH. Hence, Run6044 was retained as the final PK-PD model for CDAI score.

Table 25. . Summary of tested covariate models: PK-PD model for CDAI score.

| Description                                    |   Δ OFV | MAH's comment                                                                                                                                                                                                                                                                                           |
|------------------------------------------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| univariate analysis: Age on I max              | -13.609 | Moderate impact at high values of AGE (not really observed in the exploratory plot); limited (2.33%) reduction in variance of ETA; moderatedOFV ~ -13.6; Percentage change in within bioequivalence boundaries. => rejected                                                                             |
| univariate analysis: Baseline albumin on I max | -12.751 | Moderate impact at high values of baseline albumin (not really observed in the exploratory plot); limited (2.16%) reduction in variance of ETA; moderatedOFV ~ -12.8; Percentage change in within bioequivalence boundaries. => rejected                                                                |
| univariate analysis: Baseline CDAI on I max    | -41.106 | Moderate impact at high values of baseline CDAI (not really observed in the exploratory plot); 4.46% reduction in variance of ETA; large dOFV ~ -41.1; Percentage change outside bioequivalence boundaries. Variability of BASE moved to covariate effect on Imax, using the baseline twice => rejected |
| univariate analysis: Race on I max             |  -0.183 | No statistically significant dOFV => rejected                                                                                                                                                                                                                                                           |

## Model update

As explained above, the population PK-PD model for CDAI score that was developed using blinded data from study CT-P13 3.8 was updated when unblinded data were available (Run6145). Parameter estimates obtained from Run6145 are summarized in Table 25. GOF plots and pcVPC plots for Run6145 are shown in Figure 17 and Figure 18, respectively.

<div style=\"page-break-after: always\"></div>

Table 26. Parameter Estimates: Final Updated PK-PD Model for CDAI Score (Run6145).

| Parameter                                             | Parameter Value   |   RSE () (%) | Shrinkage (%)   | Parameter Value (Original Scale)   |
|-------------------------------------------------------|-------------------|--------------|-----------------|------------------------------------|
| log.(Baseline CDAI Score)                             | 5.70              |        0.164 | n/a             | 297                                |
| log。(kou) (/h)                                        | -6.24             |        1.5   | n/a             | 0.00195                            |
| Im.x (e)                                              | 0.376             |        7.51  | n/a             | 0.647                              |
| log.(ICso) (μg/mL)                                    | -49.2             |        9.16  | n/a             | 4.29 x 10-22                       |
| Additive Residual Error (SD)                          | -2.79             |        1.91  | n/a             | 7.77                               |
| Unexplained IIV in Baseline CDAI Score [VAR (CV%)] @) | 0.0104 (10.2)     |       46.2   | 61.2            | n/a                                |
| Unexplained IIV in Imx [VAR (CV%)] 0)                 | 0.472 (68.7)      |        7.72  | 13.4            | n/a                                |

Parameter units are those associated with the oniginal scale.

( CV% = V(exp(o²)-1)*100 () CV% = Vo2*100 (Φ RSE of the IIV parameters relate to the untransformed parameter  probit transfomed

CV=coefficient of variation; IIV=interindividual variability; ICso=drug concentration that produces 50% of maximum imhibition; Imax=maximum factional ability of the dnug to affect baseline CDAI score; kour=firstorder rate constant for the amelioration of response; n/a=not applicable; RSE=relative standard error, SD=standard deviation; VAR=variance

<div style=\"page-break-after: always\"></div>

Figure 17. Goodness of Fit Diagnostic Plots: Final Updated PK-PD Model for CDAI Score (Run6145)

<!-- image -->

Observed data are presented as black open symbols.The line of unity (the expectation) is shown in the solid black line. The blue line and associated grey area reflect a generalized additive smooth of the data, and associated 95% confidence interval.

Note:Plots of CWRESare presented from run6146,which is equivalent to run6145(see Table 70 for further details)

<div style=\"page-break-after: always\"></div>

Figure 18. Prediction Corrected VPC, Stratified by Maintenance Dose Route of Administration (Square Root Transformed): Final Updated PK-PD Model for CDAI Score (Run6145).

<!-- image -->

Time (Veeks)

Time (Weeks)

Route reflects the maintenance dosing regimens, administered after the IV loading dose phase applicable in each study.

Prediction corrected square root observed CDAI scores are represented by open grey symbols. The median percentiles of the prediction corrected square root observed CDAI scores are represented by dashed grey lines. The dark blue shaded area represents the 95% confidence intervals of the median of the prediction corrected model predicted data. The light blue shaded areas represent the 95% confidence intervals of the 5th and 95th percentiles of the prediction corrected model predicted data. The pcVPC was obtained from the updated model. including the additive residual error, resulting in the negative scores retumed by the simulation.

IV=intravenous; SC=subcutaneous

## CHMP comments

The estimate of IC50 of the final PK-PD model for CDAI score is extremely small (4.29 x 10 -22 μ g/mL; Run6145). For comparison, the lower limit of quantitation (LLOQ) is 1 x 10 -1 μ g/mL. It is not plausible that 50% of the drug effect is achieved with concentration markedly below the LLOQ. Therefore, the PK-PD model developed by the MAH is not considered adequate to predict the efficacy of an untested infliximab dose regimen in treatment of Crohn's disease. Other aspects of the PK-PD model have not been assessed in detail due to an unplausible crucial parameter estimate.

The Applicant conducted PK-PD simulations for dose regimen Scenarios A, B, C, D, and Reference (see Population PK modelling and simulations for description of the regimens) to support the SC induction posology in patients with Crohn's disease. In brief, the PK-PD model indicated that the clinical response is identical for each Test Scenario and the Reference regimen. This is not surprising because the PK-PD model predicts  that  maximal  response  will  be  achieved  if  CTP13 concentration is  ≥  LLOQ. Detailed results of the simulations are omitted because the PK-PD model is not considered adequate.

<div style=\"page-break-after: always\"></div>

## PK-PD model for partial Mayo score

The observed partial Mayo scores, stratified by maintenance dosing regimen, are presented in Figure 19. The induction regimen (initial 2 or 3 doses) was administered intravenously in each study. The mean partial Mayo score decreased rapidly over the first 1 to 2 months (i.e., during the induction treatment with IV infliximab)  and  tended  to  plateau  at  approximately  Week  14.  However,  individual  partial  Mayo  scores fluctuated markedly over time (Figure 20).

Figure 19. Observed Individual and Mean (± SD) Partial Mayo Score Versus Nominal Time Since First Dose Profiles, Stratified by Maintenance Dosing Regimen.

<!-- image -->

End-of-Study visit data excluded from plot. Observed data (independent variable = planned time) are presented as a jitter plot for ease of visualization.

Treatment reflects the maintenance dosing regimens, administered after the IV loading dose phase applicable in each study.

IV=intravenous; SC=subcutaneous; Q2W=dosing every 2 weeks; Q8W=dosing every 8 weeks

<div style=\"page-break-after: always\"></div>

Figure 20. Individual Partial Mayo Scores Versus Actual Time Since First Dose Profiles (All Patients)

<!-- image -->

Model development : The partial Mayo score was characterized by an indirect response model wherein a probit transformed inhibitory Imax model was used to describe the suppressive effect of CT-P13 on the zeroorder rate constant of partial Mayo score production (kin) while the baseline partial Mayo score was defined as the ratio of kin to the first order rate constant of the amelioration of partial Mayo score (kout). Model structure is shown in Figure 21.

Figure 21. . Equations and Model Diagram: Population PK-PD Model of Partial Mayo Score.

<!-- image -->

Initially,  the  model  was  applied  to  untransformed  partial  Mayo  score  data  (Run7001).  Data  driven optimization of the random effects model was performed, resulting finally in a model with IIV for kout and for the probit transformed Imax (Run7007). However, VPCs indicated that the candidate model Run7007 was not acceptable (underprediction of the central tendency of the CT-P13 effect and overprediction of the CT -P13 effect at the lower scores).

<div style=\"page-break-after: always\"></div>

The untransformed partial Mayo data had a positively skewed distribution (Figure 6.2.3.10, A). To improve the description of the partial Mayo score data, the data was transformed. Initially, a log(x+1) transformation was applied, reducing the skewness of the distribution (Figure 6.2.3.10, B). The model was applied to the log(x+1) transformed data and the random effects model was reoptimized, resulting in a model with IIV for  kout  and  the  probit  transformed  Imax,  and  an  additive  residual  error  on  log(x+1)  transformed  data (Run7012).

An  alternative  transformation  of  the  partial  Mayo  score  data  was  also  evaluated:  the  square  root transformation, which pushed the data even closer to a normal distribution (Figure 22, C). The random effects structure was reevaluated with square root transformed data, and found again to be optimal with IIV in kout and Imax (Run7024). VPC plots indicated that overall, the first 22 weeks of score data were better described  by  based  on  the  log(x+1)  transformation  (Run7012)  than  based  on  the  square  root transformation (Run7024), and Run7012 was declared the final base model. Parameter estimates obtained from Run7012 are summarized in Table 26. Successful minimization was obtained in 83.3% of bootstrap analyses, demonstrating moderate robustness of the model. The median of the bootstrap estimates was in close  agreement  with  the  final  parameter  estimates  from  the  final  model  obtained  during  the  model development analyses (Run7012). The range in the confidence intervals for each parameter was broadly proportional to the RSE of the parameter obtained from the final model, except for the IC50 for which a wide range in CI was returned from the bootstrap analyses.

Figure 22. Distribution of Untransformed and Transformed Partial Mayo Score.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 27. Parameter Estimates: Population PK-PD model of Partial Mayo Score (Run7012)

| Parameter                               | Parameter Value   |   RSE (c) (%) | Shrinkage (%)   | Parameter Value (Original Scale)   |
|-----------------------------------------|-------------------|---------------|-----------------|------------------------------------|
| Baseline partial Mayo Score             | 0.606             |         5.05  | n/a             | 5.82                               |
| kout (/h)                               | -6.04             |         1.46  | n/a             | 0.00238                            |
| Imas                                    | 0.578             |         8.67  | n/a             | 0.718                              |
| ICs0 (μg/mL)                            | -41.9             |         0.655 | n/a             | 6.17 x 10-19                       |
| Additive Residual Error (SD)            | 0.392             |         2.43  | n/a             | 0.48                               |
| Unexplained IIV in kout [VAR (CV%)] (@) | 0.961 (127)       |        12.2   | 35.8            | n/a                                |
| Unexplained IIV in Imax. [VAR (CV%)] () | 0.954 (97.7)      |        10     | 17.3            | n/a                                |

CV=coefficient of variation; IIV=interindividual variability; ICso=drug concentration that produces 50% of maximum inhibition; Imax=maximum fractional ability of the drug to affect baseline partial Mayo score; kout=first-order rate constant for the amelioration of response; n/a=not applicable; RSE=relative standard error; SD=standard deviation; VAR=variance

Exploratory graphical analysis suggested no strong relationship between the potential covariates (baseline partial Mayo score, age, albumin, disease duration, gender, race, and concomitant treatment with 6-mercaptopurine, azathioprine, and methotrexate) and IIV in Imax. Subsequent model based assessment of selected covariate effects was conducted (Table 27); none of the covariates were considered clinically relevant by the MAH. Hence, Run7012 was retained as the final PK-PD model for partial Mayo score.

Table 28. Summary of tested covariate models: PK-PD model for Partial Mayo score.

| Description                                                       |   Δ OFV | MAH's comment                                                                                                                                                                                                         |
|-------------------------------------------------------------------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| univariate analysis: Baseline albumin on I max                    | -13.532 | Minimization terminated, no covariance step; reduction in variance of ETA Imax 4.02%; Statistically significant dOFV ~ -13.5; impact at high and low values of BALB (13.9 and -11.67) within bioeq. bounds=> rejected |
| univariate analysis: Baseline albumin on I max ; changed initials | -13.518 | Minimization terminated no covariance step; rounding issues could not be resolved                                                                                                                                     |
| univariate analysis: Baseline partial Mayo Score on I max         | -21.159 | reduction in variance of ETA Imax 4.87%; statistically significant dOFV ~ -21.2.; Impact at high and low values of BMAYO (18.1 and 9.6%) within bioeq. Bounds => rejected                                             |

## Model update

As explained above, the population PK-PD model for partial Mayo score that was developed using blinded data from study CT-P13 3.7 was updated with unblinded data (Run7114). Parameter estimates obtained from Run7114 are summarized in Table 28. GOF plots and pcVPC plots for Run7114 are shown in Figure 23 and Figure 24, respectively.

<div style=\"page-break-after: always\"></div>

Table 29. Parameter Estimates: Final Updated PK-PD Model for Partial Mayo Score (Run7114).

<!-- image -->

| Parameter                              | Parameter Value   |   RSE () (%) | Shrinkage (%)   | Parameter Value (Original Scale)   |
|----------------------------------------|-------------------|--------------|-----------------|------------------------------------|
| Baseline partial Mayo Score (@)        | 0.598             |        0.202 | n/a             | 5.81                               |
| 1oge(kout) (/h)                        | -6.11             |        0.204 | n/a             | 0.00222                            |
| Imax (e)                               | 0.628             |        0.2   | n/a             | 0.735                              |
| 1oge(ICso) (μg/mL)                     | -40.0             |        0.785 | n/a             | 4.08 x 10-18                       |
| Additive Residual Error (SD)           | 0.388             |        0.206 | n/a             | 0.475                              |
| Unexplained IIV in kout [VAR (CV%)] () | 0.911 (122)       |       15.8   | 34              | n/a                                |
| Unexplained IIV in Imax [VAR (CV%)] () | 0.871 (93.3)      |        0.545 | 16.1            | n/a                                |

Parameter units are those associated with the original scale.

CV=coefficient of variation; IIV=interindividual variability; ICso=drug concentration that produces 50% of maximum inhibition; Imax=maximum fractional ability of the drug to affect baseline partial Mayo score; kour=first-order rate constant for the amelioration of response; n/a=not applicable; RSE=relative standard error; SD=standard deviation; VAR=variance

- () CV% = V(exp(o²)-1)*100 () CV% = √o²*100 ( RSE of the IIV parameters relate to the untransformed parameter (@ transformed to limit to the plausible range of baseline values (as described in Section 3.3.4.1.4) probit transformed

<div style=\"page-break-after: always\"></div>

Figure 23. Goodness of Fit Diagnostic Plots: Final Updated PK-PD Model for Partial Mayo Score (Run7114)

<!-- image -->

Observed data are presented as black open symbols. The line of unity (the expectation) is shown in the solid black line.The blue line and associated grey area reflect a generalized additive smooth of the data, and associated 95% confidence interval.

<div style=\"page-break-after: always\"></div>

Figure 24. Prediction Corrected VPC, Stratified by Maintenance Dose Route of Administration [log(x+1) transformed]: Final Updated PK-PD Model for Partial Mayo Score (Run7114).

<!-- image -->

## Route reflects the maintenance dosing regimens, administered after the IV loading dose phase applicable in each study.

Prediction corrected log(x+1) observed partial Mayo scores are represented by open grey symbols. The median prediction corrected log(x+1) observed partiai Mayo scores afe fepresented by a grey solid line. The 5t and 95th percentiles of the prediction log(x+1) corrected partial Mayo scores are represented by dashed grey lines. The dark blue shaded area represents the 95% confidence intervals of the median of the prediction corrected model predicted data. The light blue shaded areas represent the 95% confidence intervals of the 5th and 95\" percentiles of the prediction corrected model predicted data. The pcVPC was obtained from the updated model, including the additive residual error, resulting in the negative scores returned by the simulation. The baseline observations are overlapping, as there was no IIV included on baseline score the prediction correction for these points does not result in a scatter like seen for the other later points.

IV=intravenous; SC=subcutaneous

## CHMP comments

The estimate of IC50 of the final PK-PD model for partial Mayo score is extremely small (4.08 x 10 -18 μ g/mL; Run7114). For comparison, the lower limit of quantitation (LLOQ) is 1 x 10 -1 μ g/mL. It is not plausible that 50% of the drug effect is achieved with concentration markedly below the LLOQ. Therefore, the PK-PD model developed by the MAH is not considered adequate to predict the efficacy of an untested infliximab dose regimen in treatment of ulcerative colitis. Other aspects of the PK-PD model have not been assessed in detail due to an unplausible crucial parameter estimate.

The  MAH  conducted  PK-PD  simulations  for  dose  regimen  Scenarios  A,  B,  C,  D,  and  Reference  (see Population  PK  modelling  and  simulations  above  for  description  of  the  regimens)  to  support  the  SC induction posology in patients with ulcerative colitis. In brief, the PK-PD model indicated that the clinical response is identical for each Test Scenario and the Reference regimen. This is not surprising because the PK-PD model predicts that maximal response will be achieved if CTP13 concentration is ≥ LLOQ. Detailed results of the simulations are omitted because the PK-PD model is not considered adequate.

<div style=\"page-break-after: always\"></div>

## 6.3. Discussion

## Bioanalytical methods

In general, the validation of modified ADA- and Nab-analytical methods was appropriate. Some concerns were  raised  concerning  matrix  interference  (ADA-method),  drug  tolerance  (NAb-method)  and  lacking bioanalytical data. The Applicant provided the requested data, and the questions were resolved.

## Population PK modelling

The population PK model is based on a large number of observations following IV and SC administration, including dense PK sampling following single SC doses in healthy subjects. In the RSI, questions were raised on population PK model dataset, bioanalytical methods, and potential misspecifications. The population PK model  was  used  to  support  the  SC  induction  dosing  regimen  for  CD  and  UC  indications,  which  was withdrawn.  Consequently,  the  related  RSI  questions  are  no  longer  relevant  and  the  Applicant  did  not response to them.

## Population PK-PD modelling

The MAH developed two PK-PD models: one for CDAI score and the other for partial Mayo score. The models had similar structure, CDAI (or partial Mayo) score was characterized by an indirect response model wherein a probit transformed inhibitory Imax model was used to describe the suppressive effect of CT-P13 on the zero-order rate constant of CDAI (or partial Mayo) score production. The models were only informed by studies which used IV induction regimen during the first 6 to 10 weeks. In both PK-PD models the estimate of IC50 was extremely small, several fold lower than the LLOQ of serum infliximab concentration. The IC50 estimates are not plausible. The consequence of extremely small IC50 estimates is that the PK-PD models will predict that any detectable concentration will be sufficient to elicit near-maximal response, and thus the models will predict no efficacy differences between SC and IV induction regimens. The submitted PKPD models for CDAI score and partial Mayo score were not considered adequate to support the variation application to add SC induction posology in treatment of CD and UC.

## Type II variation to add subcutaneous induction regimen in treatment of CD and UC

It needs to be mentioned that SC loading regimen for weeks 0 to 6 in treatment of RA was approved for Remsima based on modelling and simulation in procedure EMEA/H/C/002576/II/0095. The PK-PD model for  DAS28  score  supporting  that  application  was  not  considered  appropriate  for  simulations  (refer  to assessment reports of procedure II/0095). However, PK simulations indicated sufficient exposure with the SC loading regimen. An important basis for approval of procedure II/0095 was that in treatment of RA the most  important  time  to  assess  the  efficacy  is relatively  late,  at  3  to  6  months  of  treatment (CPMP/EWP/556/95 Rev. 2, and differences in exposure during the first 6 weeks of treatment were not expected to have clinically relevant effect on efficacy at months 3 to 6. In contrast, the EMA Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis (CHMP/EWP/18463/2006 Rev.1) and the EMA Guideline on the development of new medicinal products for the treatment of Crohn's Disease (CPMP/EWP/2284/99 Rev. 2) state that for the demonstration of short-term efficacy ('induction of remission'), significant effects would need to be demonstrated at early time point (usually 6-12 weeks).

SC maintenance regimen (120 mg Q2W starting at Week 6) in treatment of CD and UC in adult patients is already approved for Remsima. Therefore, the main issue for this variation application is whether the MAH can exclude the possibility of worsening of efficacy and safety during the first 6 weeks of treatment with the proposed SC induction regimen (Scenario B: 240 mg SC at Week 0, followed by 120 mg SC at Weeks 1, 2 and 3, followed by 120 mg SC Q2W from Week 4) compared with the approved IV induction regimen.

The MAH's justifications for adding SC induction regimen in treatment of CD and UC, presented in Module 2.7.2 of the dossier, are based entirely on PK simulations. There are no data from human clinical trial

<div style=\"page-break-after: always\"></div>

studies for the proposed SC induction dosing regimen and the presented population PK-PD models are not considered adequate for predicting the efficacy of untested dose regimens.

As discussed in the Q&amp;A document by EMA [Model-based approaches for approval of alternative dosing regimens  and  routes  of  administration  of  (anti  PD-1  and  PD-L1)  monoclonal  antibodies],  model-based approaches may be acceptable as the main source of evidence to inform approval of alternative posology or route of administration for monoclonal antibodies, provided that the relevant PK metrics (such as Cmin, AUC or Cmax) will be similar to the exposure reached with the dosing regimen for which positive benefit/risk has  been  established.  The  relevance  of  the  PK  parameter/metric  and  the  acceptance  criteria  for  PK comparability for the efficacy and safety should be adequately justified based on established exposureresponse relationship. It is the uncertainty of the exposure-response relationship that is a crucial weakness in the justifications by the MAH. In their population PK-PD models for CDAI score and partial Mayo score the estimated IC50 (i.e., infliximab concentration associated with 50% of maximal response) was 4.29 x 10 -22  and 6.17 x 10 -19 μ g/mL, respectively, which are not plausible values.

In terms of PK, the MAH seeks to justify the efficacy of the proposed SC induction regimen by stating that the  predicted  median  Ctrough  at  Week  2  was  slightly  lower  and  at  Week  6  slightly  higher  than  the corresponding Ctrough values of the IV induction regimen (see Table 6.2.2.8) and, overall, higher than a therapeutic threshold of 5 μ g/mL which was based on studies by Morita et al. 2016 and Bortlik et al. 2013. However,  in  these  studies  only  one  PK  sample,  Ctrough  drawn  during  maintenance  therapy  phase,  was evaluated. Therefore, the data are insufficient to unequivocally demonstrate that the pivotal PK exposure parameter for efficacy is Ctrough and not, e.g., AUC. In addition, exposure-response relationship for the maintenance therapy phase may not be directly applicable to the induction therapy phase because during the first weeks of treatment the levels of the target (i.e., soluble and membrane-bound TNFα) may be significantly higher compared with the maintenance phase when the disease activity is attenuated. Hence, it  cannot  be  assumed  without  justifications  that  the  target  concentration  should  be  the  same  during induction and maintenance therapy.

The MAH stated that they do not foresee safety risk with the proposed SC induction regimen because the predicted Cmax and AUC are much lower than those of the approved IV induction regimen. It is acknowledged that the predicted Cmax and AUC values over the first 6 weeks of treatment are much lower for the SC induction regimen compared with the approved IV induction regimen even in patients with the lowest body weight (50-60 kg) and safety risks related to increased exposure during that time are not expected.

The  MAH's  justifications  for  the  proposed  SC  induction  regimen  in  treatment  of  CD  and  UC  were  not sufficient and an MO was raised. The Applicant withdrew this part of the grouped variation application after the first RSI and corresponding changes are no longer proposed to the PI.

<div style=\"page-break-after: always\"></div>

## 7. Clinical Efficacy aspects

## The first proposed variation is as follows:

- Update of section 4.2, 4.8 and 5.1 of the SmPC in order to add 3-IV induction dosing regimen and dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response and update efficacy and safety information based on Week 54 data from studies CTP13 3.7 (ulcerative colitis) and CT-P13 3.8 (crohn's disease), listed as a category 3 study in the RMP; Study CT-P13 3.7 is a Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of  the  Subcutaneous Injection  of  CT-P13  (CT-P13  SC)  as  Maintenance  Therapy  in  Patients  with Moderately to Severely Active Ulcerative Colitis and study CT-P13 3.8 is a Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease.

In EMA: deletion not agreed. This is part of assessment.

Study CT-P13 3.7 was a randomised, placebo-controlled, double-blind, multicentre, parallel-group Phase 3 study to evaluate the efficacy, PK, PD and safety of CT P13 SC as maintenance therapy in patients with moderately  to  severely  active  UC.  The  duration  of  the  study  will  be  up  to  112  weeks,  which  includes screening (up to 6 weeks) and treatment period (up to the last dosing visit of study drug at Week 102) followed by EOS visit (after 4 weeks off dose period). With this variation application, data up to week 54 was submitted. The Week 54 visit date of the last patient was 07 July 2022 and after further data cleaning, the database was locked for this analysis on 15 September 2022.

Figure 25. Overview of study design

<!-- image -->

Abbreviations: IV, intravenous; PFS, pre-filled syringe; SC, subcutaneous.

1. Clinical response by modified Mayo score: a decrease in modified Mayo score from baseline of at least 2 points and at least  30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1 point.
2. From Week 22 through Week 54, dose adjustment was allowed. The patients who received CT-P13 SC 120 mg could increase the dose to CT-P13 SC 240 mg every 2 weeks, and the patients who received Placebo SC could receive CT-P13 SC 240 mg every 2 weeks, if they initially responded but then lost response according to the loss of response criteria.

<div style=\"page-break-after: always\"></div>

3. In the extension phase, all patients who completed the maintenance phase up to Week 54 and could benefit from continued treatment, in the opinion of the investigator, received active treatment with CTP13 SC 120 mg via PFS from Week 56.

In  the open-label  induction  phase ,  the  patients  who  met  all  the  inclusion  criteria  and  none  of  the exclusion criteria were enrolled on Day 0 (Week 0). All enrolled patients received a

2-hour CT-P13 IV infusion (5 mg/kg) during on-site visits at Weeks 0, 2, and 6 as induction treatments. At Week 8, only endoscopy and biopsy for histologic assessment were performed for the evaluation of Mayo score and endoscopic-histologic mucosal improvement at Week 10. The endoscopy result at Week 8 were used for randomization at Week 10. Patients who were classified as a clinical responder at Week 10 based on modified Mayo score after receiving 3 full doses of CT-P13 via IV infusion and for whom there were no safety concerns based on the investigator's discretion were randomly assigned to receive either CT-P13 SC or Placebo SC, before treatment on Day 70 (Week 10).

A clinical responder at Week 10 was defined as a patient with a decrease in modified Mayo score from baseline  of  at  least  2  points  and  at  least  30%,  with  an  accompanying  decrease  in  the  rectal  bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1 point.

Figure 26. Study Design for Induction and Maintenance Phase

<!-- image -->

Abbreviations: IV, intravenous; PFS, pre-filled syringe; PK, pharmacokinetics; SC, subcutaneous.

1. Clinical remission by modified Mayo score: stool frequency subscore of 0 or 1 point, and rectal bleeding subscore of 0 point, and an endoscopic subscore of 0 or 1 point.
2. At Week 8, only endoscopy and biopsy were performed for the evaluation of Mayo score and histological assessments at Week 10. The endoscopy results at Week 8 were used for randomization at Week 10. Patients who were classified as a clinical responder at Week 10 were randomly assigned to receive either

CT-P13 SC or Placebo SC at Week 10.

3. Additional PK sampling visits were conducted only on patients who agreed to collect further blood samples for population PK analysis.
4. Patients who complete the maintenance phase up to Week 54 and may benefit from continued treatment, in the opinion of investigator, will continue into the extension phase.

<div style=\"page-break-after: always\"></div>

5. For all patients in the treatment group 1 and 2, dose adjustment to CT-P13 SC 240 mg every 2 weeks were allowed starting from Week 22, if the patients initially responded but then lost response according to the loss of response criteria.

The double-blind maintenance phase consisted of further doses of CT-P13 SC or Placebo SC with the last dose administered no later than Week 54.

1. Treatment Group 1, CT-P13 SC: from Week 10, CT-P13 SC 120 mg was administered every 2 weeks via PFS through Week 54
2. Treatment Group 2, Placebo SC: from Week 10, Placebo SC (matching volume to CT-P13 SC 120 mg) was administered every 2 weeks via PFS through Week 54.

From Week 22 through Week 102, dose adjustment was allowed as follows:

3. The patients who received CT-P13 SC 120 mg might increase the dose to CT-P13 SC 240 mg (double injection [2 shots] of CT-P13 SC 120 mg) every 2 weeks, if patients initially responded but then lost response according to the loss of response criteria.
4. The patients who received Placebo SC might receive CT-P13 SC 240 mg (double injection [2 shots] of CT-P13 SC 120 mg) every 2 weeks, if patients initially responded but then lost response according to the loss of response criteria.

Loss of response was defined as an increase in modified Mayo score ≥2 points and ≥30% from the Week 10 modified Mayo score with actual value of ≥5 points, and endoscopic subscore of ≥2 points. The patients whose dose was adjusted to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitter or nonresponder at Week 54 in the analysis of the primary endpoint and key secondary endpoints.

In the open-label extension phase , all patients who complete the maintenance phase up to Week 54 and may benefit from continued treatment, in the opinion of the investigator, will receive active treatment with CT-P13 SC 120 mg via PFS from Week 56. The patients who received the adjusted dose of CT-P13 SC 240 mg in the maintenance phase continued receiving the same doses of CT-P13 SC for the study treatment in the extension phase. The extension phase will continue up to Week 102. Results from the extension phase were not provided with this submission.

## End of study

The EOS visit occurred 4 weeks after the last dose of study drug was received. For patients who early discontinued the study drug before administration of CT-P13 SC or Placebo SC at Week 10, the EOS visit occurred 8 weeks after the last dose of CT-P13 IV was received.

## CHMP comment

This Phase 3 study was designed to evaluate the efficacy, PK, PD, and safety of the SC injection of CT-P13 (CT-P13  SC)  as  maintenance  therapy  in  patients  with  moderately  to  severely  active  UC,  after  having received induction therapy with three IV-doses.

The design as such was reasonably adequate to answer the question whether maintenance therapy with SC Remsima is superior to placebo, after an initial response to induction treatment has been achieved but not the question whether a dose increase is effective.

As patients who lost response in both treatment arms were offered a switch to Remsima 240 mg Q2W from week 22 onward, comparisons of efficacy between Remsima SC 120mg Q2W and placebo beyond week 22 are compromised due to the intercurrent event. Basically, patients in the placebo group who received active treatment after loss of response are automatically counted as non-responders which may skew the results

<div style=\"page-break-after: always\"></div>

in favour of the active arm because placebo patients are more likely to lose their response as they receive no active treatment. These patients are automatically counted as non-responders although we see from historical data and data from this study that it is possible for patients to reach 'response' in the placebo arm due to the nature of the endpoint and the natural fluctuation of the disease. As loss of response after switching to placebo is very different from loss of response during maintenance treatment with 120 mg Remsima SC, we do not know whether the fluctuation back to 'responder' would have occurred with equal frequency in each arm.

In the context of this variation application, study CT-P13 3.7 was submitted to support a) addition of a new induction regimen (longer induction with IV), b) addition of the possibility to increase the dose for patients with loss of initial response c) inclusion of the efficacy and safety results in Section 5.1 and 4.8.

## Induction with 3 IV doses

The design as such is adequate to answer the question whether maintenance therapy with Remsima SC (CT-P13) in the treatment of UC is superior to placebo when administered with an induction regimen of 3 IV doses (5 mg/kg at Weeks 0, 2 and 6) followed by SC maintenance treatment (120 mg Q2W starting from week 10).

While the primary endpoint at week 54 is somewhat hampered by the design of study 3.7, Week 22 efficacy is considered to be a clinically relevant endpoint and acceptable by the EMA guideline on UC studies. As the new proposed induction regimen does not differ a lot from the already approved one, the W54 data is not considered crucial and the benefit-risk may be assessed based on totality of data.

## Dose adjustment

The question to be answered is whether dose adjustment from SC 120 mg to 240 mg for patients with loss of response is more effective (and sufficiently safe) compared to continuing treatment with SC 120 mg. The study design is not adequate to answer this question.

As  there  was  no  randomised  treatment  arm  where  patients  with  a  loss  of  response  continued  on  the previously assigned SC 120mg treatment, it is difficult to know how the disease would have progressed without the dose escalation. As UC is a fluctuating refractory disease with sometimes long symptom free periods, some patients could have achieved remission again by week 54 after loss of response, even without dose escalation. Furthermore, as dose escalation was not mandatory for all patients who fulfilled the criteria, there is a potential for selection bias. Assessment of the BR of a dose escalation could in theory be addressed based on totality of data including PK, efficacy, safety and immunogenicity data. In this case the results need to be exceptionally compelling. The risk of higher exposure in the long term needs to be clearly overridden by the benefits.

## Efficacy results in SPC 5.1

While the design is not optimal for interpretation of the results at Week 54 (primary endpoint), the increase of the dose in both arms after week 22 (i.e. in placebo arm switch to high-dose active drug, and in Remsima arm increase of the dose from 120mg to 240mg) when loss of response occurred could be seen as a rescue therapy/  escape  procedure at  intermediate  time-point,  which  is  in  line  with  the  EMA  guideline  on development of medicinal products for ulcerative colitis/ Crohn's disease. Subjects who initiated Remsima 240mg treatment as 'rescue treatment' (placebo-group) or had a dose escalation to 240mg (Remsima SC group), were categorized as non-responders for primary efficacy analyses of co-primary endpoints. Overall, this study design was not optimal, but still considered of value if the data is presented with sufficient detail (see requests in LoQ). Similar designs have been used earlier in the same therapeutic field and have been found suitable for regulatory decision-making. However, it is noted that Remsima is already an approved maintenance therapy which was not the case for the other products. Notably, in the current submission the overall B/R of induction/maintenance treatments is not questioned, as those have already been approved

<div style=\"page-break-after: always\"></div>

and included in the SmPC of IV and SC Remsima. The question is if these new phase 3 studies provide statistically and clinically significant and robust enough/valuable information for the prescriber to be placed into the SmPC 5.1, to replace the earlier data from the previous smaller studies in CD and UC. For these purposes, even though the design is not optimal, as discussed above, it can be agreed that the results are of value for the prescriber and could be described in SmPC 5.1 provided that satisfactory answers are given to the LoQ .

## Updated comments (1 st  RSI AR)

As the MAH withdrew the initial proposal for a dose escalation in UC patients, questions related purely to the efficacy and safety of the 240mg dose are no longer relevant. However, the possibility to dose adjust is significantly intertwined in the primary endpoints as only patients who did not dose adjust had a possibility to be responders at week 54. Moreover, the intercurrent event of loss of response was handled differently for different patients and this flaw in the study design could skew the results of the primary outcome. Some patients who lost response were dose adjusted and others were not, but these different pathways were neither randomised nor based on any predefined characteristics. Therefore, week 54 results cannot be presented in the SPC without mentioning the possibility to dose adjust. However, as a dose increase is no longer proposed, this would be promoting an off label posology, which is not acceptable. Therefore, only W22 results from the UC study may be presented in the SPC.

The Final study report up to W102 was provided with the responses and the main results have been included in this AR.

## Updated comments (2 nd  RSI AR)

The Applicant has provided the requested tables and figures.

According to study protocol, patients were offered a dose escalation if they met LoR criteria after week 22. However, based on the provided results, 29/294 patients in the infliximab group and 21/144 in the placebo group were switched to 240 mg Remsima despite not meeting LoR criteria. Hence, a total of 35% (50/144) of all patients who received a dose adjustment did not meet LoR criteria. No special criteria for these dose escalation decisions were prespecified or explained post hoc.

Out of all non-responders at W54, only 5.5% were classified as non-responders based on clinical criteria, with no difference between treatment groups, while the rest of the non-responders were due to intercurrent events, mainly dose adjustment, which did not equal LoR.

The reason for the high number of this type of protocol violations may be related to the definition of LoR. In the protocol, the LoR criteria were based on modified Mayo score (including the endoscopic subscore). However, the modified Mayo score was only recorded at weeks 10, 22 and 54. Hence, according to protocol it was not even possible to detect a LoR between W22 and 54.

As all patients randomised are included in the primary endpoint, all the aforementioned issues have a direct impact on the results of the primary endpoint.

While there is no doubt that Remsima SC is in fact more effective than placebo in the treatment of UC, the magnitude of the difference  cannot  be  accurately  estimated  based  on  the  results  of  this  trial.  The  UC indication is already granted and is not put into question but no new useful information for the prescriber has been presented with this application.

To conclude, the results from study 3.7 are invalid for inclusion in the SPC.

## Updated comments (3 rd  RSI AR)

<div style=\"page-break-after: always\"></div>

Upon rejection of the Week 54 endpoints, the MAH proposed to include W22 results in the SPC instead. Week  22  endpoints  were  not  pre-specified  in  the  protocol  and  SAP.  Generally,  post-hoc  analyses  are included in SmPC 5.1. only in exceptional situations. There is no clinical necessity to include these results.

Furthermore,  it  has  become  apparent  during  the  assessment  that  the  overall  study  conduct  and  the concordance of the protocol and planned statistical analyses are not considered to produce reliable and robust results. For all the aforementioned reasons, the Week 22 results are not considered adequate for inclusion in the SmPC.

Study 3.7 in UC patients does not provide methodologically robust and clinically significant information for the prescriber. The study was not conducted according to protocol. The number and nature of the protocol violations are such that the W54 results do not provide a meaningful interpretation. Further, it would not be possible to describe the study appropriately without mentioning the possibility to increase the dose from the currently approved 120mg SC to 240mg, which would be promoting an off-label posology.

Hence the description of study 3.7 should be removed from SPC 5.1.

## Updated comments (4 th  RSI AR)

The MAH has agreed to the assessment. No new data from study 3.7 is included in the SPC section 5.1.

## CHMP/PRAC table describing current and proposed treatment regimens of IV and SC Remsima in the treatment of UC.

<!-- image -->

| weeks                                 | 0                  | 1                  | 2   | 4   | 5   | 6   | 7   | 9   | 10 11   | 12   | 13   |    | 14 15   | 17   | 19   | 20   | 22   |
|---------------------------------------|--------------------|--------------------|-----|-----|-----|-----|-----|-----|---------|------|------|----|---------|------|------|------|------|
| Currently approved regimens           |                    |                    |     |     |     |     |     |     |         |      |      |    |         |      |      |      |      |
| 1. IVi + IVm x                        | 1. IVi + IVm x     | 1. IVi + IVm x     |     | x   |     |     | x   |     |         |      |      |    | x       |      |      |      | x    |
| 2. IVi + SCm x                        | 2. IVi + SCm x     | 2. IVi + SCm x     |     | x p | p   | p   | x   | x   | x       |      | x    |    | x       | x    | x    |      | x    |
| 3. IVi +IVm -> SCm                    | 3. IVi +IVm -> SCm | 3. IVi +IVm -> SCm | x   | x   |     |     | x   | p   | p p     | p    | p    | p  | x       | x    | x    |      | x    |
| Proposed regimens                     |                    |                    |     |     |     |     |     |     |         |      |      |    |         |      |      |      |      |
| 4. IVi + SCm                          | 4. IVi + SCm       | 4. IVi + SCm       | x   | x   |     |     | x   | p p | x       |      | x    |    | x       | x    | x    |      | x    |
| 5. SCi+SCm                            | 5. SCi+SCm         | 5. SCi+SCm         | xx  | x x | x   |     | x   | x   | x       |      | x    |    | x       | x    | x    |      | x    |
| IVi: IV induction IVm: IV maintenance |                    |                    |     |     |     |     |     |     |         |      |      |    |         |      |      |      |      |
| SCi: SC induction SCm: SC maintenance |                    |                    |     |     |     |     |     |     |         |      |      |    |         |      |      |      |      |
| P: pause between IV and SC            |                    |                    |     |     |     |     |     |     |         |      |      |    |         |      |      |      |      |

## 7.1.1. Methods

## Study participants

A total of 800 patients were screened and 548 patients from 92 study centers in 14 countries were enrolled in this study. Male or female patients aged 18 to 75 years old with moderately to severely active UC who had a modified Mayo score without physician global assessment (PGA) subscore of  5  to 9 points  with endoscopic subscore of ≥2 points and had an inadequate response to conventional therapy were considered for enrolment. The patients had been treated for active UC but had not responded despite conventional therapy including corticosteroids alone or in combination with 6-mercaptopurine (6-MP) or azathioprine (AZA), or were intolerant to or had medical contraindications to such therapies. Detailed inclusion criteria are given in the clinical study report (CSR).

<div style=\"page-break-after: always\"></div>

The  exclusion  criteria  were  divided  into  2  categories:  general  exclusion  criteria,  TB  exclusion  criteria. Patients meeting any of the general and TB exclusion criteria according to their indication were excluded from this study. The main exclusion criteria were as follows:

1. Patient who had previously received 2 or more biologic agents, 2 or more JAK inhibitors, or 2 or more both biologic agents and JAK inhibitors.
2. Patient who had previously received either a TNF α inhibitor or biologic agent within 5 half-lives prior to the first administration of the study drug (Day 0).
3. Patient who had previously demonstrated inadequate response or intolerance to TNF α inhibitors for the treatment of UC.
4. Patient who had previously received infliximab for treatment of UC or other disease.
5. Patient  who  had  received  or  had  a  plan  to  receive  any  of  following  prohibited  medications  or treatments:
6. -Parenteral corticosteroids for the treatment of UC within 2 weeks prior to the first administration of the study drug (Day 0)
7. -Rectally administered medications containing corticosteroids or 5 -ASA for the treatment of UC within 2 weeks prior to the first administration of the study drug (Day 0)
8. -JAK inhibitors including but not limited to tofacitinib and baricitinib within 4 weeks prior to the first administration of the study drug (Day 0)
9. -Alkylating agents within 12 months prior to the first administration of the study drug (Day 0)
10. -Cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks prior to the first administration of the study drug (Day 0)

More detailed inclusion criteria are given in the clinical study report (CSR).

## CHMP comment

The inclusion and exclusion criteria are in line with the target population, i.e the UC patients for whom Remsima is approved:

Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

## Treatments

The  dosing  regimen  of  3  IV  induction  doses  of  CT-P13  5  mg/kg  at  Weeks  0,  2,  and  6  followed  by maintenance doses of CT-P13 SC 120 mg every 2 weeks starting at Week 10 was selected for this study.

The dosing regimen for the IV induction period for this study was the same as the currently approved induction dosing regimen for IV infliximab, and the SC dosing started at Week 10, which was 4 weeks after the last IV induction dose at Week 6 (see assessor's table under section 7.1). According to the MAH, this timing of first SC dose was chosen to ensure trough concentration (Ctrough) levels remained close to the steady state plasma concentration throughout the SC dosing regimen, minimizing low plasma levels and thereby preventing potential enhancement of immunogenicity.

<div style=\"page-break-after: always\"></div>

Patients entered into open-label Induction Phase were administered three doses of CT-P13 IV 5 mg/kg at Weeks 0, 2 and 6. Patients who classified as a clinical responder at Week 10 based on modified Mayo score without PGA  subscore and had no safety concerns based on the investigator's discretion were randomly assigned  to  either  CT-P13  SC  treatment  arm  or  Placebo  SC  treatment  arm  in  a  2:1  ratio  for  the Maintenance Phase. Dose adjustment was allowed from Week 22 if patients initially responded but then lost response according to the loss of response criteria (an increase in modified Mayo score of ≥ 2 points and ≥ 30% from the Week 10 modified Mayo score with actual value of ≥ 5 points, and endoscopic subscore of ≥ 2 points). These patients received CT-P13 SC 240 mg (double injection [2 shots] of CT-P13 SC 120 mg) every 2 weeks regardless of whether they had previously received CT-P13 SC 120 mg or Placebo SC.

## Concomitant medication

Immunomodulators (such as AZA, 6-MP, or MTX) were allowed if patients maintained stable doses for at least 8 weeks prior to first administration of the study drug (Day 0) according to the inclusion criteria.

Oral corticosteroids at the equivalent dose of 20 mg/day or less of prednisone were allowed if the patient had received a stable dose for at least 2 weeks prior to the first administration of the study drug (Day 0).

Only oral 5-ASA was allowed if patients maintained stable doses for at least 4 weeks prior to the first administration of study drug (Day 0) and the stable dose was maintained throughout Week 54. Antibiotics (such as ciprofloxacin, metronidazole) for the treatment of UC were allowed if patients maintained a stable dose for at least 4 weeks prior to the first administration of the study drug (Day 0).

## CHMP comment

The timing of first SC dose was chosen to ensure trough drug concentration levels remained close to the steady state plasma concentration throughout the SC dosing regimen. This target was achieved (see PK assessment in section 6).

As discussed above in 'Study design' the possibility to switch to higher dose/active treatment hampers the ability to assess the study objectives.

## Objectives

## Primary objective:

To demonstrate superiority of CT-P13 subcutaneous (SC) over Placebo SC based on clinical remission at Week 54

## Secondary objective:

To  evaluate  additional  efficacy,  pharmacokinetics  (PK),  pharmacodynamics  (PD),  and  overall  safety including immunogenicity

## Exploratory objective:

To evaluate additional efficacy

## Outcomes/endpoints

## Primary Efficacy Endpoint:

Clinical remission at Week 54, defined as the following modified Mayo score:

- Stool frequency subscore of 0 or 1 point, and

<div style=\"page-break-after: always\"></div>

- Rectal bleeding subscore of 0 point, and
- Endoscopic subscore of 0 or 1 point Key

## Key Secondary Efficacy Endpoints:

- Clinical response at Week 54, defined as a decrease in modified Mayo score from baseline of at least 2 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1 point
- Endoscopic-histologic  mucosal  improvement  at  Week  54,  defined  as  an  absolute  endoscopic subscore of 0 or 1 point from modified Mayo score and an absolute Robarts Histopathology Index (RHI) score of 3 points or less with an accompanying laminal propria neutrophils and neutrophils in epithelium subscore of 0 points
- Corticosteroid-free remission at Week 54, defined as being in clinical remission by modified Mayo score in addition to not requiring any treatment with corticosteroid for at least 8 weeks at Week 54, among the patients who used oral corticosteroids at baseline

## Other Secondary Efficacy Endpoints:

- Clinical remission assessed at Weeks other than Week 54, by modified Mayo score
- Maintenance of clinical remission at Week 54, defined as being in clinical remission by modified Mayo score, among the patients in clinical remission by modified Mayo score at Week 10
- Sustained clinical remission at both Week 22 and Week 54, defined as a stool frequency subscore of 0 or 1, and rectal bleeding subscore of 0
- Clinical response assessed at Weeks other than Week 54, defined as a decrease in modified Mayo score from baseline of at least 2 points and at least 30%, with an accompanying decrease in rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1 point
- Endoscopic-histologic mucosal improvement assessed at Weeks other than Week 54, defined as an absolute endoscopic subscore of 0 or 1 point from modified Mayo score and an absolute RHI score of 3 points or less with an accompanying laminal propria neutrophils and neutrophils in epithelium subscore of 0 points
- The scores and change from baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ)

## Exploratory Efficacy Endpoints:

-  Clinical remission with normalization of stool frequency at Week 54, defined as following modified Mayo score:
- Stool frequency subscore of 0 point, and
- Rectal bleeding subscore of 0 point, and
- Endoscopic subscore of 0 or 1 point
-  Total clinical remission, defined as a total Mayo score (stool frequency, rectal bleeding, endoscopic, and PGA subscores) of 2 points or lower with no individual subscore exceeding 1 point

<div style=\"page-break-after: always\"></div>

-  Total clinical response, defined as a decrease in total Mayo score from baseline of at least 3 points and at least 30%, with an accompanying decrease in rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1 point
-  Partial clinical remission, defined as a partial Mayo score (stool frequency, rectal bleeding, and PGA subscores) of 1 point or lower
-  Partial clinical response, defined as a decrease in partial Mayo score from baseline of at least 2 points, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point, or an absolute subscore for rectal bleeding of 0 or 1 point

## Pharmacokinetic Assessments:

- Trough  concentration  (Ctrough)  up  to  Week  100  (concentration  before  the  next  study  drug administration)
- Observed maximum serum concentration (Cmax) at Week 6

## Pharmacodynamic Assessments:

- Faecal calprotectin (FC)
- C-reactive protein (CRP)

## CHMP comment

The chosen efficacy parameters were often used in randomized clinical trials indicated for UC patients and are listed as possible endpoints in the EMA Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis (CHMP/EWP/18463/2006 Rev.1) The FDA guidance (Guidance for Industry. Ulcerative Colitis [2022]), recommends using clinical remission by modified Mayo score as the primary endpoint. The modified Mayo score includes the endoscopic sub-score. According to the EMA guideline, symptomatic  remission  (e.g.,  by  patient  reported  sub-score  (Partial  Mayo))  and  endoscopic  remission should be assessed separately as co-primary endpoints.

The primary objective of this study was to demonstrate superiority of Remsima SC over placebo in the maintenance treatment of UC patients at week 54. This is not relevant for the variation at hand as Remsima SC is  already  approved  for  maintenance  treatment  and  it  is  not  likely  that  a  small  adjustment  of  the induction regimen would render the whole treatment ineffective. However, as the MAH proposes to include the main results from study 3.7 in the SPC section 5.1, the primary endpoint also needs to be assessed.

Importantly, there is no pre-defined endpoint to assess whether high dose maintenance is effective.

## Sample size

The sample size of 417 patients (278 in CT-P13 SC group and 139 in Placebo SC group) was estimated to provide  80%  statistical  power  to  detect  a  statistically  significant  effectiveness  of  CT-P13  SC  group  in comparison  with  Placebo  SC  group  based  on  the  clinical  remission  at  Week  54  assuming  a  treatment difference of 15% and Placebo rate of 45% at the 1-sided significance level of 2.5%.

Considering a 32% non-responder rate of clinical response at Week 10 before randomization, a total of approximately 615 patients provided at least 90% statistical power for clinical response at Week 54, one of the key secondary endpoints, under the assumption of a treatment difference of 20% and Placebo rate

<div style=\"page-break-after: always\"></div>

of 50% at the 1-sided significance level of 2.5%. Key secondary endpoints other than clinical response at Week 54 were not applicable for power calculation due to lack of relevant references.

## CHMP comment

The sample size calculation is technically adequate for the question the study was designed to answer.

However, the protocol assumptions differ to a large degree from what was observed in the study. In the protocol a 45% response rate in the placebo arm was expected whereas the results show a response rate of 20.8%. Furthermore, in the protocol a 15% delta was expected which would have translated into 60% response rate in the active arm. This is also notably lower (43%) though the expected delta was observed. The Applicant should discuss whether the difference in the expected vs observed results is due to low number of true responders or whether the dose escalation/switch to placebo allowed in the protocol, or some other reason, explains the difference. The response may refer to the OC in the efficacy section related to categories for non-responders.

## Updated comments (RSI AR)

As the MAH states, it appears that the lower absolute number of responders could be linked to the fact that patients whose dose was escalated were automatically counted as non-responders. This further confirms the  impression  that  the  impact  of  dose  escalation  in  both  active  and  placebo  groups  on  the  overall robustness of the results was not adequately considered at the planning stage of the study. This impacts the robustness of the results at Week 54.

## Randomisation

For initiating the double-blind maintenance phase, an interactive web response system (IWRS) was used for the randomization. Biostatistician generated the randomization schedule for the IWRS, which linked sequential patient randomization numbers to treatment codes. Patients classified as a clinical responder by modified Mayo score at Week 10 after receiving 3 full doses of CT-P13 via IV infusion and with no safety concern based on the investigator's discretion were randomized in a 2:1 ratio to receive either CT-P13 SC or Placebo SC, before starting treatment at Day 70 (Week 10).

The randomization was stratified by previous exposure to biologic agent and/or JAK inhibitors (used or not used), use of treatment with oral corticosteroids at Week 0 (used or not used) and clinical remission at Week 10 (remitter or non-remitter by modified Mayo score).

## CHMP comment

The stratification factors are adequate.

Importantly, as commented elsewhere in this report, the benefits of randomization are lost for the primary and  secondary  efficacy  objectives  at  week  54  because  changes  based  on  subjective  criteria  in  the randomized  dosing  regimen  are  allowed.  Furthermore,  randomization  is  not  relevant  for  the  question whether high dose maintenance is an option for patients with loss of response. This would have required randomization at the time of loss of response (week 22).

## Blinding (masking)

This study had a double-blind maintenance phase, the treatment assignment for the maintenance phase was blinded to the investigators, patients, and predefined CELLTRION, Inc. and PPD-blinded teams until this Week 54 CSR was generated and will remain blinded until the Week 102 CSR is generated.

<div style=\"page-break-after: always\"></div>

## CHMP comment

In  theory,  the  study  is  double  blind.  However,  the  investigator  and  patient  know  that  if  the  dose  was escalated, the patient received active treatment. Furthermore, the investigator knows that as a result of dose escalation the patient automatically is a non-responder in the efficacy analyses. Hence, the study cannot be considered adequately blinded.

## Statistical methods

For the efficacy endpoints related remission or response, the following patients were considered as nonremitter or non-responder:

- Patients who did not meet the clinical remission or response criteria
- Patients with missing or incomplete data for the evaluation of each endpoint at their scheduled visit of interest
- Patients with dose adjustment to CT-P13 SC 240 mg prior to their scheduled visit of interest

The primary endpoint tested at the 2-sided significance level of 5% on the all-randomized population using the p-value from Cochran-Mantel-Haenszel (CMH) test stratified by previous exposure to biologic agent and/or JAK inhibitors (used or not used), use of treatment with oral corticosteroids at Week 0 (used or not used) and clinical remission at Week 10 (remitter or non-remitter by modified Mayo score). If the p-value was ≤0.05, the statistical significance of the primary endpoint was concluded. If the pri mary endpoint was significant, the fixed sequence procedure was used for key secondary endpoints in order to preserve the Type I error. The supportive analysis for the primary endpoint was performed in the PP population.

## CHMP comment

The Applicant has outlined one intercurrent event which results into a patient counted as non-responder, namely that the patient´s dose was escalated. For patients in the placebo arm, dose escalation means that they started to receive active treatment. It is inherently difficult to assess the impact of this on study results.

The statistical test for the primary endpoint was changed late in the study based on a comment from the FDA. This is acceptable and the test is considered adequate.

Importantly, there are no pre-defined methodological aspects and endpoints to assess the impact of dose escalation which is one major focus of this submission. On the other hand, the impact of dose escalation on the primary and secondary endpoints has not been adequately prospectively considered. The number of patients with dose escalation/switch to active treatment is high (see results) and imbalanced between the arms. Though designs and endpoints similar to this study have been accepted before, the situation  is different for this study because maintenance was already an approved treatment regimen at study initiation.

One analysis was included in the SAP to assess dose escalation: I n addition, for the descriptive comparison of the treatment effect between patients with and without dose adjustment to CT-P13 SC 240 mg prior to Week 54 within CT-P13 SC treatment group, the primary endpoint was summarized by patients with and without dose adjustment in CT-P13 SC treatment group using frequency table without the statistical test. In this analysis, remitter was determined as per remission criteria regardless of dose adjustment. This analysis  is,  however,  not  included  in  the  submitted  dossier  which  is  rather  surprising  considering  the intended changes to the SmPC. This analysis should be provided.

Updated comments (RSI AR)

<div style=\"page-break-after: always\"></div>

The requested analysis was not provided but the question is no longer relevant as the dose adjustment was withdrawn for UC.

## 7.1.2. Results

## Participant flow

A total of 800 patients were screened. There were 252 screening failures; the most frequently reported primary reason for screening failure were inclusion/exclusion criteria not met.

Out of 800 patients, 548 patients were enrolled in the study, and were treated with CT-P13 5 mg/kg via IV infusion in the open-label induction phase. Of these patients, 110 patients discontinued the study during the induction phase. The most frequently reported primary reason for discontinuation during the induction phase was non-responder at Week 10 (65/548, 11.9%).

A  total  of  438  patients  were  randomly  assigned  to  study  treatment  and  initiated  the  double-blind maintenance phase at Week 10 (294 and 144 patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively).  Eighty-five  (19.4%)  patients  discontinued  the  study  during  the  maintenance  phase  (54 [18.4%] and 31 [21.5%] patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively).

Overall, the most frequently reported primary reason for discontinuation during the maintenance phase was withdrawal by subject (23 [7.8%] patients in the CT-P13 SC 120 mg group and 12 [8.3%] patients in Placebo SC group, respectively). The mean (SD) time on study drug prior to discontinuation during the maintenance phase was 201.9 (95.97) and 259.5 (91.83) days in the CT-P13 SC 120 mg and Placebo SC groups, respectively.

A total of 353 (80.6%) patients (240 [81.6%] patients in the CT-P13 SC 120 mg group and 113 [78.5%] patients in Placebo SC group) were ongoing with the study at Week 54.

During  maintenance,  13  (4.4%)  patients  in  the  SC  120mg  arm  and  9  (6.3%)  in  the  placebo  arm discontinued due to progressive disease.

<div style=\"page-break-after: always\"></div>

Figure 27. Patient Disposition: All-Randomized Population

<!-- image -->

## CHMP comment

The number of discontinuations is fairly high but balanced between the groups.

The Applicant is requested to provide a Figure of Patient Disposition which outlines for how many patients the dose was escalated at/after week 22.

It  should  be  clarified  how  patients  with  progressive  disease  who  discontinued  the  study  differed  from patients who received a dose increase. If possible, the differentiation should be displayed in the flow chart Figure of Patient Disposition.

## Updated comments (RSI AR)

An updated flow chart of patient disposition up to W102 was provided and is presented above.

<div style=\"page-break-after: always\"></div>

## Recruitment

A total of 800 patients from 104 study centers in 15 countries were screened and 548 patients from 92 study centers in 14 countries were enrolled in this study.

01 September 2020 (first patient's first study drug administration date) to 07 July 2022 (study cut-off date: date for each patient's Week 54 visit [07 July 2022 as the last patient's Week 54 visit])

## Conduct of the study

Table 30. Major Protocol Deviations: All-Randomized Population

|                                                                                     | CT-P13SC120mg (N=294)   | Placebo (N=144)        | Total (N=438)          | Excluded Populations 1   |
|-------------------------------------------------------------------------------------|-------------------------|------------------------|------------------------|--------------------------|
|                                                                                     | Number (%) of patients  | Number (%) of patients | Number (%) of patients | Number (%) of patients   |
| Major protocol deviation                                                            | 5 (1.7)                 | 6 (4.2)                | 11 (2.5)               |                          |
| Mis-randomization                                                                   | 0                       | 2 (1.4)                | 2 (0.5)                | PK, PP                   |
| Non-compliance of inclusion or exclusion criteria which affect the efficacy results | 1 (0.3)                 | 1 (0.7)                | 2 (0.5)                | PP                       |
| Randomization without clinical response at Week 10 2                                | 2 (0.7)                 | 2 (1.4)                | 4 (0.9)                | PP                       |
| Prohibit therapy during treatment Period                                            | 2 (0.7)                 | 1 (0.7)                | 3 (0.7)                | PP                       |

Abbreviations: PK, pharmacokinetic; PP, per-protocol.

1. Major protocol deviation excluded patients from the specified population(s).

2. Four patients were re-confirmed as non-responder at Week 10 after randomization.

## Numbers analysed

All 548 enrolled patients were included in the ITT population.

All-randomized population consisted of 438 patients who were randomly assigned to study treatment and initiated the maintenance phase at Week 10 (294 and 144 patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively).

The PP population included 421 patients (286 and 135 patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively). A total of 17 patients (11 patients with major protocol deviations, 2 patients without any full dose of study drug at Week 10 or thereafter prior to Week 54 and 4 patients without any efficacy evaluation result after Week 10 study drug administration) were excluded from PP population.

## CHMP comment

Major protocol deviations were few and balanced across treatment arms. No major concerns regarding GCP have emerged based on study conduct.

## Updated comments (3 rd  RSI AR)

It has become apparent during the assessment that the overall study conduct and the concordance of the protocol  and  planned  statistical  analyses  were  not  adequate.  The  number  and  nature  of  the  protocol violations are such that the results do not provide a meaningful interpretation.

<div style=\"page-break-after: always\"></div>

## Baseline data

Baseline data are presented only for patients who were randomised at week 10, i.e those who responded to the induction treatment.

The mean (SD) age of patients was 38.2 (12.78) and 40.4 (13.49) years in the CT-P13 SC 120 mg and Placebo SC groups, respectively. The majority of patients were White (428 [97.7%] patients). The mean (SD) screening weight of patients was 72.40 (16.511) and 75.76 (15.011) kg in the CT-P13 SC 120 mg and Placebo SC groups, respectively and the mean (SD) screening BMI of patients was 24.160 (4.3858) and 25.091 (4.1768) kg/m 2  in the CT-P13 SC 120 mg and Placebo SC groups, respectively.

Among responders to the induction, the mean modified Mayo score at baseline was 6.6 for the CT-P13 SC 120 mg group and 6.7 for the placebo group.

Table 31. Baseline characteristics of randomised subjects in study CT-P13 3.7

| Parameter Statistics                            | CT-P13SC120mg (N=294)   | Placebo (N=144)   | Total (N=438)   |
|-------------------------------------------------|-------------------------|-------------------|-----------------|
| Age (years)                                     |                         |                   |                 |
| n                                               | 294                     | 144               | 438             |
| Mean (SD)                                       | 38.2 (12.78)            | 40.4 (13.49)      | 38.9 (13.04)    |
| Median                                          | 37                      | 39                | 37              |
| Min, Max                                        | 18, 73                  | 18, 75            | 18, 75          |
| Sex, n (%)                                      |                         |                   |                 |
| Male                                            | 163 (55.4)              | 83 (57.6)         | 246 (56.2)      |
| Female                                          | 131 (44.6)              | 61 (42.4)         | 192 (43.8)      |
| Female fertility status, n (%) 1                |                         |                   |                 |
| Pre-menarche                                    | 0                       | 0                 | 0               |
| Surgically sterilized                           | 4 (3.1)                 | 1 (1.6)           | 5 (2.6)         |
| Post-menopausal                                 | 22 (16.8)               | 17 (27.9)         | 39 (20.3)       |
| Potentially able to bear children               | 105 (80.2)              | 43 (70.5)         | 148 (77.1)      |
| Other                                           | 0                       | 0                 | 0               |
| Race, n (%)                                     |                         |                   |                 |
| American Indian or Alaska Native                | 6 (2.0)                 | 4 (2.8)           | 10 (2.3)        |
| Asian                                           | 0                       | 0                 | 0               |
| Black or African American                       | 0                       | 0                 | 0               |
| Native Hawaiian or other Pacific Islander       | 0                       | 0                 | 0               |
| White                                           | 288 (98.0)              | 140 (97.2)        | 428 (97.7)      |
| Not allowed by investigator country regulations | 0                       | 0                 | 0               |
| Other                                           | 0                       | 0                 | 0               |
| Ethnicity, n (%)                                |                         |                   |                 |
| Hispanic or Latino                              | 7 (2.4)                 | 4 (2.8)           | 11 (2.5)        |
| Non-Hispanic or Non-Latino                      | 285 (96.9)              | 140 (97.2)        | 425 (97.0)      |
| Unknown                                         | 2 (0.7)                 | 0                 | 2 (0.5)         |

<div style=\"page-break-after: always\"></div>

| n                                                                | 294             | 144            | 438            |
|------------------------------------------------------------------|-----------------|----------------|----------------|
| Mean (SD)                                                        | 172.59(9.711)   | 173.43 (9.514) | 172.86 (9.644) |
| Median                                                           | 173             | 174            | 173            |
| Min, Max                                                         | 145, 208        | 150, 194       | 145, 208       |
| Screening weight (kg)                                            |                 |                |                |
| n                                                                | 294             | 144            | 438            |
| Mean (SD)                                                        | 72.40 (16.511)  | 75.76 (15.011) | 73.50 (16.094) |
| Median                                                           | 70.90           | 76.85          | 72.30          |
| Min, Max                                                         | 42.1, 130.2     | 44.4, 108.8    | 42.1, 130.2    |
| Screening body mass index (kg/m 2 )                              |                 |                |                |
| n                                                                | 294             | 144            | 438            |
| Mean (SD)                                                        | 24.160 (4.3858) | 25.091(4.1768) | 24.466(4.3356) |
| Median                                                           | 23.260          | 24.715         | 23.715         |
| Min, Max                                                         | 15.09, 35.96    | 16.53, 34.51   | 15.09, 35.96   |
| Previous exposure to biologic agent and/or JAK inhibitors, n (%) |                 |                |                |
| Used                                                             | 29 (9.9)        | 13 (9.0)       | 42 (9.6)       |
| Not used                                                         | 265 (90.1)      | 131 (91.0)     | 396 (90.4)     |
| Use of treatment with oral corticosteroids at Week 0, n (%)      |                 |                |                |
| Used                                                             | 120 (40.8)      | 61 (42.4)      | 181 (41.3)     |
| Not used                                                         | 174 (59.2)      | 83 (57.6)      | 257 (58.7)     |
| Clinical remission at Week 10 by modified Mayo score, n (%)      |                 |                |                |
| Remitter                                                         | 143 (48.6)      | 66 (45.8)      | 209 (47.7)     |
| Non-remitter                                                     | 151 (51.4)      | 78 (54.2)      | 229 (52.3)     |

Abbreviations: JAK, Janus kinase; Max, maximum; Min, minimum; N, number of the patients; SC, subcutaneous; SD, standard deviation.

Note: Percentages were calculated by using the number of patients in the all-randomized population as the denominator.

1.   Percentages were based on the number of female patients.

## Concomitant Medications

A total of 434 (99.5%) patients had taken at least 1 concomitant medication (295 [99.7%] and 139 [99.3%] patients in the CT-P13 SC 120 mg and Placebo SC treatment groups, respectively) during the treatment period (from Week 0 through Week 54). The most commonly reported concomitant medications by drug class  were  antidiarrheals,  intestinal  anti-inflammatory/anti-infective  agents  (407  [93.3%]in  total;  276 [93.2%] and 131 [93.6%] patients in the CT-P13 SC 120 mg group and Placebo SC group, respectively). Among them, mesalazine was the most commonly used concomitant medication by preferred term (PT) (382 [87.6%] patients in total; 254 [85.8%] and 128 [91.4%] patients in the CT-P13 SC 120 mg group and Placebo SC group, respectively).

A total 91 (20.9%) patients (64 [21.6%] and 27 [19.3%] patients in CT-P13 SC 120 mg and Placebo SC groups, respectively) had taken immunosuppressants during maintenance phase. Among  them, azathioprine was the most commonly used concomitant medication by PT (90 [20.6%] patients in total; 63 [21.3%] and 27 [19.3%] patients in CT-P13 SC 120 mg and Placebo SC groups, respectively).

## CHMP comment

<div style=\"page-break-after: always\"></div>

All  baseline  data  were  presented  only  for  patients  who  were  randomised  at  week  10,  i.e  those  who responded to the induction treatment. It is not known how non-responders differed from responders.

Among responders at week 10, demographic characteristics at baseline were balanced between CT-P13 SC 120 mg and Placebo treatment groups. The mean body weight among all subjects was 73.50 kg with a range of 42.1 to 130.2 kg. In this study, all patients received the same dose of CT-P13, regardless of weight.

No baseline characteristics were presented for the patient groups relevant for the proposed dose escalation. Baseline characteristics should be tabled for patients who required/received dose escalation and compared to those who did not.

## Updated comments (RSI AR)

The baseline  characteristics  of  dose  adjusted  patients  are  no  longer  relevant  as  the  proposal  for  dose adjustment was withdrawn.

## Outcomes and estimation

## Primary Endpoint

The primary efficacy endpoint of the study was clinical remission at Week 54, by modified Mayo score.

In the All-randomized Population, at Week 54, 127 (43.2%) patients receiving CT-P13 SC 120 mg achieved clinical  remission  compared  to  30  (20.8%)  patients  receiving  placebo  SC.  The  estimated  difference  in proportion between the treatment groups was 21.1 (95% CI: 11.8-29.3, p-value &lt;0.0001) in favour of CTP13 SC 120 mg.

## Sensitivity analysis

Results of the primary endpoint variable were very similar in the All-Randomized Population and in the PerProtocol population as well as in the sensitivity analyses utilizing Fisher's exact test, logistic regression model, excluding war-affected patients in Ukraine and excluding all patients in Ukraine.

To evaluate the effect of missing data on the primary endpoint, tipping point analysis was conducted on the all-randomized population. A total of 191 patients (109 [37.1%] and 82 [56.9%] patients in the CTP13 SC and Placebo groups, respectively) were considered missing in the tipping point analysis, including 151 patients (81 [27.6%] and 70 [48.6%] patients in the CT-P13 SC and Placebo groups, respectively) who received a dose adjustment prior to Week 54 and an additional 40 patients (28 [9.5%] and 12 [8.3%] patients  in  the  CT-P13  SC  and  Placebo  groups,  respectively)  with  missing  or  incomplete  data  for  the evaluation of the primary efficacy assessment.

The tipping point analysis was conducted using stratified CMH test of the same method for the primary endpoint  analysis.  It  was  shown  that  the  proportion  of  patients  achieving  the  clinical  remission  was significantly higher in CT-P13 SC 120 mg group (p-value &lt; 0.05) if the increased proportion of remitters in the Placebo SC group was not more than 7 percentage points higher than the increased proportion of remitters in the CT-P13 SC 120 mg group. Given that the estimated treatment effect over Placebo is 21.1%, the conclusion of the primary analysis does not seem to have been significantly impacted by missing data.

## Effect of Dose Adjustment on Clinical Remission at Week 54

To evaluate the treatment effect in patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 within  CT-P13  SC  group,  the  primary  endpoint  was  summarized  for  patients  with  and  without  dose adjustment in CT-P13 SC 120 mg group using a frequency table without statistical test.

<div style=\"page-break-after: always\"></div>

A total of 81 patients with dose adjustment prior to Week 54 in the CT-P13 SC 120 mg group were assessed for clinical remission. Among the patients with dose adjustment in CT-P13 SC 120 mg group, 20/81 (24.7%) patients achieved clinical remission at Week 54.

Subgroup analyses

Table 32. Proportion of Patients Achieving Clinical Remission at Week 54 by subgroup (Subgroups - Sex, Age, and Race [White]): All-Randomized Population

|                                                                | CT-P13 SC 120 mg (N=294)   | Placebo (N=144)      | Difference (95% CI)1   | P-value2   |
|----------------------------------------------------------------|----------------------------|----------------------|------------------------|------------|
|                                                                | n/N' (%) of patients       | n/N' (%) of patients |                        |            |
| Subgroup by Sex                                                |                            |                      |                        |            |
| Male                                                           |                            |                      |                        |            |
| Proportion of patients achieving clinical remission at Week 54 | 70/163 (42.9)              | 12/83 (14.5)         | 26.1 (14.2, 36.2)      | <.0001     |
| Female                                                         |                            |                      |                        |            |
| Proportion of patients achieving clinical remission at Week 54 | 57/131 (43.5)              | 18/61 (29.5)         | 14.3 (-0.7, 27.5)      | 0.0500     |
| Subgroup by Age                                                |                            |                      |                        |            |
| <35 years                                                      |                            |                      |                        |            |
| Proportion of patients achieving clinical remission at Week 54 | 58/129 (45.0)              | 11/54 (20.4)         | 23.7 (8.4, 36.0)       | 0.0017     |
| ≥35 years                                                      |                            |                      |                        |            |
| Proportion of patients achieving clinical remission at Week 54 | 69/165 (41.8)              | 19/90 (21.1)         | 19.1 (7.0, 29.7)       | 0.0014     |
| Subgroup by Race                                               |                            |                      |                        |            |
| White                                                          |                            |                      |                        |            |
| Proportion of patients achieving clinical remission at Week 54 | 124/288 (43.1)             | 30/140 (21.4)        | 20.5 (11.0, 28.9)      | <.0001     |

Abbreviations: CI, confidence interval; CMH, Cochran-Mantel-Haenszel; JAK, Janus kinase; SC, subcutaneous.

Note: Clinical remission was defined as modified Mayo score with a stool frequency subscore of O or 1 point, rectal bleeding subscore of 0 point, and endoscopic subscore of 0 or 1 point. Analysis was stratified by previous exposure to biologic agent and/or JAK inhibitors (used or not used), use of treatment with oral corticosteroids at Week 0 (used or not used) and clinical remission at Week 10 (remitter or non-remitter by modified Mayo score). Patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitter.

N' = number of patients in the subgroup

- The difference of proportions between 2 treatment groups was estimated using CMH weights, and the 95% stratified Newcombe CI with CMH weights were presented.
- The nominal p-value from stratified CMH test is presented in descriptive purpose.

<div style=\"page-break-after: always\"></div>

Table 33. Proportion of Patients Achieving Key Secondary Endpoints at Week 54 in Study CT-P13 3.7: All-Randomized Population

|                                                        | CT-P13SC120mg (N=294)   | PlaceboSC (N=144)   | Difference (95%CI) 1   | P-value 2   |
|--------------------------------------------------------|-------------------------|---------------------|------------------------|-------------|
| Clinical response at Week 54 3                         | 158 (53.7%)             | 45 (31.3%)          | 21.1 (11.2, 30.1)      | <0.0001     |
| Endoscopic-histologic mucosal improvement at Week 54 4 | 105 (35.7%)             | 24 (16.7%)          | 18.0 (9.1, 25.7)       | <0.0001     |
| Corticosteroid-free remission at Week 54 5             | 44/120 (36.7%)          | 11/61 (18.0%)       | 17.3 (3.1, 28.9)       | 0.0127      |

Source: CSR CT-P13 3.7 Post-text Tables 14.2.2.1, 14.2.2.2, 14.2.2.3

Note: Analysis was stratified by previous exposure to biologic agent and/or JAK inhibitors (used or not used), use of treatment with oral corticosteroids at Week 0 (used or not used) and clinical remission at Week 10 (remitter or non-remitter by modified Mayo score). Patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-responders or non-remitters.

- 1  The difference of proportions between 2 treatment groups estimated using CMH weights, and the 95% stratified Newcombe CI with CMH weights were presented.
- 2 The p-value from stratified CMH test was presented.
- 3 Clinical response was defined as a decrease in modified Mayo score from baseline of at least 2 points and at least 30%, with  an  accompanying decrease  in  the  rectal  bleeding  subscore  of  at  least  1  point  or  an  absolute  rectal bleeding subscore of 0 or 1 point.
- 4 Endoscopic histologic mucosal improvement was defined as an absolute endoscopic subscore of 0 or 1 point from modified  Mayo  score  and  an  absolute  RHI  score  of  3  points  or  less  with  an  accompanying  lamina  propria neutrophils and neutrophils in epithelium subscore of 0 point.
- 5 Corticosteroid-free remission was defined as being in clinical remission by modified Mayo score in addition to not requiring any treatment with corticosteroid for at least 8 weeks at Week 54, among the patients who used oral corticosteroids  at  baseline.  Percentages  were  calculated  by  using  the  number  of  patients  who  used  oral corticosteroids at baseline as the denominator.

Abbreviations: CMH, Cochran-Mantel-Haenszel; CI, confidence interval; JAK, Janus kinase; SC, Subcutaneous.

## Sensitivity and subgroup analyses

Results of key secondary endpoint variables were very similar in the All-Randomized Population and in the Per-Protocol population as well as in the sensitivity analyses utilizing Fisher's exact test, logistic regression model, excluding war-affected patients in Ukraine and excluding all patients in Ukraine.

Subgroup analyses of key secondary endpoints by sex are presented in the tables below.

Table 34. Proportion of Patients Achieving Clinical Response at Week 54 (Subgroup - Sex): AllRandomized Population

|                                                               | CT-P13 SC 120 mg (N=294)   | Placebo (N=144)      | Difference (95% CI)   | P-value2   |
|---------------------------------------------------------------|----------------------------|----------------------|-----------------------|------------|
|                                                               | n/N' (%) of patients       | n/N' (%) of patients |                       |            |
| Subgroup by Sex                                               |                            |                      |                       |            |
| Male                                                          |                            |                      |                       |            |
| Proportion of patients achieving clinical response at Week 54 | 85/163 (52.1)              | 20/83 (24.1)         | 25.5 (12.6, 36.8)     | <.0001     |

Female

<div style=\"page-break-after: always\"></div>

Table 35. Proportion of Patients Achieving Endoscopic Histologic Mucosal Improvement at Week 54 (Subgroup - Sex): All-Randomized Population

|                                                                 | CT-P13 SC 120 mg (N=294)   | Placebo (N=144)      | Difference (95% CI)   | P-value'   |
|-----------------------------------------------------------------|----------------------------|----------------------|-----------------------|------------|
|                                                                 | n/N* (%) of patients       | n/N* (%) of patients |                       |            |
| Subgroup by Sex                                                 |                            |                      |                       |            |
| Male                                                            |                            |                      |                       |            |
| Proportion of patients achieving endoscopic- histologic mucosal | 56/163 (34.4)              | 10/83 (12.0)         | 20.2 (8.9, 29.8)      | 0.0004     |
| Female                                                          |                            |                      |                       |            |
| Proportion of patients achieving endoscopic                     | 49/131 (37.4)              | 14/61 (23.0)         | 14.6 (0.0, 27.0)      | 0.0379     |

Table 36. Proportion of Patients Achieving Corticosteroid-Free Remission at Week 54 (Subgroup - Sex): All-Randomized Population

|                                                                           | CT-P13 SC 120 mg (N=292)   | Placebo (N=140)       | Difference (95% CI)   | P-value2   |
|---------------------------------------------------------------------------|----------------------------|-----------------------|-----------------------|------------|
|                                                                           | n/N* (%o) of patients      | n/N* (%o) of patients |                       |            |
| Subgroup by Ser                                                           |                            |                       |                       |            |
| Male                                                                      |                            |                       |                       |            |
| Proportion of patients achieving corticosteroid-free remission at Week 54 | 25/70 (35.7)               | 3/38 (7.9)            | 26.3 (9.3, 39.4)      | 0.0017     |
| Female                                                                    |                            |                       |                       |            |
| Proportion of patients achieving corticosteroid-free remission at Week 54 | 19/50 (38)                 | 8/23 (34.8)           | 4.2 (-19.4, 25.0)     | 0.7185     |

## Effect of Dose Adjustment on Clinical Response at Week 54

A total of 81 patients with dose adjustment prior to Week 54 in the CT-P13 SC 120 mg group were assessed for clinical response at Week 54. Among the patients with dose adjustment in CT-P13 SC 120 mg group, 40/81  (49.4%)  patients  achieved  clinical  response  at  Week  54,  18/81  (22.2%)  patients  achieved endoscopic-histologic mucosal improvement at Week  54 and 13/43 (30.2%) patients achieved corticosteroid-free remission at Week 54.

## Other Secondary Efficacy Endpoints

Other secondary efficacy endpoints were clinical remission assessed at weeks 10 and 22, maintenance of clinical remission at Week 54, sustained remission at both Week 22 and Week 54, clinical response assessed at weeks at weeks 10 and 22, endoscopic-histologic mucosal improvement assessed at weeks at weeks 8 and 22and scores and change from baseline in SIBDQ. The main results are summarised in tables below.

<div style=\"page-break-after: always\"></div>

Table 37. Proportion of Patients Achieving Clinical Remission by modified Mayo score at Weeks Other Than Week 54: All-Randomized Population

|                               | CT-P13 SC 120 mg (N=294)   | PlaceboSC (N=144)   | Difference (95%CI) 1   | P-value 2   |
|-------------------------------|----------------------------|---------------------|------------------------|-------------|
| Clinical remission at Week 10 | 143 (48.6%)                | 66 (45.8%)          |                        |             |
| Clinical remission at Week 22 | 128 (43.5%)                | 41 (28.5%)          | 13.8 (4.1, 22.7)       | 0.0025      |
| Clinical remission at Week 54 | 127 (43.2%)                | 30 (20.8%)          | 21.1 (11.8, 29.3)      | <0.0001     |

Among the patients with clinical remission at Week 10, 91/143 (63.6%) patients in the CT-P13 SC 120 mg group maintained clinical remission at Week 54, compared to 18/66 (27.3) in the Placebo SC group.

Table 37 and Table 38 present the proportion of patients in the all-randomised population achieving clinical response at weeks 10, 22 and 54. At week 10 patients were per definition responders by modified Mayo score, as only responders were randomised. However, due to a few misclassifications, the responder percentages are not 100 at week 10. Of note, among patients enrolled in the induction phase, 65/548, 11.9% were non-responders at Week 10.

Table 38. Proportion of Patients Achieving Clinical Response by modified Mayo score at Weeks Other Than Week 54: All-Randomized Population

|                              | CT-P13 SC 120 mg (N=294)   | PlaceboSC (N=144)   | Difference (95%CI) 1   | P-value 2   |
|------------------------------|----------------------------|---------------------|------------------------|-------------|
| Clinical Response at Week 10 | 292 (99.3)                 | 142 (98.6)          |                        |             |
| Clinical Response at Week 22 | 187 (63.6)                 | 64 (44.4)           | 18.3 (8.4, 27.9)       | 0.0002      |
| Clinical Response at Week 54 | 158 (53.7)                 | 45 (31.3)           | 21.1 (11.2, 30.1)      | <.0001      |

<div style=\"page-break-after: always\"></div>

Table 39. Proportion of Patients Achieving Total and Partial Clinical Response: All-Randomized Population

| Parameter Visit           | CT-P13 SC 120 mg (N=294)   | Placebo (N=144)        | Difference (95% CI)1   | P-value2   |
|---------------------------|----------------------------|------------------------|------------------------|------------|
|                           | Number (%) of patients     | Number (%) of patients |                        |            |
| Total clinical response   |                            |                        |                        |            |
| Week 10                   | 288 (98.0)                 | 140 (97.2)             |                        |            |
| Week 22                   | 188 (63.9)                 | 68 (47.2)              | 16.0 (6.1, 25.6)       | 0.0011     |
| Week 54                   | 156 (53.1)                 | 46 (31.9)              | 19.7 (9.8, 28.8)       | <.0001     |
| Partial clinical response |                            |                        |                        |            |
| Week 2                    | 219 (74.5)                 | 110 (76.4)             |                        |            |
| Week 6                    | 257 (87.4)                 | 118 (81.9)             |                        |            |
| Week 10                   | 293 (99.7)                 | 143 (99.3)             |                        |            |
| Week 14                   | 267 (90.8)                 | 122 (84.7)             | 5.6 (-0.8, 13.0)       | 0.0812     |
| Week 22                   | 214 (72.8)                 | 85 (59.0)              | 13.3 (3.9, 22.8)       | 0.0044     |
| Week 30                   | 194 (66.0)                 | 68 (47.2)              | 17.8 (7.9, 27.4)       | 0.0002     |
| Week 38                   | 188 (63.9)                 | 60 (41.7)              | 21.2 (11.3, 30.6)      | <.0001     |
| Week 46                   | 183 (62.2)                 | 56 (38.9)              | 21.9 (11.9, 31.2)      | <.0001     |
| Week 54                   | 173 (58.8)                 | 52 (36.1)              | 21.2 (11.3, 30.5)      | <.0001     |

Abbreviations: CI, confidence interval; CMH, Cochran-Mantel-Haenszel; JAK, Janus kinase;

SC, subcutaneous.

Note: Total clinical response was defined as decrease in total Mayo score from baseline of at least 3 points and at least 30%, with an accompanying decrease in rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1 point. Partial clinical response was defined as a decrease in partial Mayo score from baseline of at least 2 points, with an accompanying decrease in the subscore for rectal bleeding of at least

1 point, or an absolute subscore for rectal bleeding of 0 or 1 point. Analysis was stratified by previous exposure to biologic agent and/or JAK inhibitors (used or not used), use of treatment with oral corticosteroids at Week 0 (used or not used) and clinical remission at Week 10 (remitter or non-remitter by modified Mayo score).

Patients with dose adjustment to CT-P13 SC 240mg prior to their scheduled visit of interest were considered as nonresponder.

1. For the results  after  Week  10  randomization,  the  difference  of  proportions  between  2  treatment  groups  was estimated using CMH weights, and the 95% stratified Newcombe CI with CMH weights were presented.
2. For the results after Week 10 randomization, the nominal p-value from stratified CMH test was presented in descriptive purpose.

Endoscopic-histologic mucosal improvement at weeks 8 and 22 is described in table 39 .

Table 40. Proportion of Patients Achieving Endoscopic-Histologic Mucosal Improvement at Weeks other than Week 54: All-Randomized Population

| Visit   | CT-P13 SC 120 mg (N=294)   | Placebo (N=144)        | Difference (95% CI)1   | P-value2   |
|---------|----------------------------|------------------------|------------------------|------------|
|         | Number (%) of patients     | Number (%) of patients |                        |            |
| Week 8  | 108 (36.7)                 | 51 (35.4)              |                        |            |
| Week22  | 105 (35.7)                 | 36 (25)                | 9.5 (0.2, 18.0)        | 0.0343     |

<div style=\"page-break-after: always\"></div>

The mean (SD) SIBDQ score were improved in both treatment groups up to Week 10. After randomization, SIBDQ score in CT-P13 SC 120 mg group were well maintained, and slightly higher than in the Placebo SC group up to Week 54 (data not shown for brevity).

Long-term follow-up

Table 41. Proportion of Patients Achieving Clinical Remission at Week 54 and Week 102: All-Randomized Population

| Visit    | CT-P13 SC 120 mg (N=294)   | Placebo (N=144)      |
|----------|----------------------------|----------------------|
|          | n/N' (%) of patients       | n/N' (%) of patients |
| Week54   | 125/224 (55.8)             | 30/99 (30.3)         |
| Week 102 | 107/178 (60.1)             | 26/82 (31.7)         |

Note: Clinical remission was defined as modified Mayo score with a stool frequency subscore of 0 or 1 point, rectal bleeding subscore of 0 point, and endoscopic subscore of 0 or 1 point. Patients with dose adjustment to CT-P13 SC 240 mg prior to their scheduled visit of interest were considered as non-remitter. Percentages are calculated using the number of patients treated in extension phase and having modified mayo score at their scheduled visit of interest as denominator.

Among patients originally randomised to placebo 26/144 (18.1%) were in clinical remission two years after a successful induction treatment with infliximab IV, despite no active treatment after week 10.

## CHMP comment

As  discussed  in  the  methods  section,  the  study´s  ability  to  provide  meaningful  results  at  Week  54  is inherently compromised due to dose escalation/switch to active treatment allowed in the protocol.

The proportion of patients who achieved a clinical remission by modified Mayo at Week 54 was significantly higher in the CT-P13 SC 120 mg treatment group (127 [43.2%]) than in the Placebo SC treatment group (30 [20.8%]). All sensitivity analyses showed similar results.

There are no tables depicting the details of the non-responder category at Week 54. The MAH should provide tables outlining the number of patients who were: a) non-responder according to the clinical criteria b) dose was escalated/switch to active c) discontinuation before Week 54 d) missing data e) incomplete data f) any other reason and corresponding combination categories.

The difference between placebo and CT-P13 SC 120 mg treatment was notable also for all secondary efficacy endpoints. At week 22, clinical remission by modified Mayo score was achieved by 128 (43.5%) and 41 (28.5%) patients  in  the  CT-P13  SC  120  mg  treatment  group  and  in  the  Placebo  SC  treatment  group, respectively. A small difference between treatment arms was seen in measured clinical parameters already at  week  14,  i.e  four  weeks  (two  SC  doses)  after  the  switch  from  IV  Remsima.  The  actual  values  of endoscopic scores continued to improve throughout the study in the treatment arm while improvement was much less pronounced in the placebo arm, although also present throughout the study.

Subgroup analyses were performed for efficacy endpoints at week 54 by sex, age, and race. There were no differences in efficacy at week 54 between patients &lt;35 or &gt;35 years of age. Subgroup analysis by race was not feasible as 98% of participants were white. Male and female patients achieved remission and response at week 54 with equal frequency in the CT-P13 SC 120 mg treatment arm. However, in the placebo arm,  women  seemed  to  achieve  response  almost  twice  as  often  as  men  and  the  difference  between treatment and placebo was not as pronounced. According to corticoid-free remission, there was no clear difference between Remsima and placebo among women (38% of women in the treatment arm and 35%

<div style=\"page-break-after: always\"></div>

in the placebo arm were remitters at 54 weeks). The MAH should discuss whether this reflects a true gender difference  in  placebo  response  or  if  the  different  criteria  leading  to  classification  as  a  non-responder (corticosteroid use, dose increase, missing value) could have caused a discrepancy between sexes. (OC) Although this question might not affect the outcome of the procedure, it is considered relevant for the overall understanding of study outcome.

The tipping point analyses demonstrate that the results are fairly robust. However, in light of the 1:2 randomization the results in the placebo arm are more sensitive to changes in absolute number of patients counted as responders. It remains unclear whether all patients who switched to active treatment in the placebo arm before week 54 would have been clinical non responders at week 54. For example, if 10 patients  of  the  ones  who  switched  to  active  treatment  would  have  been  responders  at  Week  54,  the observed efficacy effect would have been only around 15%.

## Proposed induction regimen

The currently approved induction regimen for IV Remsima is identical to the one proposed now and used in  study 3.7. Instead of continuing with SC 120mg Q2W from week 10 onward (as proposed now) the approved regimen is to continue with IV 5 mg/kg Q8W from week 14. Before evaluation at week 14 (as advised in the SPC) patients on this new regimen will have received two doses with Remsima SC 120mg while patient on the approved regimen will have received none. Otherwise, the posology is identical. Hence, at week 14 efficacy of the newly proposed regimen cannot be worse than the one already approved.

It has already been shown that a switch to SC Remsima from IV Remsima does not attenuate efficacy after an initial induction of 6 weeks and a switch to SC Remsima is approved at any time during maintenance, starting 8 weeks after the last IV dose. Therefore, the switch to SC Remsima at week 10, starting only 4 weeks after the last IV dose, as proposed now, does not introduce any new efficacy issues compared to already approved regimens.

Also PK analyses showed that trough drug concentration levels remained close to the steady state plasma concentration throughout the SC dosing regimen without any concentration falls due to the switch (see PK assessment in section 6).

To conclude, based on pharmacokinetic reasoning and previously established positive benefit-risk for very similar dosing regimens, introduction of the 3-IV induction dosing regimen (5 mg/kg at Weeks 0, 2 and 6) followed by SC maintenance treatment (120 mg Q2W from week 10) is acceptable from the efficacy point of  view.  However, as results are intended to be included in the SPC, some scrutiny of the numbers is warranted (see LoQ). Please see section 8 for safety assessment.

According to the label, available data suggest that clinical response is usually achieved within 14 weeks in the treatment of UC. This recommendation stems from the initial IV formulation and dosing intervals. The MAH is invited to discuss, whether another time point could be introduced with the current and newly proposed SC regimen.

## Effect of dose adjustment

Responders at week 10 who lost response were allowed a dose increase from week 22 onward. UC is a fluctuating refractory disease with sometimes long symptom free periods. Therefore, some patients could have achieved remission again by week 54 after loss of response, even without dose escalation. Hence, the effect of dose escalation is difficult to contextualize due to the lack of an adequate control group.

Moreover, the MAH has provided a minimal amount of data to support the intended update in SPC section 4.2 to allow dose escalation. 81 [27.6%] and 70 [48.6%] patients in the CT-P13 SC and Placebo groups, respectively received a dose adjustment prior to Week 54. Among the patients with dose adjustment in the CT-P13 SC 120 mg group 40/81 (49.4%) patients regained clinical response by Week 54. Patients in the

<div style=\"page-break-after: always\"></div>

placebo arm and patients who stayed on the initial dose of CT-P13 were not described at all. It is not clear how many patients were eligible for dose increase, how many got it, how many of these had missing data at week 54, and how the disease progressed in patients who stayed on the initial dose.

Approximately 20% of patients in active arm who underwent dose escalation were responders at Week 54 which  is  approximately  the  same  number  as  the  percentage  of  responders  in  the  placebo  arm.  The interpretation of this result is not straight forward but it illustrates how difficult definitive interpretations of the results are in the absence of a properly designed study.

As the study design is inadequate to answer the relevant questions regarding the benefit/risk of a dose increase and the MAH provided virtually no details to enable assessment of the totality of data, the benefitrisk  of  a  dose  increase  is  unknown. To enable any assessment of the impact of a dose increase in UC patients, the MAH should address the following questions:

a) How many patients in each treatment arm were eligible for a dose increase before Week 54 and how many got it? The data should be presented by sex, body weight, disease severity, drug concentration and ADA status. It should also be clarified which weeks the dose increase was initiated at, i.e for how long the patients were exposed to the higher dose.

b) How did the disease progress among those who stayed on initial treatment regimen versus those who had a dose escalation? The analysis should be conducted for patients for whom dose was escalated/not escalated and patients who were eligible for dose escalation but did not escalate/did escalate. Did regain of response occur in patients who continued on placebo? Spontaneous fluctuation of the disease should be discussed and comparison should be made to patients who did not escalate and to historical controls. The MAH  should  provide  spaghetti  plots  (overlay  and  individual)  where  time  point  of  dose  escalation  is standardized in the middle of the graph and 4 visits before and after dose escalation are included.

c) Tha MAH claims that for patients who adjusted the dose, the reduction in the efficacy scores was observed from their following scheduled visit after the first dose adjustment. Appropriate data should be provided to support this claim.

d) Did the groups (i.e., patients for whom dose was escalated/not escalated and patients who were eligible for dose escalation but did not escalate/did escalate) differ in terms of compliance with the protocol or other parameters which could describe their well-being in addition to the primary endpoint?

e) Did loss of response or regain of response correlate with PK and/or ADA titres? Did the subjects needing dose escalation have lower concentrations of CT-P13 during the induction treatment (placebo group) and during induction and maintenance treatment (CT-P13 group)? Did the subjects who regained response have higher concentrations of CT-P13 compared to those who did not? Was the need for dose escalation or failure to  regain  response  associated  with  high  ADA  titres?  Were  high  ADA  titres  associated  with  low  drug concentrations?

f) The MAH should provide analysis according to principal stratum estimand.

g) The MAH should discuss how the fact that patients and investigators were effectively unblinded at the time of dose escalation impacts the results.

It should be noted that the results will be based on post-hoc analyses that were not pre-defined in the protocol.

The benefit-risk balance of a dose escalation from 120mg SC Q2W to 240mg SC Q2W is very uncertain. With this initial submission, efficacy cannot be determined since very limited data was provided. Moreover, the safety of the higher dose is not known. It seems that 157 UC patients were exposed to the 240mg dose but exposure time is not known. In light of the fact that trough drug concentrations are much higher with SC dosing than with IV dosing, the dose escalation becomes even more problematic. In previous studies

<div style=\"page-break-after: always\"></div>

on UC, the steady state Ctrough of infliximab has been around 8 microg/l with the double IV dose of 10 mg/kg. In study 3.7, the normal SC dose of 120mg gave median Ctrough concentrations of 13.3 microg/l. Hence,  already  the  120mg  SC  dose  gives  rise  to  considerably  higher  drug  concentrations  than  those achieved with the highest approved IV dosing. Sufficient safety data with long-time exposure to such high drug concentrations has not been provided.

Of  note,  in  the  assessment  report  of  the  initial  MA  of  Remsima  SC  in  the  treatment  of  UC  and  CD (EMEA/H/C/002576/II/0082), it was concluded based on data from Study CT-P13 1.6, that loss of response was not driven by low drug concentrations. After a dose increase from 120mg SC to 240mg SC 7/14 patients showed some sign of improvement but evidence for causality between improvement and dose increase was lacking. Moreover, the follow-up time was very limited and, therefore, the duration of the renewed response as well as the long-term safety of the high dos remained uncertain.

## Updated comments (RSI AR)

Detailed characteristics of dose adjusted patients are no longer relevant as the proposal for dose adjustment was withdrawn. Since dose escalation is thus off-label, it should not be mentioned in the SPC.

## 7.2. Study CT-P13 3.8

## 7.2.1. Study design

Study  CT-P13  3.8  was  a  randomised,  placebo-controlled,  double-blind,  Phase  3  study  to  evaluate  the efficacy  and  safety  of  the  CT-P13  SC  as  maintenance  therapy  in  patients  with  moderately  to severely active CD.

This  study  comprises  of  3  study  periods  including  screening,  treatment  period  (Induction  Phase, Maintenance Phase, and Extension Phase), and EOS visit. The schematic outline of Study CT-P13 3.8 design is illustrated in Figure 28.

This study is ongoing. The total duration of the study will be up to 112 weeks, which included screening (up to 6 weeks) and treatment period (up to the last dosing visit of study drug at Week 102) followed by EOS visit (after 4 weeks off dose period).

<div style=\"page-break-after: always\"></div>

Figure 28. Schematic Diagram of Study CT-P13 3.8 Design

<!-- image -->

- 1 From Week 22 through Week 54, dose adjustment was allowed. The patients who received CT-P13 SC 120 mg could increase the dose to CT-P13 SC 240 mg Q2W and the patients who received Placebo SC could receive CT-P13 SC 240 mg Q2W, if they initially responded but then lost response according to the loss of response criteria. Loss of Response was defined as an increase in CDAI of≥100 points from Week 10 CDAI score with a total score ≥220.
- 2 In the open-label Extension Phase, all patients who completed the Maintenance Phase up to Week 54 and who, in the opinion of the investigator, may benefit from continued treatment, will receive active treatment with CT-P13 SC 120 mg via PFS or AI from Week 56. The patients who received the adjusted dose of CT P13 SC 240 mg (double injection [2 shots] of CT-P13 SC 120 mg) Q2W in the Maintenance Phase will continue receiving the same doses of CT-P13 SC for the study treatment in the Extension Phase.

## CHMP comment

This Phase 3 study was designed to evaluate the efficacy, PK, PD, and safety of the SC injection of CT-P13 (CT-P13  SC)  as  maintenance  therapy  in  patients  with  moderately  to  severely  active  CD,  after  having received induction therapy with three IV-doses.

The design as such was reasonably adequate to answer the question whether maintenance therapy with SC Remsima is superior to placebo, after an initial response to induction treatment has been achieved but not the question whether a dose increase is effective. Please see further reasoning in section 7.1.1. As the design of study 3.8 was very similar to that of study 3.7, the critique will not be repeated here if the issues are identical.

Of note, for CD a dose increase is already approved for the IV maintenance regimen, but it is not comparable to the SC regimen since the PK of SC Remsima is very different. The target concentration of ≥5 μ g/mL is often not reached when treating patients with IV infliximab with the 5mg/kg dosing and therefore, a dose increase may be beneficial for some patients, as stated in the approved SPC of the IV product. However, the target concentration is usually well exceeded with SC 120 mg and therefore, it is on one hand not clear whether a dose increase from Remsima SC 120mg can add efficacy and on the other hand, the safety profile cannot be extrapolated from the IV dose.

<div style=\"page-break-after: always\"></div>

## 7.2.2. Methods

## Study participants

The study population consisted of patients aged 18 to 75 years old, inclusive, with moderately to severely active CD who had a Crohn's disease activity index (CDAI) score between 220 and 450 points  and  had an  inadequate  response  to  conventional  therapy.

The exclusion criteria were divided into 2 categories: general and TB exclusion criteria. Patients meeting any of the general and TB exclusion criteria were excluded from this study.

Main general Exclusion Criteria

1. Patient who had previously received 2 or more biologic agents, 2 or more JAK inhibitors, or 2 or more of both biologic agents and JAK inhibitors.
2. Patient who had previously received either a TNF α inhibitor or biologic agent within 5 half-lives prior to the first administration of the study drug (Day 0).
3. Patient who had previously demonstrated inadequate response or intolerance to TNF α inhibitors for the treatment of CD.
4. Patient who had previously received infliximab for treatment of CD or other disease.
5. Patient who had allergies to any of the excipients of infliximab or any other murine and/or human proteins or had a hypersensitivity to immunoglobulin products.
6. Patient who had received or had a plan to receive any of following prohibited medications or treatments:
- Parenteral corticosteroids for the treatment of CD within 2 weeks prior to the first administration of the study drug (Day 0)
- JAK inhibitors including but not limited to tofacitinib and baricitinib within 4 weeks prior to the first administration of the study drug (Day 0)
- Alkylating agents within 12 months prior to the first administration of the study drug (Day 0)
- Cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks prior to the first administration of the study drug (Day 0)
- Live or live-attenuated vaccine within 4 weeks prior to the first administration of the study drug (Day 0)
- Abdominal surgery for, including but not limited to, active gastrointestinal bleeding, peritonitis, intestinal obstruction, gastrointestinal resection, or intra-abdominal or pancreatic abscess requiring surgical drainage within 6 months prior to the first administration of the study drug (Day 0)
- Nonautologous stem cell therapy (e.g., Prochymal) within 12 months prior to the first administration of the study drug (Day 0)
- Apheresis (e.g., Adacolumn apheresis) for the treatment of CD within 3 weeks prior to the first administration of the study drug (Day 0)
- Use of total parenteral nutrition within a month prior to the first administration of the study drug (Day 0)

<div style=\"page-break-after: always\"></div>

- Use of exclusive enteral nutrition for more than 3 consecutive days within a month or any single day of exclusive enteral nutrition within 2 weeks prior to the first administration of the study drug (Day 0)

Patients with a history of certain serious infections and medical conditions were also excluded. For example: Active entero-vesical, entero-retroperitoneal, entero-cutaneous, or entero-vaginal fistulae within 6 months prior to the first administration of the study drug (Day 0). Entero-enteral fistulae without clinically significant symptoms in the investigator's opinion and anal fistulae without draining problems were allowed.

## CHMP comment

The inclusion and exclusion criteria are only partly in line with the target population for this variation, i.e the CD patients for whom Remsima is approved:

- treatment of moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
- treatment of fistulising, active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).

Only patients with anal fistulae were included (11 (4.8%) and 7 (6.3%) patients in the CT-P13 and placebo arms,  respectively),  while  patients  with  entero-vesical,  entero-retroperitoneal,  entero-cutaneous,  or entero-vaginal fistulae within 6 months prior to the trial were excluded. It is not clear how well the current study results are applicable to patients with active fistulising CD. According to the EMA guideline on the development of new medicinal products for the treatment of Crohn's Disease (CPMP/EWP/2284/99 Rev. 2), the therapeutic goals of management of fistulising CD are to close fistulas and maintain their closure, to reduce the incidence of infections in persisting fistulas, and to limit the need for surgical interventions. These endpoints have not been assessed in study 3.8.

The proposed update of section 4.2 for Remsima SC includes a harmonisation of posologies between active Crohn's disease and fistulising active Crohn's disease but many patients with active fistulising CD were excluded from the study. Taking into account the exclusion criteria, the MAH should discuss how well the current study results and resulting amendments to the SPC are applicable to patients with active fistulising CD.

## Updated comments (RSI AR)

After the first RSI the MAH withdrew the proposal to harmonise posologies between active Crohn's disease and fistulising active Crohn's disease regarding timing of decision on continuation.

The newly included possibility to use a 3 IV induction regimen in addition to the 2 IV induction regimen is a minor amendment for which the small differences in the indications are not relevant. Therefore, the 3 IV regimen can be applied also to the fCD although such patients were not included in the clinical study.

Although there is no data available on the effect of dose escalation in fistulising CD, it can be assumed that the  benefit  is  not  significantly  different  from  that  seen  in  CD  and  with  IV  Remsima,  for  which  a  dose escalation is approved in fCD. Hence, the OC on inclusion criteria is resolved.

<div style=\"page-break-after: always\"></div>

## Treatments

In  the open-label  induction  phase ,  the  patients  who  met  all  the  inclusion  criteria  and  none  of  the exclusion  criteria  were  enrolled  on  Day  0  (Week  0). All  enrolled  patients  received  a  2-hour  CT-P13  IV infusion (5 mg/kg) during onsite visits at Weeks 0, 2, and 6 as induction treatments. Patients who were classified as a Crohn's disease activity index (CDAI)-100 responder at Week 10 after receiving 3 full doses of CT-P13 via IV infusion and for whom there were no safety concerns based on the investigator's discretion were randomly assigned to receive either CT-P13 SC or placebo SC, before treatment on Week 10.

The double-blind maintenance phase consisted of further doses of CT-P13 SC or placebo SC with the last dose administered no later than Week 54.

1. Treatment Group 1, CT-P13 SC: from Week 10, CT-P13 SC 120 mg was administered every 2 weeks via PFS through Week 54
2. Treatment Group 2, placebo SC: from Week 10, placebo SC (matching volume to CT-P13 SC 120 mg) was administered every 2 weeks via PFS through Week 54

In the open-label extension phase , all patients who complete the maintenance phase up to Week 54 and may benefit from continued treatment, in the opinion of the investigator, will receive active treatment with CT-P13 SC 120 mg via PFS or AI from Week 56. The patients who received the adjusted dose of CT-P13 SC 240 mg in the maintenance phase continued receiving the same doses of CT-P13 SC for the study treatment in the extension phase. The extension phase will continue up to Week 102.

From Week 22 through Week 102, dose adjustment was allowed as follows:

1. The patients who received CT-P13 SC 120 mg may increase the dose to CT-P13 SC 240 mg (double injection [2 shots] of CT-P13 SC 120 mg) every 2 weeks, if patients initially responded but then lost response according to the loss of response criteria
2. The patients who received placebo SC may receive CT-P13 SC 240 mg (double injection [2 shots] of CT-P13 SC 120 mg) every 2 weeks, if patients initially responded but then lost response according to the loss of response criteria

Loss of response was defined as an increase in CDAI of ≥100 points from the Week 10 CDAI score with a total score of ≥220.

## CHMP comment

All patients received the same induction treatment with Remsima IV infusion (5 mg/kg) at Weeks 0, 2, and 6. After randomisation at week 10, only responders continued and received Remsima SC 120 mg or placebo every 2 weeks.

From Week 22 a dose adjustment was allowed but not mandatory and not randomised. As discussed above in section 7.1.1 the possibility to switch to higher dose/active treatment hampers the ability to assess the study objectives.

There  are  slight  differences  in  the  posology  for  CD  and  fistulising  CD  which  are  now  proposed  to  be harmonised:

In  the  currently  approved  posology  for  CD,  treatment  should  not  be  continued  beyond  6  weeks  if  no response is seen. In fistulising CD, the decision on continuation of treatment should be made at week 14. In all other aspects the posology in CD and fistulising CD are identical.

This difference has its origin in the IV posology of the originator infliximab (Remicade) and it is assumed that there is clinical data to support it. Although it is acknowledged that the amount of weeks needed before

<div style=\"page-break-after: always\"></div>

response is assessed is dictated by the actual dosing/visit interval more than the exact time to response and that there is no clinical data available on fistulising CD with the SC presentation, it seems evident based on the approved wording for the IV originator that response is reached slower in fistulising CD than in CD.

With the current variation, the MAH proposes to change the timing for decision on continuation of treatment to 10 weeks for both CD and fistulising CD. Since patients with active fistulising CD were excluded, Study CT-P13 3.8 cannot support this change for all fistulising CD. Furthermore, no discussion on this aspect of the amended wording was provided in the dossier.

## Updated comments (RSI AR)

The Applicant has withdrawn the changes to the PI regarding timing of decision on continuation.

## Objectives

## Primary objective:

To demonstrate superiority of CT-P13 subcutaneous (SC) over Placebo SC based on clinical remission and endoscopic response at Week 54

## Secondary objective:

To  evaluate  additional  efficacy,  pharmacokinetics  (PK),  pharmacodynamics  (PD),  usability,  and  overall safety including immunogenicity

## Outcomes/endpoints

## Co-Primary Efficacy Endpoints:

In Study CT-P13 3.8, co-primary endpoints were:

- Clinical remission at Week 54, defined as an absolute CDAI score of &lt;150 points
- Endoscopic response at Week 54, defined as a 50% decrease in SES-CD score from the baseline value

## Key Secondary Efficacy Endpoints:

- CDAI-100 response at Week 54, defined as a decrease in CDAI score of 100 points or more from the baseline value
- Clinical remission (based on AP [abdominal pain] and SF [stool frequency]) at Week 54, defined as  an  average  worst  daily  AP  score  of ≤1 (using 4-point  scale),  and  an  average loose/watery SF score of ≤3 (of Type 6 or Type 7 on Bristol stool form scale [BSFS]) with no worsening in either score compared to the baseline value
- Endoscopic remission at Week 54, defined as an absolute SESCD score of ≤4 and at least 2-point reduction from the baseline value with no sub-score of &gt;1
- Corticosteroid-free remission at Week 54, defined as being in clinical remission (by an absolute CDAI score of &lt;150) in addition to not receiving any corticosteroids for at least 8 weeks prior to Week 54, among the patients who used oral corticosteroids at baseline

## Other Secondary Efficacy Endpoints:

- Clinical remission, defined as an absolute CDAI score of &lt;150 points

<div style=\"page-break-after: always\"></div>

- Maintenance  of  clinical  remission  at  Week 54,  defined  as  being  in  clinical  remission  by CDAI score of &lt;150 points, among the patients in clinical remission at Week 10
- Sustained clinical  remission at  both Week 22 and  Week 54, defined  as an  average worst daily AP score of ≤1 (using 4-point scale), and an average loose/watery SF score of ≤3 (of Type 6 or Type 7 on BSFS) at both Week 22 and Week 54 with no worsening in either score compared to the baseline value
- CDAI-70 response, defined as a decrease in CDAI score of 70 points or more from the baseline value
- CDAI-100 response, defined as a decrease in CDAI score of 100 points or more from the baseline value
- Maintenance of clinical  response at  Week 54,  defined  as  being  in  CDAI-100 response at Week 54, among the patients in CDAI-100 response at Week 10
- Sustained clinical response at both Week 22 and Week 54, defined as a reduction from the baseline value in average worst daily AP score (using 4-point scale) and/or in average daily loose/watery SF (of Type 6 or Type 7 on BSFS) at both Week 22 and Week 54
- Endoscopic remission, defined as an absolute SES-CD score of ≤ 4 and at least 2-point reduction from the baseline value with no sub-score of &gt;1
- Endoscopic response, defined as a 50% decrease in SES-CD score from the baseline value
- Patient  global  scale,  defined  as  a  question  that  asked  a  patient's  position  on  achieving remission from his or her CD symptoms (Yes or No)
- SIBDQ

## CHMP comment

The chosen efficacy parameters are in line with the EMA guideline on the development of new medicinal products for the treatment of Crohn's Disease (CPMP/EWP/2284/99 Rev. 2).

The primary objective of this study was to demonstrate superiority of Remsima SC over placebo in the maintenance treatment of CD patients at week 54. This is not relevant for the variation at hand as Remsima SC is  already  approved  for  maintenance  treatment  and  it  is  not  likely  that  a  small  adjustment  of  the induction regimen would render the whole treatment ineffective. However, as the MAH proposes to include the main results from study 3.8 in the SPC section 5.1, the primary endpoints also need to be assessed.

Importantly, there is no pre-defined endpoint to assess whether high dose maintenance is effective.

## Sample size

The sample size of 360 patients (240 in CT-P13 SC 120 mg group and 120 in placebo SC group) was estimated to provide at least 90% statistical power to detect a statistically significant clinical effectiveness of  CT-P13  SC  in  comparison  with  placebo  SC  in  the  following  co-primary  endpoints  at  the  one-sided significance level of 2.5%.

- Clinical  remission  at  Week  54,  defined  as  an  absolute  CDAI  score  of  &lt;150  points,  assuming  a treatment difference of 18% and placebo rate of 19%
- Endoscopic response at Week 54 assuming a treatment difference of 26% and placebo rate of 2%

Considering  a  40%  non-responder  rate  of  CDAI-100  at  Week  10  before  randomization,  a  total  of approximately 600 patients were to be enrolled at Week 0. The number

<div style=\"page-break-after: always\"></div>

## CHMP comment

The study includes co-primary endpoints and the sample size has been set up to test both at alpha-level 2.5%, one sided. Study success is only to be concluded if both endpoints are positive. This is appropriate.

In the protocol, a 2% response rate in placebo has been assumed for endoscopic response at Week 54. In the end 17.9% response rate was observed. The difference between the assumed (basically no responders) and observed (a meaningful proportion of responders) cannot be neglected because it reflects that either the study population or the behavior of the endpoint (potentially including data analysis), or something else, is not as expected. The MAH should elaborate on the potential root cause(s) for this finding.

The comments outlined for study CT-P13.3.7. are relevant also here.

## Updated comments (RSI AR)

The issue on discrepant response rate is not pursued further.

## Randomisation

For initiating the double-blind maintenance phase, an interactive web response system (IWRS) was used for the randomization. A biostatistician generated the randomization schedule for the IWRS, which linked sequential patient randomization numbers to treatment codes. Patients classified as a CDAI-100 responder at Week 10 after receiving 3 full doses of CT-P13 via  IV  infusion  and  have  no  safety  concern  based  on the  investigator's  discretion  were randomized in a 2:1 ratio to receive either CT-P13 SC or Placebo SC, before treatment on Week 10.

The randomization was stratified  by previous  exposure to biologic  agent  and/or  JAK inhibitors (used or not used), use of treatment with oral corticosteroids at Week 0 (used or not used), and clinical remission at  Week  10  (remitter  or  non-remitter  by  CDAI  score).  Permuted  block  design  was  used  to  randomize patients  to  treatment  groups,  where  within  each  block  the  same  pre-specified  ratio  of  patients  was allocated to the treatment groups. The block size was not revealed.

## CHMP comment

The stratification factors are adequate.

Importantly, as commented elsewhere in this report, the benefits of randomization are lost for the primary and  secondary  efficacy  objectives  at  week  54  because  changes  based  on  subjective  criteria  in  the randomized  dosing  regimen  are  allowed.  Furthermore,  randomization  is  not  relevant  for  the  question whether high dose maintenance is an option for patients with loss of response. This would have required randomization at the time of loss of response (week 22).

## Blinding (masking)

This study had a double-blind maintenance phase, the treatment assignment for the maintenance phase was blinded to the investigators, patients, and predefined CELLTRION, Inc. and PPD-blinded teams until this Week 54 CSR was generated and will remain blinded until the Week 102 CSR is generated.

## CHMP comment

In  theory,  the  study  is  double  blind.  However,  the  investigator  and  patient  know  that  if  the  dose  was escalated, the patient received active treatment. Furthermore, the investigator knows that as a result of

<div style=\"page-break-after: always\"></div>

dose escalation the patient automatically is a non-responder in the efficacy analyses. Hence, the study cannot be considered adequately blinded.

## Statistical methods

For the efficacy endpoints related remission or response, the following patients were considered as nonremitter or non-responder:

- Patients who did not met the remission or response criteria
- Patients with missing or incomplete data for the evaluation of each endpoint at their scheduled visit of interest, even after applying the data handling rule
- Patients with dose adjustment to CT-P13 SC 240 mg prior to their scheduled visit of interest

The following efficacy parameters were determined as the co-primary efficacy endpoints:

- Clinical remission at Week 54, defined as an absolute CDAI score of &lt;150 points
- Endoscopic response at Week 54, defined as a 50% decrease in SES-CD score from the baseline value

The co-primary endpoints were tested at the two-sided significance level of 5% on the all-randomized population using the p-value from Cochran-Mantel-Haenszel (CMH) test stratified by previous exposure to biologic agent and/or JAK inhibitors (used or not used), use of treatment with oral corticosteroids at Week 0 (used or not used) and clinical remission at Week 10 (remitter or non-remitter by CDAI score). If both pvalues were ≤0.05, the statistical significance of both co -primary endpoints was planned to be concluded.

## CHMP comment

The assessment of statistical methods is as for study CT-P13 3.7.

## 7.2.3. Results

## Participant flow

A total of 787 patients were screened. Out of 787 patients, 396 patients were enrolled in the study in which, all-randomized patients were treated with CT-P13 5 mg/kg via IV infusion in the open-label induction phase. Of these patients, 53 patients discontinued the study during the induction phase. The most frequently reported primary reason for discontinuation during the induction phase was non-responder at Week 10 (22 patients). The mean (SD) time on CT-P13 5 mg/kg via IV infusion prior to discontinuation in the induction phase was 36.5 (14.97) days.

A  total  of  343  patients  were  randomly  assigned  to  study  treatment  and  initiated  the  double-blind maintenance phase at Week 10 (231 and 112 patients in the CT-P13 SC 120 mg and placebo SC groups, respectively). All randomly assigned patients were treated in the maintenance phase (231 and 112 patients in the CT-P13 SC 120 mg and placebo SC groups, respectively). Sixty (17.5%) patients discontinued the study during the maintenance phase (35 [15.2%] and 25 [22.3%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively).

Overall, the most frequently reported primary reason for discontinuation during the maintenance phase was progressive disease (12 [5.2%] patients in the CT-P13 SC 120 mg group and 6 [5.4%] patients in placebo SC group). The mean (SD) time on study drug prior to discontinuation during the maintenance

<div style=\"page-break-after: always\"></div>

phase was 235.7 (96.90) and 256.7 (106.90) days in the CT-P13 SC 120 mg and placebo SC groups, respectively.

Figure 29. Patient Disposition: All-Randomized Population

<!-- image -->

Abbreviation: SC, subcutaneous.

1. A patient in CT-P13 SC 120 mg group was excluded from all analysis populations due to significant GCP noncompliance of the study EMA: deletion agreed, but pleacenter 3001.

Source: Post-text Table 14.1.1.

<div style=\"page-break-after: always\"></div>

<!-- image -->

## CHMP comment

The Applicant is requested to provide a Figure of Patient Disposition which outlines for how many patients the dose was escalated at/after week 22.

It  should  be  clarified  how  patients  with  progressive  disease  who  discontinued  the  study  differed  from patients who received a dose increase. If possible, the differentiation should be displayed in the flow chart Figure of Patient Disposition.

## Updated comments (RSI AR)

The number of patients with dose adjustment has been clarified (see section 13 for assessment of responses).

The MAH has explained that dose adjustment and disease progression had different indicators and were independently decided. Only two patients in each treatment arm had disease progression but did not receive a dose escalation and were discontinued instead.

The final flow chart has been added with data up to W102.

## Recruitment

A total of 787 patients from 148 study centers in 26 countries were screened and 396 patients from 114 study centers in 26 countries were enrolled in this study.

28 October 2019 (first patient's first drug administration date) to 23 August 2022 (Date for last patient's Week 54 visit).

<div style=\"page-break-after: always\"></div>

## Conduct of the study

The  most  frequently  reported  major  protocol  deviations  were  patients  who  were  non-compliance  with inclusion or exclusion criteria which affect the efficacy result (4 [1.7%] patients and 2 [1.8%] patients in the CT-P13 SC and placebo SC groups, respectively). Patients with major protocol deviations were excluded from the PP population or PP and PK populations.

There was a site () with significant GCP non-compliance. The site failed to conduct the study in accordance with ICH GCP guidelines based on the findings detected during the on-site monitoring visit. A patient, who was the only one enrolled in this study from the site, was excluded from all analysis population analysis in accordance with the Statistical Analysis Plan (SAP) version 1.0.

Table 42. Major Protocol Deviations: All-Randomized Population

|                                                                                    | CT-P13 SC 120 mg (N=231)   | Placebo SC (N=112)     | Total (N=343)          | Excluded Populationsl   |
|------------------------------------------------------------------------------------|----------------------------|------------------------|------------------------|-------------------------|
|                                                                                    | Number (%) of patients     | Number (%) of patients | Number (%) of patients | Number (%) of patients  |
| Major protocol deviation                                                           | 7 (3.0%)                   | 4 (3.6%)               | 11 (3.2%)              |                         |
| Mis-randomizations                                                                 | 2 (0.9%)                   | 1 (0.9%)               | 3 (0.9%)               | PP, PK                  |
| Non-compliance of inclusion or exclusion criteria which affect the efficacy result | 4 (1.7%)                   | 2 (1.8%)               | 6 (1.7%)               | PP                      |
| Randomization without CDAI-100 response at Week 102                                | 2 (0.9%)                   | 0                      | 2 (0.6%)               | PP                      |
| Other deviation which affects the efficacy results3                                | 1 (0.4%)                   | 1 (0.9%)               | 2 (0.6%)               | PP                      |

## Numbers analysed

All 396 enrolled patients were included in the ITT population.

All-randomized population consisted of 343 patients who were randomly assigned to study treatment and initiated the maintenance phase at Week 10 (231 and 112 patients in the CT-P13 SC 120 mg and placebo SC groups, respectively).

The PP population included 332 patients (230 and 102 patients in the CT-P13 SC 120 mg and placebo SC groups, respectively). Among the randomized patients, 11 patients with major protocol deviation were excluded from the PP population.

## CHMP comment

The reported major protocol deviations were few and balanced across treatment arms.

However, there is a discrepancy in the reported number of patients analysed per protocol. It is stated that 11 patients with major protocol deviation were excluded from the PP population, only one of whom was in the CT-P13 arm. However, in Table 7.2.3.1 it is stated that 7 major protocol deviations occurred in the CTP13 arm and 4 in the placebo arm. The numbers should be clarified and aligned.

<div style=\"page-break-after: always\"></div>

No other concerns regarding GCP or validity of the results have emerged based on study conduct. Exclusion of the GCP non-compliant site is endorsed.

## Updated comments (RSI AR)

The discrepancies have been clarified.

## Baseline data

Baseline data are presented only for patients who were randomised at week 10, i.e those who responded to the induction treatment.

The mean (SD) age of patients was 36.0 (12.53) and 32.3 (11.53) years in the CT-P13 SC 120 mg and placebo SC groups, respectively. In total, there was a slightly higher proportion of male patients than female patients (203 [59.2%] male and 140 [40.8%] female patients). Most patients were White (312 [91.0%] patients). The mean (SD) screening weight of patients was 68.88 (15.584) and 67.32 (15.241) kg in the CT-P13 SC 120 mg and placebo SC groups, respectively. The mean (SD) screening BMI of patients was 23.272 (4.3960) and 22.549 (4.3786) kg/m 2  in the CT-P13 SC 120 mg and placebo SC groups, respectively.

Overall, the mean (SD) time since active CD diagnosis was 4.38 (5.375) years and similar between the 2 groups  (4.34  [5.183]  and  4.45  [5.775]  years  for  the  CT-P13  SC  120  mg  and  placebo  SC  groups, respectively).

Among responders to the induction, the mean CDAI score at baseline was 312 for the CT-P13 SC 120 mg group and 310 for the placebo group.

<div style=\"page-break-after: always\"></div>

Table 43. Baseline characteristics

| Parameter Statistics              | CT-P13 SC 120 mg (N=231)   | Placebo SC (N=112)   | Total (N=343)   |
|-----------------------------------|----------------------------|----------------------|-----------------|
| Age (years)                       |                            |                      |                 |
| n                                 | 231                        | 112                  | 343             |
| Mean (SD)                         | 36.0 (12.53)               | 32.3 (11.53)         | 34.8 (12.32)    |
| Median                            | 36.0                       | 29.0                 | 33.0            |
| Min, Max                          | 18,75                      | 18, 66               | 18, 75          |
| Gender, n (%)                     |                            |                      |                 |
| Male                              | 134 (58.0%)                | 69 (61.6%)           | 203 (59.2%)     |
| Female                            | 97 (42.0%)                 | 43 (38.4%)           | 140 (40.8%)     |
| Female fertility status, n (%)    |                            |                      |                 |
| Surgically sterilized             | 1 (1.0%)                   | 2 (4.7%)             | 3 (2.1%)        |
| Post-menopausal                   | 21 (21.6%)                 | 4 (9.3%)             | 25 (17.9%)      |
| Potentially able to bear children | 75 (77.3%)                 | 37 (86.0%)           | 112 (80%)       |
| Race, n (%)                       |                            |                      |                 |
| American Indian or Alaska Native  | 8 (3.5%)                   | 5 (4.5%)             | 13 (3.8%)       |
| Asian                             | 9 (3.9%)                   | 4 (3.6%)             | 13 (3.8%)       |
| Black or African American         | 1 (0.4%)                   | 0                    | 1 (0.3%)        |
| White                             | 211 (91.3%)                | 101 (90.2%)          | 312 (91.0%)     |
| Other                             | 2 (0.9%)                   | 2 (1.8%)             | 4 (1.2%)        |
| Ethnicity, n (%)                  |                            |                      |                 |
| Hispanic or Latino                | 12 (5.2%)                  | 7 (6.3%)             | 19 (5.5%)       |
| Non-Hispanic or Non-Latino        | 219 (94.8%)                | 105 (93.8%)          | 324 (94.5%)     |
| Unknown                           | 0                          | 0                    | 0               |
| Screening height (cm)             |                            |                      |                 |
| n1                                | 231                        | 112                  | 343             |
| Mean (SD)                         | 171.63 (8.902)             | 172.41 (10.585)      | 171.89 (9.476)  |
| Median                            | 172.00                     | 173.00               | 172.00          |
| Min, Max                          | 148, 194                   | 145,203              | 145, 203        |

Screening weight (kg)

<div style=\"page-break-after: always\"></div>

| Parameter Statistics                                             | CT-P13 SC 120 mg (N=231)   | Placebo SC (N=112)   | Total (N=343)   |
|------------------------------------------------------------------|----------------------------|----------------------|-----------------|
| n                                                                | 231                        | 112                  | 343             |
| Mean (SD)                                                        | 68.88 (15.584)             | 67.32 (15.241)       | 68.37 (15.467)  |
| Median                                                           | 66.00                      | 65.00                | 65.60           |
| Min, Max                                                         | 41, 126                    | 40, 101.5            | 40,126          |
| Screening BMII (kg/m2)                                           |                            |                      |                 |
|                                                                  | 231                        | 112                  | 343             |
| Mean (SD)                                                        | 23.272 (4.3960)            | 22.549 (4.3786)      | 23.036 (4.3970) |
| Median                                                           | 22.700                     | 21.755               | 22.280          |
| Min, Max                                                         | 14.2,34.61                 | 15.93,34.72          | 14.2,34.72      |
| Previous exposure to biologic agent and/or JAK inhibitors, n (%) |                            |                      |                 |
| Used                                                             | 26 (11.3%)                 | 9 (8.0%)             | 35 (10.2%)      |
| pesn joN                                                         | 205 (88.7%)                | 103 (92.0%)          | 308 (89.8%)     |
| Use of treatment with oral corticosteroids at Week 0, n (%)      |                            |                      |                 |
| Used                                                             | 99 (42.9%)                 | 43 (38.4%)           | 142 (41.4%)     |
| Not used                                                         | 132 (57.1%)                | 692 (61.6%)          | 201 (58.6%)     |
| Clinical remission at Week 10 by CDAI score, n (%)               |                            |                      |                 |
| Remitter                                                         | 174 (75.3%)                | 91 (81.3%)           | 265 (77.3%)     |
| Non-remitter                                                     | 57 (24.7%)                 | 21 (18.8%)           | 78 (22.7%)      |

Abbreviations: BMI, body mass index; CDAI, Crohn's disease activity index; JAK, Janus kinase; Max, maximum; Min, minimum; SC, subcutaneous; SD, standard deviation.

Note: Percentages were calculated by using the number of patients in the all-randomized population as the denominator.

1. Percentages were based on the number of female patients.
2. A patient was reported 'Not used' of the use of treatment with oral corticosteroids at Week 0 in the stratification factor at the first Week 54 CSR. However, the use of oral corticosteroid was recorded at Week 0 in concomitant medication page and was confirmed by the investigator. As a result, the patient was corrected as used patient for the treatment with oral corticosteroids at Week 0 in this final CSR. The analysis for this correction had been included in the first Week 54 CSR.

## Prior and Concomitant Medications

A total  of  325  (94.8%) patients had taken at least 1 prior medication (225 [94.5%] and 100 [95.2%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively). The most commonly reported prior medications by drug class was drugs for constipation (251 [73.2%] patients in total; 173 [72.7%] and 78 [74.3%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively), and the second was antidiarrheals,  intestinal  anti-  inflammatory/anti-infective  agents  (186  [54.2%]  patients  in  total;  129 [54.2%] and 57 [54.3%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively).

A total of 339 (98.8%) patients had taken at least 1 concomitant medication (235 [98.7%] and 104 [99.0%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively) during the treatment period (from Week 0 through Week  54). The most  commonly reported  concomitant  medications  by  drug  class  was antidiarrheals, intestinal anti-inflammatory/anti- infective agents (180 [75.6%] and 71 [67.6%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively). Among them, mesalazine was the most

<div style=\"page-break-after: always\"></div>

commonly used concomitant medication by PT (142 [59.7%] and 57 [54.3%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively).

## CHMP comment

All  baseline  data  were  presented  only  for  patients  who  were  randomised  at  week  10,  i.e  those  who responded to the induction treatment. It is not known how non-responders differed from responders.

Among  responders  at  week  10,  demographic  characteristics  at  baseline  were  balanced  between  the treatment groups. The mean body weight among all subjects was 68.4 kg with a range of 40 to 126 kg. In this study, all patients received the same dose of CT-P13, regardless of weight.

No baseline characteristics were presented for the patient groups relevant for the proposed dose escalation. Baseline characteristics should be tabled for patients who required/received dose escalation and compared to those who did not.

## Updated comments (RSI AR)

Among patients who received a dose escalation the use of oral corticosteroids was more frequent at baseline compared to those who did not require a dose increase (see section 13 Q28 for details). This could possibly reflect a more severe form of disease among those who lost response.

## Outcomes and estimation

## Primary Endpoint

The results of the co-primary endpoints (clinical remission based on CDAI at Week 54 and endoscopic response based on central SES-CD at Week 54) are presented in Table 43.

<div style=\"page-break-after: always\"></div>

Table 44. Proportion of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 and Endoscopic Response (Based on Central SES-CD) at Week 54 in Study CT-P13 3.8: All-randomized Population

|                                                    | CT-P13 SC 120 mg (N=231)   | Placebo SC (N=112)   | Difference (95% CI)1   | P-value2   |
|----------------------------------------------------|----------------------------|----------------------|------------------------|------------|
| Clinical Iremission based on CDAI atWeek54         | 144 (62.3%)                | 36 (32.1%)           | 32.1 (20.9, 42.1).     | <0.0001    |
| Endoscopicresponsebasedon central SES-CD atWeek 54 | 118 (51.1%)                | 20 (17.9%)           | 34.7 (24.2, 43.5)      | <0.0001    |

Source: CSR CT-P13 3.8 Post-text Table 14.2.1.1 and Table 14.2.1.2

Note: Clinicalremission was defined as an absolute CDAI score of &lt;150 points. Analysis was stratified by previous exposure to biologic agents and/or JAK inhibitors (used or not used), use of treatment with oral corticosteroids at Week 0 (used or not used) and clinical remission at Week 10 (remitter or non-remitter by CDAI score). Patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitters.

Endoscopic response was defined as a 50% decrease in SES-CD score from the baseline value. Analysis was stratified by previous exposure to biologic agents and/or JAK inhibitors (used or not used), use of treatment with oral corticosteroids at Week 0 (used or not used) and clinical remission at Week 10 (remitter or non-remitter by CDAI score). Patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as nonresponders

2 The p-value from stratified CMH test is presented.

1 The difference of proportions between 2 treatment groups estimated using CMH weights, and the 95% stratified Newcombe CI with CMH weights are presented.

Abbreviations: CDAI, Crohn's disease activity index; CMH, Cochran-Mantel-Haenszel; CI, confidence interval; JAK, Janus kinase; SES-CD, Simplified endoscopic activity score for Crohn's disease; SC, Subcutaneous.

<div style=\"page-break-after: always\"></div>

## Sensitivity analysis

Results of the primary endpoint variable were very similar in the All-Randomized Population and in the PerProtocol population as well as in the sensitivity analyses utilizing Fisher's exact test, logistic regression model, excluding war-affected patients in Ukraine and excluding all patients in Ukraine.

The subgroup analysis for clinical remission and endoscopic response based on gender, age and race in allrandomized population showed that gender and age generally did not have a major impact on the response at Week 54. For the subgroup based on race, only the white subgroup was analyzed since the other race subgroups were less than 5% of the all- randomized population according to SAP (results not shown here for brevity).

## Effect of dose adjustment on clinical remission and endoscopic response at week 54

Thirty-nine patients with dose adjustment prior to Week 54 in the CT-P13 SC 120 mg group were assessed for clinical remission at Week 54. Among 39 patients with dose adjustment, 21 (53.8 %) patients achieved clinical remission and 11 (28.2 %) patients achieved endoscopic response at Week 54.

## Key secondary efficacy endpoints

A summary of the key secondary efficacy endpoints is presented for the All-randomized Population in Table 44.

<div style=\"page-break-after: always\"></div>

Table 45. Key secondary efficacy outcome in study CT-P13 3.8

|                                                   | CT-P13 SC 120 mg (N=231)   | Placebo SC (N=112)      | Difference (95% CI)   | P-value2   |
|---------------------------------------------------|----------------------------|-------------------------|-----------------------|------------|
|                                                   | Number (%o) of patients    | Number (%o) of patients |                       |            |
| CDAI-100 response at Week 54                      | 152 (65.8%)                | 43 (38.4%)              | 29.0 (17.7, 39.3)     | <0.0001    |
| Clinical remission based on AP andSFatWeek54      | 131 (56.7%)                | 35 (31.3%)              | 27.0 (15.8, 37.1)     | <0.0001    |
| Endoscopic remission at Week 54                   | 80 (34.6%)                 | 12 (10.7%)              | 24.9 (15.4, 32.8)     | <0.0001    |
| Corticosteroid-free remission basedonCDAIatWeek54 | 39/98 (39.8%)              | 10/44 (22.7%)           | 17.1 (-0.4, 31.5)     | 0.0434     |

Source:CSR CT-P13 3.8Post-text Tables 14.2.2.1,14.2.2.2,14.2.2.3,14.2.2.4

Note: CDAI-100 response is defined as a decrease in CDAI score of 100 points or more from the baseline value. Clinical remission based on AP and SF was defined as an average worst daily AP score of≤1 (using 4-point scale) and an average daily loose/watery SF score of ≤3 (of Type 6 or Type 7 on BSFS) with no worsening in either average score compared with the baseline value. Endoscopic remission is defined as an absolute SES-CD score of ≤4 and at least 2-point reduction from the baseline value with no segment sub-score of &gt;1. Corticosteroid-free remission at Week 54 is defined as being in clinical remission (by an absolute CDAI score of &lt;150) in addition to not receiving any corticosteroids for at least 8 weeks prior to Week 54, among the patients who used oral corticosteroids at baseline. Percentages are calculated by using the number of patients who used oral corticosteroids at baseline as the denominator. Analysis is stratified by Previous exposure to biologic agents and/or JAK imhibitors (used or not used), Use of treatment with oral corticosteroids at Week 0 (used or not used) and Clinical remission at Week 10 (remitter or non-remitter by CDAI score). Patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 are considered as non-remitter/non-responder.

2 The p-value from stratified CMH test is presented.

1 The difference of proportions between 2 treatment groups estimated using CMH weights, and the 95% stratified Newcombe CI with CMH weights are presented.

Abbreviations: AP, Abdominal pain; CDAI, Crohn's disease activity index; CI, confidence interval; JAK, Janus kinase; SC, Subcutaneous; SF, Stool frequency.

Clinical remission based on abdominal pain and stool frequency at Week 54 was defined as an average worst daily AP score of ≤1 (using 4-point scale) and an average daily loose/watery SF score of ≤3 (of Type 6 or Type 7 on BSFS) with no worsening in either average score compared with the baseline value.

In all-randomized population, the proportion of patients who achieved clinical remission based on AP and SF at Week 54 was higher in the CT-P13 SC 120 mg group (131 [56.7 %]) than in the placebo SC group (35 [31.3%]).

Sustained clinical remission at both Week 22 and Week 54 was defined as an average worst daily AP score of ≤ 1 (using 4-point scale) and an average loose/watery SF score of ≤ 3 (of Type 6 or Type 7 on BSFS) at both Week 22 and Week 54 with no worsening in either average score compared with the baseline value. Sustained clinical remission at both Week 22 and Week 54 was achieved by 120 (51.9%) and 33 (29.5%) patients in the CT-P13 and placebo arms, respectively.

Clinical remission defined as an absolute CDAI score of &lt;150 points was assessed at all scheduled visits at all scheduled visits for the all-randomized population is presented in Table 45.

<div style=\"page-break-after: always\"></div>

Table 46. Proportion of Patients Achieving Clinical Remission (Based on CDAI): All-Randomized Population

|         | CT-P13 SC 120 mg (N=231)   | Placebo SC (N=112)     | Difference (95% CI)   | P-value2   |
|---------|----------------------------|------------------------|-----------------------|------------|
|         | Number (%) of patients     | Number (%) of patients |                       |            |
| Week 2  | 83 (35.9)                  | 32 (28.6)              |                       |            |
| Week 6  | 132 (57.1)                 | 61 (54.5)              |                       |            |
| Week 10 | 174 (75.3)                 | 91 (81.3)              |                       |            |
| Week 14 | 181 (78.4)                 | 89 (79.5)              | 2.4 (-6.2, 12.0)      | 0.5663     |
| Week 22 | 181 (78.4)                 | 62 (55.4)              | 25.5 (14.9, 35.9)     | <.0001     |
| Week 30 | 171 (74.0)                 | 51 (45.5)              | 30.5 (19.5, 40.8)     | <.0001     |
| Week 38 | 155 (67.1)                 | 48 (42.9)              | 25.9 (14.7, 36.4)     | <.0001     |
| Week 46 | 145 (62.8)                 | 42 (37.5)              | 27.2 (15.9, 37.5)     | <.0001     |
| Week 54 | 144 (62.3)                 | 36 (32.1)              | 32.1 (20.9, 42.1)     | <.0001     |

Abbreviations: CDAI, Crohn's disease activity index; CI, confidence interval; CMH, Cochran-MantelHaenszel; JAK, Janus kinase; SC, subcutaneous.

Note: Clinical remission was defined as an absolute CDAI score of&lt;150 points. Analysis was stratified by previous exposure to biologic agent and/or JAK inhibitors (used or not used), use of treatment with oral corticosteroids at Week 0 (used or not used) and clinical remission at Week 10 (remitter or non-remitter by CDAI score). Patients with dose adjustment to CT-P13 SC 240 mg prior to their scheduled visit of interest were considered as non-remitter.

1. For the results after Week 10 randomization, the difference of proportions between 2 treatment groups estimated using CMH weights, and the 95% stratified Newcombe CI with CMH weights are presented.
2. For the results after Week 10 randomization, the nominal p-value from stratified CMH test is presented in descriptive purpose.

In the open label extension phase 192 patients on CT-P13 and 86 patients on placebo continued the study after week 54. The proportion of patients who achieved clinical remission was well maintained at Week 102 compared to Week 54 in both CT-P13 and placebo groups (Table 46).

<div style=\"page-break-after: always\"></div>

Table 47. Proportion of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 and Week 102: All-Randomized Population

| Visit    | CT-P13 SC 120 mg (N=231)   | Placebo SC (N=112)     |
|----------|----------------------------|------------------------|
|          | Number (%) of patients     | Number (%) of patients |
| Week 62  | 137 (59.3)                 | 36 (32.1)              |
| Week 70  | 132 (57.1)                 | 36 (32.1)              |
| Week 78  | 131 (56.7)                 | 34 (30.4)              |
| Visit    | CT-P13 SC 120 mg (N=231)   | Placebo SC (N=112)     |
|          | Number (%) of patients     | Number (%) of patients |
| Week 86  | 129 (55.8)                 | 32 (28.6)              |
| Week 94  | 126 (54.5)                 | 33 (29.5)              |
| Week 102 | 122 (52.8)                 | 31 (27.7)              |

Abbreviations: CDAI, Crohn's disease activity index; SC, subcutaneous.

Note: Clinical remission is defined as an absolute CDAI score of less than 150 points. Patients with dose adjustment to CT-P13 SC 240 mg prior to their scheduled visit of interest were considered as non-remitter.

## CHMP comment

The proportion of patients who achieved clinical remission by CDAI at Week 54 was higher in the CT-P13 SC 120 mg group than Placebo SC group (144 [62.3%] and 36 [32.1%] patients in CT-P13 SC 120 mg and Placebo SC groups, respectively). The estimated difference (95% CI) in proportion between the treatment groups was 32.1 (20.9, 42.1).

The proportion of patients who achieved endoscopic response (defined as a 50% decrease in SES-CD score) at Week 54 was 118 [51.1%] and 20 [17.9%] in CT-P13 SC 120 mg and Placebo SC groups, respectively. The estimated difference (95% CI) in proportion between the treatment groups was 34.7 (24.2, 43.5).

All  sensitivity  analyses  and  subgroup  analyses  of  the  primary  endpoints  showed  similar  results.  All secondary endpoints supported the finding that CT-P13 SC 120mg is superior to placebo in the maintenance treatment of patients with moderately to severely active CD.

However, as discussed in the methods section, the study´s ability to provide meaningful results at Week 54 is inherently compromised due to dose escalation/switch to active treatment allowed in the protocol.

There are no tables depicting the details of the non-responder category at Week 54. The MAH should provide tables outlining the number of patients who were: a) non-responder according to the clinical criteria b) dose was escalated/switch to active c) discontinuation before Week 54 d) missing data e) incomplete data f) any other reason and corresponding combination categories.

## Proposed induction regimen

Based on pharmacokinetic reasoning (see section 7.1.3) and previously established positive benefit-risk for very similar dosing regimens, introduction of the 3-IV induction dosing regimen (5 mg/kg at Weeks 0, 2 and 6) followed by SC maintenance treatment (120 mg Q2W from week 10) is acceptable from the efficacy point of view. However, as efficacy results are intended to be included in the SPC, some scrutiny of the numbers is warranted.

<div style=\"page-break-after: always\"></div>

According to the current label, available data suggest that clinical response is usually achieved within 6 weeks in the treatment of CD and 14 weeks in the treatment of fistulising CD. With the current variation, the MAH proposes to change the timing for decision on continuation of treatment to 10 weeks for both CD and fistulising CD. Since patients with active fistulising CD were excluded, Study CT-P13 3.8 cannot support this change for all fistulising CD. Furthermore, no discussion on this aspect of the amended wording was provided in the dossier.

The MAH should provide scientific justification for the newly proposed time frame for decision making in both  CD  and  fistulising  CD.  It  should  also  be  noted  that  decision  after  6  weeks  of  treatment  is  still recommended with IV Remsima in CD and that this wording for IV is bound by the originator wording.

## Effect of dose adjustment

Responders at week 10 who later lost response were allowed a dose increase from week 22 onward. CD is a fluctuating refractory disease with sometimes long symptom free periods. Therefore, some patients could have achieved remission again by week 54 after loss of response, even without dose escalation. Hence, the effect of dose escalation is difficult to contextualize due to the lack of an adequate control group.

Moreover, the MAH has provided a minimal amount of data to support the intended update in SPC section 4.2 to allow dose escalation. 84 patients (39 [16.9%] and 45 [40.2%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively) received a dose adjustment prior to Week 54. Among the 39 patients with dose adjustment in the CT-P13 SC 120 mg group 21 (53.8 %) patients achieved clinical remission by CDAI and 11 (28.2 %) patients achieved endoscopic response at Week 54. Patients who stayed on the initial dose of CT-P13 were not described at all, and neither were the 45 patients originally in the placebo arm who later switched to the double dose of CT-P13. It is not clear how many patients were eligible for dose increase, how many got it, how many of these had missing data at week 54, and how the disease progressed in patients who stayed on the initial dose.

As the study design is inadequate to answer the relevant questions regarding the benefit/risk of a dose increase and the MAH provided virtually no details to enable assessment of the totality of data, the benefitrisk  of  a  dose  increase  is  unknown. To enable any assessment of the impact of a dose increase in CD patients, the MAH should address the following questions:

a) How many patients in each treatment arm were eligible for a dose increase before Week 54 and how many got it? The data should be presented by sex, body weight, disease severity, drug concentration and ADA status. It should also be clarified which weeks the dose increase was initiated at, i.e for how long the patients were exposed to the higher dose.

b) How did the disease progress among those who stayed on initial treatment regimen versus those who had a dose escalation? The analysis should be conducted for patients for whom dose was escalated/not escalated and patients who were eligible for dose escalation but did not escalate/did escalate. Did regain of response occur in patients who continued on placebo? Spontaneous fluctuation of the disease should be discussed and comparison should be made to patients who did not escalate and to historical controls. The MAH  should  provide  spaghetti  plots  (overlay  and  individual)  where  time  point  of  dose  escalation  is standardized in the middle of the graph and 4 visits before and after dose escalation are included.

c) The MAH claims that for patients who adjusted the dose, the reduction in the efficacy scores was observed from their following scheduled visit after the first dose adjustment. Appropriate data should be provided to support this claim.

d) Did the groups (i.e., patients for whom dose was escalated/not escalated and patients who were eligible for dose escalation but did not escalate/did escalate) differ in terms of compliance with the protocol or other parameters which could describe their well-being in addition to the primary endpoint?

<div style=\"page-break-after: always\"></div>

- e) Did loss of response or regain of response correlate with PK and/or ADA titres?
- f) The MAH should provide analysis according to principal stratum estimand.

g) The MAH should discuss how the fact that patients and investigators were effectively unblinded at the time of dose escalation impacts the results.

It should be noted that the results will be based on post-hoc analyses that were not pre-defined in the protocol.

The benefit-risk balance of a dose escalation from 120mg SC Q2W to 240mg SC Q2W is very uncertain. With this initial submission, efficacy cannot be determined since very limited data was provided. Moreover, the safety of the higher dose is not known. It seems that 93 CD patients were exposed to the 240mg dose but exposure time is not known. In light of the fact that trough drug concentrations are much higher with SC dosing than with IV dosing, the dose escalation becomes even more problematic. In previous studies on CD, the steady state Ctrough of infliximab has been around 6 microg/l with the double IV dose of 10 mg/kg. In study 3.8, the normal SC dose of 120mg gave median Ctrough concentrations of 16 microg/l. Hence, already the 120mg SC dose gives rise to considerably higher trough concentrations than those achieved with the highest approved IV dosing. Sufficient safety data with long-time exposure to such high drug concentrations has not been provided.

Of  note,  in  the  assessment  report  of  the  initial  MA  of  Remsima  SC  in  the  treatment  of  UC  and  CD (EMEA/H/C/002576/II/0082), it was concluded based on data from Study CT-P13 1.6, that loss of response was not driven by low drug concentrations. After a dose increase from 120mg SC to 240mg SC 7/14 patients showed some sign of improvement but evidence for causality between improvement and dose increase was lacking. Moreover, the follow-up time was very limited and, therefore, the duration of the renewed response as well as the long-term safety of the high dos remained uncertain.

## Updated comments (RSI AR)

- -The requested additional information has been provided and is discussed in sections 7.4 and 13. Some additional clarifications are requested before a possibility for dose escalation could be approved.
- -The MAH proposed to keep the approved wording unchanged regarding the time point for decision on maintenance in both CD (6 weeks) and fCD (14 weeks). This is endorsed.
- -New data from the open label extension phase were submitted. The proportion of patients who achieved clinical  remission and the improved mean CDAI scores were more or less maintained at Week 102 compared to Week 54 in both CT-P13 and placebo groups. Of patients originally randomised to placebo 27/112 were in clinical remission two years after a successful induction treatment with infliximab IV despite no active treatment after week 10.

## 7.2.4. Usability

## Study background

One of the secondary objectives of the Study CT-P13 3.8 was to evaluate usability.

The CT-P13 SC or placebo SC via PFS was injected by the investigator or designee at Weeks 10 and 12, or until the patient (or caregiver, if needed) was properly trained and confident to administer the study drug at home or the study center at Weeks 14, 16, 18, 20, and 22. If needed, the patient or caregiver were retrained during the study on how to perform the injection of the study drug.

<div style=\"page-break-after: always\"></div>

The usability population for PFS was defined as all randomly assigned patients who self-injected at least one (partial or full) dose of study drug via PFS from Week 14 to 22 and who had at least one usability assessment in maintenance phase.

Self-injection training was provided at Week 56 prior to the first AI injection. After proper training in AI injection technique, patient will self-inject with CT-P13 SC via AI at Weeks 56, 58, 60, and 62. If the patient requested it, additional training could be provided during the visits to the study center.

The usability population for AI was defined as all randomly assigned patients who self-injected at least one (partial or full) dose of study drug via AI from Week 56 to 62 and who had at least one usability assessment in extension phase.

From Week 22 through Week 102, dose adjustment was allowed. The patients who received CT-P13 SC 120 mg could increase the dose to CT-P13 SC 240 mg (double injection [2 shots] of CT-P13 SC 120 mg) every 2 weeks, if patients initially  responded but then lost  response according to the loss of response criteria. The patients who received placebo could also receive CT-P13 SC as described above.

## Assessment

The following usability endpoints for PFS or AI were assessed as secondary endpoints only for self-injected patients.

-  Usability  for  PFS  as  assessed  by  patient  rating  using  PRE-  and  POST-self-injection  assessment questionnaire (SIAQ) at Weeks 14, 16, 18, 20, and 22
- Usability for AI as assessed by patient rating using PRE- and POST-SIAQ at Weeks 56, 58, 60, and 62
- The observer rating of successful self-injection for PFS, indicated by complete dose delivery, using P8, P9, and P10 of the self-injection assessment checklist at Weeks 14 and 22
- The observer rating of successful self-injection for AI, indicated by complete dose delivery, using P8, P9, P10, and P11 of the self-injection assessment checklist at Weeks 56 and 62
- The observer rating of completion of all instructions in the self-injection assessment checklist for PFS at Weeks 14 and 22
- The observer rating of completion of all instructions in the self-injection assessment checklist for AI at Weeks 56 and 62
- Device integrity for used PFS at Weeks 14 and 22
- Device integrity for used AI at Weeks 56 and 62

## Study design

Printed instructions for use (IFU) of PFS and AI, and the patient's self-injection diary for PFS or AI were provided to the patient that served as a guide while administering the study drug.

During a study center visit, the investigator or designee observed the patient how they performed the injection without assistance or guidance provided from the investigator or designee.

At each instance of CT-P13 SC or placebo SC self-injection, each patient recorded details of the injection in their patient diary including the date and time of injection, kit number of each syringe, the number of

<div style=\"page-break-after: always\"></div>

syringes administered, and administration sites. At each visit date, the investigator or designee reviewed the patient diary and checked the number of returned syringes (unused), to judge the patient's dosing compliance and the source data was recorded in the eCRF.

The PRE-SIAQ module is a 7-item questionnaire that assessed feelings about injections, self-confidence (regarding  self-injection),  and  satisfaction  with  self-injection.  The  patients  completed  the  PRE-SIAQ immediately (not exceeding 1 hour) before the administration of the study drug.

The POST-SIAQ module is a 27-item questionnaire that assessed feelings about injections, self-image, selfconfidence (regarding self-injection), pain and skin reactions during or after the injection (localized injection site reactions), ease of use of PFS or AI, and satisfaction with self-injection. The patients completed the POST-SIAQ immediately (not exceeding 1 hour) after the administration of the study drug.

Item score was transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.

The patient's ability to successfully follow the steps in the printed instruction for use to self-administer the study drugs was assessed using the self-injection assessment checklist. The self-injection assessment for PFS was coded as successful if instructions (P8, P9, and P10), which ask complete dose delivery in the selfinjection assessment checklist, were checked as Yes. The self-injection assessment for AI was coded as successful if instructions (P8, P9, P10, and P11), which ask complete dose delivery in the self-injection assessment  checklist,  were  checked  as  Yes.  The  investigator  or  designee  observed  the  patient's  selfinjection and completed the checklist within 15 minutes after patient's self-injection.

The structural or mechanical integrity issues of used PFS and AI after the completion of the self-injection was assessed by the observer using a question that asked clear evidence of damage and/or compromised structural or mechanical integrity based on a visual examination (Yes or No).

## Results

The CT-P13 SC 120 mg (N= 142) and placebo (N=61) SC PFS self-injection groups had totally 203 patients.

For PFS, the mean PRE-SIAQ scores (feelings about injections, self-confidence [regarding self-injection], and  satisfaction  with  self-injection)  and  POST-SIAQ  scores  (feelings  about  injections,  self-image,  selfconfidence [regarding self-injection], ease of use) for all the domains were high in both treatment groups from Week 14 to Week 22 (PRE-SIAQ mean values: 7.27 - 8.16 out of 10 and POST-SIAQ mean values: 7.38 - 8.44 out of 10). Mean POST-SIAQ scores for pain and skin reactions during or after the injection (localized injection site reactions), were 9.16 - 9.30 out of 10.

The CT-P13 SC 120 mg (N= 42) and placebo (N=19) SC AI self-injection groups had totally 61 patients.

For AI, the mean PRE-SIAQ scores and POST-SIAQ scores for all the domains were high in all patients with CT-P13 AI administration from Week 56 to Week 62 (PRE-SIAQ mean values: 7.30 - 8.00 out of 10 and POST-SIAQ mean values: 7.26 - 8.26 out of 10). Mean POST-SIAQ scores for pain and skin reactions during or after the injection (localized injection site reactions), were 8.76 - 8.88 out of 10.

For PFS, at both Week 14 and Week 22, most patients in both treatment groups successfully self-injected (completing  P8,  P9,  and  P10)  and  completed  all  instructions.  A  total  of  203  patients  were  in  usability population for PFS and 176 patients performed self-injection assessment checklist with self-injection at Week 14. Among 176 patients, 175 patients in both groups successfully self-injected (completing P8, P9, and P10) and completed all instruction (120/121 and 55/55 patients in CT-P13 SC 120 mg and placebo SC groups, respectively) at Week 14. At Week 22, 171 patients performed self-injection assessment checklist

<div style=\"page-break-after: always\"></div>

with  self-injection.  Among  171  patients  who  performed  self-injection  assessment  checklist  with  selfinjection at Week 22, all patients successfully self-injected (completing P8, P9, and P10) and completed all instruction in both treatment groups (121/121 and 50/50 patients in CT-P13 SC 120 mg and placebo SC groups, respectively).

For AI, at both Week 56 and Week 62, most of patients in both treatment groups successfully self-injected (completing P8, P9, P10, and P11) and completed all instructions. A total of 61 patients were in usability population for AI and 58 patients performed self-injection assessment checklist with self-injection at Week 56. Among 58 patients, all patients successfully self-injected (completing P8, P9, and P10) and completed all instruction. Among 57 patients who performed self-injection assessment checklist with self-injection at Week 62, all patients successfully self-injected (completing P8, P9, and P10) and completed all instruction in both treatment groups.

No structural or mechanical integrity issues for PFS (CT-P13 SC 120 mg, N= 142 and placebo, N=61, total N=203) and AI (CT-P13 SC 120 mg, N= 42 and placebo, N=19, total N=61) after the completion of the self-injection in both the CT-P13 SC 120 mg and placebo SC groups were reported.

## CHMP comment

The protocol to study usability was well-designed. The assessment and methodology to verify usability was appropriately planned and performed.

Summaries of the self-injection assessment checklist results could have been also presented as tabular format.

As a conclusion, based on the results, the usability of the PFS and AI in clinical use has been demonstrated and is acceptable.

## 7.3. REMSWITCH

The  REMSWITCH  Study  was  designed  to  assess  the  effectiveness  of  switching  from  intravenous  to subcutaneous  infliximab  in  patients  with  inflammatory  bowel  diseases  (IBDs)  treated  with  or  without intensified intravenous regimen.

This summary is based only on a published peer reviewed article and no complete CSR was available. The study was independent but received a grant from Celltrion Healthcare.

## Study design

The REMSWITCH Study was a multicenter observational study performed in 3 IBD referral centers in France.

A switch from IV infliximab to SC Remsima was proposed to all Crohn's disease and ulcerative colitis patients treated with IV infliximab who were in steroid -free clinical remission (partial Mayo score ≤ 2 or Harvey -Bradshaw index ≤ 4). All the patients who were considered for switching between Feb ruary and August 2021 were included.

It was decided that all the patients would be switched at a SC dose of 120 mg every other week regardless of the initial IV regimen, which could be 5 mg/kg every 8 weeks or 10 mg/kg every 4 weeks, 6 weeks, or 8 weeks. Dose escalation to 240 mg every 2 weeks was applied in case of relapse. The theoretical date of next IV infusion was considered as baseline or visit 0 (V0), and data were collected at V1 (between 4 and

<div style=\"page-break-after: always\"></div>

8 weeks after the switch), V2 (between 8 and 16 weeks after the switch), and V3 (between 16 and 24 weeks after the switch).

## Endpoints

Clinical and pharmacological outcomes were assessed at baseline or visit 0 (V0), V1 (between 4 and 8 weeks after the switch), V2 (between 8 and 16 weeks after the switch), and V3 (between 16 and 24 weeks after the switch).

Rate of relapse after switching was the primary focus. Relapse was defined as a clinical recurrence (partial Mayo score &gt;2 or Harvey-Bradshaw index &gt;4) leading to therapeutic escalation or an increase of fecal calpro- tectin value of more than 150 mg/g compared with baseline (V0).

Median trough concentrations of infliximab were measured at each visit to assess the equivalence of serum levels between IV and SC infliximab. Three categories of patients were distinguished based on the variation of infliximab serum levels from baseline to first visit after the switch: increased (increase &gt;1 mg/mL), stable (variation ≤±1 mg/mL), and reduced (decrease &gt;1 mg/mL) levels.

Acceptability of both IV and SC infliximab administration was evaluated with a numerical 10 -points scale.

## Results

Among 184 eligible patients, 72.3% (n=133 of 184) agreed to switch to subcutaneous infliximab.

The participant flow is described in Figure 30 and the baseline characteristics, including dosing regimens are described in table 47. In this cohort, 25.6% (n=34 of 133) of them were treated with concomitant immunosuppressive therapy.

Figure 30. Flow chart illustrating the selection of the patients included into the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses (REMSWITCH) study.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 48. Baseline Characteristics of the 133 Patients With IBD Included in the REMSWITCH Study

| Age at the time of inclusion, y            | 39.3 ± 15.5      |
|--------------------------------------------|------------------|
| Female                                     | 72 (54.1)        |
| Disease duration at baseline, y            | 13.5 ±9.4        |
| Body mass index, kg/m2                     | 22.2 (21.1-25.6) |
| Type of IBD                                |                  |
| CD                                         | 96 (72.2)        |
| UC                                         | 37 (27.8)        |
| Montreal classification                    |                  |
| UC extent                                  |                  |
| E1                                         | 3/37 (8.1)       |
| E2                                         | 10/37 (27.0)     |
| E3                                         | 24/37 (64.9)     |
| CD behavior                                |                  |
| B1                                         | 46/96 (47.9)     |
| B2                                         | 23/96 (24.0)     |
| B3                                         | 26/96 (27.1)     |
| Perianal lesions                           | 40/96 (41.6)     |
| Prior intestinal resection                 | 32/96 (33.3)     |
| Disease activity at baseline               |                  |
| Harvey-Bradshaw index                      | 0 (0-1)          |
| Partial Mayo score                         | 0 (0-1)          |
| C-reactive protein level, mg/L             | 1 (0-3.4)        |
| Fecal calprotectin level, μg/g             | 39 (16-112)      |
| Medications at baseline                    |                  |
| Infliximab maintenance therapy duration, y | 5.4± 3.8         |
| Intravenous infliximab maintenance regimen |                  |
| 5 mg/kg every 8 wk                         | 59 (44.4)        |
| 10 mg/kg every 8 wk                        | 41 (30.8)        |
| 10 mg/kg every 6 wk                        | 18 (13.5)        |
| 10 mg/kg every 4 wk                        | 15 (11.3)        |
| Infliximab trough level at baseline, μg/mL | 6.5 (4.0-11.5)   |
| Detectable anti-infliximab antibodies      | 2 (1.5)          |
| Concomitant immunosuppressive therapy      | 34 (25.6)        |

Values are mean ± SD, n (%), median (interquartile range), or n/n (%). CD, Crohn's disease; IV, intravenous; IBD, inflammatory bowel disease; REMSWITCH, effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses; UC, ulcerative colitis.

<div style=\"page-break-after: always\"></div>

## Rate of Relapse After Switching From IV to SC Infliximab

At visit 3, a relapse occurred in 10.2% (n=6 of 59), 7.3% (n=3 of 38), 16.7% (n=3 of 18), and 66.7% (n=10 of 15) (P &lt; .001) of patients receiving 5 mg/kg Q8W, 10 mg/kg Q8W, 10 mg/kg Q6W, and 10 mg/kg Q4W, respectively. The side-by-side comparisons at V1, V2, and V3 are shown in Figure 31.

Figure 31. Cumulative rate of relapse at V1, V2, and V3 according to the IV infliximab maintenance regimen at baseline.

<!-- image -->

## Drug concentrations After Switching From IV to SC Infliximab

The median trough levels according to the IV maintenance regimen at baseline were 4.7 (IQR, 2.4 to 6.8) mg/mL, 7.2 (IQR, 4.4 to 11.9) mg/mL, 8.1 (IQR, 6.2 to 15.1) mg/mL, and 18.5 (IQR, 11.9 to 20.0) mg/mL (P &lt; 0.001) among the patients treated with IV 5 mg/kg Q8W, 10 mg/kg Q8W, 10 mg/kg Q6W, and 10 mg/kg Q4W, respectively.

Serum  levels  of  infliximab  significantly  increased  after  the  switch  from  IV  to  SC  infliximab  in  all  the subgroups except for the patients receiving 10 mg/kg every 4 weeks (Figures 32 A-D).

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 32. Evolution of infliximab serum levels after switching from intravenous to subcutaneous formulation in patients with IBD treated with (A) 5 mg/kg every 8 weeks (B), 10 mg/kg every 8 weeks (C), 10 mg/kg every 6 weeks (D), and 10 mg/kg every 4 weeks of intravenous infliximab at baseline (only stat istically significant P values were depicted).

<!-- image -->

<!-- image -->

## Prediction of Relapse After Switching From IV to SC Infliximab

None of the following baseline factors were associated with the risk of relapse: sex ( P= 0 .24), body weight ( P= 0 .097), body mass index ( P= 0 .10), Crohn's disease location ( P= 0 .66), Crohn's disease phenotype ( P= 0 .34), perianal lesions ( P= 0 .79), ulcerative colitis extension ( P= 0 .29), concomitant immunosuppressive therapy ( P= 0 .42), Harvey-Bradshaw index ( P= 0 .30), partial Mayo score ( P= 0 .49), and C-reactive protein level at baseline ( P= 0 .32).

In univariable analysis including the 133 patients, older age (46.3 ± 16.6 years vs 38.4 ± 16.6 years; P= 0 .048) and higher fecal calprotectin level at baseline (272 [IQR, 52 to 899] mg/g vs 30 [IQR, 15 to 100] mg/g; P &lt; 0.001) were associated with higher risk of relapse. Regarding pharmacokinetics data, higher infliximab trough level at baseline (11.7 [IQR, 5.8 -18.5] mg/mL vs 6.1 [IQR, 3.8 to 9.0] mg/mL; P ¼ .035) was associated with higher risk of relapse while the serum level of infliximab at V1 (first visi t after the switch) did not (15.2 [IQR, 10.1 to 20.0] mg/mL in non-relapsers vs 12.1 [IQR, 8.9 to 17.6] mg/mL in relapsers; P= 0 .21).  Using  a  receiveroperating  characteristic  curve,  we  determined  that  an  infliximab trough level &gt;11.0 mg/mL and a level of fecal calprotectin &gt;250 mg/g at baseline were associated with the risk of relapse.

<div style=\"page-break-after: always\"></div>

## Recapture of Clinical Remission After Therapeutic Escalation Among the Patients Who Relapsed After Switching From IV to SC Infliximab

Among the 22 patients who experienced relapse within the first 6 months after the switch, 15 received therapeutic escalation to 240 mg every other week including 10 patients before V1, 3 patients between V1 and V2, and 2 patients between V2 and V3. Dose escalation led to recapture of clinical remission in 93.3% (n=14 of 15) of the patients and combined clinical and biological remission (fecal calprotectin &lt;150 mg/g) in 80.0% (n = 12 of 15) of them at V3.

## CHMP comment:

The REMSWITCH study was submitted to justify the following amendment in section 4.2 of the SPC:

There is insufficient information regarding the switching of patients who received the intravenous infusions of infliximab higher than 3 mg/kg for rheumatoid arthritis or 5 mg/kg for Crohn's disease every 8 weeks to the subcutaneous formulation of Remsima.

The MAH proposes to delete the part of the phrase concerning Crohn's disease since new information about switching of patients who received IV infusions higher than 5 mg/kg Q8W for CD patients to Remsima SC is now available from the REMSWITCH study.

However, it is confusing to imply in the SPC that there is sufficient information on switching in Crohn's (but not  in  rheumatoid  arthritis)  but  not  to  include  any  details  regarding  this  information.  Therefore,  the REMSWITCH study is assessed here based on what additional information could potentially be added to be useful for the prescriber.

In this context, it is a major problem that the REMSWITCH study was not designed to demonstrate either an absolute benefit risk of a switching regimen or non-inferiority of switching compared to not switching from high-dose (&gt; 5 mg/kg) IV maintenance to SC 120mg.

In the REMSWITCH study, 37 UC and 96 CD patients in remission who were initially on infliximab IV 5 mg/kg Q8W, 10 mg/kg Q8W, 10 mg/kg Q6W or 10 mg/kg Q4W were all switched to Remsima 120mg SC and there was no control group of patients who did not switch.

Rates of relapse and drug concentrations were collected for up to 6 months after the switch. In general, patients with a very high dose at baseline had a higher risk of relapse after the switch to Remsima SC than those with a standard dose. Within 6 months after the switch, patients who were initially treated with IV 5 mg/kg Q8W, 10 mg/kg Q8W or 10 mg/kg Q6W relapsed with a frequency of 10.2% and 7.3% and 16.7%, respectively, while patients initially treated with IV 10 mg/kg Q4W relapsed with a frequency of 66.7%.

It is not known whether the patients differed at baseline in terms of disease duration, duration of remission, concomitant medication or other characteristics relevant for the risk of relapse as no randomisation was performed and there were no true control groups. It can be assumed that patients who were initially on high dose infliximab (10mg/kg Q4W) have a different disease profile than those who responded to lower doses and stayed on the initial dose. Therefore, no causality can be deduced between the switch to SC and risk of relapse in patients with high baseline dose as we do not know how many of the high dose patients would have relapsed within 6 months if they remained on the IV treatment.

The median trough serum levels of infliximab significantly increased after the switch from IV to SC infliximab in all the subgroups except for the patients receiving 10 mg/kg every 4 weeks. In line with this observation, the authors concluded that variation of serum levels of infliximab between

<div style=\"page-break-after: always\"></div>

baseline (V0) and the first visit after the switch (V1) was associated with the risk of relapse. Especially an infliximab  trough  level  &gt;11.0  mg/mL  and  a  level  of  faecal  calprotectin  &gt;250  mg/g  at  baseline  were associated with a higher risk of relapse. Interestingly, while patients with increased serum infliximab levels experienced some relapses after the switch (12.7%), both reduced (41.7%) and stable (36.8%) serum levels of infliximab were associated with a clearly higher risk of relapse. Hence, maintaining a stable Ctrough was not sufficient to protect from relapses. Moreover, serum level of infliximab at V1 (first visit after the switch) was not associated with the risk of relapse as relapsers and non-relapsers had similar levels.

Based on these results, it is still unclear whether the high concentrations following IV administration are important in terms of efficacy and the results even imply that the maximum concentrations (Cmax), which are higher after the IV administration compared to the SC formulation, could be more important for efficacy than previously thought as relapses occurred frequently among patients with a stable Ctrough.  It is not known whether these relapses would have occurred anyway or whether they could have been caused by a difference in PK parameters.

To conclude, the REMSWITCH study offers descriptive data on 74 UC and CD patients who were switched from a higher dose than 5 mg/kg of IV infliximab to Remsima SC 120mg Q2W. 41 patients were initially on IV 10mg/kg Q8W. This is the group of relevance for this variation, as it is the only approved elevated dose (described in section 5.1 of the SPC). However, it is not clear how many of these patients had UC and how many CD.

Some patients relapsed, others did not, but the study design does not enable conclusions on causality of the outcome and information on what dose to use in case of a switch cannot be substantiated. Hence, information is available, as the MAH states, but the data is of limited value for decision making.

The provided data does not justify the proposed amendment to the wording of the SPC which implies that sufficient information on switching from higher than 5 mg/kg IV doses to SC Remsima is available in Crohn's disease.

Other indications than RA and CD have not been mentioned in the paragraph on switching from high dose IV as a possibility for dose increase of the IV product has only been approved for RA and CD (as described in section 5.1 of the SPC). While it is understood by the regulator that this paragraph only mentions the indications where higher IV doses are approved, it is considered confusing for non-regulators. Therefore, it is proposed to delete any reference to indications from the paragraph, as follows:

There  is  insufficient  information  regarding  switching  to  the  subcutaneous  formulation  of  Remsima  in patients who received the intravenous infusions of infliximab in doses higher than the initial maintenance dose (see section 5.1).

Information on the PK of Remsima after SC dosing is already available in the SPC and can be of some guidance to the clinician in case a switch from high dose IV to SC is warranted.

On an additional note, while the study reports that dose escalation led to recapture of clinical remission in 93.3% (n=14 of 15) of the patients, no information is given on patient characteristics, the time to response or duration of response. Without a proper control group and sufficient follow-up time, this information is not helpful in determining the B/R balance of the 240mg Q2W dosing.

## Updated comments (RSI AR)

After the first RSI the Applicant withdrew the proposal of  switching  from  high-dose  (&gt;5  mg/kg)  IV maintenance to SC treatment. Therefore, questions related to this variation are no longer relevant.

<div style=\"page-break-after: always\"></div>

## 7.4. Discussion

## Design and conduct of clinical studies

Two clinical studies were submitted to support the proposed variations in posology.

Study CT-P3.7 was a randomised, placebo-controlled Phase 3 study to evaluate the efficacy, PK, PD and safety of CT P13 SC as maintenance therapy in patients with moderately to severely active UC.

Study CT-P3.8 was a randomised, placebo-controlled Phase 3 study to evaluate the efficacy, PK, PD and safety of CT P13 SC as maintenance therapy in patients with moderately to severely active CD.

Both studies included an open-label induction phase where the patients received a CT-P13 (Remsima) IV infusion (5 mg/kg) during on-site visits at Weeks 0, 2, and 6 as induction treatments. Patients who were classified as a clinical responder at Week 10 after receiving 3 full doses of CT-P13 5 mg/kg IV were randomly assigned to receive either CT-P13 120mg SC or Placebo SC, before treatment on Day 70 (Week 10). The double-blind  maintenance  phase  consisted  of  CT-P13 120mg SC or Placebo SC  every  2  weeks  via  PFS through Week 54 in both studies. Open-label extension phases up to week 102 were ongoing at the time of  initial  submission.  During  the  assessment  process,  safety  and  efficacy  data  up  to  week  102  were submitted for both studies. Usability data for patients who self-injected a study drug via AI were submitted up to Week 62 from study 3.8.

In study 3.7 response and remission was primarily assessed using the modified Mayo score, which includes the endoscopic sub-score. In study 3.8 absolute CDAI score and endoscopic response were the primary efficacy parameters. These endpoints are in line with EMA guidance and are as such acceptable but the results are confounded because patients were allowed to switch to higher dose of Remsima (also in the placebo group) before the analysis timing for the primary endpoint.

In both studies, patients who lost response in both treatment arms were offered a switch to Remsima 240 mg Q2W from week 22 onward. In theory, the studies were double blind and the blinding was adequate up to week 22. However, if the dose was escalated, both the investigator and the patient knew that the patient received active treatment because a double dose was always active. Furthermore, the investigator knew that as a result of dose escalation the patient automatically is a non-responder in the efficacy analyses. Hence,  the  studies  cannot  be  considered  adequately  blinded  up  to  week  54,  which  was  the  time  of assessment of the primary efficacy endpoint in both studies.

Furthermore, as patients who lost response in both treatment arms were offered a switch to Remsima 240 mg Q2W from week 22 onward, comparisons of efficacy between Remsima SC 120mg Q2W and placebo beyond week 22 are compromised due to the intercurrent event, including the primary endpoint measured at Week 54. Basically, patients in the placebo group who received active treatment after loss of response are  automatically  counted  as  non-responders  which  may  skew  the  results  in  favour  of  the  active  arm because placebo patients are more likely to lose their response and hence, be offered a higher dose.  After dose  increase,  these  patients  are  automatically  counted  as  non-responders  although  we  do  not  know whether a fluctuation back to 'responder' would have occurred with equal frequency in each arm due to the natural course of the disease.

In the context of this variation application, studies 3.7 and 3.8 were submitted to support the following amendments to the SPC:

- a) addition of a new induction regimen (induction with 3-IV doses instead of 2)
- b) addition of the possibility to increase the dose for patients with loss of initial response
- c) inclusion of the efficacy and safety results in Section 5.1 and 4.8.

After the first RSI the MAH withdrew the proposal for dose escalation in UC.

<div style=\"page-break-after: always\"></div>

While no comparative data is available for the new proposed induction, the benefit-risk of the regimen may be  assessed  based  on  totality  of  data  as  it  does  not  differ  a  lot  from  the  already  approved  induction regimens.

However, the study designs were not adequate to answer the question whether dose adjustment from SC 120 mg to 240 mg for patients with loss of response is more effective (and sufficiently safe) compared to continuing treatment with SC 120 mg.

As  there  was  no  randomised  treatment  arm  where  patients  with  a  loss  of  response  continued  on  the previously assigned SC 120mg treatment, it is difficult to know how the disease would have progressed without the dose escalation. As UC and CD are fluctuating refractory diseases with sometimes long symptom free periods, some patients could have achieved remission again by week 54 after loss of response, even without dose escalation. Furthermore, as dose escalation was not mandatory for all patients who fulfilled the criteria, there is a potential for selection bias. Some patients who lost response were dose adjusted and others  were  not,  but  these  different  pathways  were  neither  randomised  nor  based  on  any  predefined characteristics. Therefore, the intercurrent event of loss of response comprises a flaw in the study design and could skew the results of both the primary outcome and the dose escalation outcome. Lastly, the studies did not include any prospectively defined endpoints to assess dose escalation and the analyses planned and included in the initial submission were minimal and not comprehensive. Despite the mentioned shortcomings of the study design, the BR of a dose escalation was assessed and conclusions were based on the totality of data including PK, efficacy, safety and immunogenicity data.

While the design of the two studies, and the dose escalation in particular, is not optimal for interpretation of the results at Week 54 (primary endpoint), the use of rescue therapy/ escape procedure at intermediate time-point is in line with the EMA guideline on development of medicinal products for ulcerative colitis/ Crohn's  disease.  However,  it  should  be  noted  that  Remsima  was  already  approved  as  maintenance treatment at the time of study initiation and was used as the protocol-defined rescue  therapy in both studies.  Hence,  the  concept  of rescue  therapy/  escape  procedure may  not  be  as  intended  in  the  EMA guideline.  Despite these shortcomings in the setup of the studies, the primary efficacy results could be considered of value for the prescriber and for inclusion in the SPC. However, because the possibility to dose adjust is significantly intertwined in the primary endpoints as only patients who did not dose adjust had a possibility to be a responder at week 54, the W54 results cannot be presented in the SPC without explaining the impact of dose adjustment.

## Efficacy data and additional analyses

## Results in patients with ulcerative colitis (Study 3.7)

Out 548 UC patients who were enrolled and treated with CT-P13 5 mg/kg IV during induction, 438 patients were randomly assigned to study treatment and initiated the double-blind maintenance phase at Week 10 (294 and 144 patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively). At Week 10 65/548 patients (11.9%) were non-responders.

Among responders at week 10, demographic characteristics at baseline were balanced between treatment groups.

The proportion of patients who achieved a clinical remission by modified Mayo at Week 54 was higher in the  CT-P13  SC  120  mg  treatment  group  (127  [43.2%])  than  in  the  Placebo  SC  treatment  group  (30 [20.8%]). All sensitivity analyses showed similar results. The difference between placebo and CT-P13 SC 120 mg treatment was notable also for all secondary efficacy endpoints. However, as there were major

<div style=\"page-break-after: always\"></div>

protocol violations affecting a high proportion of patients, the results of the primary endpoint do not provide an accurate estimate of the treatment effect and do not provide a clinically meaningful interpretation.

## Effect of dose adjustment in UC

81 [27.6%] and 70 [48.6%] UC patients in the CT-P13 SC and Placebo groups, respectively received a dose adjustment prior to Week 54. Among the patients with dose adjustment in the CT-P13 SC 120 mg group 40/81 (49.4%) patients regained clinical response by Week 54. However, upon repeated request, the MAH provided data which showed that 35% of the dose escalation decisions were off protocol. These patients never  lost  response  according  to  the  protocol  defined  criteria  and  could  therefore  not  be  classified  as regainers of response either.

The MAH withdrew the application for a dose adjustment in UC patients but the possibility to adjust the dose and the handling of the intercurrent event of loss of response affect the primary outcome rendering it unintelligible.

## Results in patients with Crohn's disease (Study 3.8)

Out of 396 CD patients who were enrolled and treated with CT-P13 5 mg/kg IV during induction, 343 patients were randomly assigned to study treatment and initiated the double-blind maintenance phase at Week 10 (231 and 112 patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively). At Week 10 22/369 patients (6%) were non-responders.

Among responders at week 10, demographic characteristics at baseline were balanced between the two main treatment groups and there was no meaningful difference between the subgroups of patients with and without dose adjustment in terms of baseline characteristics. However, among patients who received a dose escalation, the use of oral corticosteroids was more frequent at baseline compared to those who did not require a dose increase. This could possibly reflect a more severe form of disease among those who lost response.

The co-primary endpoints were clinical remission based on CDAI at Week 54 and endoscopic response based on central SES-CD at Week 54. Patients who received a dose escalation after W22 were automatically classified as non-responders although some of them did not lose response and some of the patients who lost response did not receive a dose escalation.

The proportion of patients who achieved clinical remission by CDAI at Week 54 was higher in the CT-P13 SC 120 mg group than Placebo SC group (144 [62.3%] and 36 [32.1%], respectively).

The proportion of patients who achieved endoscopic response (defined as a 50% decrease in SES-CD score) at Week 54 was 118 [51.1%] and 20 [17.9%] in CT-P13 SC 120 mg and Placebo SC groups, respectively.

All  sensitivity  analyses  and  subgroup  analyses  of  the  primary  endpoints  showed  similar  results.  All secondary endpoints supported the finding that CT-P13 SC 120mg is superior to placebo in the maintenance treatment of patients with moderately to severely active CD.

Although the intercurrent event of loss of response was handled differently for different patients and this flaw in the study design could skew the results of the primary outcome, the difference in the proportion of remitters is considered clinically meaningful and the magnitude of the difference sufficiently large to be relevant for the prescriber and to be included in Section 5.1 even if there was some bias involved.

In an open label extension phase 192 patients on CT-P13 and 86 patients on placebo continued the study after week 54. The proportion of patients who achieved clinical remission and the improved mean CDAI scores were more or less maintained at Week 102 compared to Week 54 in both CT-P13 and placebo groups. Of patients originally randomised to placebo 27/112 (24%) were in clinical remission two years after a successful induction treatment with infliximab IV despite no active treatment after week 10.

<div style=\"page-break-after: always\"></div>

## Effect of dose adjustment in CD

A total of 41 patients in the CT-P13 SC 120 mg group and 48 patients in the placebo group experienced LoR prior to Week 54. Among these patients, 34/41 (82.9%) in CT-P13 SC 120 mg group and 41/48 (85.4%) in placebo group received adjusted dose while 7 patients in each group remained on the initially assigned treatment.  A few patients received adjusted dose despite not being eligible for the dose adjustment, 5/182 (2.7%) in CT-P13 SC 120 mg group and 4/57 (7.0%) in placebo group. This protocol violation seems to be driven by the clinicians' desire to improve the treatment for poor responders but exposes poor adherence to GCP. However, the frequency of these protocol violations is small enough not to pursue the issue further. .

Among the 34 patients with dose adjustment in the CT-P13 SC 120 mg group 17 (50%) patients achieved clinical remission by CDAI and 7 (20.6%) patients achieved endoscopic response at Week 54. On the other hand, in the 7 patients who experienced a LoR but did not receive a dose adjustment, regain of clinical remission by CDAI occurred in 1/7 (14.3%) and endoscopic response re-emerged in 3 (42.9%) of these patients on initial active treatment. Regain of response occurred in 21/34 (61.8%) patients with a dose escalation while patients who lost response but remained on active treatment had a renewed response in 2 (28.6%) cases. Spontaneous regain of response and remission was also seen in patients who remained on placebo (3 and 1 patients, respectively).

Although the numbers are small, it can be concluded that spontaneous regain of response is not negligible. However, regain of response according to CDAI is more common and the improvement in absolute CDAI score  is  more  pronounced  in  patients  with  a  dose  adjustment  than  in  those  who  remained  on  initial treatment  despite  a  LoR.  Although  the  groups  are  not  comparable,  the  totality  of  data  is  sufficiently compelling in terms of magnitude and consistency to support a dose increase in patients who lost response.

A clear difference between patients who experienced LoR and those who did not is seen in terms of serum drug concentration before LoR. This finding supports the theory of loss of response being associated with suboptimal  drug  concentrations.  It  seems  that  loss  of  response  is  often  due  to  a  more  pronounced development of ADAs (higher titres) and lower drug concentrations as a result. It is still unclear how drug concentrations developed among those with a dose increase and for how long patients with high ADA titres at dose adjustment could maintain a potential benefit from a higher dose. However, as these are not issues which could affect the wording in the SPC, they will not be pursued further. Anyway, the provided spaghetti plots show that a majority of patients in the active treatment arm who received a dose adjustment had a positive outcome 16 weeks after the dose increase.

## Data on switching from high dose IV infliximab to 120mg SC Remsima ( REMSWITCH Study)

To  support  amendments  regarding  switching  from  high  dose  IV  regimens  to  Remsima  SC,  the  MAH submitted a published peer reviewed article of the REMSWITCH Study. No complete CSR was available.

The REMSWITCH Study was a multicenter observational study performed in 3 IBD referral centers in France. In this study, 37 UC and 96 CD patients in remission who were initially on infliximab IV 5 mg/kg Q8W, 10 mg/kg Q8W, 10 mg/kg Q6W or 10 mg/kg Q4W were all switched to Remsima 120mg SC. There was no control group of patients who did not switch as the REMSWITCH study was not designed to demonstrate either  an  absolute  benefit  risk  of  a  switching  regimen  or  non-inferiority  of  switching  compared  to  not switching from high-dose (&gt; 5 mg/kg) IV maintenance to SC 120mg.

Rates of relapse and drug concentrations were collected for up to 6 months after the switch. Within 6 months after the switch, patients who were initially treated with IV 5 mg/kg Q8W, 10 mg/kg Q8W or 10 mg/kg Q6W relapsed with a frequency of 6/49 (10.2%) and 3/41 (7.3%) and 3/18 (16.7%), respectively, while patients initially treated with IV 10 mg/kg Q4W relapsed with a frequency of 10/15 (66.7%).

<div style=\"page-break-after: always\"></div>

It is not known whether the patients differed at baseline in terms of disease duration, duration of remission, concomitant medication or other characteristics relevant for the risk of relapse as no randomisation was performed and there were no true control groups. It can be assumed that patients who were initially on high dose infliximab (10mg/kg Q4W) have a different disease profile than those who responded to lower doses and stayed on the initial dose. Therefore, no causality can be deduced between the switch to SC and risk of relapse in patients with high baseline dose as we do not know how many of the high dose patients would have relapsed within 6 months if they remained on the IV treatment.

Questions related to this variation are no longer relevant as the Applicant withdrew the proposed changes to the PI.

## New proposed 3-IV induction regimen

The induction regimen proposed now for UC, CD and fistulising CD and used in studies 3.7 and 3.8 is identical to the induction regimens currently approved for all above indications with IV Remsima. It has already been shown that a switch to SC Remsima from IV Remsima does not attenuate efficacy after an initial  induction  of  6  weeks  and  a  switch  to  SC  Remsima is approved at any time during maintenance, starting 8 weeks after the last IV dose. Therefore, the switch to SC Remsima at week 10, starting only 4 weeks after the last IV dose, as proposed now, does not introduce any new efficacy issues compared to already approved regimens.

Also PK analyses showed that trough drug concentration levels remained close to the steady state plasma concentration throughout the SC dosing regimen without any concentration falls due to the switch (see PK assessment in section 6).

To conclude, based on pharmacokinetic reasoning and previously established positive benefit-risk for very similar dosing regimens, introduction of the 3-IV induction dosing regimen (5 mg/kg at Weeks 0, 2 and 6) followed by SC maintenance treatment (120 mg Q2W from week 10) is acceptable for both CD and UC patients.

## 7.4.1. Conclusions

- -Addition  of  a  3-IV  induction  dosing  regimen  (5  mg/kg  at  Weeks  0,  2  and  6)  followed  by  SC maintenance treatment (120 mg Q2W) is acceptable for CD and UC.
- -The benefit-risk of a dose adjustment from Remsima SC 120 mg to Remsima SC 240 mg for CD patients with loss of response is positive. It should be noted that the study design was not suitable to conclude on the benefit-risk balance of a dose adjustment and the assessment is based on posthoc analyses that were not pre-defined in the protocol.
- -SmPC-updates pertaining to description of the new phase 3 study in CD patients in sections 5.1 are acceptable.
- -Results from Study 3.7 in UC patients do not provide an accurate estimate of the treatment effect nor a clinically meaningful interpretation. Hence, these results will not be included in the SPC section 5.1.

<div style=\"page-break-after: always\"></div>

## 8. Clinical Safety aspects

## 8.1. Methods - analysis of data submitted

The assessment of the safety of the currently proposed amended posology in CD and UC is based on the results of two clinical studies included in the submission with Week 54 clinical study reports:

- Study CT-P13 3.7: Phase 3, randomised, double-blind, placebo-controlled, parallel group study in which 436 patients with moderately to severely active UC were treated with Placebo SC or CT-P13 SC via pre-filled syringe (PFS)
- Study CT-P13 3.8: Phase 3, randomised, double-blind, placebo-controlled, parallel group study in which 343 patients with moderately to severely active CD were treated with Placebo SC or CT-P13 SC via PFS (from Week 56, CT-P13 SC 120 mg via PFS or auto-injector [AI] through Week 102)

## Prior data on CT-P13 SC

The safety results from six controlled, comparative, clinical studies during the development of CT-P13 SC were included in previous submission packages with the final CSRs and are not included in the current analysis. A total of 1,598 subjects have been treated in these six studies for CT-P13 SC:

- Study CT-P13 3.5 Part 1 and Part 2: Phase 1/3, randomised, multi-dose, parallel-group study in which 391 patients with rheumatoid arthritis (RA) (48 patients in Part 1 and 343 patients in Part 2) were treated with CT-P13 SC or CT-P13 IV
- Study CT-P13 1.6 Part 1 and Part 2: Phase 1, open-label, randomised, multi-dose, parallel-group study in which 175 patients with UC or CD (44 CD patients in Part 1 and 78 UC and 53 CD patients in Part 2) were treated with CT-P13 SC or CT-P13 IV
- Study CT-P13 1.5: Phase 1, open-label, dose-escalating, single-dose study in which 38 healthy subjects were treated with CT-P13 SC or CT-P13 IV
- Study CT-P13 1.9: Phase 1, open-label, single-dose pharmacokinetics (PK) and safety study in which 215 healthy subjects were treated with CT-P13 SC via AI or PFS.

See Section 7.1, figures 7.1.1.1, 7.1.1.2 and 7.2.1.1 for details of studies CT-P13 3.7 and CT-P13 3.8.

In both studies, there was an open-label induction phase, for which the patients who met all the inclusion criteria and none of the exclusion criteria were enrolled on Day 0 (Week 0). All enrolled patients received a 2-hour CT-P13 IV infusion (5 mg/kg) during onsite visits at Weeks 0, 2, and 6 as induction treatments. Only subjects that were deemed to be responders at Week 10 after receiving 3 full doses of CT-P13 via IV infusion and for whom there were no safety concerns based on the investigator's discretion were randomly assigned to receive either CT-P13 SC or placebo SC, before treatment on Week 10.

The safety assessments in studies CT-P13 3.7 and Study CT-P13 3.8 included monitoring of adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs) and death; hypersensitivity monitoring  (including  delayed  hypersensitivity  monitoring);  vital  signs  measurements  (including  blood pressure, heart rate, respiratory rate and body temperature); weight; 12-lead electrocardiogram (ECG); monitoring for signs and symptoms of tuberculosis, chest X-ray and interferonγ release assay (IGRA); diabetes mellitus assessment; physical examination; clinical laboratory analyses; local site pain using 100 mm  Visual  Analogue  Scale  (VAS);  recording  of  prior  and  concomitant  medications;  pregnancy  tests; monitoring of cardiovascular disease related signs and symptoms and monitoring of drug-induced liver injury.

<div style=\"page-break-after: always\"></div>

Adverse events were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 with Grade 1=Mild AE; Grade 2=Moderate AE; Grade 3=Severe and undesirable AE; Grade 4=Life-threatening or disabling AE; and Grade 5=Death related to AE.

The  causality  or  association  to  study  drug  in  causing  or  contributing  to  the  AE  was  classified  into  the following categories:

-  Unrelated: This relationship suggests that there was no association between the study drug and the reported event.
-  Possible: This relationship suggests that treatment with the study drug caused or contributed to the AE, i.e.,  the  event  followed  a  reasonable  temporal  sequence  from  the  time  of  drug  administration  or followed a known response pattern to the study drug but could also have been produced by other factors.
-  Probable:  This  relationship  suggests  that  a  reasonable  temporal  sequence  of  the  event  with  drug administration  existed  and  based  upon  the  known  pharmacological  action  of  the  drug,  known  or previously reported adverse drug reactions to the drug or class of drugs, or judgment based on the Investigator's clinical experience, the association of the event with the study drug seemed likely.
-  Definite: This relationship suggests  that  a definite  causal  relationship  existed  between  drug administration and the AE, and other conditions (concurrent illness, progression/expression of disease state, or concurrent medication reaction) did not appear to explain the event.

The immunogenicity of CT-P13 was assessed by measuring anti-drug antibodies (ADA) and neutralising antibodies (NAb) at Weeks 10, 22, 30 and 54.

An independent data and safety monitoring board (DSMB) assessed the progress of each clinical study, including unblinded safety assessments at specified intervals, and recommended to the Sponsor whether to continue, modify, or stop the study.

Safety analyses were performed on the safety population, defined as all randomised patients who received a  complete  (full)  or  partial  dose  of  study  drug  at  Week  10  or  thereafter.  Non-responders  to  induction treatment  and  subjects  with  safety  concerns  during  the  induction  phase  were  not  randomised  to  the maintenance phase and were not included in the safety population. The adverse event data are partly also reported for the 'treatment period', which includes the induction phase and maintenance phase of the studies.

For safety and immunogenicity assessment, only data collected before initiation of dose adjustment was used for Placebo SC group and all data collected regardless of dose adjustment was used for CT-P13 120 mg SC group, unless otherwise specified.

## CHMP comment

The adverse event data are partly also reported for the 'treatment period', which includes the induction phase and maintenance phase of the studies. Comparison of the active and placebo groups is not feasible for such data, since both study arms received active induction treatment during the induction phase in both phase 3 studies.

The MAH had not described in detail the populations for the comparison between placebo and CT-P13 SC and between the 120 mg and 240 mg doses and how exposure time for each dose was accounted in the analyses. Therefore, the submitted safety data was not considered robust.

<div style=\"page-break-after: always\"></div>

Furthermore, taking in account the effects from active IV induction treatment in both study arms, the results from the treatment period (which includes the induction and maintenance periods) were not suitable for comparison of safety between placebo and CT-P13 SC.

Several clarifications and reanalyses were requested, and the MAH provided an adequate response to all safety questions, including analyses on TEAEs observed during use of both the 120 mg SC dose and the 240 mg SC dose vs. placebo. The duration of treatment with each dosing regimen (120 mg SC, 240 mg SC and placebo) was accounted for by calculating the incidence of TEAEs per 100 PY. These analyses included final study data per 100 patient years (PY).

It  is  noteworthy  that  no  comparative  data  between induction treatment with 2 IV doses vs. the newly proposed induction treatment with 3 IV doses are available. Comparison between the currently submitted phase 3 studies and a former Phase I study (CT-P13 1.6 Part 2) have however been conducted (see Section 8.2.5 of this AR). Nevertheless, such comparison between different trials is not regarded as robust evidence on comparative safety of the two IV induction regimens.

## 8.2. Results

## 8.2.1. Patient exposure

In study CT-P13 3.7 (Ulcerative Colitis), all 548 enrolled patients received CT-P13 IV in the induction phase. 110 patients discontinued in the induction phase due to being non-responder at Week 10 (65 patients), withdrawal  by  patient  (15  patients),  adverse  event  (13  patients),  progressive  disease  (6  patients), physician's decision (5 patients), protocol deviation (3 patients), lost to follow-up (2 patients) and other (1 patient). (Figure 7.1.3.1 of this AR).  The mean total dose administered during the induction phase was similar between the two treatment arms (1094.01 mg in the active arm and 1145.78 mg in the placebo arm). Of 438 randomised subjects, 436 were treated: 294 received CT-P13 SC 120 mg and 144 received placebo SC.

In study CT-P13 3.8 (Crohn's Disease), all 396 enrolled patients received CT-P13 IV in the induction phase. According to the CSR, 53 patients discontinued in the induction phase due to being non-responder at Week 10 (22 patients), withdrawal by patient (12 patients), adverse event (11 patients), progressive disease (2 patients), protocol deviation (2 patients), lost to follow-up (2 patients), and death and physician decision (1 patient each) (Figure 7.2.3.1 of this AR). The mean total dose administered during the induction phase was similar between the two treatment arms (1047.67 mg in the active arm and 1018.64 mg in the placebo arm). Of 343 randomised subjects, 231 received CT-P13 SC 120 mg and 112 received placebo SC.

The safety population from both studies consists of 779 patients (436 UC patients from Study CT-P13 3.7 and 343 CD patients from Study CT-P13 3.8), who were exposed to at least 1 dose (full or partial) of CTP13 SC or Placebo SC. The number of patients exposed to CT-P13 SC in the two studies is summarised in Table 48.

<div style=\"page-break-after: always\"></div>

Table 49. Number of Patients Exposed to CT-P13 SC in Studies CT-P13 3.7 and CT-P13 3.8: Safety Population

|            |            |             |                | NumberofPatients                 | NumberofPatients                             |
|------------|------------|-------------|----------------|----------------------------------|----------------------------------------------|
| Study      | Indication | Dosage (mg) | Study Duration | ReceivingatLeast1 DoseofCT-P13SC | Completing CT-P13 SC Treatment up to Week 54 |
| CT-P13 3.7 | UC         | 120         | 54 Weeks       | 296                              | 244                                          |
| CT-P13 3.8 | CD         | 120         | 54 Weeks       | 238                              | 203                                          |
| Total      | Total      | Total       | Total          | 534                              | 447                                          |

Sources:CSRCT-P133.7Post-textTable14.1.10:CSRCT-P133.8Post-textTable14.1.10

Note: For the number of patients completing the Maintenance Phase with CT-P13 SC treatment up to Week 54, the number of patients who completed treatment is counted regardless of doses skipped in between or dose adjustment from 120 mg to 240 mg of CT-P13 SC.

Abbreviations: CD, Crohn's disease; UC, ulcerative colitis

In Studies CT-P13 3.7 and CT-P13 3.8, dose adjustment was allowed from the Week 22. Patients in both CT-P13 SC 120 mg and Placebo SC groups were allowed dose adjustment if patients initially responded but then lost response according to the loss of response criteria.

In  Study  CTP-13  3.7  (ulcerative  colitis),  92/296  (31.1%)  of  patients  in  the  active  group  had  a  dose escalation from 120 to 240 mg and 75/140 (53.6 % in the placebo group had a dose adjustment from placebo to 240 mg during the maintenance phase. In Study CT-P13 3.8 (Crohn's disease) dose was adjusted at least once for 45 subjects [18.9%] and 48 [45.1%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively.

## CHMP comment

It is noteworthy that randomisation to the active and placebo groups only occurred at end of the open-label induction period at Week 10. During the induction period, study subjects received a 2-hour CT-P13 IV infusion (5 mg/kg) during onsite visits at Weeks 0, 2, and 6 as induction treatment. Any subjects who were non-responders to induction treatment (as assessed at 10 weeks) or had safety concerns during the openlabel induction period were excluded from randomisation in the study at Week 10.

Notably, there are now data on 92 patients with UC and 45 patients with CD, who were switched to the higher 240mg dose from the 120 mg dose and 75 UC patients and 48 CD patients who were switched from placebo to the 240 mg dose. In previous studies on UC and CD, the steady state Ctrough of infliximab has been around 6-8 microg/l with the double IV dose of 10 mg/kg. In studies 3.7 and 3.8, the normal SC dose of 120mg gave median Ctrough concentrations of 13-16 microg/l. Hence, already the 120mg SC dose gives rise to considerably higher trough concentrations than those achieved with the highest approved IV dosing in CD. With the proposed 240mg SC dosing the Ctrough levels would be even higher and especially the long term safety of such doses is unknown.

Originally, only subjects from the active study group were included in the comparative analyses between doses.  Furthermore,  it  was  unclear  if  the  dose  adjustment  (escalation  to  240  mg)  could  only  occur temporarily or if the escalated dose was continued throughout the study (See Section 8.2.3.4 of this AR). From tables included in the document 'Post-hoc Analyses' (Module 5.3.5.3) it is understood that there were 534 subjects in the pooled analysis, of whom 137 with dose adjustment and 397 without dose adjustment. The MAH was requested to further clarify the patient populations used for investigating effects of dose escalation in the pooled data set and in the separate analyses of both phase 3 trials. The MAH informed that for the active arm group with dose adjustment, all data were collected regardless of dose adjustment for CT-P13 SC 120 mg group and for the placebo arm, data collected before initiation of dose adjustment to 240 mg were included. However, it was unclear if data data from subjects who were switched from

<div style=\"page-break-after: always\"></div>

placebo to active treatment with 240 dose were omitted; if the data for subjects with dose escalation only from the period when the patient used that dose or from the entire study duration; and how different duration of use of different doses addressed in the analyses.

In their response, the Applicant stated that they are no more applying for dose escalation to subjects with UC. Therefore, re-analyses were performed only on subjects with CD from study CT-P13 3.8. The Applicant compared safety of the 120 SC dose, 240 mg SC dose and placebo according to exposure of all patients to study treatment (Placebo, CT-P13 SC 120 mg or CT-P13 SC 240 mg), regardless of treatment phase and treatment group. Also, to take into account the different duration of use for each treatment (Placebo, CTP13 SC 120 mg and CT-P13 SC 240 mg), the incidence rates per 100 Person Year (PY) was calculated,(table 8.2.1.2, table 1 from the response document). The safety data were analysed for the maintenance and extension phases of the study.

Table 50. Summary of Safety by the Dosage of Study Drug in Study CT-P13 3.8 (Maintenance Phase + Extension Phase): Safety Population

<!-- image -->

Source:Section5.3.5.3Post-hocTable3.114

|                                            | Placebo (N=105,PY=60.22)              | CT-P13 SC 120 mg (N=275,PY=363.58)    | CT-P13 SC 240 mg (N=105,PY=118.54)    |
|--------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                                            | Number(%o,1ooPY)ofPatientswith≥1Event | Number(%o,1ooPY)ofPatientswith≥1Event | Number(%o,1ooPY)ofPatientswith≥1Event |
| TEAE                                       | 64 (61.0%, 106.27)                    | 202 (73.5%, 55.56)                    | 67 (63.8%, 56.52)                     |
| TESAE                                      | 8 (7.6%, 13.28)                       | 28 (10.2%,7.70)                       | 7 (6.7%, 5.91)                        |
| TEAE Leading to Study Drug Discontinuation | 5 (4.8%, 8.30)                        | 14 (5.1%, 3.85)                       | 5 (4.8%,4.22)                         |
| SIR                                        | 1 (1.0%,1.66)                         | 3 (1.1%, 0.83)                        | 0                                     |
| DelayedHypersensitivity                    | 0                                     | 0                                     | 0                                     |
| Localised ISR                              | 1 (1.0%, 1.66)                        | 18 (6.5%, 4.95)                       | 8 (7.6%, 6.75)                        |
| Infection                                  | 19 (18.1%, 31.55)                     | 105 (38.2%, 28.88)                    | 40 (38.1%,33.74)                      |
| Malignancy                                 | 1 (1.0%,1.66)                         | 0                                     | 0                                     |

emergent adverse event; TESAE, treatment-emergent serious adverse event

Based on the submitted data, the 240 mg SC dose is overall associated with a closely similar safety profile as the 120 mg SC dose in subjects with CD. There were somewhat more infections with the 240 mg dose (table 8.2.1.2). However, the number of treatment-emergent serious adverse events (TESAE) was similar: 28/275 (10.2%, PY 7.70) during use of CT-P13 120 mg SC and 7/105 (6.7%, PY 5.91) during use of CTP13 240 mg SC. Furthermore, injections-site reactions were more frequent with the higher dose, but this was expected since the 240 mg SC regimen included two injections instead of only one.

<div style=\"page-break-after: always\"></div>

Table 50 (of CSR CT-P13 37) Summary of Total Number of Doses and Total Amount of Study Drug Received (Extension Phase): Safety Population

|                                | CT-P13 SC 120 mg (N=296)   | Placebo (N=140)    | Total (N=436)      |
|--------------------------------|----------------------------|--------------------|--------------------|
| Extension Phase                |                            |                    |                    |
| Total number of doses received |                            |                    |                    |
| 11                             | 241                        | 107                | 348                |
| Mean (SD)                      | 22.3 (5.06)                | 22.7 (4.43)        | 22.4 (4.87)        |
| Median (min, max)              | 24.0 (1, 24)               | 24.0 (1, 24)       | 24.0 (1, 24)       |
| Total administered dose (mg)   |                            |                    |                    |
| 11                             | 241                        | 107                | 348                |
| Mean (SD)                      | 3363.49 (1351.550)         | 4175.33 (1586.401) | 3613.10 (1474.090) |
| Median (min, max)              | 2880.00 (240,5760)         | 3480.00 (120,5760) | 2880.00 (120,5760) |

Abbreviations: max, maximum; min, minimum; SC, subcutaneous; SD, standard deviation.

Note: For patients with dose adjustment, all data collected regardless of dose adjustment for both treatment groups were included in this summary.

Table 51 (of CSR CT-P13 38) Summary of Total Number of Doses and Total Amount of Study Drug Received (Extension Phase): Safety Population

|                               | CT-P13 SC 120 mg (N=238)   | Placebo SC (N=105)   | Total (N=343)      |
|-------------------------------|----------------------------|----------------------|--------------------|
| ExtensionPhase                |                            |                      |                    |
| Total number of dosesreceived |                            |                      |                    |
| n1                            | 199                        | 79                   | 278                |
| Mean (SD)                     | 22.64 (4.758)              | 23.10 (3.041)        | 22.77 (4.339)      |
| Median (min, max)             | 24.00 (1, 24)              | 24.00 (6, 24)        | 24.00 (1, 24)      |
| Total administered dose (mg)  |                            |                      |                    |
| 11                            | 199                        | 79                   | 278                |
| Mean (SD)                     | 3209.82 (1218.336)         | 4285.06 (1506.436)   | 3515.37 (1391.425) |
| Median (min, max)             | 2880.00 (120,5760)         | 5280.00 (720,5760)   | 2880.00 (120,5760) |

Abbreviations: max, maximum; min, minimum; SC, subcutaneous; SD, standard deviation.

Note: For patients with dose adjustment, all data collected regardless of dose adjustment for both treatment groups were included in this summary.

In study CT-P13 3.8 (CD), the mean and median duration of treatment for patients who received CT-P13 SC 240 mg were 58.9 weeks and 68.1 weeks, respectively, and 73 patients received CT-P13 SC 240 mg as maintenance treatment for at least 44 weeks. Therefore, the post-hoc analysis result is considered to sufficiently represent long-term safety profile of CT-P13 SC 240 mg in subjects with CD.

For subjects with UC, the MAH no more applies for dose escalation to 240 mg SC.

<div style=\"page-break-after: always\"></div>

## 8.2.2. Adverse events

The intensity of the AE was graded based on the Common Terminology Criteria for Adverse Events (CTCAE v5.0) or based on the following general guidelines (a semicolon indicates 'or' within each description):

Grade  1:  Mild  AE  (minor;  no  specific  medical  intervention;  asymptomatic  laboratory  findings  only; radiographic findings only; marginal clinical relevance)

Grade  2:  Moderate  AE  (minimal  intervention;  local  intervention;  non-invasive  intervention  [packing, cautery])

Grade  3:  Severe  and  undesirable  AE  (significant  symptoms  requiring  hospitalization  or  invasive intervention; transfusion; elective interventional radiological procedure; therapeutic  endoscopy  or operation)

Grade 4: Life-threatening or disabling AE (complicated by acute, life-threatening metabolic or cardiovascular complications such as circulatory failure, haemorrhage,  or  sepsis; life-threatening physiological consequences;  need  for intensive care or emergent  invasive  procedure;  emergent interventional radiological procedure, therapeutic endoscopy, or operation)

Grade 5: Death related to AE

## 8.2.2.1. Treatment-emergent adverse events (TEAE)

Summaries of TEAEs during the treatment period (which includes the induction and maintenance phases of the studies, but not the extension phase, for which results are still pending) are given for both phase 3 studies in tables 50 and 51. In both studies, around ¾ of subjects experienced adverse events, and around ¼ experienced  adverse  events  deemed  to  be  related  to  study  medications.  In  tables  50  and  51,  the proportions  of  subjects  experiencing  adverse  events  is  approximately  similar  in  the  active  and  placebo groups. However, the tables include adverse events occurring during the treatment period that includes both the active induction phase with CT-P13 induction treatment given to all subjects and the placebocontrolled maintenance period. Since the adverse events for the induction phase in both studies were not reported separately, as detailed below, assessment of tolerability of CT-P13 based on the numbers in tables 8.2.2.1.1 and 8.2.2.1.2 is not possible.

In the CSR of study CT-P13 3.7 (ulcerative colitis), according to data on patient disposition a total of 110 subjects  who  discontinued  induction  phase,  13  subjects  discontinued  induction  phase  due  to  adverse events. Of 54 subjects who discontinued maintenance phase, 11 subjects discontinued due to adverse events. Hence, the number of subjects who discontinued treatment phase due to adverse events should be 24. However, according to table 50, in total only 14 subjects discontinued study due to TEAEs during the treatment phase that includes both induction and maintenance phases of the study.

<div style=\"page-break-after: always\"></div>

Table 52. Summary of Treatment-Emergent Adverse Events during the Treatment Period: Safety Population, CT-P13 3.7, Ulcerative colitis

|                                                                                    | CT-P13 SC 120 mg (N=296)   | Placebo (N=140)   | Total (N=436)   |
|------------------------------------------------------------------------------------|----------------------------|-------------------|-----------------|
| TotalnumberofTEAEs                                                                 | 828                        | 337               | 1165            |
| Number (%) of patients with at least 1 TEAE                                        | 227 (76.7)                 | 103 (73.6)        | 330 (75.7)      |
| Related to the study drug                                                          | 72 (24.3)                  | 37 (26.4)         | 109 (25.0)      |
| Unrelated to the study drug                                                        | 215 (72.6)                 | 94 (67.1)         | 309 (70.9)      |
| Totalnumber ofTESAEs                                                               | 31                         | 11                | 42              |
| Number (%) of patients with at least 1 TESAE                                       | 25 (8.4)                   | 9 (6.4)           | 34 (7.8)        |
| Related to the study drug                                                          | 3 (1.0)                    | 1 (0.7)           | 4 (0.9)         |
| Unrelated to the study drug                                                        | 22 (7.4)                   | 8 (5.7)           | 30 (6.9)        |
| Total number of TEAEs leading to study drug discontinuation                        | 10                         | 4                 | 14              |
| Number (%) of patients with at least 1 TEAE leading to study diug discontinuation  | 10 (3.4)                   | 4 (2.9)           | 14 (3.2)        |
| Related to the study drug                                                          | 5 (1.7)                    | 2 (1.4)           | 7 (1.6)         |
| Unrelated to the study drug                                                        | 5 (1.7)                    | 2 (1.4)           | 7 (1.6)         |
| TotalnumberofTEAEsclassifiedasIRR                                                  | 10                         | 4                 | 14              |
| Number (%) of patients with at least 1 TEAE classified as IRR                      | 9 (3.0)                    | 3 (2.1)           | 12 (2.8)        |
| TotalnunberofTEAEsclassifiedasSIR                                                  | 19                         | 4                 | 23              |
| Number (%) of patients with at least 1 TEAE classified as SIR                      | 12 (4.1)                   | 4 (2.9)           | 16 (3.7)        |
| Total number of TEAEs classified as delayed hypersensitivity                       | 0                          | 0                 | 0               |
| Number (%) of patients with at least 1 TEAE classified as delayed hypersensitivity | 0                          | 0                 | 0               |
| Total number of TEAEs classified as localized ISR                                  | 47                         | 4                 | 51              |
| Number (%) of patients with at least 1 TEAE classified as localized ISR            | 11 (3.7)                   | 3 (2.1%)          | 14 (3.2)        |
| TotalnumberofTEAEsclassifiedasinfection                                            | 169                        | 68                | 237             |
| Number (%) of patients with at least 1 TEAE classified as infection                | 103 (34.8)                 | 49 (35)           | 152 (34.9)      |
| Total number ofTEAEsclassified asmalignancy                                        | 1                          | 0                 | 1               |
| Number (%) of patients with at least 1 TEAE classified as malignancy               | 1 (0.3)                    | 0                 | 1 (0.2)         |
| Total number of TEAEsclassified as COVID-19                                        | 43                         | 13                | 56              |
| Number (%) of patients with at least 1 TEAE classified as COVID-19                 | 39 (13.2)                  | 12 (8.6)          | 51 (11.7)       |
| Total number of TEAEs classified as ADE                                            | 0                          | 0                 | 0               |
| Number (%) of patients with at least 1 TEAE classified as ADE                      | 0                          | 0                 | 0               |

Similar to study CT-P13 3.7, the CSR of study CT-P13 3.8 (Crohn's disease) does not report separately for the  induction  phase  the  TEAEs  leading  to  discontinuation  of  the  study.  However,  according  to  data  on patient disposition (figure 7.2.3.1 in Section 7.2.3), of a total of 53 subjects who discontinued induction phase,11 subjects discontinued induction phase due to adverse events. Of 35 subjects who discontinued maintenance phase, 8 subjects discontinued due to adverse events. Hence, the number of subjects who discontinued treatment phase due to adverse events should be 19, but according to table 8.2.2.1.2, in total only 16 subjects discontinued study due to TEAEs during the treatment phase.

<div style=\"page-break-after: always\"></div>

Table 53. Summary of Treatment-Emergent Adverse Events During the Treatment Period: Safety Population, CT-P13 38, Crohn's disease

|                                                                                    | CT-P13 SC 120 mg (N=238)   | Placebo SC (N=105)   | Total (N=343)   |
|------------------------------------------------------------------------------------|----------------------------|----------------------|-----------------|
| TotalnumberofTEAEs                                                                 | 786                        | 253                  | 1039            |
| Number (%) of patients with at least 1 TEAE                                        | 187 (78.6)                 | 80 (76.2)            | 267 (77.8)      |
| Related                                                                            | 80 (33.6)                  | 23 (21.9)            | 103 (30.0)      |
| Unrelated                                                                          | 174 (73.1)                 | 73 (69.5)            | 247 (72.0)      |
| Total numberofTESAEs                                                               | 19                         | 11                   | 30              |
| Number (%) of patients with at least 1 TESAE                                       | 16 (6.7)                   | 9 (8.6)              | 25 (7.3)        |
| Related                                                                            | 1 (0.4)                    | 1 (1.0)              | 2 (0.6)         |
| Unrelated                                                                          | 16 (6.7)                   | 8 (7.6)              | 24 (7.0)        |
| Total number of TEAEs leading to study drug discontinuation                        | 10                         | 6                    | 16              |
| Number (%) of patients with at least 1 TEAE leading to study drug discontinuation  | 10 (4.2)                   | 6 (5.7)              | 16 (4.7)        |
| Related                                                                            | 6 (2.5)                    | 2 (1.9)              | 8 (2.3)         |
| Unrelated                                                                          | 4 (1.7)                    | 4 (3.8)              | 8 (2.3)         |
| Total number of TEAEs classified as IRR1                                           | 9                          | 2                    | 11              |
| Number (%) of patients with at least 1 TEAE classified as IRR                      | 7 (2.9)                    | 2 (1.9.)             | 9 (2.6)         |
| Total number of TEAEs classified asSIR1                                            | 5                          | 2                    | 7               |
| Number (%) of patients with at least 1 TEAE classified as SIR                      | 3 (1.3)                    | 2 (1.9)              | 5 (1.5)         |
| Totalnumber ofTEAEsclassifiedasdelayed hypersensitivity                            | 0                          | 0                    | 0               |
| Number (%) of patients with at least 1 TEAE classified as delayed hypersensitivity | 0                          | 0                    | 0               |
| Total number of TEAEs classified as localizedISR                                   | 51                         | 7                    | 58              |
| Number (%) of patients with at least 1 TEAE classified as localized ISR            | 15 (6.3)                   | 1 (1.0)              | 16 (4.7)        |
| Total number of TEAEs classified as infection                                      | 134                        | 39                   | 173             |
| Number (%) of patients with at least 1 TEAE classified as infection                | 88 (37.0)                  | 29 (27.6)            | 117 (34.1)      |
| Totalnumber ofTEAEsclassifiedasmalignancy                                          | 0                          | 1                    | 1               |
| Number (%) of patients with at least 1 TEAE classified as malignancy               | 0                          | 1 (1.0)              | 1 (0.3)         |
| Total number of TEAEs classified as COVID-19                                       | 35                         | 7                    | 42              |
| Number (%) of patients with at least 1 TEAE classified as COVID-19                 | 34 (14.3)                  | 7 (6.7)              | 41 (12.0)       |
| Total number ofTEAEsclassifiedasADE                                                | 0                          | 0                    | 0               |
| Number (%) of patients with at least 1 TEAE classified as ADE                      | 0                          | 0                    | 0               |

## CHMP comment:

During the open-label induction phase subjects were administered three doses of CT-P13 IV 5 mg/kg at Weeks 0,  2  and  6.  For  both  pivotal  trials,  discrepant  numbers  are  given  in  the  figures  and  tables  on disposition  of  patients  vs.  the  summary  tables  on  adverse  events  regarding  subjects  discontinuing treatment due to adverse events during the induction and maintenance phases of the studies. The Applicant was requested to clarify the root cause of these discrepancies and to confirm numbers of subjects who discontinued treatment due to adverse events during the induction and maintenance phases of studies CTP13 37 and CTP-13 38. Details of TEAEs leading to discontinuation were reported by the MAH separately for

<div style=\"page-break-after: always\"></div>

the induction and maintenance periods of both studies. The received clarifications on this issue are deemed adequate (see assessment of question 43 in Section 13.2 of this AR).

Overall, the number of reported TEAEs and subcategories thereof were similar in subjects with UC and CD Further clarifications and analyses were requested from the MAH. Since the MAH withdrew the application for dose escalation in patients with UC, re-analyses were only received for patients with CD.

Sufficient data were received for subjects with CD, confirming that the higher dose of 240 mg caused per patient year slightly more infections and injection site reactions overall than the 120 mg dose, but there was no difference in treatment-emergent serious adverse events (TESAE). Injection site reactions were probably more frequent also because the 240 mg dose involved two injections and the 120 mg SC dose only one injection. All TEAE were markedly more frequent per patient year in the placebo group vs. both active groups. Potentially a large part of reported TEAEs represented symptoms of the disease, which might be speculated to explain the larger among of TEAEs in the placebo group (see also assessment of Question 42 in Section 13.2 of this AR).

## 8.2.3. TEAEs during maintenance phase

In the tables reporting adverse events, at each level of summarization, patients were counted once if they reported one or more events. Only the most severe event was counted. The event was considered to be related if the relationship was defined as 'Possible', 'Probable', or 'Definite'.

TEAEs reported from the maintenance phase of Studies CT-P13 3.7 and CT-P13, from randomization at Week 10 to Week 54 are presented in table 8.2.3.1.

A majority of subjects experienced TEAEs in Study CT-P13 3.7 (ulcerative colitis): 200/296 (67.6%) in the active group and 83/140 (59.3 %) in the placebo group. The proportions of subjects experiencing TEAEs in the active and placebo arms of study CT-P13 3.8 (Crohn's disease) were similar: 172/238 (72.3 %) and 65/105 (61.9 %), respectively. The proportion of subjects experiencing TEAEs considered to be related to study drug were in the active arms of studies CT-P13 3.7 and CT-P13 3.8 the following: 19.3 % and 26.1 %, respectively.

## CHMP comment:

It is noteworthy that even in the placebo arms of the study, 15.0 % and 14.3 % of subjects in studies CTP13 3.7 and CT-P13 3.8, respectively, experienced TEAEs that were considered to be related to study drug. The MAH was requested to clarify if the TEAEs related to study drug occurred in the placebo group during placebo treatment or during active treatment with CT-P13 after dose adjustment.  The MAH confirmed that for both Study CT-P13 3.7 and Study CT-P13 3.8, only data collected before initiation of dose adjustment for Placebo SC group were included in Treatment-Emergent Adverse Event (TEAE) summary tables. Hence, these AEs that were reported for the Placebo group in the blind state were in retrospect not drug-related.

<div style=\"page-break-after: always\"></div>

Table 54. Overview of Treatment-Emergent Adverse Events in Patients with Ulcerative Colitis or Crohn's Disease (Maintenance Phase): Safety

|                                                                            | Ulcerative Colitis (Study CT-P13 3.7)   | Ulcerative Colitis (Study CT-P13 3.7)   | Crohn's Disease (Study CT-P13 3.8)   | Crohn's Disease (Study CT-P13 3.8)   |
|----------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------|--------------------------------------|--------------------------------------|
|                                                                            | CT-P13 SC 120 mg (N=296)                | Placebo SC (N=140)                      | CT-P13 SC 120 mg (N=238)             | Placebo SC (N=105)                   |
| Total number of TEAEs                                                      | 595                                     | 207                                     | 569                                  | 170                                  |
| Number (%) of patients with ≥ 1 TEAE                                       | 200 (67.6)                              | 83 (59.3)                               | 172 (72.3)                           | 65 (61.9)                            |
| Related                                                                    | 57 (19.3)                               | 21 (15.0)                               | 62 (26.1)                            | 15 (14.3)                            |
| Unrelated                                                                  | 184 (62.2)                              | 76 (54.3)                               | 156 (65.5)                           | 59 (56.2)                            |
| Number (%) of patients with ≥ 1 TEAE leading to death                      | 0                                       | 0                                       | 1 (0.4)                              | 0                                    |
| Related                                                                    | 0                                       | 0                                       | 0                                    | 0                                    |
| Unrelated                                                                  | 0                                       | 0                                       | 1 (0.4)                              | 0                                    |
| Number (%) of patients with ≥ 1 TESAE                                      | 19 (6.4)                                | 4 (2.9)                                 | 16 (6.7)                             | 8 (7.6)                              |
| Related                                                                    | 2 (0.7)                                 | 1 (0.7)                                 | 1 (0.4)                              | 1 (1.0)                              |
| Unrelated                                                                  | 17 (5.7)                                | 3 (2.1)                                 | 16 (6.7)                             | 7 (6.7)                              |
| Number (%) of patients with ≥ 1 TEAE leading to study drug discontinuation | 10 (3.4)                                | 4 (2.9)                                 | 9 (3.8)                              | 5 (4.8)                              |
| Related                                                                    | 5 (1.7)                                 | 2 (1.4)                                 | 6 (2.5)                              | 2 (1.9)                              |
| Unrelated                                                                  | 5 (1.7)                                 | 2 (1.4)                                 | 3 (1.3)                              | 3 (2.9)                              |
| Number (%) of patients with ≥ 1 TEAE of SIR1                               | 12 (4.1)                                | 4 (2.9)                                 | 3 (1.3)                              | 1 (1.0)                              |
| Related                                                                    | 12 (4.1)                                | 4 (2.9)                                 | 3 (1.3)                              | 1 (1.0)                              |
| Unrelated                                                                  | 0                                       | 0                                       | 0                                    | 0                                    |
| Number (%) of patients with ≥ 1 TEAE of delayed hypersensitivity1          | 0                                       | 0                                       | 0                                    | 0                                    |
| Number (%) of patients with ≥ 1 TEAE of localised ISR2                     | 10 (3.4)                                | 3 (2.1)                                 | 14 (5.9)                             | 1 (1.0)                              |
| Related                                                                    | 10 (3.4)                                | 3 (2.1)                                 | 14 (5.9)                             | 1 (1.0)                              |
| Unrelated                                                                  | 0                                       | 0                                       | 0                                    | 0                                    |
| Number (%) of patients with ≥ 1 TEAE of infection                          | 83 (28.0)                               | 36 (25.7)                               | 74 (31.1)                            | 19 (18.1)                            |
| Related                                                                    | 11 (3.7)                                | 10 (7.1)                                | 15 (6.3)                             | 6 (5.7)                              |
| Unrelated                                                                  | 80 (27.0)                               | 29 (20.7)                               | 65 (27.3)                            | 16 (15.2)                            |
| Number (%) of patients with ≥ 1 TEAE of malignancy                         | 1 (0.3)                                 | 0                                       | 0                                    | 1 (1.0)                              |
| Related                                                                    | 0                                       | 0                                       | 0                                    | 0                                    |
| Unrelated                                                                  | 1 (0.3)                                 | 0                                       | 0                                    | 1 (1.0)                              |

Sources: CSR CT-P13 3.7 Post-text Tables 14.3.1.1A,14.3.1.2A, 14.3.1.4A, 14.3.1.5A,14.3.1.7A,14.3.1.9A and 14.3.1.10A; CSR CT-P13 3.8 P0st-teXt Tables 14.3.1.1A, 14.3.1.2A, 14.3.1.4A, 14.3.1.5A, 14.3.1.7A, 14.3.1.9A and 14.3.1.10A

1 SIR/delayed hypersensitivity was reported as injection related reaction in the eCRF.

Abbreviations: eCRF, electronic case report form; ISR, injection site reaction; SIR, systemic injection reaction;

2 Localised ISR was reported as injection site reaction in the eCRF.

TEAE, treatment-emergent adverse event; TESAE, treatment-emergent serious adverse event

## 8.2.3.1. Most Commonly Reported Treatment-Emergent Adverse Events

The TEAEs reported for at least 2 % of subjects in the active arms of the study and more frequently than in the placebo arms are presented for study CT-P13 3.7 (ulcerative colitis) in table 53 and for study CT-P13 3.8 (Crohn's disease) in table 54.

Of the events that occurred in at least 2 % of patients in the CT-P13 SC 120 mg arm of study CT-P13 3.7 (ulcerative  colitis),  TEAEs  of  (aggravation  of)  colitis  ulcerative,  nasopharyngitis  and  blood  creatine phosphokinase increased were according to the MAH reported at a higher rate in the Placebo SC arm compared to the CT-P13 SC 120 mg arm.  In study CT-P13 3.8 (Crohn's disease), adverse events occurring in at least 2% of subjects in the active arm but with a higher rate in the placebo arm, according to the

<div style=\"page-break-after: always\"></div>

MAH, were anaemia, (aggravation of) Crohn's disease and nausea. Contrary to study CT-P13 3.8, CPK elevations were more frequent in the placebo than active arm in study CT-P13 3.7.

Table 55. TEAEs Reported for at Least 2 % of Patients in the CT-P13 SC Treatment Arm and Higher than the Placebo SC Arm by SOC and PT in Study CT-P13 3.7 (Maintenance Phase): Safety Population

| System Organ Class Preferred Term                | CT-P13 SC 120 mg (N=296)   | Placebo SC (N=140)   |
|--------------------------------------------------|----------------------------|----------------------|
| Number (%) of patients with ≥ 1 TEAE             | 200 (67.6)                 | 83 (59.3)            |
| Blood and lymphatic system disorders             | 27 (9.1)                   | 11 (7.9)             |
| Anaemia                                          | 14 (4.7)                   | 5 (3.6)              |
| Thrombocytosis                                   | 6 (2.0)                    | 2 (1.4)              |
| General disordersandadministrationsiteconditions | 31 (10.5)                  | 10 (7.1)             |
| Injection site reaction1                         | 10 (3.4)                   | 3 (2.1)              |
| Pyrexia                                          | 8 (2.7)                    | 3 (2.1)              |
| Infections and infestations                      | 83 (28.0)                  | 36 (25.7)            |
| COVID-19                                         | 30 (10.1)                  | 9 (6.4)              |
| Pharyngitis                                      | 6 (2.0)                    | 0                    |
| Upper respiratory tract infection                | 9 (3.0)                    | 3 (2.1)              |
| Urinary tract infection                          | 6 (2.0)                    | 2 (1.4)              |
| Injury, poisoning and procedural complications   | 19 (6.4)                   | 4 (2.9)              |
| Injection related reaction2                      | 12 (4.1)                   | 4 (2.9)              |
| Investigations                                   | 33 (11.1)                  | 17 (12.1)            |
| Alanine aminotransferase increased               | 10 (3.4)                   | 2 (1.4)              |
| Musculoskeletal and connective tissue disorders  | 28 (9.5)                   | 7 (5.0)              |
| Arthralgia                                       | 13 (4.4)                   | 2 (1.4)              |
| Nervous system disorders                         | 24 (8.1)                   | 9 (6.4)              |
| Headache                                         | 17 (5.7)                   | 7 (5.0)              |
| Vascular disorders                               | 13 (4.4)                   | 3 (2.1)              |
| Hypertension                                     | 9 (3.0)                    | 1 (0.7)              |

<div style=\"page-break-after: always\"></div>

Table 56. TEAEs Reported for at Least 2 % of Patients in the CT-P13 SC Treatment Arm and Higher than the Placebo SC Arm by SOC and PT in Study CT-P13 3.8 (Maintenance Phase): Safety Population

| System Organ Class Preferred Term                  | CT-P13 SC 120 mg (N=238)   | Placebo SC (N=105)   |
|----------------------------------------------------|----------------------------|----------------------|
| Number (%) of patients with ≥ 1 TEAE               | 172 (72.3)                 | 65 (61.9)            |
| Blood and lymphatic system disorders               | 27 (11.3)                  | 8 (7.6)              |
| Leukopenia                                         | 6 (2.5)                    | 0                    |
| Neutropenia                                        | 8 (3.4)                    | 0                    |
| Gastrointestinal disorder's                        | 55 (23.1)                  | 34 (32.4)            |
| Abdominal pain                                     | 11 (4.6)                   | 4 (3.8)              |
| Diarrhoea                                          | 11 (4.6)                   | 2 (1.9)              |
| General disorders and administrationsiteconditions | 32 (13.4)                  | 7 (6.7)              |
| Injection site reaction1                           | 14 (5.9)                   | 1 (1.0)              |
| Infections and infestations                        | 74 (31.1)                  | 19 (18.1)            |
| COVID-19                                           | 27 (11.3)                  | 5 (4.8)              |
| Nasopharyngitis                                    | 5 (2.1)                    | 2 (1.9)              |
| Oral herpes                                        | 6 (2.5)                    | 1 (1.0)              |
| Urinary tract infection                            | 7 (2.9)                    | 2 (1.9)              |
| Investigations                                     | 32 (13.4)                  | 10 (9.5)             |
| Alanine aminotransferase increased                 | 9 (3.8)                    | 1 (1.0)              |
| Blood creatine phosphokinase increased             | 9 (3.8)                    | 2 (1.9)              |
| Metabolismandnutritiondisorder's                   | 10 (4.2)                   | 2 (1.9)              |
| Hypertriglyceridemia                               | 5 (2.1)                    | 1 (1.0)              |
| Musculoskeletal and connective tissue disorders    | 22 (9.2)                   | 6 (5.7)              |
| Arthralgia                                         | 9 (3.8)                    | 3 (2.9)              |
| Nervous system disorders                           | 26 (10.9)                  | 5 (4.8)              |
| Dizziness                                          | 6 (2.5)                    | 0                    |
| Headache                                           | 18 (7.6)                   | 5 (4.8)              |
| Vascular disorder's                                | 10 (4.2)                   | 2 (1.9)              |
| Hypertension                                       | 8 (3.4)                    | 1 (1.0)              |

## TEAEs by relationship to treatment

## Study CT-P13 3.7 (Ulcerative Colitis)

During the Maintenance Phase, TEAEs considered to be related to study drug were reported for 57 (19.3%) and 21 (15.0%) patients in the CT-P13 SC 120 mg and Placebo SC arms, respectively. The most commonly reported related TEAEs in the CT-P13 SC 120 mg arm (≥ 2% patients in the CT-P13 SC 120 mg arm and reported at a higher rate than the Placebo SC arm) were SIR (PT injection related reaction) (12 [4.1%] and 4 [2.9%] patients, respectively) and localised ISR (PT injection site reaction) (10 [3.4%] and 3 [2.1%] patients, respectively).

## Study CT-P13 3.8 (Crohn's Disease)

During the Maintenance Phase, TEAEs considered to be related to study drug were reported for 62 (26.1%) and 15 (14.3%) patients in the CT-P13 SC 120 mg and Placebo SC arms, respectively. The most commonly reported drug-related TEAEs in the CT-P13 SC 120 mg arm (≥ 2% patients in the CT-P13 SC 120 mg arm and reported at a higher rate than the Placebo SC arm) were localised ISR (14 [5.9%] and 1 [1.0%]

<div style=\"page-break-after: always\"></div>

patients, respectively), alanine aminotransferase increased (7 [2.9%] patients in the CT-P13 SC 120 mg arm) and neutropenia (5 [2.1%] patients in the CT-P13 SC 120 mg arm).

## CHMP comment

Of the adverse reactions occurring more frequently in the active than placebo arm of study CT-P13 3.7 (table  8.2.3.1.1),  thrombocytosis  is  not  currently  included  in  Section  4.8  of  the  SmPC  of  Remsima. Furthermore, the adverse reactions hypertriglyceridaemia, and increase in creatine phosphokinase (CPK) were more frequent in the active than placebo arm of study CT-P13 3.8 (table 8.2.3.1.2) and are not mentioned in Section 4.8 of the SmPC. The MAH was requested to clarify for both pivotal studies the numbers of the adverse reactions which occurred more frequently in active than placebo arms but are nevertheless not proposed to be included in the SmPC and to discuss the potential relatedness of these ADRs with the medication and justify for each adverse reaction why they are not proposed to be included in the SmPC or alternatively, add them in the proposed SmPC. The MAH submitted information from pooled placebo-controlled studies on TEAEs reported for at least 1% of patients in the CT-P13 SC 120 mg group and  at  a  higher  rate  than  the  Placebo  SC  group  and  adequately  justified  for  each  observed  TEAE  the inclusion or omission of that AE from the table in Section 4.8 of the SmPC (see assessment of Question 45 in Section 13.2 of this AR). Based on these data, no change is warranted on the table except for Covid-19, which was added in the updated tabulated list in Section 4.8 of SmPC as Very Common adverse event of Viral infection.

## 8.2.3.2. Serious adverse events and deaths

## Study CT-P13 3.7 (Ulcerative Colitis)

All treatment-emergent serious adverse events (TESAE) experienced during the maintenance phase are summarized by SOC and PT for the safety population in Table 55.

Treatment-emergent  SAEs  considered  by  the  investigator  to  be  related  to  study  drug  during  the maintenance  phase  were  similar  between  CT-P13  SC  120  mg  group  and  Placebo  SC  group  (2  [0.7%] patients  in  the  CT-P13  SC  120  mg  group  and  1  [0.7%]  patient  in  the  Placebo  SC  group).  All  TESAEs considered by the investigator to be related to study drug during maintenance phase were grade 3 in intensity (urinary tract infection and pneumonia were reported in CT-P13 SC 120 mg group and cellulitis was reported in Placebo SC group).

<div style=\"page-break-after: always\"></div>

Table 57. Treatment-Emergent Serious Adverse Events During the Maintenance Phase by System Organ Class and Preferred Term: Safety Population, study CT-P13 3.7 (Ulcerative Colitis)

| System Organ Class1 Preferred Term                                  | CT-P13 SC 120 mg (N=296)   | Placebo (N=140)        | Total (N=436)          |
|---------------------------------------------------------------------|----------------------------|------------------------|------------------------|
|                                                                     | Number (%) of patients     | Number (%) of patients | Number (%) of patients |
| TotalnumberofTESAEs                                                 | 25                         | 5                      | 30                     |
| Number (%) of patients with at least 1 TESAE                        | 19 (6.4)                   | 4 (2.9)                | 23 (5.3)               |
| Related                                                             | 2 (0.7)                    | 1 (0.7)                | 3 (0.7)                |
| Unrelated                                                           | 17 (5.7)                   | 3 (2.1)                | 20 (4.6)               |
| Blood and lymphaticsystemdisorders                                  | 2 (0.7)                    | 0                      | 2 (0.5)                |
| Anaemia                                                             | 2 (0.7)                    | 0                      | 2 (0.5)                |
| Iron deficiency anaemia                                             | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Cardiac disorders                                                   | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Aortic valve incompetence                                           | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Cardiac failure                                                     | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Gastrointestinaldisorder's                                          | 4 (1.4)                    | 2 (1.4)                | 6 (1.4)                |
| Colitis ulcerative                                                  | 3 (1.0)                    | 1 (0.7)                | 4 (0.9)                |
| Duodenal ulcer perforation                                          | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Rectal haemorrhage                                                  | 0                          | 1 (0.7)                | 1 (0.2)                |
| Infections andinfestations                                          | 7 (2.4)                    | 1 (0.7)                | 8 (1.8)                |
| COVID-19                                                            | 1 (0.3)                    | 0                      | 1 (0.2)                |
| COVID-19pneumonia                                                   | 2 (0.7)                    | 0                      | 2 (0.5)                |
| Cellulitis                                                          | 0                          | 1 (0.7)                | 1 (0.2)                |
| Cystitis                                                            | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Pneumonia                                                           | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Salpingitis                                                         | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Urinary tract infection                                             | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Injury,poisoning and procedural complications                       | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Clavicle fracture                                                   | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Metabolismandnutritiondisorders                                     | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Hypokalaemia                                                        | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Musculoskeletalandconnectivetissuedisorder's                        | 3 (1.0)                    | 0                      | 3 (0.7)                |
| Arthritis                                                           | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Scleroderma                                                         | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Spondyloarthropathy                                                 | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Colorectal adenoma                                                  | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Nervoussystem disorder's                                            | 0                          | 1 (0.7)                | 1 (0.2)                |
| Neuromyopathy                                                       | 0                          | 1 (0.7)                | 1 (0.2)                |
| Vasculardisorders                                                   | 0                          | 1 (0.7)                | 1 (0.2)                |
| Deep vein thrombosis                                                | 0                          | 1 (0.7)                | 1 (0.2)                |

## CHMP comment

Even though only 2 subjects in the active arm and one subject in the placebo arm experienced TESAEs considered by the investigator to be related to study drug, it is noteworthy that more than twice as great percentage of subjects experienced at least one TESAE in the active arm (n=19/296, 6.4%) vs. placebo arm (n=4/140, 2.9%) of the study. The total number of TESAEs was 25/296 in the active vs. 5/140 in the

<div style=\"page-break-after: always\"></div>

placebo arm (table 8.2.3.2.1). Regardless of investigator-assessed non-relation to study drug, it is likely that the higher incidence of TESAE's in the active group is caused by the active treatment.

## Study CT-P13 3.8 (Crohn's Disease)

All  TESAEs  experienced  during  the  maintenance  phase  are  summarized  by  SOC  and  PT  for  the  safety population in Table 56.

The TESAEs considered by the investigator to be related to study drug during the maintenance phase were reported for 1 (0.4%) patient in the CT-P13 SC 120 mg and 1 (1.0%) patient in the placebo SC group.

<div style=\"page-break-after: always\"></div>

Table 58. Treatment-Emergent Serious Adverse Events During the Maintenance phase by System Organ Class and Preferred Term: Safety Population, Study CT P13 3.8 (Crohn's Disease)

| System Organ Classl                                                 | CT-P13 SC 120 mg (N=238)   | Placebo SC (N=105)     | Total (N=343)          |
|---------------------------------------------------------------------|----------------------------|------------------------|------------------------|
| Preferred Term                                                      | Number (%) of patients     | Number (%) of patients | Number (%) of patients |
| TotalnumberofTESAEs                                                 | 19                         | 9                      | 28                     |
| Number (%) of patients with at least 1 TESAE                        | 16 (6.7)                   | 8 (7.6)                | 24 (7.0)               |
| Related                                                             | 1 (0.4)                    | 1 (1.0)                | 2 (0.6)                |
| Unrelated                                                           | 16 (6.7)                   | 7 (6.7)                | 23 (6.7)               |
| Bloodand lymphaticsystemdisorders                                   | 0                          | 1 (1.0)                | 1 (0.3)                |
| Anaemia                                                             | 0                          | 1 (1.0)                | 1 (0.3)                |
| Gastrointestinaldisorders                                           | 5 (2.1)                    | 2 (1.9)                | 7 (2.0)                |
| Crohn's disease                                                     | 3 (1.3)                    | 1 (1.0)                | 4 (1.2)                |
| Haemorrhoids                                                        | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Intestinal perforation                                              | 0                          | 1 (1.0)                | 1 (0.3)                |
| Subileus                                                            | 1 (0.4)                    | 0                      | 1 (0.3)                |
| General disorder'sandadministrationsiteconditions                   | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Accidental death                                                    | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Infections andinfestations                                          | 6 (2.5)                    | 1 (1.0)                | 7 (2.0)                |
| Abscess intestinal                                                  | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Anal abscess                                                        | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Appendicitis                                                        | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Arthritis bacterial                                                 | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Bartholinitis                                                       | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Bronchiolitis                                                       | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Peritonitis                                                         | 0                          | 1 (1.0)                | 1 (0.3)                |
| Urinary tract infection                                             | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Injury,poisoning and procedural complications                       | 1(0.4)                     | 1 (1.0)                | 2 (0.6)                |
| Humerus fracture                                                    | 0                          | 1 (1.0)                | 1 (0.3)                |
| Skin laceration                                                     | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Investigations                                                      | 0                          | 1 (1.0)                | 1 (0.3)                |
| Blood creatine phosphokinase increased                              | 0                          | 1 (1.0)                | 1 (0.3)                |
| Musculoskeletalandconnectivetissuedisorder's                        | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Intervertebral disc degeneration                                    | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0                          | 1(1.0)                 | 1 (0.3)                |
| Colon cancer stage III                                              | 0                          | 1 (1.0)                | 1 (0.3)                |
| Nervoussystemdisorder's                                             | 2 (0.8)                    | 0                      | 2 (0.6)                |
| Altered state of consciousness                                      | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Neurovascular conflict                                              | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Psychiatric disorders                                               | 1(0.4)                     | 1 (1.0)                | 2 (0.6)                |
| Mixed anxiety and depressive disorder                               | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Psychotic disorder                                                  | 0                          | 1 (1.0)                | 1 (0.3)                |
| Skinandsubcutaneoustissuedisorder's                                 | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Acne fulminans                                                      | 1 (0.4)                    | 0                      | 1 (0.3)                |

## CHMP comment

Contrary  to  Study  CT-P13  3.7,  in  this  study,  the  percentage  of  patients  with  Crohn's  disease  who experienced at least 1 TESAE during the maintenance phase was similar between 2 groups (16 [6.7%] and 8 [7.6%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively).

<div style=\"page-break-after: always\"></div>

## Deaths

There  were  no  deaths  reported  in  patients  from  study  CT-P13  3.7  (ulcerative  colitis).  One  death  was reported in study CT-P13 3.8 (Crohn's disease): a  patient (CT-P13 SC 120 mg arm) experienced a Grade 5 treatment-emergent serious adverse event (TESAE) of accidental death which was fatal, and the patient died on the same day. The patient's wife reported that there was an explosion in a garage where the patient was working. The patient subsequently had a cardiac arrest which was fatal. The event of accidental death was considered by the investigator to be unrelated to the study drug.

## 8.2.3.3. TEAEs of special interest

The following events were evaluated as protocol-defined adverse events of special interest (AESI): SIR (hypersensitivity/anaphylactic reaction), delayed hypersensitivity, localised ISR, infection, and malignancy.

## Study CT-P13 3.7 (Ulcerative Colitis)

## Systemic Injection Reaction (SIR)

During the Maintenance Phase, SIRs were reported for 12 (4.1%) and 4 (2.9%) patients in the CT-P13 SC 120 mg and placebo SC arms, respectively. Grade 3 SIR was reported for 3 (1.0%) patients in the CT-P13 SC 120 mg arm and 1 (0.7%) patient in the placebo SC arm. One patient in each treatment arm experienced SIR that led to study drug discontinuation. The patient in the CT-P13 SC 120 mg arm who discontinued study medication first experienced grade 3 TEAE of SIR with signs and symptoms of pruritus, rash, throat irritation and urticaria 1 day after Week 18 SC administration. The patient recovered by receiving treatment of desloratadine and prednisone. The symptoms recurred on the day of Week 20 SC administration, after which the patient was withdrawn from the study.

## Delayed Hypersensitivity

During the Maintenance Phase, no delayed hypersensitivity was reported in either treatment arm.

## Localised Injection Site Reaction (ISR)

During the Maintenance Phase, localised ISRs were reported for 10 (3.4%) and 3 (2.1%) patients in the CT-P13 SC 120 mg and placebo SC arms, respectively. All events were grade 1 or 2 in severity, non-serious, and did not lead to study drug discontinuation.

## CHMP comments

The  MAH  proposes  to  update  the  data  on  injection  site  and  systemic  injection  reactions  in  adults administered Remsima SC in Section 4.8 of the SmPC based on a Phase 1 study conducted in patients with active Crohn's disease and active ulcerative colitis and the phase 3 studies assessed in this variation. The proposed updated text is the following:

'In the integrated analysis including a Phase I study conducted in patients with active Crohn's disease and active ulcerative colitis, a Phase III study conducted in patients with active Crohn's disease and a Phase III study conducted in patients with active ulcerative colitis, the safety population consisted of 631 patients in the Remsima subcutaneous group (297 patients with active Crohn's disease and 334 patients with active ulcerative colitis) and 245 patients in the Placebo group (105 patients with active Crohn's disease and 140 patients with active ulcerative colitis). For study details, see Section 5.1.

The incidence rate of systemic injection reactions (e.g. nausea and dizziness) was 3.56 patients per 100 patient-years in the Remsima subcutaneous group.

<div style=\"page-break-after: always\"></div>

The incidence rate of localised injection site reactions (e.g. injection site erythema, pain, pruritus, bruising) was 8.68 patients per 100 patient-years in the Remsima subcutaneous group. Most of these reactions were mild to moderate and mostly resolved spontaneously without any treatment within a few days.'

However, the accuracy of the proposed update could not be assessed since the assessor could not locate in the submission the integrated safety data compiled from the Phase 1 study in UC/CD and the two Phase 3 studies. Some integrated post-hoc analyses were presented in Module 5.3.5.3 of the submission, but the data presented there were pooled from the two Phase 3 studies and do not include the Phase 1 study.

It was not clear why the new data were only included in the SmPC for SIR and ISR and not for any other adverse reactions. Furthermore, it was not understood why the integrated analyses did not include all studies conducted with SC administered Remsima but only the one Phase 1 study in CD/UC in addition to the two Phase 3 studies included in the current variation. After all, according to the MAH, there have been two controlled, comparative, clinical studies in patients during the development of CT-P13 SC prior to the two Phase 3 studies that are currently under assessment.

The current safety database in the SPC includes 168 patients with RA and 97 patients with CD or UC. In the current variation, additional &gt;600 patients have been exposed to Remsima SC (297 CD and 334 UC). This is a significant amount of new safety data. Thus, a new integrated safety analysis was requested, including all exposed patients in clinical trials on SC administered Remsima in the approved indications: studies CT-P13 3.7 (UC), CT-P13 3.8 (CD),  CT-P13 3.5 Part 1 and Part 2 (rheumatoid arthritis, RA) and CT-P13 1.6 Part 1 and Part 2 (UC and CD) for subjects administered 120 mg or 240 mg SC doses (90 mg and 180 mg SC doses should be omitted as not relevant for the current update and not feasible to be administered by the approved formulations). These data were also requested to include patients from the placebo group who received the 240 mg SC Remsima as 'rescue medication' in the currently assessed studies.

In  conclusion,  the  MAH  was  requested  to  submit  analyses  for  the  integrated  data  for  SC  administered Remsima in all approved indications separately 1) for subjects who were administered the 120 mg SC dose and 2) for subjects who were administered the 240 mg SC dose in studies CT-P13 3.7 (UC), CT-P13 3.8 (CD),  CT-P13 3.5 Part 1 and Part 2 (rheumatoid arthritis, RA) and CT-P13 1.6 Part 1 and Part 2 (UC and CD); and 3) pooled together for both SC doses. Adverse events occurring prior to dose escalation from 120 mg SC to 240 mg SC vs. after dose escalation should be compared, with adjustment for duration of exposure to  each  dose.  The  same  analysis  was  requested  to  be  conducted  for  the  patients  who  originally  were administered placebo and were switched to the 240 mg SC dose. The MAH provided in their response the requested analyses. The pooled analysis included final data from each study:

- Study 1.6 Part 1 (CD): CT-P13 SC 120 mg group and CT-P13 SC 240 mg group from Week 6
- Study 1.6 Part 2 (CD/UC): CT-P13 SC 120/240 mg group from Week 6 and CT-P13 IV 5 mg/kg group from Week 30
- Study 3.5 Part 1 (RA): CT-P13 SC 120 mg group from Week 6
- Study 3.5 Part 2 (RA): CT-P13 SC 120 mg group from Week 6 and CT-P13 IV 3 mg/kg group from Week 30
- Study CT-P13 3.7 (UC): CT-P13 SC 120 mg group from Week 10 and Placebo group from Week 56 or after dose adjustment
- Study CT-P13 3.8 (CD): CT-P13 SC 120 mg group from Week 10 and Placebo group from Week 56 or after dose adjustment.

For the Phase 3 studies, the analysis on dose adjustment was performed only for Study CT-P13 3.8, since the MAH withdrew the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for patients with ulcerative colitis (UC),

<div style=\"page-break-after: always\"></div>

In the pooled analysis of all CT-P13 SC studies, there were slightly more TEAE, TESAE, TEAE leading to study drug discontinuation, SIR, delayed hypersensitivity and infections with the 240 mg SC dose than the 120  mg  SC  dose  (Table  7  of  the  response;  see  Section  13.2,  assessment  of  question  46).  Regarding malignancy, there were only 2/1056 cases (0.2%, 0.18 100 PY) in the 120 mg SC group and 3/342 cases (0.9%, 0.87 100PY) in the 240 mg SC group, so interpretation of the difference in malignancy is futile.

In study CT-P13 3.8, interestingly, there were markedly more TEAE with placebo (54%, 151.42/100 PY)) and CT-P13 120 mg SC (61.1%, 107.07/100 PY) than in subjects with dose escalation from 120 mg to 240 mg  SC  (63.0%,  64.66/100  PY)  or  subjects  with  dose  escalation  from  placebo  to  240  mg  SC  (64%, 49.14/100 PY) (Table 8 of the response). Hence, these TEAE may have actually been symptoms of CD?

Only studies CT-P13 3.7, CT-P13 3.8 and CT-P13 1.6 Part 2 were included in the pooled analysis on safety of dose escalation, as these are the only studies that allowed dose adjustment to CT-P13 SC 240 mg. In this analysis (table 9 of the response) that includes subjects with both CD and UC (from studies CT-P13 3.7, CT-P13 3.8 and CT-P13 1.6), there were also markedly more TEAE in the CT-P13 120 mg SC group than in the CT-P13 240 mg SC groups (escalation from 120 mg SC of from placebo) or placebo. However, the occurrence of TESAE was slightly larger in the 240 mg SC group, regardless of if the escalation occurred from placebo or from CT-P13 120 mg SC. Notably, also infections occurred less often during treatment with CT-P13 240 mg SC than CT-P13 120 mg SC or placebo.

Overall, the results do not indicate that the safety profile of the 240 mg SC dose would relevantly differ from the safety profile of 120 mg SC of CT-P 13. The MAH did not propose changes in the submitted Product Information based on these data and none are deemed to be warranted.

## Infection

During the Maintenance Phase, infections were reported for 83 (28.0%) and 36 (25.7%) patients in the CT-P13 SC 120 mg and Placebo SC arms, respectively. A majority of the infections were Grade 1 or 2 (Table 57).

Table 59. Summary of Infection in Study CT-P13 3.7 (UC, Maintenance Phase): Safety Population

|                                           | CT-P13 SC 120 mg (N=296)   | Placebo SC (N=140)   |
|-------------------------------------------|----------------------------|----------------------|
| Totalnumberofinfection                    | 127                        | 46                   |
| Number (%) of patients with ≥ 1 infection | 83 (28.0)                  | 36 (25.7)            |
| Related                                   | 11 (3.7)                   | 10 (7.1)             |
| Grade 1                                   | 2 (0.7)                    | 5 (3.6)              |
| Grade 2                                   | 6 (2.0)                    | 3 (2.1)              |
| Grade 3                                   | 3 (1.0)                    | 2 (1.4)              |
| Unrelated                                 | 80 (27.0)                  | 29 (20.7)            |
| Grade 1                                   | 34 (11.5)                  | 18 (12.9)            |
| Grade 2                                   | 39 (13.2)                  | 10 (7.1)             |
| Grade 3                                   | 6 (2.0)                    | 1 (0.7)              |
| Grade 4                                   | 1 (0.3)                    | 0                    |

The most commonly reported infection in the CT-P13 SC 120 mg arm ( ≥ 2% patients in the CT-P13 SC 120 mg arm and reported at a higher rate than the placebo SC arm) was COVID-19 reported in 30 (10.1%) patients for the CT-P13 SC 120 mg group and 9 (6.4%) patients for the placebo SC group. (Table 58)

<div style=\"page-break-after: always\"></div>

Table 60. Treatment-Emergent Adverse Events Classified as Infection During the Maintenance Phase: Safety Population Study CT-P13 3.7 (UC)

| System Organ Class1 Preferred Term                                  | CT-P13 SC 120 mg (N=296)   | Placebo (N=140)        | Total (N=436)          |
|---------------------------------------------------------------------|----------------------------|------------------------|------------------------|
|                                                                     | Number (%) of patients     | Number (%) of patients | Number (%) of patients |
| Total number of TEAEs classified as infection                       | 127                        | 46                     | 173                    |
| Number (%) of patients with at least 1 TEAE classified as infection | 83 (28.0)                  | 36 (25.7)              | 119 (27.3)             |
| Related                                                             | 11 (3.7)                   | 10 (7.1)               | 21 (4.8)               |
| Unrelated                                                           | 80 (27.0)                  | 29 (20.7)              | 109 (25)               |
| Infections and infestations                                         | 83 (28.0)                  | 36 (25.7)              | 119 (27.3)             |
| Abscess limb                                                        | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Anal abscess                                                        | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Ascariasis                                                          | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Asymptomatic bacteruria                                             | 0                          | 1 (0.7)                | 1 (0.2)                |
| Bronchitis                                                          | 3 (1.0)                    | 0                      | 3 (0.7)                |
| COVID-19                                                            | 30 (10.1)                  | 9 (6.4)                | 39 (8.9)               |
| COVID-19 pneumonia                                                  | 3 (1.0)                    | 0                      | 3 (0.7)                |
| Candida infection                                                   | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Cellulitis                                                          | 0                          | 1 (0.7)                | 1 (0.2)                |

<div style=\"page-break-after: always\"></div>

Table 61. Treatment-Emergent Adverse Events Classified as Infection During the Maintenance Phase: Safety Population Study CT-P13 3.7 (UC) - continued

| System Organ Classl Preferred Term'     | CT-P13 SC 120 mg (N=296)   | Placebo (N=140)        | Total (N=436)          |
|-----------------------------------------|----------------------------|------------------------|------------------------|
|                                         | Number (%) of patients     | Number (%) of patients | Number (%) of patients |
| Chronic sinusitis                       | 2 (0.7)                    | 0                      | 2 (0.5)                |
| Conjunctivitis                          | 2 (0.7)                    | 0                      | 2 (0.5)                |
| Cystitis                                | 4 (1.4)                    | 0                      | 4 (0.9)                |
| Erythema migrans                        | 0                          | 1 (0.7)                | 1 (0.2)                |
| Escherichia urinary tract infection     | 0                          | 1 (0.7)                | 1 (0.2)                |
| Furuncle                                | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Gastroenteritis                         | 2 (0.7)                    | 0                      | 2 (0.5)                |
| Gastrointestinal viral infection        | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Herpes simplex                          | 2 (0.7)                    | 2 (1.4)                | 4 (0.9)                |
| Herpes zoster                           | 3 (1.0)                    | 2 (1.4)                | 5 (1.1)                |
| Influenza                               | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Latent tuberculosis                     | 2 (0.7)                    | 3 (2.1)                | 5 (1.1)                |
| Nasopharyngitis                         | 7 (2.4)                    | 7 (5)                  | 14 (3.2)               |
| Oral candidiasis                        | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Oral herpes                             | 5 (1.7)                    | 0                      | 5 (1.1)                |
| Otitis externa                          | 2 (0.7)                    | 0                      | 2 (0.5)                |
| Otitis media acute                      | 0                          | 1 (0.7)                | 1 (0.2)                |
| Peritonitis                             | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Pharyngitis                             | 6 (2.0)                    | 0                      | 6 (1.4)                |
| Pneumonia                               | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Pulpitis dental                         | 0                          | 1 (0.7)                | 1 (0.2)                |
| Pyelonephritis                          | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Respiratory tract infection             | 3 (1.0)                    | 1 (0.7)                | 4 (0.9)                |
| Respiratory tract infection viral       | 2 (0.7)                    | 0                      | 2 (0.5)                |
| Rhinitis                                | 2 (0.7)                    | 2 (1.4)                | 4 (0.9)                |
| Salpingitis                             | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Salpingo-oophoritis                     | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Sinusitis                               | 2 (0.7)                    | 0                      | 2 (0.5)                |
| Streptococcal impetigo                  | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Tinea cruris                            | 0                          | 1 (0.7)                | 1 (0.2)                |
| Tinea pedis                             | 0                          | 1 (0.7)                | 1 (0.2)                |
| Tonsillitis                             | 1 (0.3)                    | 2 (1.4)                | 3 (0.7)                |
| Tooth abscess                           | 0                          | 1 (0.7)                | 1 (0.2)                |
| Upper respiratory tract infection       | 9 (3.0)                    | 3 (2.1)                | 12 (2.8)               |
| Urinary tract infection                 | 6 (2.0)                    | 2 (1.4)                | 8 (1.8)                |
| Vaginal infection                       | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Varicella                               | 1 (0.3)                    | 0                      | 1 (0.2)                |
| Viral upper respiratory tract infection | 1 (0.3)                    | 1 (0.7)                | 2 (0.5)                |

<div style=\"page-break-after: always\"></div>

The TEAEs classified as infection considered by the investigator to be related to study drug during the maintenance phase were reported in 21 (4.8%) patients (11 [3.7%] and 10 [7.1%] patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively).

Treatment-emergent serious adverse events (TESAE) of infection were reported for 7/296 subjects in the CT\\_P13 SC group and 1/140 subjects in the placebo group. These included in the active group, COVID-19 (n=1), COVID-19 pneumonia (n=2), cystitis (n=1), pneumonia (n=1), salpingitis (n=1) and urinary trat infection (n=1), and in the placebo group, cellulitis (n=1).

During the Maintenance Phase, TEAE of latent tuberculosis was reported for 2 (0.7%) patients in the CTP13 SC 120 mg arm and 3 (2.1%) patients in the placebo SC arm.

## CHMP comment

The overall incidence of infections reported as TEAE was closely similar between the study arms: 28.0% vs. 25.7.% of study subjects suffered an infection in the CT-P13 and placebo arms, respectively. However, treatment-emergent serious adverse events (TESAE) occurred in 7 subjects in the active and only 1 subject in the placebo arm.

Of the 39 COVID-19 cases, 30 occurred in the active arm. Additionally, there were three cases of COVID19 pneumonia in the active group and none in the placebo group. Hence, it is obvious that infliximab predisposes to symptomatic COVID-19 infection. The SmPC of Remsima already includes the information on susceptibility to infections caused by infliximab and that viral infections (e.g., influenza, herpes virus infection) are a very common adverse reactions of infliximab. COVID-19 was requested to be added in these examples of infections mentioned in parentheses, with an asterisk referring to a footnote describing that these ADRs were seen with the SC administered Remsima; and the MAH performed this change.

Section 4.8 of the SmPC is proposed to be updated regarding description of the adverse drug reactions 'systemic injection reaction' and 'localised injection site reaction'. As described earlier, the update of Section 4.8 is based on data pooled from the two phase 3 studies currently under assessment and one phase 1 study.  However,  the  update  should  be  based  on  the  comprehensive  data  package  obtained  so  far  for approved SC doses used for approved indications. With their response, the MAH provided pooled analyses that did not change the safety profile (see assessment of Question 46 in Section 13.2 of this AR). Also, the injection site reactions in the pooled analyses corresponded to the frequency of 'common', in line with the currently proposed Product Information.

## Malignancy

In Study CT-P13 3.7, during the Maintenance Phase, grade 3 TEAE of prostate cancer was reported for 1 patient in the CT-P13 SC 120 mg arm. The AE was deemed unrelated to study drug by the investigator.

## Study CT-P13 3.8 (Crohn's Disease)

## Systemic Injection Reaction

During the maintenance phase, SIRs were reported for 3 (1.3%) and 1 (1.0%) patients in the CT-P13 SC 120 mg and placebo SC arms, respectively. All events were grade 1 in severity and non-serious. No action was taken with the study drug and all patients recovered without receiving treatment for the SIR.

## Delayed Hypersensitivity

No cases of delayed hypersensitivity were reported.

<div style=\"page-break-after: always\"></div>

## Localised Injection Site Reaction

During the Maintenance Phase, localised ISRs were reported for 14 (5.9%) and 1 (1.0%) patients in the CT-P13 SC 120 mg and placebo SC groups, respectively. All TEAEs classified as localized ISRs were grade 1 or 2 in intensity and most patients' localized ISR recovered in both treatment groups. No serious localized ISRs were reported.

## Infection

The TEAEs classified as infection are presented in table 8.2.3.3.3. Overall, at least one TEAE of infection was reported for 31.1% of subjects in the CT-P13 group and 18.1% of subjects in the placebo group. Of these, investigators assessed the TEAEs to be related to study drug in 15 subjects (6.3%) in the active group and 6 subjects (5.7%) in the placebo group.

The most frequently reported TEAEs classified as infection during the maintenance phase were COVID-19 reported in 32 (9.3%) patients (27 [11.3%] and 5 [4.8%]) and patients for the CT-P13 SC 120 mg and placebo SC groups, respectively), followed by urinary tract infection in 7 (2.9%) patients for the CT-P13 SC 120 mg group and latent tuberculosis, nasopharyngitis, respiratory tract infection viral, and urinary tract infection each reported in 2 (1.9%) patients for the placebo SC group.

Treatment-emergent serious  adverse  events  (TESAE)  of  infection  were  reported  according  to  Table    1 (under subtitle 8.2.3.2 Serious adverse events and deaths) for 6/238 (2.5%) subjects in the CT-P13 SC group and 1 (1.0%) subjects in the placebo group. The seven TESAE reported for the six subjects in the active group included one of each of the following: abscess intestinal, anal abscess, appendicitis, arthritis bacterial, bartholinitis, bronchiolitis, and urinary tract infection. In the placebo group there was one TESAE of peritonitis.

Two cases of latent tuberculosis were reported in the placebo group and none in the active group.

Table 62. Preferred Term: Safety Population Study CT-P13 3.8 (Crohn's disease)

| System Organ Classl                                                 | CT-P13 SC 120 mg (N=238)   | Placebo SC (N=105)     | Total (N=343)          |
|---------------------------------------------------------------------|----------------------------|------------------------|------------------------|
| Preferred Term'                                                     | Number (%) of patients     | Number (%) of patients | Number (%) of patients |
| Total number of TEAEsclassified asinfection                         | 108                        | 25                     | 133                    |
| Number (%) of patients with at least 1 TEAE classified as infection | 74 (31.1)                  | 19 (18.1)              | 93 (27.1)              |
| Related                                                             | 15 (6.3)                   | 6 (5.7)                | 21 (6.1)               |
| Grade 1                                                             | 4 (1.7)                    | 5 (4.8)                | 9 (2.6)                |
| Grade 2                                                             | 10 (4.2)                   | 1 (1.0)                | 11 (3.2)               |
| Grade 3                                                             | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Unrelated                                                           | 65 (27.3)                  | 16 (15.2)              | 81 (23.6)              |
| Grade 1                                                             | 27 (11.3)                  | 6 (5.7)                | 33 (9.6)               |
| Grade 2                                                             | 34 (14.3)                  | 7 (6.7)                | 41 (12.0)              |
| Grade 3                                                             | 4 (1.7)                    | 2 (1.9)                | 6 (1.7)                |
| Grade 4                                                             | 0                          | 1 (1.0)                | 1 (0.3)                |
| Infections and infestations                                         | 74 (31.1)                  | 19 (18.1)              | 93 (27.1)              |
| Abdominal abscess                                                   | 0                          | 1 (1.0)                | 1 (0.3)                |
| Abscess intestinal                                                  | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Abscess limb                                                        | 0                          | 1 (1.0)                | 1 (0.3)                |
| Abscess rupture                                                     | 1 (0.4)                    | 0                      | 1 (0.3)                |

<div style=\"page-break-after: always\"></div>

| System Organ Class1               | CT-P13 SC 120 mg (N=238)   | Placebo SC (N=105)     | Total (N=343)          |
|-----------------------------------|----------------------------|------------------------|------------------------|
| Preferred Term'                   | Number (%) of patients     | Number (%) of patients | Number (%) of patients |
| Acute sinusitis                   | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Anal abscess                      | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Appendicitis                      | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Arthritis bacterial               | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Bartholinitis                     | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Bronchiolitis                     | 1 (0.4)                    | 0                      | 1 (0.3)                |
| COVID-19                          | 27 (11.3)                  | 5 (4.8)                | 32 (9.3)               |
| Cellulitis                        | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Chronic sinusitis                 | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Conjunctivitis                    | 2 (0.8)                    | 0                      | 2 (0.6)                |
| Cystitis                          | 0                          | 1 (1.0)                | 1 (0.3)                |
| Ear infection                     | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Folliculitis                      | 2 (0.8)                    | 0                      | 2 (0.6)                |
| Gastroenteritis                   | 3 (1.3)                    | 1 (1.0)                | 4 (1.2)                |
| Gastroenteritis viral             | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Gingivitis                        | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Herpes dermatitis                 | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Herpes zoster                     | 4 (1.7)                    | 0                      | 4 (1.2)                |
| Infected fistula                  | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Latent tuberculosis               | 0                          | 2 (1.9)                | 2 (0.6)                |
| Nasal herpes                      | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Nasopharyngitis                   | 5 (2.1)                    | 2 (1.9)                | 7 (2.0)                |
| Onychomycosis                     | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Oral herpes                       | 6 (2.5)                    | 1 (1.0)                | 7 (2.0)                |
| Orchitis                          | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Otitis media                      | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Periodontitis                     | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Peritonitis                       | 0                          | 1 (1.0)                | 1 (0.3)                |
| Pharyngitis                       | 4 (1.7)                    | 0                      | 4 (1.2)                |
| Pharyngitis streptococcal         | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Pilonidal disease                 | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Pneumonia                         | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Pulpitis dental                   | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Pustule                           | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Pyoderma                          | 2 (0.8)                    | 1 (1.0)                | 3 (0.9)                |
| Respiratory tract infection       | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Respiratory tract infection viral | 3 (1.3)                    | 2 (1.9)                | 5 (1.5)                |
| Rhinitis                          | 2 (0.8)                    | 0                      | 2 (0.6)                |

<div style=\"page-break-after: always\"></div>

| System Organ Classl               | CT-P13 SC 120 mg (N=238)   | Placebo SC (N=105)     | Total (N=343)          |
|-----------------------------------|----------------------------|------------------------|------------------------|
| Preferred Term'                   | Number (%) of patients     | Number (%) of patients | Number (%) of patients |
| Rhinovirus infection              | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Sinusitis                         | 2 (0.8)                    | 0                      | 2 (0.6)                |
| Skin bacterial infection          | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Tinea versicolour                 | 1 (0.4)                    | 0                      | 1 (0.3)                |
| Tonsillitis                       | 0                          | 1 (1.0)                | 1 (0.3)                |
| Tooth infection                   | 2 (0.8)                    | 0                      | 2 (0.6)                |
| Upper respiratory tract infection | 1 (0.4)                    | 1 (1.0)                | 2 (0.6)                |
| Urinary tract infection           | 7 (2.9)                    | 2 (1.9)                | 9 (2.6)                |

Abbreviations: MedDRA, medical dictionary for regulatory activities; SC, subcutaneous; TEAE, treatment-emergent adverse event.

Note: At each level of summarization, patients were counted once if they reported 1 or more events. Only the most severe event was counted. The event was considered to be related to the study drug by the investigator if the relationship was defined as 'possible', 'probable', or 'definite'. The intensity was defined as Grade 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Life-threatening, 5 = Death. For patients with dose adjustment, all data collected regardless of dose adjustment for CT-P13 SC 120 mg group and data collected before initiation of dose adjustment for placebo SC group were included in this summary.

## CHMP comment

Overall, TEAEs reported as infection were markedly more frequent in the active group (31.1% of subjects) than the placebo group (18.1% of subjects). Of these, investigators assessed the TEAEs to be related to study drug in 15 subjects (6.3%) in the active group and 6 subjects (5.7%) in the placebo group. It is obvious that the assessment of relatedness has not been accurate.

Subjects in the active group were more susceptible to clinical COVID-19 infection, which was reported for 11.3% of subjects in the active group and only 4.8% in the placebo group. Five cases of herpes infections were reported in the active group: 4 herpes zoster and 1 herpes dermatitis, whereas no cases of herpes were reported in the placebo group. The Section 4.4 (Warnings and precautions for use) of the SmPC of Remsima already includes the information that patients taking TNF-blockers are more susceptible to serious infections. Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other opportunistic infections have been observed in patients treated with infliximab. Advice is included that patients should be advised of and avoid exposure to potential risk factors for infection as appropriate; and  that  patients  who  develop  a  new  infection  should  be  monitored  closely  and  undergo  a  complete diagnostic evaluation and that administration of infliximab should be discontinued if a patient develops a new serious infection or sepsis. As described earlier in this AR, Table 1 of Section 4.8. of the SmPC includes the information that viral infection (e.g., influenza, herpes virus infection) is a very common AE, in line with the SmPC of the originator product. Upon request, the MAH added COVID-19 to the list of examples together with influenza and herpes virus infection.

## Malignancy

In Study CT-P13 3.8, during the Maintenance Phase, only one case of malignancy (stage III colon cancer) was reported in the placebo group and none in the active group. The AE was deemed unrelated to study drug by the investigator.

<div style=\"page-break-after: always\"></div>

## 8.2.3.4. Dose adjustment vs. no dose adjustment

Dose adjustment from CT-P13 SC 120 mg to 240 mg every 2 weeks was allowed for patients with loss of response starting from Week 22 in both pivotal trials. The data on subgroups treated with CT-P13 SC and with and without dose escalation have been provided by the MAH 1) separately for both trials and 2) pooled across the two trials. The MAH explains that pooling of safety data provides a larger number of patients within each subgroup for the evaluation of rare events and other targeted events in a controlled setting such as serious infection. The patients from these studies are considered to be sufficiently similar that pooling of the data is appropriate.

## CHMP comment

It is agreed that pooling of data of patients with ulcerative colitis and Crohn's disease according to dose adjustment is acceptable, as far as data from both studies are also provided for each individual study. From tables included in the document 'Post-hoc Analyses' (Module 5.3.5.3) it is understood that there were 534 subjects in the pooled analysis, of whom 137 with dose adjustment and 397 without dose adjustment. The MAH was however requested to further clarify the patient populations used for investigating effects of dose escalation in the pooled data set and in the separate analyses of both phase 3 trials. The re-analyses were requested to be also performed separately for subjects with UC and CD for confirmation of safety in each indication. The  MAH  provided  the  requested  pooled  analyses  from  all  studies  where  CT-P13  was administered SC and also separately for study CTP-13 3.8 (CS) for subjects administered the 120 mg SC dose, 240 mg SC dose, or placebo, where incidence of TEAEs was calculated per 100 patient-years (PY). Similar analyses were not performed in subjects with UC in study CT-P 13 3.7, since the MAH withdraws the escalation in UC patients due to insufficient data. Please see assessments of questions 42 and 46 in Section 13.2 of this AR.

In Study CTP-13 3.7 (ulcerative colitis), 92/296 (31.1%) of patients in the active group needed dose escalation from 120 to 240 mg and 75/140 (53.6 % in the placebo group and needed dose escalation from placebo to 240 mg during the maintenance phase.

Amongst these patients, TEAEs were reported for 67 (72.8%) and 133 (65.2%) patients in the subgroups with dose adjustment and without dose adjustment, respectively, apparently only from the active study group. More subjects suffered (aggravation of) colitis ulcerative in the active vs. placebo group (15 [16.3%] and  5  [2.5%]  patients,  respectively)  and  anaemia  (6  [6.5%]  and  8  [3.9%]  patients,  respectively). Discontinuation of study drug or numbers of treatment-emergent adverse events of special interest were not affected by dose adjustment, including systemic and injection site reactions (data for the individual study not shown for brevity).

In Study CT-P13 3.8 (Crohn's disease) , in the maintenance phase, dose was adjusted at least once for 45  subjects  [18.9%]  and  48  [45.1%]  patients  in  the  CT-P13  SC  120  mg  and  placebo  SC  groups, respectively.  Apparently,  only  subjects  from  the  active  study  group  were  included  in  the  comparison between doses (see earlier). Amongst these patients, TEAEs were reported for 32 (71.1%) and 140 (72.5%) patients in the subgroups with dose adjustment and without dose adjustment, respectively. Similar to the study CT-P13 3.7, aggravation of the disease to be treated - in this study, Crohn's disease - was more common in the group with dose escalation. By SOC, the largest difference was seen in musculoskeletal and connective tissue disorders including arthralgia, which AEs were however mostly considered unrelated to study drug (data not shown for brevity).

The MAH concludes that dose escalation did not increase TEAEs leading to drug discontinuation rate or frequency of AESI.

<div style=\"page-break-after: always\"></div>

## CHMP comment

As described earlier, the subjects switched from placebo to 240 mg dose of CT-P13 SC constituted a great part of subjects using the 240 mg dose, since dose escalation was more frequent in the placebo groups than in the active study groups of both phase 3 trials, as expectable. Therefore, these subjects should be included in the analyses on safety of the 240 mg dose. Nevertheless, for comparison of safety between the 120 mg and 240 mg doses it is of utmost importance that the ADRs for each dose are only included for the time when the dose was used. The MAH provided analyses on TEAE per exposure time to each dose (per 100 PY), as requested..

The currently submitted data on safety of the 240 mg dose are now available for the entire treatment time (induction, maintenance and long-term extension periods) and are considered sufficient for confirmation of safety of this proposed higher dose (please see assessment of Questions 42 and 46 in Section 13.2 of this AR and the assessment of the final CSR later in this section).

## Pooled data

The subgroup analysis of TEAEs by dose adjustment in the pooled analysis of Studies CT-P13 3.7 and CTP13 3.8 is provided in Table 8.2.3.4.1.  In the pooled data, the number of CT-P13 SC treated patients with dose adjustment from CT-P13 SC 120 mg to 240 mg was 137/534 (25.7%) patients and without dose adjustment was 397/534 (74.3%) patients during the Maintenance Phase.

TEAEs were reported for 99 (72.3%) and 273 (68.8%) patients in the subgroups with dose adjustment and without dose adjustment, respectively. The most commonly reported TEAEs in the subgroup with dose escalation ( ≥ 5% patients in the subgroup with dose adjustment and reported at a higher rate than the subgroup without dose adjustment) were (aggravation of) colitis ulcerative (15 [10.9%] and 5 [1.3%] patients, respectively), (aggravation of) Crohn's disease (8 [5.8%] and 7 [1.8%] patients, respectively), anaemia (9 [6.6%] and 18 [4.5%] patients, respectively), localised ISR (7 [5.1%] and 17 [4.3%] patients, respectively) and arthralgia (7 [5.1%] and 15 [3.8%] patients, respectively).  By SOC, the largest difference was seen in gastrointestinal disorders; however, this was due to (aggravation of) colitis ulcerative and (aggravation  of)  Crohn's  disease,  which  were  TEAEs  by  PT  with  the  largest  difference  between  the subgroups.

<div style=\"page-break-after: always\"></div>

Table 63. TEAEs by Dose Adjustment Reported for at Least 2% of Patients in the Subgroup with Dose Adjustment by SOC and PT in the Pooled Analysis (Maintenance Phase): Safety Population

|                                                      | Pooled CT-P13 SC (N=534)               | Pooled CT-P13 SC (N=534)                  |
|------------------------------------------------------|----------------------------------------|-------------------------------------------|
| System Organ Class Preferred Tenm                    | Patients with Dose Adjustment (N'=137) | Patients without Dose Adjustment (N'=397) |
| Total number of TEAEs                                | 301                                    | 863                                       |
| Number (%o) of patients with ≥ 1 TEAE                | 99 (72.3)                              | 273 (68.8)                                |
| Blood and lymphatic system disorders                 | 15 (10.9)                              | 39 (9.8)                                  |
| Anaemia                                              | 9 (6.6)                                | 18 (4.5)                                  |
| Iron deficiency anaemia                              | 3 (2.2)                                | 2 (0.5)                                   |
| Neutropenia                                          | 3 (2.2)                                | 8 (2.0)                                   |
| Gastrointestinal disorder's                          | 38 (27.7)                              | 63 (15.9)                                 |
| Abdominal pain                                       | 4 (2.9)                                | 10 (2.5)                                  |
| (Aggravation of) colitis ulcerative                  | 15 (10.9)                              | 5 (1.3)                                   |
| (Aggravation of) Crohn's disease                     | 8 (5.8)                                | 7 (1.8)                                   |
| Dianhoea                                             | 3 (2.2)                                | 11 (2.8)                                  |
| Haemorhoids                                          | 3 (2.2)                                | 2 (0.5)                                   |
| Large intestine polyp                                | 3 (2.2)                                | 3 (0.8)                                   |
| General disorders and administration site conditions | 20 (14.6)                              | 43 (10.8)                                 |
| Injection site reaction?                             | 7 (5.1)                                | 17 (4.3)                                  |
| Peripheral swelling                                  | 3 (2.2)                                | 2 (0.5)                                   |
| Pyrexia                                              | 4 (2.9)                                | 6 (1.5)                                   |
| Infections and infestations                          | 41 (29.9)                              | 116 (29.2)                                |
| COVID-19                                             | 13 (9.5)                               | 44 (11.1)                                 |
| Oral herpes                                          | 4 (2.9)                                | 7 (1.8)                                   |
| Upper respiratory tract infection                    | 4 (2.9)                                | 6 (1.5)                                   |
| Injury. poisoning and procedural complications       | 8 (5.8)                                | 22 (5.5)                                  |
| Injection related reaction?                          | 5 (3.6)                                | 10 (2.5)                                  |
| Investigations                                       | 17 (12.4)                              | 48 (12.1)                                 |
| Alanine aminotransferase increased                   | 3 (2.2)                                | 16 (4.0)                                  |
| Musculoskeletal and connective tissue disorders      | 18 (13.1)                              | 32 (8.1)                                  |
| Arthralgia                                           | 7 (5.1)                                | 15 (3.8)                                  |
| Arthritis                                            | 3 (2.2)                                | 4 (1.0)                                   |
| Nervous svstem disorders                             | 11 (8.0)                               | 39 (9.8)                                  |
| Headache                                             | 7 (5.1)                                | 28 (7.1)                                  |
| Skin and subcutaneous tissue disorders               | 17 (12.4)                              | 34 (8.6)                                  |
| Pnuitus                                              | 3 (2.2)                                | 3 (0.8)                                   |
| Rash                                                 | 3 (2.2)                                | 5 (1.3)                                   |
| Vascular disorders                                   | 8 (5.8)                                | 15 (3.8)                                  |
| Hypertension                                         | 5 (3.6)                                | 12 (3.0)                                  |

Dose adjustment did not affect the incidence rates of TESAE, TEAE leading to study drug discontinuation or TEAESIs. The incidence rates of SIR (3.6% vs 2.5%), localised ISR (5.1% vs 4.3%) and infection (29.9% vs 29.2%) were similar between the subgroups with and without dose escalation, respectively. (Table 61)

<div style=\"page-break-after: always\"></div>

Table 64. Summary of TESAE, TEAE Leading to Study Drug Discontinuation and TEAESIs by Dose Adjustment for Patients from the CT-P13 SC Treatment Groups in the Pooled Analysis (Maintenance Phase): Safety Population

|                                                                            | CT-P13 SC 120 mg (N=534)               | CT-P13 SC 120 mg (N=534)                 |
|----------------------------------------------------------------------------|----------------------------------------|------------------------------------------|
|                                                                            | Patients with Dose Adjustment (N'=137) | Patientswithout Dose Adjustment (N'=397) |
| Number (%) of patients with ≥ 1 TESAE                                      | 8 (5.8)                                | 27 (6.8)                                 |
| Number (%) of patients with ≥ 1 TEAE leading to study drug discontinuation | 3 (2.2)                                | 16 (4.0)                                 |
| Number (%) of patients with ≥ 1 SIR                                        | 5 (3.6)                                | 10 (2.5)                                 |
| Number (%) of patients with ≥ 1 localised ISR                              | 7 (5.1)                                | 17 (4.3)                                 |
| Number (%) of patients with ≥ 1 infection                                  | 41 (29.9)                              | 116 (29.2)                               |
| Number (%) of patients with ≥ 1 malignancy                                 | 0                                      | 1 (0.3)                                  |

## Assessor's conclusions on comparison between doses of 120 mg and 240 mg

The reported results on subgroups administered the 120 mg and 240 mg dose showed no dose-dependently increased  risk  for  infection  or  serious  adverse  reactions  with  the  higher  vs.  lower  dose.  Systemic  and localised injection reaction rates were similar between the two doses.

It is an expected finding that aggravation of the disease was more frequent in patients with loss of response who needed dose escalation from 120 mg to 240 mg of CT-P13 SC. However, the submitted data are not deemed confirmatory.

From tables included in the document 'Post-hoc Analyses' (Module 5.3.5.3) it is understood that there were 534 subjects in the pooled analysis, of whom 137 with dose adjustment and 397 without dose adjustment. The MAH was however requested to further clarify the patient populations used for investigating effects of dose escalation in the pooled data set and in the separate analyses of both phase 3 trials.

For further assessment of the effects of dose escalation, the MAH was requested to conduct an additional analysis of the patients in the active arm who received dose escalation from 120 mg to 240 mg, where adverse events occurring prior to dose escalation vs. after dose escalation are compared, with adjustment for duration of exposure to each dose. The same analysis was requested to be conducted for the patients who originally were administered placebo and were switched to the 240mg dose. The requested pooled analyses were received, as were data on the 240 mg SC dose in subjects with CD in study CT-P13 38. The data on 240 mg SC dose form study CT-P13 37 were not included separately in the MAH's response, since the MAH no more applies for dose escalation in subjects with UC. (please see assessment of Questions 42 and 46 in Section 13.2 and assessment of the final CSR in Section 8.2.3.7 of this AR).

## 8.2.3.5. Clinical laboratory evaluation and vital signs

The majority of laboratory parameters had no CTCAE grade (e.g., the post-baseline laboratory result did not satisfy any CTCAE grade criteria) or were CTCAE Grade 1 (mild) or Grade 2 (moderate) with transient changes over time. Grade 3 (severe) or higher clinical laboratory findings from Studies CT-P13 3.7 and CTP13 3.8 are summarised below. Laboratory parameters evaluated as PD parameters (C-reactive protein [CRP] and faecal calprotectin [FC] concentrations) are not included in this section of the AR.

<div style=\"page-break-after: always\"></div>

In Study CT-P13 3.7 (ulcerative  colitis),  there  were  no  notable  differences  of  the  mean  change  from baseline for all clinical chemistry, haematology, and urinalysis laboratory parameters in both treatment groups (except for CRP, erythrocyte sedimentation rate [ESR], and FC, the levels of which changed in line with treatment effect).

However, individual patients had clinically relevant changes in laboratory values. CTCAE Grade 3 or higher laboratory results are summarized in Table 63. Apart from anaemia and neutropenia, both of which occurred more frequently in the active group, there appear to be no relevant differences between the active and placebo arms of the study in ≥Grade 3 laboratory results.

Table 65. Post-baseline CTCAE Grade 3 or Higher Laboratory Results in Study CT-P13

## 3.7 (Maintenance Phase): Safety Population (ulcerative colitis)

| Parameter CTCAE Grade              | CT-P13 SC 120 mg (N=296)   | Placebo SC (N=140)   |
|------------------------------------|----------------------------|----------------------|
| Clinical Chemistry                 |                            |                      |
| ALTincreased Grade 3               | 1 (0.3)                    | 0                    |
| ASTincreased Grade 3               | 2 (0.7)                    | 0                    |
| CPK increased                      |                            |                      |
| Grade 3                            | 5 (1.7)                    | 4 (2.9)              |
| Grade 4                            | 4 (1.4)                    | 2 (1.4)              |
| Cholesterol high Grade 3           | 0                          | 1 (0.7)              |
| GGT increased Grade 3              | 0                          | 1 (0.7)              |
| Hyperkalemia Grade 3               | 1 (0.3)                    | 0                    |
| Hypertriglyceridemia               |                            |                      |
| Grade 3                            | 4 (1.4)                    | 1 (0.7)              |
| Grade 4                            | 0                          | 1 (0.7)              |
| Hyponatremia Grade 4               | 1 (0.3)                    | 0                    |
| Haematology                        |                            |                      |
| Anemia Grade 3                     | 6 (2.0)                    | 1 (0.7)              |
| Lymphocyte count decreased Grade 3 | 1 (0.3)                    | 1 (0.7)              |
| Neutrophil count decreased         |                            |                      |
| Grade 3                            | 11 (3.7)                   | 1 (0.7)              |
| Grade 4                            | 0                          | 1 (0.7)              |
| Whitebloodcell decreased Grade 3   |                            | 1 (0.7)              |

Note: At each level of summarisation, only the most severe case is counted. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; CTCAE, common terminology criteria for adverse events; GGT, gamma-glutamyl transferase

<div style=\"page-break-after: always\"></div>

## Study CT-P13 3.8 (Crohn's Disease)

Post-baseline CTCAE grade 3 or higher laboratory results are summarised for the safety population in Table 8.2.3.5.1.

Grade 3 neutropenia was reported for 11 subjects (3.7%) in the active group, whereas 2 subjects had Grade 3 or 4 neutropenia in the placebo group.

In this study, unlike study CT-P13 3.7,  CPK increase was more frequent in the active arm than the placebo arm. Grade 4 CPK increased was reported for 8 (3.4%) and 2 (1.9%) patients in the CT-P13 SC 120 mg and placebo SC arms, respectively. Except for one subject in the CT-P13 SC 120 mg arm, these findings were either reported as a study drug-unrelated TEAE or not reported as a TEAE. The CPK levels for all patients immediately returned to normal by the next assessment except for CPK increased reported at Week 54.

Grade 3 and grade 4 hypertriglyceridemia were reported for 5 (2.1%) and 1 (0.4) patients, respectively, in the CT-P13 SC 120 mg arm. For the 5 patients with grade 3 hypertriglyceridemia, two patients had medical history of hypertriglyceridemia or obesity and other three patients had grade 2 or 3 hypertriglyceridemia during the Induction Phase. One patient had grade 4 hypertriglyceridemia at Week 46, which was reported as study drug-unrelated TEAE of hypertriglyceridemia. The patient received medication treatment for the event and was recovering as triglyceride level decreased at Week 54.

<div style=\"page-break-after: always\"></div>

Table 66. Post-baseline CTCAE Grade 3 or Higher Laboratory Results in Study CT-P13 3.8 (Maintenance Phase): Safety Population (Crohn's disease)

| Parameter CTCAE Grade             | CT-P13 SC 120 mg (N=238)   | Placebo SC (N=105)   |
|-----------------------------------|----------------------------|----------------------|
| Clinical Chemistry                |                            |                      |
| ALTincreased Grade 3              | 2 (0.8)                    | 0                    |
| ASTincreased Grade 3              | 1 (0.4)                    | 0                    |
| Bloodbilirubinincreased Grade 3   | 5 (2.1)                    | 1 (1.0)              |
| CPK increased Grade 3 Grade 4     | 6 (2.5) 8 (3.4)            | 1 (1.0) 2 (1.9)      |
| GGTincreased Grade 3              | 1 (0.4)                    | 1 (1.0)              |
| Hypertriglyceridemia Grade 3      | 5 (2.1)                    | 0                    |
| Hypocalcemia Grade 3              | 1 (0.4)                    | 0                    |
| Hypokalemia Grade 3               | 1 (0.4)                    | 0                    |
| Haematology Anemia Grade 3        | 5 (2.1)                    | 4 (3.8)              |
| Lymphocytecount decreased Grade 3 |                            | 5 (4.8)              |
| Neutrophilcount decreased Grade 3 | 2 (0.8)                    |                      |
|                                   | 11 (4.6)                   | 0                    |
| Grade 4                           | 2 (0.8)                    | 0                    |

## CHMP comment

Laboratory findings showed increased frequency of Grade 3 to 4 neutropenia in active arms of both studies and anaemia in study CT-P13 3.7.  Neutropenia and anaemia are known common side effects of infliximab; hence, this is an expected finding.  Neutropenia was in most cases transient, and neutrophil levels returned to normal immediately. Dyslipidaemia is mentioned in Table 1 of Section 4.8 of the SmPC with the frequency of uncommon. The patients with hypertriglyceridaemia had also other risk factors for hypertriglyceridaemia.

## Vital signs, physical examination and other observations related to safety

## Vital signs

In studies CT-P13 3.7 and CT-P13 3.8, mean changes from baseline in vital sign values were small, and there were no notable differences between the treatment arms at any time point (data not shown for brevity).

Hypersensitivity monitoring (including delayed hypersensitivity) was assessed in both studies by vital signs (including BP, heart and respiratory rates, and body temperature) measured prior to the beginning of study drug administration, within 15 minutes and 1 hour (+ 10 minutes) after the drug administration. If patients

<div style=\"page-break-after: always\"></div>

had signs and symptoms of hypersensitivity at home, patients or caregivers were advised to call the study centre or get immediate help.

In both treatment groups in both trials, the most commonly reported clinically notable vital sign results during  hypersensitivity  monitoring  were  high  diastolic  blood  pressure  (DBP).  Generally,  there  were  no clinically notable differences between the treatment groups for vital sign results after the start of the study drug administration during hypersensitivity monitoring (data not shown for brevity).

## ECG

Three patients in study CT-P13 3.7 had electrocardiogram findings, all of which were considered unrelated to study drug. One case of atrioventricular (AV) block was reported at screening (I degree AV block with sequalae of II degree AV block, recovered without treatment) and again during maintenance phase (II degree AV block, recovered without treatment) in the CT-P13 SC 120 mg group. One case was reported of abnormal, clinically significant single ventricular ectopic beats at Weeks 6 and 14 in the CT-P13 SC 120 mg group; considered unrelated to study drug and recovered without medication. One case of supraventricular extrasystoles at week 6., 10. and 14 in the CT-P13 SC 120 mg group was reported as TEAE related to the study drug; dose of study drug was not changed, and the events recovered without medication.

In study CT-P13 3.8, 3 patients in the CT-P13 SC 120 mg group and one patient in the placebo SC group had  ECG  findings:  all  four  reports  concerned  a  grade  1  TEAE  of  right  bundle  branch  block  during  the maintenance phase (while the ECG had been normal at screening). All of these grade 1 TEAEs recovered without treatment medication and were considered as unrelated to the study drug, and the dose of the study medication was not changed.

## Physical examination

The majority of patients in both studies had normal baseline physical examination findings, which remained normal at each post-baseline visit. There were no notable differences between active and placebo groups (data not shown for brevity).

## Tuberculosis assessment

Tuberculosis  (TB)  was  assessed  using  interferonγ release  assay  (IGRA),  chest  X-ray,  and  clinically monitored throughout the study.

In study CT-P13 3.7, at baseline, the IGRA results were negative and positive for 429 (98.4%) and 7 (1.6%) patients respectively during the treatment period (post-baseline). All 7 patients who reported positive IGRA results  at  baseline  reported  latent  TB  or  IGRA  assay  positive  as  medical  history  or  adverse  event  and received prophylaxis for latent TB. In total, 12 (2.8%) patients (6 patients each [2.0% and 4.3%] in the CT-P13 SC 120 mg and placebo SC group) were reported as IGRA positive conversion (positive result from the post-baseline IGRA test following a negative result at baseline). None of the 12 patients who had IGRA conversion during treatment period developed an active TB. None of the patients had signs or symptoms present indicative of TB during the treatment period.

In study CT-P13 3.8, at baseline, IGRA results were negative for 332 (96.8%) and positive for 9 (2.6%) patients. All 9 patients with positive IGRA results at baseline reported latent TB or IGRA assay positive as medical  history  or  adverse  event  and  received  prophylaxis  for  latent  TB.  During  the  treatment  period (except for the extension phase), 9 (2.6%) patients (7 [2.9%] and 2 [1.9%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively) were reported as IGRA positive conversion. All IGRA conversions were reported as TEAE of latent TB or interferonγ release assay positive. During treatment period (except for the extension phase), 4 (1.2%) patients (3 [1.3%] patient and 1 [1.0%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively) were reported indeterminate IGRA result without positive result, following negative result at baseline. None of the patients had the progression to active TB during the treatment period.

<div style=\"page-break-after: always\"></div>

In Studies CT-P13 3.7 and CT-P13 3.8, all patients had normal or abnormal, not clinically significant results for chest X-ray at screening and no abnormal, clinically significant chest X-ray results related to tuberculosis were reported.

## CHMP comment

There were no notable effects on vital signs or physical examination. A few ECG findings were reported in both  phase  3  studies  (including  right  bundle  branch  block,  AV  block,  ventricular  and  supraventricular extrasystoles)  in  both  active  and  placebo  arms  of  the  studies.  These  abnormalities  were  considered unrelated to study drug except for one (a patient with recurring supraventricular extrasystoles) and all of them resolved without medicinal treatment.

At baseline, 1.6% patients in study CT-P13 3.7 and 2.6% patients in study CT-P13 3.8 were IGRA positive at baseline, all reported latent TB or IGRA assay positive as medical history or adverse event and received prophylaxis for latent TB.  In study CT-P13 3.7, IGRA positive conversion occurred in 2.0% and 4.3% in the CT-P13 SC 120 mg and placebo SC groups. In study CT-P13 3.8, IGRA conversion occurred in 2.9% and 1.9% patients in the CT-P13 SC 120 mg and placebo SC groups, respectively. Furthermore, in study CT-P13 3.8, during the treatment period, 1.3% and 1.0% patients in the CT-P13 SC 120 mg and placebo SC groups, respectively, were reported indeterminate IGRA result without positive result, following negative result  at  baseline.  None  of  the  patients  with  positive  conversion  progressed  to  active  TB  during  the treatment period in either study.

Local site pain assessment: Visual Analogue Scale (VAS)

The scale of VAS value is from 0 to 100 mm. In study CT-P13 3.7, during the maintenance phase, the mean VAS of local site pain for the CT-P13 SC 120 mg arm ranged from 8.88 to 10.44 mm, and for the placebo arm from 3.90 to 6.68 mm. In study CT-P13 3.8, the mean VAS of local stie pain was in the range of 10.77 to 14.68 in the CT-P13 SC 120 arm and in the range of 6.10 to 8.34 mm in the placebo arm.

## CHMP comment

The VAS of local site pain was generally higher in the active than placebo arms of both phase 3 studies. However, considering the maximum VAS value of 100 mm, the VAS values were relatively low (up to 10.44 for UC patients and 14.68 for CD patients in the active arms of the studies).

## 8.2.3.6. Subgroup analyses

The  MAH  pooled  data  from  studies  CT-P13  3.7  and  CT-P13  3.8  for  subgroup  analyses  conducted  for incidence rates of TEAE, TESAE, TEAE leading to study drug discontinuation and TEAESIs by the following categories:

- Age: &lt; 65 years old and ≥ 65 years old
- Gender: Male and Female
- Race: Asian/Oriental, Caucasian/White, American Indian/Alaska Native and Other
- Baseline disease activity: Moderate and Severe

For  patients  with  dose  adjustment  to  240  mg  of  CT-P13  SC,  data  collected  before  initiation  of  dose adjustment for the CT-P13 SC and Placebo SC arms are included in the subgroup analyses.

## CHMP comment

It is noteworthy that in studies CT-P13 3.7 and CT-P13 3.8, the age-based subgroup analysis on efficacy was conducted with a markedly lower cut-point (&lt;35 years, ≥ 35 years). No subgroup analysis on safety were predefined in the protocols of studies CT-P13 3.7 and CT-P13 3.8.

<div style=\"page-break-after: always\"></div>

## Age

Safety data for the subgroups aged &lt; 65 years and ≥ 65 years are presented below in table 65. Two subjects in the age group ≥ 65 years were reported to have experienced TESAE. One patient from the CTP13 SC 120 mg arm of study CT-P13 3.7 had Grade 2 TESAEs of aortic valve incompetence and cardiac failure and grade 4 TESAE of duodenal ulcer perforation. Another subject from the CT-P13 SC 120 mg arm of Study CT-P13 3.8 was reported to have had Grade 2 TESAE of bronchiolitis. All of these TESAEs were considered unrelated to study medication.

Table 67. Summary of Safety by Age for Patients in the Pooled Analysis (Maintenance

Phase): Safety Population

Souuces: Section 5.3.5.3 Post-hoc Tables 3.065,3.066, 3.067,3.068,3.069, 3.070 and 3.071

|                                            | Pooled CT-P13 SC1                             | Pooled CT-P13 SC1                             | Pooled Placebo SC?                            | Pooled Placebo SC?                            |
|--------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                            | ≤ 65 Years (N=520)                            | 2 65 Years (N=14)                             | ≤ 65 Years (N=238)                            | ≥ 65 Years (N=7)                              |
|                                            | Number (%o) of Patients with at Least l Event | Number (%o) of Patients with at Least l Event | Number (%o) of Patients with at Least l Event | Number (%o) of Patients with at Least l Event |
| TEAE                                       | 343 (66.0)                                    | 7 (50.0)                                      | 144 (60.5)                                    | 4 (57.1)                                      |
| TESAE                                      | 28 (5.4)                                      | 2 (14.3)                                      | 12 (5.0)                                      | 0                                             |
| TEAE leading to study dmug discontinuation | 15 (2.9)                                      | 1 (7.1)                                       | 8 (3.4)                                       | 1 (14.3)                                      |
| TEAE ofSIR                                 | 11 (2.1)                                      | 1 (7.1)                                       | 5 (2.1)                                       | 0                                             |
| TEAE of delayed hypersensitivity           | 0                                             | 0                                             | 0                                             | 0                                             |
| TEAE of localised ISR                      | 21 (4.0)                                      | 0                                             | 4 (1.7)                                       | 0                                             |
| TEAE of infection                          | 138 (26.5)                                    | 2 (14.3)                                      | 52 (21.8)                                     | 3 (42.9)                                      |
| TEAE of malignancy                         | 0                                             | 1 (7.1)                                       | 1(0.4)                                        | 0                                             |

## CHMP comment

The number of subjects aged ≥ 65 years was only 14 in the pooled safety data set from studies CT-P13 3.7 and CT-P13 3.8, and TEAEs were reported for 7 subjects of this subgroup. Due to low number of subjects and reported TEAEs in patients aged ≥ 65 years, no firm conclusions are possible. Since the elderly more often suffer from multiple background diseases and are more prone to infections (e.g., herpes zoster and severe influenza or COVID-19), the MAH was requested to submit data on exposure to the 240 mg dose in subjects aged 65 years and above, and if such subjects exist, safety data in these subjects. Upon request, the MAH informed that two subjects aged above 65 years received the adjusted dose of CT-P13 SC 240 mg during Treatment Period in study CT-P13 3.8 (Crohn's disease). One subject was not reported to have experienced any TEAEs. The other subject was reported with 2 TEAEs of infection and 1 TEAE of blood creatine phosphokinase increased after dose adjustment from placebo to 240 mg S.C.

Hence, one of the two subjects aged &gt;65 years experienced infections (respiratory tract infection and latent tuberculosis) and one did not. For comparison, in the entire study population, the incidence of infections during treatment with the 240 mg SC dose was 21/54 (38.9%, 39.94/100 PY) in subjects who escalated from 120 mg SC, and 19/50 (38%, 29.18/100 PY) in subjects who escalated from placebo (table 8 of the response document, see assessment of Question 46). It is known from previous scientific data that the elderly are more at risk of serious infections during infliximab treatment; but there exists no definitive information if the risk is associated with the level of infliximab. Since the increased risk of infections is already covered in the SmPC Sections 4.4 and 4.8, it is agreed that no amendment is warranted in Section 4.2, which refers to Sections 4.4 and 4.8 regarding this risk in the elderly.

<div style=\"page-break-after: always\"></div>

## Gender

There were 303 male and 231 female subjects in the pooled safety analysis set. The MAH states that the incidence rates of TEAEs were similar between male and female patients for both CT-P13 SC-treated and Placebo SC-treated groups in the pooled analysis and that gender did not have a significant impact on the safety profile of CT-P13 SC.

## CHMP comment

No integrated tables with safety results in both male and female subjects are provided by the MAH. Instead, tables on TEAE analyses have been provided separately for the male subgroup and the female subgroup of the pooled safety analysis set for each ADR (Post-hoc Analysis, Module 5.3.5.3). Therefore, comparison of safety between male and female subjects is cumbersome from the submitted data. The MAH however claims that similar safety results were obtained for both sexes.

Race

The MAH states that the incidence rates of TEAEs were similar regardless of race.

## CHMP comment

Similar to gender, the results for each ethnic group have been reported separately and not in an integrated table. The numbers of subjects in different ethnic groups in the pooled analyses are tabulated below by the assessor from multiple submitted tables:

|                               |   CT-P13 SC |   Placebo |
|-------------------------------|-------------|-----------|
| Asian/Oriental                |          10 |         3 |
| Caucasian/White               |         505 |       233 |
| American Indian/Alaska Native |          16 |         7 |
| Other                         |           3 |         2 |

Hence, the numbers of other than Caucasian subjects was very low, therefore, any comparison between ethnic subgroups is futile.

## Baseline Disease Activity

To determine the effect of baseline disease activity on the safety profile of CT-P13 SC, the TEAEs were assessed by moderate and severe disease activity based on the following categories:

| Category   | UC Patients                   | CDPatients       |
|------------|-------------------------------|------------------|
| Moderate   | median of modified mayo score | ≤ 300 CDAI score |
| Severe     | median of modified mayo score | > 300 CDAI sc0re |

Note: Modified Mayo score is sum of Mayo Scoring System, ranges from O to 9, excluding PGA. The baseline value is the last non-missing value before the first administration at Week O.

Abbreviations: CD, Crohn's disease; CDAI, Crohn's Disease Activity Index; PGA, physician global assessment; UC,ulcerative colitis

In the group with moderate disease activity, 66.1% of subjects in the active group and 61.8% in the placebo group experienced TEAEs. Of subjects with severe disease activity, 64.9% and 57.6 % in the active and placebo groups experienced TEAEs, respectively (tables 66 and 67).

<div style=\"page-break-after: always\"></div>

Table 68. TEAEs by Baseline Disease Activity - Pooled Safety Population - Subgroup: Moderate

|                                                               | Studies3.7+3.8     | Studies3.7+3.8   |
|---------------------------------------------------------------|--------------------|------------------|
| SystemOrganClass[1] PreferredTerm[1]                          | CT-P13 SC (N'=330) | Placebo (N'=152) |
| TotalNumberofTreatment-EmergentAdverseEvents                  | 677                | 265              |
| NumberofPatientsWithatLeastOneTreatment-EmergentAdverseEvents | 218 (66.1%)        | 94 (61.8%)       |
| Related                                                       | 64 (19.4%)         | 25 (16.4%)       |
| Grade 1                                                       | 29 (8.8%)          | 15 (9.9%)        |
| Grade 2                                                       | 24 (7.3%)          | 6 (3.9%)         |
| Grade 3                                                       | 10 (3.0%)          | 4 (2.6%)         |
| Grade 4                                                       | 1 (0.3%)           | 0                |
| Unrelated                                                     | 197 (59.7%)        | 88 (57.9%)       |
| Grade 1                                                       | 73 (22.1%)         | 35 (23.0%)       |
| Grade 2                                                       | 82 (24.8%)         | 39 (25.7%)       |
| Grade 3                                                       | 34 (10.3%)         | 11 (7.2%)        |
| Grade 4                                                       | 7 (2.1%)           | 3 (2.0%)         |
| Grade 5                                                       | 1 (0.3%)           | 0                |

Table 69. TEAEs by Baseline Disease Activity - Pooled Safety Population - Subgroup: Severe

|                                                                 | Studies3.7+3.8     | Studies3.7+3.8   |
|-----------------------------------------------------------------|--------------------|------------------|
| SystemOrganClass[1] Preferred Term [1]                          | CT-P13 SC (N'=202) | Placebo (N'=92)  |
| TotalNumberofTreatment-EmergentAdverseEvents                    | 356                | 106              |
| NumberofPatientsWith at LeastOneTreatment-EmergentAdverseEvents | 131 (64.9%)        | 53 (57.6%)       |
| Related                                                         | 45 (22.3%)         | 11 (12.0%)       |
| Grade 1                                                         | 25 (12.4%)         | 4 (4.3%)         |
| Grade 2                                                         | 17 (8.4%)          | 3 (3.3%)         |
| Grade 3                                                         | 3 (1.5%)           | 3 (3.3%)         |
| Grade 4                                                         | 0                  | 1 (1.1%)         |
| Unrelated                                                       | 119 (58.9%)        | 46 (50%)         |
| Grade 1                                                         | 48 (23.8%)         | 13 (14.1%)       |
| Grade 2                                                         | 53 (26.2%)         | 21 (22.8%)       |
| Grade3                                                          | 17 (8.4%)          | 10 (10.9%)       |
| Grade 4                                                         | 1 (0.5%)           | 2 (2.2%)         |
| Grade 5                                                         | 0                  | 0                |

## CHMP comment

Similar  to  gender  and  ethnicity,  the  results  for  subgroups  with  moderate  and  severe  baseline  disease activity have not been reported in an integrated table but separately. Comparison of subgroups is therefore difficult for, e.g., adverse events of special interest or for TESAEs. The MAH however claims that baseline disease activity did not have a significant impact on the safety profile of CT-P13 SC.

## 8.2.3.7. Safety data in final study reports for the extension phases of the phase 3 studies

In their response, the MAH submitted data on the entire treatment phase and separately for the extension phase in the final study reports.

Since the interim data for the placebo-controlled double-blind induction and maintenance phases were already assessed during the previous round, only the safety data for the open-label placebo-controlled extension phase of the two phase 3 studies are included below. Relatedness of observed TEAEs is not copied in  this  AR,  since  from the reported TEAEs it is obvious that differentiation of TEAEs from symptoms of background diseases has been difficult.

In study CT-P13 3.7 , 519 TEAEs were reported during extension phase in 189 (43.3%) patients (127 [42.9%] patients in the CT-P13 SC 120 mg group and 62 [44.3%] patients in the Placebo SC group). The TESAEs during extension phase were reported for 12 (4.1%) patients in the CT-P13 SC 120 mg group and 5 (3.6%) patients in the Placebo SC group.

The TEAEs leading to permanent discontinuation of study drug during the extension phase were reported for 5 (1.7%) patients in CT-P13 SC 120 mg group and 2 (1.4%) patients in the Placebo SC group.

The TEAEs classified as SIR during the extension phase were reported for 4 (1.4%) patients in the CT-P13 SC 120 mg group and 1 (0.7%) patient in the Placebo SC group. All TEAEs classified as SIR during the

<div style=\"page-break-after: always\"></div>

extension phase were Grade 1 or 2 in intensity and were considered by the investigator as related to the study drug but were non-serious. No SIR events were reported as TESAE in both CT-P13 SC 120 mg and Placebo SC groups during the extension phase. One delayed hypersensitivity event was reported in the CTP13  SC  120  mg  group  during  the  extension  phase.  There  were  no  delayed  hypersensitivity  events reported in the Placebo SC group during the extension phase.

The TEAEs classified as localized ISR during the extension phase were reported for 7 (2.4%) patients in CT-P13 SC 120 mg group and 5 (3.6%) patients in the Placebo SC group. All TEAEs classified as localized ISR during the extension phase were Grade 1 or 2 in intensity.

The TEAEs classified as infection during the extension phase were reported for 61 (20.6%) patients in CTP13 SC 120 mg group and 28 (20%) patients in the Placebo SC group.

No TEAEs classified as malignancy during the extension phase were reported for either treatment group.

In study CT-P13 3.8, 448 TEAEs during extension phase were reported in 152 (44.3%) patients (106 [44.5%] and 46 [43.8%] patients in the CT-P13 SC 120 mg and the placebo SC groups, respectively). The majority of TEAEs were grade 1 or 2 in intensity.

The TESAEs during the extension phase were reported for 16 (6.7%) patients and 4 (3.8%) patients in the CT-P13 SC 120 mg and placebo SC groups, respectively.

The TEAEs leading to discontinuation of study drug during the extension phase were reported for 5 (2.1%) patients and 4 (3.8%) patients in the CT-P13 SC 120 mg and placebo SC groups, respectively.

No TEAEs classified as SIR during the extension phase were reported for either treatment group. No TEAEs classified as delayed hypersensitivity during the extension phase were reported for either treatment group. The TEAEs classified as localized ISR during the extension phase were reported for 4 (1.7%) patients and 5 (4.8%) patients in the CT-P13 SC 120 mg and the placebo SC groups, respectively.

TEAEs classified as infection during the extension phase were reported for 61 (25.6%) patients and 27 (25.7%) patients in the CT-P13 SC 120 mg and the placebo SC groups, respectively.

No TEAEs classified as malignancy during the extension phase were reported for either treatment group.

No death was reported during the extension phase for both treatment groups.

For both phase 3 trials , there were no notable differences of the mean change from baseline for all clinical chemistry,  haematology,  and  urinalysis  laboratory  parameters  in  either  treatment  group  during  the extension phase.

## CHMP comment

There were no notable differences in safety between CT-P13 SC 120 mg and placebo SC groups during the extension phase. No new safety findings occurred during the extension phases of studies CT-P13 3.7 and CT-P13 3.8.

Comparative data on the 120 mg SC and 240 mg SC vs. placebo were received for study CT-P13 3.8 and are assessed in Section 13.2 of this AR.

## 8.2.4. Immunogenicity

The  submission  contains  immunogenicity  data  from  779  patients  (436  UC  and  343  CD  patients)  from Studies CT-P13 3.7 and CT-P13 3.8. Among the 779 patients, 534 patients (296 UC and 238 CD patients) received at least 1 proposed dose of 120 mg of CT-P13 SC and 447 IBD patients (244 UC and 203 CD patients) provide 1-year immunogenicity data at CT-P13 SC 120 mg.

<div style=\"page-break-after: always\"></div>

Methodology for determination of anti-drug antibodies (ADA) and neutralising antibodies (Nab) is assessed in Section 6.1 and discussed in Section 6.3 of this AR. Samples that were positive in the ADA assay were analysed further to conduct a NAb assessment.

ADA testing was conducted in both studies before study drug administration at baseline and at weeks 10, 14, 22, 30, 38, 46, 54 and end-of-study (4 weeks after the last dose of CT-P13. On the day of initiation of dose  adjustment,  serum  samples  for  immunogenicity  analysis  were  collected  before  study  drug administration. Additional serum samples for immunogenicity testing could be collected if a patient had experienced any delayed hypersensitivity to determine serum sickness. Analysis was performed at the central laboratory.

The rule of ADA and NAb conversion was following

-  ADA  conversion  was  defined  as  patients  who  reported  at  least  1  ADA  positive  result  after  Week  0 administration in patients who
1. Had at least 1 immunogenicity result after Week 0 administration, and
2. Did not have any ADA positive result before Week 0 administration.
-  NAb  conversion  was  defined  as  patients  who  reported  at  least  1  NAb  positive  result  after  Week  0 administration in patients who
1. Had at least 1 immunogenicity result after Week 0 administration, and
2. Did not have any NAb positive result before Week 0 administration.

A listing showing immunogenicity test results for each patient was provided by treatment group and visit for the ITT population.

Immunogenicity  test  findings  for  study  CT-P13  3.7  (Ulcerative  colitis)  are  summarised  for  the  safety population in Table 8.2.4.1. A total of 12 (2.8%) patients (6 [2.0% and 4.3%] patients each in CT-P13 SC 120 mg group and Placebo SC group, respectively) reported positive ADA already at Week 0, before study drug administration. None of the 12 patients had received biologics for treatment of IBD and/or TNF α inhibitors for treatment of other disease before first study drug administration. None of patients received infliximab before study drug administration.

All subjects in both study groups received treatment with CT-P13 during the open-label induction phase (dosing at Weeks 0, 2, and 6). At 10 weeks (baseline of maintenance period), 10.9 % and 13.7% of subjects were ADA positive in the CT-P13 and placebo groups, respectively. Thereafter, a majority of study subjects conversed to ADA-positivity, with a higher proportion of ADA-positive subjects in the placebo group. Of ADA positive subjects, a great majority were also NAb positive in both active and placebo groups.

The proportion of ADA-positive subjects was lower in subjects with dose adjustment from 120 mg to 240 mg dose (in the active study arm) than in subjects without dose escalation. The proportion of subjects conversing to ADA positivity increased in the active study arm up to week 30, whereafter the proportion slowly reached a plateau. In the placebo arm, the proportion conversing to ADA positivity increased up to week 30, after which a slow decline in the proportion of ADA positive subjects is seen. Similar to the active study arm, in the placebo study the proportion of ADA positive subjects was smaller in patients with dose escalation from placebo to 240 mg of CT-P13 than in subjects continuing with placebo treatment.

<div style=\"page-break-after: always\"></div>

Table 70. Frequency of ADA and NAb, study CT-P13-3.7

| Visit Result                                                    | CT-P13 SC 120 mg (N=296)                                        | CT-P13 SC 120 mg (N=296)   | CT-P13 SC 120 mg (N=296)   | Placebo SC (N=140)   | Placebo SC (N=140)      | Placebo SC (N=140)   |
|-----------------------------------------------------------------|-----------------------------------------------------------------|----------------------------|----------------------------|----------------------|-------------------------|----------------------|
| Visit Result                                                    | With Dose Adjustment                                            | Without Dose Adjustment    | Total                      | With Dose Adjustment | Without Dose Adjustment | Total                |
| Week 0 (Pre-dose), n (%)                                        |                                                                 |                            |                            |                      |                         |                      |
| ADA Positive                                                    | N/A                                                             | 6/294 (2.0)                | 6/294 (2.0)                | N/A                  | 6/140 (4.3)             | 6/140 (4.3)          |
| NAb Positive (as % of ADA positive)                             | N/A                                                             | 1/6 (16.7)                 | 1/6 (16.7)                 | N/A                  | 1/6 (16.7)              | 1/6 (16.7)           |
| Week 10, n (%)                                                  |                                                                 |                            |                            |                      |                         |                      |
| ADA Positive                                                    | N/A                                                             | 32/294 (10.9)              | 32/294 (10.9)              | N/A                  | 19/139 (13.7)           | 19/139 (13.7)        |
| NAb Positive (as % of ADA positive)                             | N/A                                                             | 28/32 (87.5)               | 28/32 (87.5)               | N/A                  | 14/19 (73.7)            | 14/19 (73.7)         |
| Week 14, n (%)                                                  |                                                                 |                            |                            |                      |                         |                      |
| ADA Positive                                                    | N/A                                                             | 76/287 (26.5)              | 76/287 (26.5)              | N/A                  | 50/139 (36.0)           | 50/139 (36.0)        |
| NAb Positive (as % of ADA positive)                             | N/A                                                             | 63/76 (82.9)               | 63/76 (82.9)               | N/A                  | 48/50 (96)              | 48/50 (96)           |
| Week 22, n (%)                                                  |                                                                 |                            |                            |                      |                         |                      |
| ADA Positive                                                    | N/A                                                             | 128/275 (46.5)             | 128/275 (46.5)             | N/A                  | 108/133 (81.2)          | 108/133 (81.2)       |
| NAb Positive (as % of ADA positive)                             | N/A                                                             | 108/128 (84.4)             | 108/128 (84.4)             | N/A                  | 105/108 (97.2)          | 105/108 (97.2)       |
| Week 30, n (%)                                                  |                                                                 |                            |                            |                      |                         |                      |
| ADA Positive                                                    | 23/57 (40.4)                                                    | 111/207 (53.6)             | 134/264 (50.8)             | 44/56 (78.6)         | 72/76 (94.7)            | 116/132 (87.9)       |
| NAb Positive (as % of ADA positive)                             | 18/23 (78.3)                                                    | 95/111 (85.6)              | 113/134 (84.3)             | 37/44 (84.1)         | 70/72 (97.2)            | 107/116 (92.2)       |
| Week 38, n (%)                                                  |                                                                 |                            |                            |                      |                         |                      |
| ADA Positive                                                    | 22/56 (39.3)                                                    | 105/191 (55.0)             | 127/247 (51.4)             | 44/57 (77.2)         | 56/65 (86.2)            | 100/122 (82.0)       |
| NAb Positive (as % of ADA positive)                             | 17/22 (77.3)                                                    | 87/105 (82.9)              | 104/127 (81.9)             | 32/44 (72.7)         | 51/56 (91.1)            | 83/100 (83)          |
| Week 46, n (%)                                                  |                                                                 |                            |                            |                      |                         |                      |
| ADA Positive                                                    | 28/62 (45.2)                                                    | 106/187 (56.7)             | 134/249 (53.8)             | 39/56 (69.6)         | 46/59 (78.0)            | 85/115 (73.9)        |
| NAb Positive (as % of ADA positive)                             | 22/28 (78.6)                                                    | 87/106 (82.1)              | 109/134 (81.3)             | 34/39 (87.2)         | 41/46 (89.1)            | 75/85 (88.2)         |
| Week 54, n (%)                                                  |                                                                 |                            |                            |                      |                         |                      |
| ADA Positive                                                    | 26/61 (42.6)                                                    | 106/186 (57.0)             | 132/247 (53.4)             | 37/56 (66.1)         | 42/57 (73.7)            | 79/113 (69.9)        |
| NAb Positive (as % of ADA positive)                             | 21/26 (80.8)                                                    | 97/106 (91.5)              | 118/132 (89.4)             | 33/37 (89.2)         | 39/42 (92.9)            | 72/79 (91.1)         |
| Treatiment Period (including EOS and unscheduled visits), n (%) | Treatiment Period (including EOS and unscheduled visits), n (%) |                            |                            |                      |                         |                      |
| Positive Conversion in ADA1                                     | 49/88 (55.7)                                                    | 134/199 (67.3)             | 183/287 (63.8)             | 68/72 (94.4)         | 57/62 (91.9)            | 125/134 (93.3)       |
| Positive Conversion in NAb1 (as % of ADA positive)              | 43/49 (87.8)                                                    | 118/134 (88.1)             | 161/183 (88.0)             | 66/68 (97.1)         | 56/57 (98.2)            | 122/125 (97.6)       |

<div style=\"page-break-after: always\"></div>

Figure 33. Frequency of ADA in Study CT-P13 3.7: Safety Population

<!-- image -->

Immunogenicity test findings for study CT-P13 3.8 (Crohn's disease) are presented in Table 69 and Figure 34. Similar to findings in study CT-P13 3.7, conversion to ADA positivity was frequent across the study. Overall, also in this study, a great majority of ADA positive subjects were also NAb positive. In the active study  group,  the  proportion  of  ADA  positive  subjects  increased  up  to  Week  30  and  reached  a  plateau between 50 % to 60 % of subjects during weeks 30 to 54.  The incidence of ADA positivity was highest in the placebo group without dose escalation and reached a peak at Week 38 (84.3% of subjects). Dose escalation from placebo to treatment with CT-P13 (240 mg) was associated with a lower incidence of ADA positivity than continuation with placebo. In subjects originally on placebo and switched to CT-P13 (240 mg), the proportion of ADA positive patients decreases clearly from 30 to 54 weeks. (Figure 34).

<div style=\"page-break-after: always\"></div>

Table 71. Frequency of ADA and NAb, study CT-P13-3.8

| Visit                                                            | CT-P13 SC 120 mg (N=238)                                         | CT-P13 SC 120 mg (N=238)   | CT-P13 SC 120 mg (N=238)   | Placebo SC (N=105)   | Placebo SC (N=105)      | Placebo SC (N=105)   |
|------------------------------------------------------------------|------------------------------------------------------------------|----------------------------|----------------------------|----------------------|-------------------------|----------------------|
| Result                                                           | With Dose Adjustment                                             | Without Dose Adjustment    | Total                      | With Dose Adjustment | Without Dose Adjustnent | Total                |
| Week 0 (Pre-dose), n (%)                                         |                                                                  |                            |                            |                      |                         |                      |
| ADA Positive                                                     | N/A                                                              | 4/236 (1.7)                | 4/236 (1.7)                | N/A                  | 4/105 (3.8)             | 4/105 (3.8)          |
| NAb Positive (as % of ADA positive)                              | N/A                                                              | 2/4 (50)                   | 2/4 (50)                   | N/A                  | 2/4 (50)                | 2/4 (50)             |
| Week 10, n (%)                                                   |                                                                  |                            |                            |                      |                         |                      |
| ADA Positive                                                     | N/A                                                              | 17/238 (7.1)               | 17/238 (7.1)               | N/A                  | 6/105 (5.7)             | 6/105 (5.7)          |
| NAb Positive (as % of ADA positive)                              | N/A                                                              | 14/17 (82.4)               | 14/17 (82.4)               | N/A                  | 4/6 (66.7)              | 4/6 (66.7)           |
| Week 14, n (%)                                                   |                                                                  |                            |                            |                      |                         |                      |
| ADA Positive                                                     | N/A                                                              | 53/232 (22.8)              | 53/232 (22.8)              | N/A                  | 21/102 (20.6)           | 21/102 (20.6)        |
| NAb Positive (as % of ADA positive)                              | N/A                                                              | 50/53 (94.3)               | 50/53 (94.3)               | N/A                  | 20/21 (95.2)            | 20/21 (95.2)         |
| Week 22, n (%)                                                   |                                                                  |                            |                            |                      |                         |                      |
| ADA Positive                                                     | N/A                                                              | 110/228 (48.2)             | 110/228 (48.2)             | N/A                  | 66/99 (66.7)            | 66/99 (66.7)         |
| NAb Positive (as % of ADA positive)                              | N/A                                                              | 101/110 (91.8)             | 101/110 (91.8)             | N/A                  | 66/66 (100)             | 66/66 (100)          |
| Week 30, n (%)                                                   |                                                                  |                            |                            |                      |                         |                      |
| ADA Positive                                                     | 13/22 (59.1)                                                     | 111/201 (55.2)             | 124/223 (55.6)             | 16/34 (47.1)         | 51/62 (82.3)            | 67/96 (69.8)         |
| NAb Positive (as % of ADA positive)                              | 12/13 (92.3)                                                     | 101/111 (91.0)             | 113/124 (91.1)             | 15/16 (93.8)         | 51/51 (100)             | 66/67 (98.5)         |
| Week 38, n (%)                                                   |                                                                  |                            |                            |                      |                         |                      |
| ADA Positive                                                     | 14/23 (60.9)                                                     | 107/185 (57.8)             | 121/208 (58.2)             | 15/38 (39.5)         | 43/51 (84.3)            | 58/89 (65.2)         |
| NAb Positive (as % of ADA positive)                              | 14/14 (100)                                                      | 103/107 (96.3)             | 117/121 (96.7)             | 15/15 (100)          | 41/43 (95.3)            | 56/58 (96.6)         |
| Week 46, n (%)                                                   |                                                                  |                            |                            |                      |                         |                      |
| ADA Positive                                                     | 19/33 (57.6)                                                     | 101/176 (57.4)             | 120/209 (57.4)             | 14/37 (37.8)         | 38/52 (73.1)            | 52/89 (58.4)         |
| NAbPositive (as % of ADA positive)                               | 16/19 (84.2)                                                     | 95/101 (94.1)              | 111/120 (92.5)             | 13/14 (92.9)         | 36/38 (94.7)            | 49/52 (94.2)         |
| Week 54, n (%)                                                   |                                                                  |                            |                            |                      |                         |                      |
| ADA Positive                                                     | 16/30 (53.3)                                                     | 98/171 (57.3)              | 114/201 (56.7)             | 15/39 (38.5)         | 31/45 (68.9)            | 46/84 (54.8)         |
| NAb Positive (as % of ADA positive)                              | 14/16 (87.5)                                                     | 91/98 (92.9)               | 105/114 (92.1)             | 12/15 (80)           | 27/31 (87.1)            | 39/46 (84.8)         |
| Treatiment Period (including EOS and unscheduled visits) , n (%) | Treatiment Period (including EOS and unscheduled visits) , n (%) |                            |                            |                      |                         |                      |
| Positive Conversion in ADA                                       | 30/44 (68.2)                                                     | 121/188 (64.4)             | 151/232 (65.1)             | 34/46 (73.9)         | 44/55 (80)              | 78/101 (77.2)        |
| Positive Conversion in NAb (as % of ADA positive)                | 29/30 (96.7)                                                     | 118/121 (97.5)             | 147/151 (97.4)             | 34/34 (100)          | 44/44 (100)             | 78/78 (100)          |

Figure 34. Frequency of ADA in Study CT-P13 3.8 (Safety Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

ADA titre results are summarised in Tables 70 (study CT-P13 3.7) and Table 71 (study CT-P13 3.8) and Figures 35 (study CT-P13 3.7) and 36 (study CT-P13 3.8). To estimate the magnitude of ADA positive response, a titration assay was performed with a series of at least five, 1:3 dilutions, starting at a 1:3 dilution.

Table 72. Summary of Non-transformed ADA Titre Results in Study CT-P13 3.7, Safety Population

|                   | CT-P13 SC 120 mg (N=296)   | CT-P13 SC 120 mg (N=296)   | CT-P13 SC 120 mg (N=296)   | Placebo SC (N=140)     | Placebo SC (N=140)      | Placebo SC (N=140)     |
|-------------------|----------------------------|----------------------------|----------------------------|------------------------|-------------------------|------------------------|
| Statistic         | With Dose Adjustment       | Without Dose Adjustment    | Total                      | With Dose Adjustment   | Without Dose Adjustment | Total                  |
| n                 | N/A                        | 6                          | 6                          | N/A                    | 6                       | 6                      |
| Mean (± SD)       | N/A                        | 21.0 (±0.00)               | 21.0 (±0.00)               | N/A                    | 49.0 (±68.59)           | 49.0 (±68.59)          |
| Median (Min, Max) | N/A                        | 21 (21, 21)                | 21 (21, 21)                | N/A                    | 21 (21, 189)            | 21 (21, 189)           |
|                   | N/A                        | 32                         | 32                         | N/A                    | 19                      | 19                     |
| Mean (± SD)       | N/A                        | 669.4 (±2691.09)           | 669.4 (±2691.09)           | N/A                    | 498.5 (±1185.64)        | 498.5 (±1185.64)       |
| Median (Min, Max) | N/A                        | 63 (21, 15309)             | 63 (21, 15309)             | N/A                    | 63 (21, 5103)           | 63 (21, 5103)          |
| n                 | N/A                        | 76                         | 76                         | N/A                    | 50                      | 50                     |
| Mean (± SD)       | N/A                        | 1682.2 (±7554.30)          | 1682.2 (±7554.30)          | N/A                    | 305.8 (±776.50)         | 305.8 (±776.50)        |
| Median (Min, Max) | N/A                        | 63 (21, 45927)             | 63 (21, 45927)             | N/A                    | 63 (21, 5103)           | 63 (21, 5103)          |
|                   | N/A                        | 128                        | 128                        | N/A                    | 108                     | 108                    |
| Mean (± SD)       | N/A                        | 1207.8 (±5853.23)          | 1207.8 (±5853.23)          | N/A                    | 494.3 (±692.86)         | 494.3 (±692.86)        |
| Median (Min, Max) | N/A                        | 189 (21, 45927)            | 189 (21, 45927)            | N/A                    | 189 (21, 5103)          | 189 (21, 5103)         |
|                   | 23                         | 111                        | 134                        | 44                     | 72                      | 116                    |
| Mean (± SD)       | 1273.7 (±3241.62)          | 838.3 (±2574.18)           | 913.0 (±2691.81)           | 30179.9 (±186683.66)   | 558.3 (±761.69)         | 11794.0 (±115064.76)   |
| Median (Min, Max) | 189 (63, 15309)            | 189 (21, 15309)            | 189 (21,15309)             | 567 (21,1240029)       | 378 (21,5103)           | 567 (21,1240029)       |
|                   | 22                         | 105                        | 127                        | 44                     | 56                      | 100                    |
| Mean (± SD)       | 4432.9 (±10261.25)         | 720.2 (±1767.27)           | 1363.3 (±4702.83)          | 32387.7 (±187444.85)   | 606.0 (±997.95)         | 14590.0 (±124550.61)   |
| Median (Min, Max) | 567 (63, 45927)            | 189 (21, 15309)            | 189 (21, 45927)            | 378 (21,1240029)       | 189 (21, 5103)          | 189 (21,1240029)       |
|                   | 28                         | 106                        | 134                        | 39                     | 46                      | 85                     |
| Mean (±SD)        | 3141.0 (±9260.09)          | 566.2 (±1633.53)           | 1104.2 (±4540.76)          | 36020.4 (±199084.94)   | 779.7 (±2335.97)        | 16949.0 (±135074.05)   |
| Median (Min, Max) | 189 (21,45927)             | 189 (21, 15309)            | 189 (21, 45927)            | 567 (21,1240029)       | 189 (21,15309)          | 189 (21,1240029)       |
| n                 | 26                         | 106                        | 132                        | 37                     | 42                      | 79                     |
| Mean (± SD)       | 4282.4 (±9794.18)          | 1852.0 (±13422.60)         | 2330.7 (±12792.81)         | 302587.9 (±1834575.34) | 1863.0 (±7383.01)       | 142708.8 (±1255476.11) |
| Median            | 567                        | 189                        | 189                        | 567                    | 189                     | 189                    |
| (Min, Max)        | (21, 45927)                | (21,137781)                | (21,137781)                | (21,11160261)          | (21, 45927)             | (21,11160261)          |

<div style=\"page-break-after: always\"></div>

Table 73. Summary of Non-transformed ADA Titre Results in Study CT-P13 3.8, Safety Population

|                 |                   | CT-P13 SC 120 mg (N=238)   | CT-P13 SC 120 mg (N=238)   | CT-P13 SC 120 mg (N=238)   | Placebo SC (N=105)   | Placebo SC (N=105)      | Placebo SC (N=105)   |
|-----------------|-------------------|----------------------------|----------------------------|----------------------------|----------------------|-------------------------|----------------------|
| Visit Statistic | Visit Statistic   | With Dose Adjustment       | Without Dose Adjustment    | Total                      | With Dose Adjustment | Without Dose Adjustment | Total                |
|                 | n                 | N/A                        | 4                          | 4                          | N/A                  | 4                       | 4                    |
|                 | Mean (±SD)        | N/A                        | 199.5 (±257.48)            | 199.5 (±257.48)            | N/A                  | 168.0 (±266.74)         | 168.0 (±266.74)      |
|                 | Median (Min, Max) | N/A                        | 105 (21, 567)              | 105 (21,567)               | N/A                  | 42 (21,567)             | 42 (21,567)          |
|                 | n                 | N/A                        | 17                         | 17                         | N/A                  | 6                       | 6                    |
|                 | Mean (±SD)        | N/A                        | 2963.5 (±11079.82)         | 2963.5 (±11079.82)         | N/A                  | 5152.0 (±7867.82)       | 5152.0 (±7867.82)    |
|                 | Median (Min, Max) | N/A                        | 63 (21, 45927)             | 63 (21, 45927)             | N/A                  | 126 (21, 15309)         | 126 (21,15309)       |
|                 |                   | N/A                        | 53                         | 53                         | N/A                  | 21                      | 21                   |
|                 | Mean (±SD)        | N/A                        | 500.4 (±1351.94)           | 500.4 (±1351.94)           | N/A                  | 615.0 (±1499.95)        | 615.0 (±1499.95)     |
|                 | Median (Min, Max) | N/A                        | 63 (21, 5103)              | 63 (21, 5103)              | N/A                  | 63 (21, 5103)           | 63 (21, 5103)        |
|                 | n                 | N/A                        | 110                        | 110                        | N/A                  | 66                      | 66                   |
|                 | Mean (±SD)        | N/A                        | 586.5 (±2183.84)           | 586.5 (±2183.84)           | N/A                  | 310.5 (±703.92)         | 310.5 (±703.92)      |
|                 | Median (Min, Max) | N/A                        | 63 (21, 15309)             | 63 (21, 15309)             | N/A                  | 63 (21, 5103)           | 63 (21, 5103)        |
|                 |                   | 13                         | 111                        | 124                        | 16                   | 51                      | 67                   |
|                 | Mean (± SD)       | 903.0 (±1431.70)           | 588.6 (±1724.05)           | 621.5 (±1693.37)           | 9069.4 (±34328.65)   | 407.2 (±516.72)         | 2475.8 (±16789.26)   |
|                 | Median (Min, Max) | 189 (21,5103)              | 189 (21, 15309)            | 189 (21, 15309)            | 189 (21, 137781)     | 189 (21,1701)           | 189 (21, 137781)     |
|                 | n                 | 14                         | 107                        | 121                        | 15                   | 43                      | 58                   |
|                 | Mean (± SD)       | 510.0 (±668.48)            | 1607.6 (±6546.57)          | 1480.6 (±6166.86)          | 3330.6 (±11785.88)   | 220.3 (±214.57)         | 1024.7 (±6003.24)    |
|                 | Median (Min, Max) | 189 (21,1701)              | 189 (21, 45927)            | 189 (21, 45927)            | 189 (63,45927)       | 189 (21, 567)           | 189 (21, 45927)      |
|                 | n                 | 19                         | 101                        | 120                        | 14                   | 38                      | 52                   |
|                 | Mean (± SD)       | 8120.4 (±31437.56)         | 1543.0 (±5436.73)          | 2584.4 (±13421.86)         | 10035.0 (±36768.19)  | 155.8 (±159.61)         | 2815.6 (±19083.99)   |
|                 | Median (Min, Max) | 189 (21,137781)            | 189 (21, 45927)            | 189 (21, 37781)            | 189 (63, 37781)      | 126 (21, 567)           | 189 (21,137781)      |
|                 | n                 | 16                         | 98                         | 114                        | 15                   | 31                      | 46                   |
|                 | Mean (± SD)       | 9045.8 (±34333.54)         | 1660.7 (±4214.08)          | 2697.2 (±13355.12)         | 3515.4 (±11802.64)   | 216.1 (±410.88)         | 1292.0 (±6774.68)    |
|                 | Median (Min, Max) | 378 (21, 137781)           | 189 (21, 15309)            | 189 (21,137781)            | 189 (63, 45927)      | 63 (21, 1701)           | 63 (21, 45927)       |

In both Phase 3 studies, the medians of ADA titres were generally comparable between the active and placebo treatment groups up to Week 54 at all sampling timepoints.  A few outliers with a high titre were seen in both studies in the placebo group with dose adjustment to active drug and also (but not as high outliers as in the placebo group) for subjects with dose escalation in the active groups.

<div style=\"page-break-after: always\"></div>

Figure 35. Scatter Plot of Transformed ADA Titre by Treatment Arm in UC Patients in Study CT-P13 3.7 (MSD ECL ACE ADA Method): Safety Population

<!-- image -->

Note: The ADA titre values are transformed using a log3(x/21) +1 transformation.

Abbreviations: ACE, affinity capture elution; ADA, anti-drug antibody; ECL, electrochemiluminescence; MSD, Meso Scale Discovery; N, number of patients in each treatment group in Safety Population; SC, subcutaneous

Figure 36. Scatter Plot of Transformed ADA Titre by Treatment Arm in UC Patients in Study CT-P13 3.8 (MSD ECL ACE ADA Method): Safety Population

<!-- image -->

The MAH has evaluated immunogenicity in all randomised subjects who received a full or partial single dose of study treatment in the previous studies CT-P13 1.5 and CT-P13 1.9 (both on healthy volunteers), CTP13 3.5 Part 1 and Part 2 (rheumatoid arthritis patients), and CT-P13 1.6 Part 1 (Crohn's Disease Patients). These results are not included in this AR for brevity. The MAH concludes that in the above-mentioned studies, the post-treatment ADA status shows correlation with PK parameters based on post-hoc analyses, but ADA presence did not have evident impact on efficacy and safety.

<div style=\"page-break-after: always\"></div>

## CHMP comments

In the placebo group with dose escalation to active treatment, occasional high titres of ADA are observed. Some outliers with high ADA titres are also seen in the active study group with dose escalation, however, the highest titres are seen in subjects switched from placebo to the 240 mg dose (Figures 8.2.4.2 and 8.2.4.3).

Upon request, the MAH provided more details on ADA titres, exposure and drug response in CD patients from study 3.8.  While it seems clear that loss of response is associated with higher ADA titres and lower drug  concentrations,  it  is  still  unclear  whether  subjects  who regained response  had  higher  drug concentrations compared to those who did not (i.e., whether the regained response can be attributable to higher exposure) and whether patients with high ADA titres at dose adjustment could maintain a potential benefit from a higher dose. While higher drug concentrations might counteract the development of ADAs it is not known whether this is true for patients who have already developed high titres of ADA. Increasing the dose may be beneficial in the short term, but it is not known whether or how fast the development of new ADAs will neutralise the potential benefit of such a dose adjustment. However, as these are not an issues which could affect the wording in SPC, they will not be pursued further. (Please see section 13.2 for more detailed assessment.)The Applicant has conducted post-hoc analyses on impact of ADA on safety in study CT-P13 3.5 Part 2 up to Week 30 (reported in CTD Module 2, Section 2.7.2.4 Integrated Summary of Immunogenicity, section 2.7.2.4.5.2.3). According to the analyses, no apparent correlation was seen between rate of infection and post-treatment ADA status (positive/negative) or titre (data not shown for brevity). No similar analyses were conducted on the phase 3 trials CT-P13 3.7 and Study CT-P13 3.8.

## CHMP comments

No information is submitted regarding potential relation of ADA positivity and ADA titres on injection site reactions and other allergic/hypersensitivity events. Since the product is old and it is known that patients who developed antibodies to infliximab were approximately 2-3 fold more likely to develop infusion related reactions, this issue is not pursued further.

Final study report data on ADA conversion during extension phases of phase 3 trials

In study CT-P13 37 , in the extension phase, the proportion of patients with the positive ADA conversion after the first study drug administration date in the extension phase was lower in CT-P13 SC 120 mg group compared to Placebo SC group (160/287 [55.7%] and 81/134 [60.4%] patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively). In the extension phase, the proportion of patients with the positive NAb conversion after the first study drug administration date in the extension phase was 140/292 (47.9%) and 79/139 (56.8%) patients in the CT-P13 SC 120 mg and Placebo SC groups, respectively. The ADA titre result was maintained in CT-P13 SC 120 mg group and decreased in Placebo SC group.

In study CT-P13 38 , in the extension phase, the proportion of patients with the positive ADA conversion after the first study drug administration date in the extension phase was similar in both CT-P13 SC 120 mg and Placebo SC groups (134/232 [57.8%] and 55/101 [54.5%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively). The proportion of patients with the positive NAb conversion after the first study drug administration date in the extension phase was also similar in both CT-P13 SC 120 mg and

<div style=\"page-break-after: always\"></div>

placebo SC groups (126/234 [53.8%] and 50/103 [48.5%] patients in the CT-P13 SC 120 mg and placebo SC groups, respectively). The ADA titre result was generally decreased in both treatment groups.

## 8.2.5. Comparison of Safety Results Across Studies

The  MAH  conducted  analyses  comparing  the  safety  results  from  patients  who  received  CT-P13  SC maintenance  after  three  IV  doses  for  induction  (Studies  CT-P13  3.7  and  CT-P13  3.8)  to  patients  who received CT-P13 SC maintenance after two IV induction doses (Study CT-P13 1.6 Part 2 - a Phase 1, openlabel, randomised, multi-dose, parallel-group study with 53 CD patients in Part 2). Regardless of number of doses received for the IV induction, comparable incidence rates of TEAEs, TESAEs, TEAEs leading to study drug discontinuation and TEAESIs were observed during the maintenance phase for UC patients and CD patients who received CT-P13 SC maintenance treatment (table 72).

<div style=\"page-break-after: always\"></div>

Table 74. Overview of Treatment-Emergent Adverse Events in Patients with Ulcerative Colitis and Crohn's Disease (Maintenance Phase): Safety Population

|                                                                            | Ulcerative Colitis         | Ulcerative Colitis          | Crohn's Disease          | Crohn's Disease             |
|----------------------------------------------------------------------------|----------------------------|-----------------------------|--------------------------|-----------------------------|
|                                                                            | Study CT-P13 3.7 CT-P13 SC | Study CT-P13 1.6 Part 2     | Study CT-P13 3.8         | Study CT-P13 1.6 Part 2     |
|                                                                            | 120 mg (N=296)             | CT-P13 SC 120/240 mg (N=38) | CT-P13 SC 120 mg (N=238) | CT-P13 SC 120/240 mg (N=28) |
| Total number of TEAEs                                                      | 595                        | 92                          | 569                      | 140                         |
| Number (%) of patients with ≥ 1 TEAE                                       | 200 (67.6)                 | 26 (68.4)                   | 172 (72.3)               | 23 (82.1)                   |
| Related                                                                    | 57 (19.3)                  | 14 (36.8)                   | 62 (26.1)                | 14 (50.0)                   |
| Unrelated                                                                  | 184 (62.2)                 | 23 (60.5)                   | 156 (65.5)               | 19 (67.9)                   |
| Number (%) of patients with ≥ 1 TEAE leading to death                      | 0                          | 0                           | 1 (0.4)                  | 0                           |
| Related                                                                    | 0                          | 0                           | 0                        | 0                           |
| Unrelated                                                                  | 0                          | 0                           | 1 (0.4)                  | 0                           |
| Number (%) of patients with ≥ 1 TESAE                                      | 19 (6.4)                   | 2 (5.3)                     | 16 (6.7)                 | 3 (10.7)                    |
| Related                                                                    | 2 (0.7)                    | 0                           | 1 (0.4)                  | 1 (3.6)                     |
| Unrelated                                                                  | 17 (5.7)                   | 2 (5.3)                     | 16 (6.7)                 | 2 (7.1)                     |
| Number (%) of patients with ≥ 1 TEAE leading to study drug discontinuation | 10 (3.4)                   | 0                           | 9 (3.8)                  | 1 (3.6)                     |
| Related                                                                    | 5 (1.7)                    | 0                           | 6 (2.5)                  | 1 (3.6)                     |
| Unrelated                                                                  | 5 (1.7)                    | 0                           | 3 (1.3)                  | 0                           |
| Number (%) of patients with ≥ 1 TEAE of IRR1                               | 0                          | 0                           | 0                        | 0                           |
| Related                                                                    | 0                          | 0                           | 0                        | 0                           |
| Unrelated                                                                  | 0                          | 0                           | 0                        | 0                           |
| Number (%) of patients with ≥ 1 TEAE of SIR1                               | 12 (4.1)                   | 0                           | 3 (1.3)                  | 2 (7.1)                     |
| Related                                                                    | 12 (4.1)                   | 0                           | 3 (1.3)                  | 2 (7.1)                     |
| Unrelated                                                                  | 0                          | 0                           | 0                        | 0                           |
| Number (%) of patients with ≥ 1 TEAE of delayed hypersensitivity1          | 0                          | 1 (2.6)                     | 0                        | 1 (3.6)                     |
| Related                                                                    | 0                          | 1 (2.6)                     | 0                        | 1 (3.6)                     |
| Unrelated                                                                  | 0                          | 0                           | 0                        | 0                           |
| Number (%) of patients with ≥ 1 TEAE of localised ISR2                     | 10 (3.4)                   | 7 (18.4)                    | 14 (5.9)                 | 8 (28.6)                    |
| Related                                                                    | 10 (3.4)                   | 6 (15.8)                    | 14 (5.9)                 | 8 (28.6)                    |
| Unrelated                                                                  | 0                          | 1 (2.6)                     | 0                        | 0                           |
| Number (%) of patients with ≥ 1 TEAE of infection                          | 83 (28.0)                  | 10 (26.3)                   | 74 (31.1)                | 11 (39.3)                   |
| Related                                                                    | 11 (3.7)                   | 4 (10.5)                    | 15 (6.3)                 | 5 (17.9)                    |
| Unrelated                                                                  | 80 (27.0)                  | 7 (18.4)                    | 65 (27.3)                | 7 (25.0)                    |
| Number (%) of patients with ≥ 1 TEAE of malignancy                         | 1 (0.3)                    | 0                           | 0                        | 1 (3.6)                     |
| Related                                                                    | 0                          | 0                           | 0                        | 1 (3.6)                     |
| Unrelated                                                                  | 1 (0.3)                    | 0                           | 0                        | 0                           |

## CHMP comment

<div style=\"page-break-after: always\"></div>

Numerically, incidence rates of TEAEs, TESAEs, TEAEs leading to study drug discontinuation and TEAESIs were similar during the maintenance period after induction treatment with three doses of CT-P13 IV (studies CT-P13 3.7 and CT-P13 3.8) than after induction treatment with two IV doses (study CT-P13 1.6 Part 2). However, no firm conclusions can be made by comparisons between different trials.

## 8.2.6. REMSWITCH study/safety

To  support  the  possibility  to  switch  from  high-dose  (&gt;5  mg/kg)  IV  maintenance  to  SC  maintenance treatment, the MAH has submitted a published article by Buisson et al (Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clinical Gastroenterology and Hepatology, Volume 21, Issue 9, August 2023, Pages 2338-2346.e3 ). (Please see Section 7.3.1 of this AR).

As described in Section 7.3.1 of this AR, no full CSR is available for assessment. The authors inform that the mean level of acceptability scale (10-point scale) was improved after switching form IV to SC infliximab. Sixteen (12.0%) of 133 patients reported an adverse event. Two subjects wanted to switch back to IV infliximab due to intolerance: one due to myalgia and one due to  mild abdominal pain. There were no SAEs. Other observed adverse events included mild and transient erythema (n = 5) or mild pain (n = 2) at the site of injection, fatigue (n = 1), bronchitis (n = 1), and IBD-related symptoms (rectal bleeding = 1, increased stools frequency = 1, or mild abdominal pain = 2). No patient required hospitalisation or surgery.

## 8.3. Discussion

To support safety of the currently proposed amended posology in CD and UC the MAH submitted results of two ongoing placebo-controlled, randomised phase 3 trials included in the submission with Week 54 interim clinical study reports: Study CT-P13 3.7 in subjects with ulcerative colitis (UC, N= 436) and Study CT-P13 3.8 in moderately to severely active Crohn's disease (CD, N = 343). Details of study designs are given in Section 7 of this AR. This discussion includes first an overall evaluation of safety of CT-P13 as observed in these studies. Thereafter, data are discussed according to each proposed variation.

## Overall evaluation of safety in studies CT-P13 3.7 and CT-P13 3.8

In total, 534 subjects received at least 1 dose of CT-P13 SC in both studies (296 UC patients in study STP13 3.7 and 238 CD subjects in study CT-P13 3.8). Of these, 447 (244 UC patients and 203 CD patients) completed CT-P13 SC treatment up to Week 54. This is a marked amount of new data on subjects with these indications. The overall findings in the currently submitted data do not raise great concern; however, there are several methodological issues rendering the data inconclusive (see below).

Discrepant numbers of subjects who discontinued treatment due to adverse events were reported in the disposition figures and summary tables of adverse events for both phase 3 trials (CT-P13 3.7 and CT-P13 3.8). The received clarifications on this issue in the MAH's response are deemed adequate (see assessment of question 43 in Section 13.2 of this AR). The root cause for the discrepancy was different source of data and analysis method in the SAP of the studies. In study CT-P13 3.7 (ulcerative colitis), more than twice as great percentage of subjects experienced at least one TESAE in the active arm (6.4%) vs. placebo arm (2.9%), though only one subject in each group had a TESAE considered to be related to study drug. The total number of TESAEs was 25/296 in the active vs. 5/140 in the placebo arm (table 8.2.3.2.1). It is likely that the higher incidence of TESAE's in the active group is caused by the active treatment regardless of investigator's assessment of relatedness. In Study CT-P13 3.8, the percentage of patients with Crohn's disease who experienced at least 1 TESAE during the maintenance phase was similar between active (16

<div style=\"page-break-after: always\"></div>

[6.7%]) and placebo groups (8 [7.6%] patients); one TESAE in each group was considered by investigator to be related to study drug.

Even in the placebo arms of the study, 15.0 % and 14.3 % of subjects in studies CT-P13 3.7 and CT-P13 3.8, respectively, experienced TEAEs that were considered to be related to study drug, raising the question if the TEAEs occurred after switch from placebo to active treatment. The MAH clarified in their response that the TEAEs related to study drug occurred in the placebo group during placebo treatment, prior to dose adjustment, since for both Study CT-P13 3.7 and Study CT-P13 3.8, only data collected before initiation of dose adjustment for Placebo SC group were included in TEAE summary tables. Therefore, these AEs were not related to escalated dose of CT-P13. In retrospect, the TEAEs in the placebo arms of the studies were not drug-related.

In UC patients, the total proportion of patients with positive ADA conversion result was 63.8% (183/287) in the CT-P13 SC 120 mg group and 93.3% (97.6%) in the placebo group. Among ADA positive patients, 161  out  of  the  183  (88.0%)  patients  developed  NAb.  In  subjects  without  dose  adjustment,  positive conversion in ADA (NAb conversion, % of ADA positive) was 67.3% (88.1%) in the active group and 91.9% (98.2%) in the placebo group. In CD patients, the proportion of patients with positive ADA conversion result was 65.1% (151/232) in the CT-P13 SC 120 mg group. Among ADA positive patients, 147 out of the 151 (97.4%) patients developed NAb. In subjects without dose adjustment, positive conversion in ADA (NAb conversion, % of ADA positive) was 64.4% (97.5%) in the active group and 80% (100%) in the placebo group. Hence, the proportion of patients with positive ADA conversion was higher in the placebo SC groups. The median values of ADA titres were roughly similar between active and placebo arms in both studies; but outliers with high ADA titres were found among subjects with dose escalation from 120 mg to 240 mg (in the active arm) and even higher titres were seen in some subjects who switched from placebo to 240 mg (placebo arm). Mean ADA titres were substantially higher among patients who lost response compared to those who did not.  No information is submitted regarding potential relation of ADA positivity and titres on injection site reactions and other allergic/hypersensitivity events. Since the product is old and it is known that patients who developed antibodies to infliximab were approximately 2-3 fold more likely to develop infusion related reactions, this issue is not pursued further.

There were no deaths reported in study CT-P13 3.7 (UC). One accidental death was reported in study CTP13 3.8 (CD) due to an explosion in a garage. Infections occurred in 28.0% and 25.7% of subjects in the CT-P13 120 mg and placebo arms of study CT-P13 3.7 (UC), respectively. In study CT-P13 3.8 (CD), 31.1% and 18.1% of subjects experienced infections in the CT-P13 SC 120 mg and placebo arms, respectively. In both studies, the occurrence of COVID-19 was markedly higher in the active arms of the studies. In study CT-P 3.7 (UC), there were 30/296 patients (10.1%) in the active arm and 9/140 (6.4%) in the placebo arm with COVID-19. In study CT-P13 3.8 (CD), the cases (percentage) of COVID-19 were 27/238 (11.3%) and 5/105 (4.8%) in the active and placebo arms, respectively.

The final reports for both phase 3 studies, CT-P13 3.7 and CT-13 3.8, were received with the MAH's response to the RSI. The safety data from the open-label extension phases include no new safety findings in either patients with UC or with CD. Additional analyses on safety of the 120 mg and 240 mg SC doses vs. placebo were received as responses to the RSI.

## Discussion on data submitted for support of each change proposed by the MAH

The grouped variation application includes the following proposed amendments to the Product Information:

1. Addition of a 3-IV induction dosing regimen (5 mg/kg at Weeks 0, 2 and 6) followed by SC maintenance treatment (120 mg Q2W);

<div style=\"page-break-after: always\"></div>

2. The  possibility  for  dose  adjustment  from  CT-P13  SC  120  mg  to  240  mg  for  patients  with  loss  of response;
3. Addition of a subcutaneous induction dosing regimen (240 mg at Week 0 followed by 120 mg at Weeks 1, 2, 3 and 4) followed by SC maintenance treatment (120 mg Q2W);
4. The possibility to switch from high-dose (&gt; 5 mg/kg) IV maintenance to subcutaneous maintenance treatment
5. Major SmPC-updates on all of the above, including description of the two new phase 3 studies (CD and UC) in sections 5.1 and 4.8.

The discussion below is numbered according to the above-listed amendments.

1. In both phase 3 studies, CT-P13 3.7 in ulcerative colitis and CT-P13 3.8 in Crohn's disease, both active and comparator arms received the newly proposed induction treatment regimen with 3 IV doses (5 mg/kg at Weeks 0, 2 and 6). Hence, safety of the proposed new induction treatment regimen has not been studied in a comparative randomised setting. Instead, the MAH has conducted analyses comparing the safety results from patients who received CT-P13 SC maintenance after three IV doses for induction in Studies CT-P13 3.7 and CT-P13 3.8 to patients who received CT-P13 SC maintenance after two IV induction doses in Study CT-P13 1.6 Part 2 (a Phase 1, open-label, randomised, multi-dose, parallelgroup study with 53 CD patients in Part 2). Comparable incidence rates of TEAEs, TESAEs, TEAEs leading to study drug discontinuation and TEAESIs were observed during maintenance treatment after the old and new induction treatment regimens in these studies. Nevertheless, no firm conclusions can be made by comparisons between very different trials. Consequently, since no comparative trial data have been submitted regarding the proposed addition  of  a  3-IV  induction  dosing  regimen  and  the currently approved 2-IV induction dosing regimen, the comparative safety of the regimens cannot be assessed based on clinical data. However, although the drug exposure is expected to be somewhat higher  during  weeks  10-14  with  the  currently  proposed  dosing  compared  to  any  of  the  previously approved regimens, the higher exposure only lasts for a few weeks and peak concentrations are much lower  than  those  seen  with  a  continuous  IV  regimen.  As  no  specific  safety  concerns  arose  during assessment, the 3-IV induction regimen can be considered sufficiently safe.
2. Safety of the proposed escalation of maintenance dose to 240 mg SC in those who lost response has been studied by comparing maintenance treatment with Remsima (CT-P13, infliximab) 120 mg SC Q2W with maintenance treatment with placebo in pooled data from CT-P13 3.7 and CT-P13 3.8. In both active and comparator groups, dose was escalated in those who lost response to 240 mg SC Q2W (from 120  mg  Q2W  or  placebo  in  the  active  and  placebo  arms  of  both  phase  3  studies,  respectively). Assessment of safety of the proposed possibility for dose adjustment from CT-P13 SC 120 mg to 240 mg for patients with loss of response needs, however, further clarifications as described below.

The  submitted  results  on  subgroups  administered  the  120  mg  and  240  mg  dose  show  no  dosedependently increased risk for infection, serious adverse reactions, or systemic and localised injection reaction rates. However, the MAH did not describe in detail the populations for the comparison between placebo and CT-P13 SC and between the 120 mg and 240 mg doses and how exposure time for each dose was accounted for in the analyses. Further clarifications and analyses were requested regarding populations  used  for  analyses  of  safety,  duration  of  use  of  the  different  doses  and  how  this  was addressed in the analyses; additionally, the analyses are requested to be submitted also separately for both UC and CD subjects. Per the comment from CHMP, the safety data were re-analysed by the MAH to include the data of all patients exposed to study treatment (Placebo, CT-P13 SC 120 mg or CT-P13 SC  240  mg),  regardless  of  treatment  phase  and  treatment  group.  The  re-analysis  included  the Extension Phase and data collected after dose adjustment from patients in the Placebo arm. All reported

<div style=\"page-break-after: always\"></div>

TEAEs had been categorised into subgroups based on the actual treatment the patients received. To take into account the different duration of use for each treatment (Placebo, CT-P13 SC 120 mg and CTP13 SC 240 mg). The incidence rates were reported per 100 Person Year (PY). The MAH withdrew the application for dose escalation in patients with UC. Re-analyses on safety were received for patients with CD in study CT-P13 3.8. In addition, the MAH conducted upon request an integrated analysis on safety across all studies with SC administration of 120 mg and/or 240 mg of CT-P13: Study 1.6 Part 1 (CD), Study 1.6 Part 2 (CD/UC), Study 3.5 Part 1 (RA), Study 3.5 Part 2 (RA), Study CT-P13 3.7 (UC), and Study CT-P13 3.8 (CD)(Table 7 of the MAH's response). Sufficient data were received, confirming that the higher dose of 240 mg caused slightly more injection site reactions (8.95/100 PY) than the 120 mg dose (5.81/100py); at least partly due to the higher dose requiring two injections instead of one. The overall incidence of TEAE was 60.94 vs. 67.39 with the 120 mg SC vs. 240 mg SC dose. The incidence of TESAE and of TEAE leading to drug discontinuation were also slightly higher with the 240 mg dose. (See assessment of Question 48 in Section 13.2 of this AR).

The rate of TEAE classified as infection was  in the integrated analysis 29.56 per 100 PY in the 120 mg SC group and 33.99 per 100 PY in the 240 mg SC group (table 7 of the MAH's response).  Analysis on events prior to vs. after dose escalation was conducted for studies that allowed for dose escalation from 120 to 240 mg SC: CT-P13 3.7, CT-P13 3.8 and CT-P13 1.6 Part 2. In this analysis, the incidence of infection as number of subjects/entire group (%, per 100PY) was 34/159 (21.4%, 45.52) with CTP13 120 mg SC before dose escalation and 51/159 (32.1%, 33.12) after escalation from 120 mg to 240 mg SC. In the placebo group, the incidence was 21/126 (16.7%, 48.25) before dose escalation, and 50/126 (39.7%, 32.65) after escalation to 240 mg SC from placebo (table 9 of the MAH's response). Hence, in the integrated analysis, the rate of infection per 100 PY was higher before escalation to 240 mg SC than after escalation, whether escalating from the 120 mg SC dose or from placebo.

In study CT-P13 3.8 (CD), the incidence of infections/100PY was slightly higher during treatment with 240 mg SC (33.74) than 120 mg SC (28.88) or placebo (31.55) (table 1 of the MAH's response). When excluding TEAEs reported from patients in the placebo group who switched from placebo to CT-P13 SC 120 mg at Week 56 then underwent dose adjustment from CT-P13 SC 120 mg to 240 mg during the extension phase, the number (%, per 100PY) of patients with ≥ 1 infection was 15/54 (27.8%, 48.67) during treatment with 120 mg SC before escalation and 21/54 (38.9%, 39.94) after escalation from 120 mg to 240 mg SC. In the placebo group the incidence of infections (% of patients, per 100PY) was 5/50 (10%, 28.04) in the placebo group prior to escalation and 19/50 (38%, 29.18) after escalation to 240 mg SC (table 8 of the MAH's response). Hence,  a larger proportion of subjects experienced adverse reactions after escalation, during treatment with 240 mg SC, than before escalation, during treatment with 120 mg SC. However, due to longer exposure time on the higher dose, the incidence of infections per 100 PY was lower after escalation. The rate of infection was high also during treatment with placebo, hence, a marked part of infections may be related to the background disease, which could explain the decline in incidence of infection after escalation. These requested analyses indicate that dose escalation would  not  increase  risk  for  infection;  even  though  from  a  methodological  point  of  view  such  nonrandomised  post-hoc  data  cannot  be  considered  robust.  The  somewhat  higher  overall  incidence  of infections during treatment with the 240 mg SC dose vs. the 120 mg dose in study CT-P13 3.8 may seem to be in contradiction with the results showing a decreased rate of infections after dose escalation. This discrepancy could however be speculated to be due to selection, since the most severely ill patients that were in need for dose escalation have probably been also most prone to infections. Hence, the lower incidence of infections among subjects treated with the 120 mg SC dose could be speculated to have been driven by the healthier part of study subjects.

There was no difference in treatment-emergent serious adverse events (TESAE) between the doses of 120 mg and 240 mg SC in study CT-P13 3.8; though in the integrated safety analysis there were slightly

<div style=\"page-break-after: always\"></div>

more TESAE (8.42 per 100 PY) in subjects administered 240 mg SC vs. subjects administered 120 mg SC (6.42 per 100PY). (see assessment of Questions 42 and 48 in Section 13.2 of this AR).

In tables with numbers of subjects with dose adjustment, the number of such subjects were at some time points reported to be lower than at the previous visit. The MAH confirmed in their response that among patients with dose adjustment in Study CT-P13 3.8 (both CT-P13 SC 120 mg and Placebo SC groups), no patients returned to their previous dose by the decision of the investigator to decrease the dose. The number of patients with dose adjustment appeared to be lower at some visits than the previous visit due to dropouts, dose skip and dosing error (e.g., human error) (CSR CT-P13 3.8 (Week 54) Section 12.1 [SN0264]). The dosing errors were corrected in the subsequent study visit. In all, a total of 93 patients received at least one adjusted dose for the safety population during the Maintenance Phase on or after Week 22 and until Week 54. Among them, 9 patients started the adjusted dose at Week 54, 67 patients maintained the adjusted dose at Week 54 and 17 patients were early terminated before the Week 54 administration.

3. The  variation  of  CT-P13  SC  induction  posology  in  patients  with  CD  and  UC  is  supported  only  by population PK and PK-PD modelling and simulation analyses. There are no observed data with the proposed dosing regimen. In absence of safety data on the proposed SC induction posology the safety of the proposed SC induction posology cannot be assessed based on clinical data. This issue is not pursued further, since the Cmax concentrations of CT-P13 are expected to be lower with the currently proposed SC induction regimen compared to the approved IV regimen (see Sections 6.2 and 6.3 of this AR). After the first RSI the MAH withdrew the proposal of SC induction. Therefore, the questions related to this variation are no longer relevant.
4. To  support  the  possibility  to  switch  from  high-dose  (&gt;  5  mg/kg)  IV  maintenance  to  subcutaneous maintenance treatment, the MAH had submitted a published article on the REMSWITCH study (see Sections 7.3.1 and 8.2.6 of this AR). There were no deaths or other serious adverse events. Sixteen of 133 (12 %) subjects experienced mild and transient adverse events. In lack of a full protocol and taking in  account  also  the  relatively  small  number  of  study  participants,  the  data  are  not  regarded  to  be confirmative, albeit no new signals regarding safety of such switch were seen. After the first RSI the MAH withdrew the proposal of switching from high-dose (&gt;5 mg/kg) IV maintenance to SC treatment. Therefore, the corresponding changes to the PI are no longer proposed and questions related to this variation are no longer relevant.
5. The update of the SmPC proposed by the MAH included new data only for systemic injection reactions (SIR) and injection site reactions (ISR) and not for any other adverse reactions. Furthermore, the MAH had updated Section 4.8 of the SmPC with integrated analyses from one Phase 1 study in UC/CD patients in addition to the two Phase 3 studies that are the basis of the current variation, instead of including all studies conducted with SC administered Remsima. In their response, the MAH justifies not including other studies with SC administered Remsima by the EMA Guideline on SmPC that emphasizes that the frequency of adverse reactions should be derived from pooled placebo-controlled studies. The MAH was also asked to clarify for both pivotal studies the numbers of the adverse reactions which occurred more frequently in active than placebo arms but were nevertheless not proposed to be included in the SmPC.  In their response, the MAH listed the TEAEs reported for at least 1% of patients in the CT-P13 SC 120 mg group and at a higher rate than the Placebo SC group. Data after switch to 240 mg SC was not included as it did not represent placebo controlled situation. The MAH identified five TEAEs by preferred term (PT) (thrombocytosis, large intestine polyp, blood creatine phosphokinase increased, arthritis  and  haematuria) as not being listed in Section 4.8 of the SmPC. The MAH has adequately justified for each observed TEAE the inclusion or omission of that AE from the table in Section 4.8 of the SmPC. Based on these data, no change is warranted on the table except for Covid-19, which was

<div style=\"page-break-after: always\"></div>

added in the updated tabulated list in Section 4.8 of SmPC as Very Common adverse event of Viral infection.

Since the elderly more often suffer from multiple background diseases and are more prone to infections (e.g., herpes zoster and severe influenza or COVID-19), the MAH was requested to discuss the safety of the SC 240 mg dosage in the elderly and if any changes to Product Information are needed regarding use of the higher dose in the elderly. The MAH responded that there were only 2 subjects in study SCP13 3.8 aged &gt;65 with dose escalation to 240 mg SC. One of the two experienced infections (respiratory tract infection and latent tuberculosis) and one experienced no TEAEs. For comparison, in the entire study population more than 1/3 of those with dose escalation experienced TEAEs classified as infection. It is known from previous scientific data that the elderly are more at risk of serious infections during infliximab  treatment;  but  there  exists  no  definitive  information  if  the  risk  is  associated  with  the circulating level of infliximab. Since the increased risk of infections is already covered in the SmPC Sections 4.4 and 4.8, it is agreed that no amendment is warranted in Section 4.2, which refers to Sections 4.4 and 4.8 regarding this risk in the elderly.

During the maintenance phase, systemic injection reactions (SIR) were reported for 12 (4.1%) and 4 (2.9%) patients in the CT-P13 SC 120 mg and placebo SC arms of study CT-P13 3.7 (UC), respectively. Grade 3 SIR was reported for 3 (1.0%) patients in the CT-P13 SC 120 mg arm and 1 (0.7%) patient in the  placebo  SC  arm.  One  patient  in  each  treatment  arm  experienced  SIR  that  led  to  study  drug discontinuation. In study CT-P13 3.8 (CD), SIRs were reported for 3 (1.3%) and 1 (1.0%) patients in the CT-P13 SC 120 mg and placebo SC arms, respectively. All events were grade 1 in severity and nonserious. No action was taken with the study drug and all patients recovered without receiving treatment for  the  SIR.  No  cases  of  delayed  hypersensitivity  were  reported  in  either  phase  3  study.  Localised injection site reactions (ISR) occurred during the maintenance phase of study CT-P13 3.7 in 10/296 (3.4%) of UC patients in the CT-P13 SC 120 mg arm and 3/140 (2.1%) in placebo SC arm, respectively. All events were grade 1 or 2 in severity, non-serious, and did not lead to study drug discontinuation. For study CT-P13 3.8, localised ISR were reported for 14/238 (5.9%) and 1/107 (1.0%) patients in the CT-P13 SC 120 mg and placebo SC groups, respectively. All localized ISRs were grade 1 or 2 in intensity and most patients' localised ISR recovered in both treatment groups. No serious localised ISRs were reported.

As a conclusion, all safety concerns were satisfactorily resolved by the MAH's response to the RSI. The MAH has withdrawn the applications for switching from high dose IV infliximab to 120 mg SC Remsima and for dose escalation to 240 mg SC in subjects with ulcerative colitis. Safety of the dose escalation from the 120 mg SC dose to the 240 mg SC dose in subjects with Crohn's disease not responding adequately to the lower dose  has  been  demonstrated  by  the  multiple  additional  analyses  provided  by  the  MAH.  The  Product Information has been updated to include COVID-19 as an example of viral infections in the list of adverse events.

## 9. PRAC advice

N/A

## 10. Risk management plan

The MAH submitted an updated RMP version (v 16.1, DLP 31 Mar 2023 and version 16.2, DLP 23 Oct 2023) with this application. The (main) proposed RMP changes were the following:

<div style=\"page-break-after: always\"></div>

Part I: Product(s) Overview was updated to propose the new posologies for SC formulation of CD and UC indications

Part II: Module SV - Post-authorisation experience was updated with data for IV and SC formulations. Clinical trial exposure was updated as studies CT-P13 SC 3.7 and 3.8 were completed.

Part II: Module SVII - Identified and potential risks - Postmarketing experience section has been updated to  replace  originator's  data  with  Remsima  Inflectra's  data.  TEAE  tables  were  updated  with  data  from completed studies CT-P13 3.7 and 3.8.

Part III: Studies CT-P13 3.7 and 3.8 were removed from the additional pharmacovigilance plan as they were completed and all sections of Part III were updated accordingly. Pharmacovigilance Plan (including post-authorisation  safety  studies)  synopsis  contents  and  milestones  regarding  Study  CT-P13  4.8  from additional pharmacovigilance plan were updated.

Part VI: Summary of the risk management plan was updated based on changes mentioned above.

The Annexes were updated to reflect the completed additional pharmacovigilance actions.

## CHMP comment

No changes to the safety specification were proposed. Based on the data provided, this can be endorsed. Most  of  the  changes  in  the  RMP  are  related  to  update  of  patient  exposure  data  and  updates  of  the characterisation data of the safety concerns. The numbers of ADR cases of different events were updated with numbers of events reported for Remsima/inflectra, instead of Remicade and updated with data from completed studies CT-P13 3.7 and 3.8. The updated data does not change the characterisation of the safety concerns. The pharmacovigilance plan and the RMP was updated throughout to reflect the completion of the additional pharmacovigilance actions. In addition, the Applicant has updated the presentation of the Additional pharmacovigilance activity Study CT-P13 SC 4.8 (An observational, prospective cohort study to evaluate safety of Remsima® Subcutaneous in patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis) The aim of the study is to collect further safety information on patients treated with Remsima SC with regard to long-term safety. The main change is that subcutaneous loading dose may be used in RA patients. The study milestones have also been updated. The protocol has been finalised 18 Oct 2022, FPFV occurred 13 Jan 2023. No changes to the planned final report of 3Q 2027 were proposed in this submission. The changes to the RMP v.16.2 are considered acceptable.

## 10.1. Overall conclusion on the RMP

The changes to the RMP are acceptable.

## 11. Changes to the Product Information

Please refer to attached annotated product information.

## 12. Request for supplementary information

## 12.1. Major objections

Please see Section 13 for 1 st  round RSI questions and assessment.

<div style=\"page-break-after: always\"></div>

## 12.2. Other concerns

Please see Section 13 for 1 st  round RSI questions and assessment.

## RMP aspects

None.

## 13. Assessment of the responses to the request for supplementary information

## 13.1. Major objections

## Clinical aspects

## Dose escalation in UC/CD

## Question 1

There is not enough evidence to support the claim on dose escalation from SC 120mg to 240mg in case of loss of response in either of the indications. The study design of both studies 3.7 and 3.8 is inadequate to answer the question on relevant efficacy and safety of this dose increase. The MAH provided virtually no details to enable assessment of the totality of data and sufficient safety of the dose increase has not been demonstrated.

It is known that the Ctrough levels are manyfold higher in all weight categories with the SC 120mg dosing compared to those achieved with IV administered Remsima. In previous studies on UC and CD, the steady state Ctrough of infliximab has been around 6-8 microg/l with the double IV dose of 10 mg/kg. In studies 3.7 and 3.8, the normal SC dose of 120mg gave median Ctrough concentrations of 13-16 microg/l. Hence, already the 120mg SC dose gives rise to considerably higher trough concentrations than those achieved with the highest approved (as described in section 5.1 of the SPC) IV dosing. With the proposed 240mg SC dosing the  Ctrough  levels  would  be  even higher.  There  is  very  limited  amount  of  safety  data  on  the  exposures achieved with the 240mg SC maintenance dose and no long-term data. The MAH should either remove from the SPC the statement of increasing the dose to 240mg at loss of response, or further justify that the benefit/risk of the claimed 240mg dose is positive in all proposed indications. (See also list of OCs).

## Summary of the MAH's response

First of all, the Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for patients with loss of response (LoR) in UC indication, and would like to pursue the dose adjustment in CD indication only. Consequently, responses to questions about dose adjustment in  UC indication  (Questions  11-15,  18-22  and  24)  are  omitted  in  this  submission  package.  The Applicant wishes to pursue approval of CT-P13 SC dose adjustment for patients with LoR in CD indication based on the result of Study CT-P13 3.8 (CSR CT-P13 3.8).

## Baseline Characteristics

In Study CT-P13 3.8, there was no meaningful difference between the subgroups of patients with and without dose adjustment in terms of baseline characteristics (Section 5.3.5.3 Post-hoc Table 2.219).

<div style=\"page-break-after: always\"></div>

## Efficacy Following Dose Adjustment

As previously discussed in Section 2.7.3.4.3 (SN0264), the proportions of patients achieving co- primary and  key  secondary  efficacy  endpoints  depending  on  the  treatment  assignment  and  dose adjustment were calculated  (Table  1).  Compared to the  Placebo  SC group, higher  proportion  of patients achieved co-primary and key secondary endpoints in the subgroup of patients who adjusted the  dose  from  CT-P13 SC  120  mg  to  240  mg.  Although  the  proportions  of  patients  achieving endoscopic  response  and endoscopic remission at Week 54 in the CT-P13 SC 120 mg with dose adjustment subgroup are lower compared  to  the  CT-P13  SC  120  mg  without  dose  adjustment subgroup, they were still higher than the proportions in the Placebo SC group. Also, for all other co- primary and key secondary endpoints, the proportions  of  patients  achieving  those  endpoints  for  the  CT-P13  SC  120  mg  with  dose  adjustment subgroup were similar to the proportions for the CT-P13 SC 120 mg without dose adjustment subgroup and markedly higher than the proportions for the Placebo SC group. Especially, 61.5% of patients with dose adjustment regained clinical response (based on CDAI-100).

Moreover, as presented in Response to Question 36, for patients who adjusted the dose, reductions in the CDAI and SES-CD scores were observed after the dose adjustment, suggesting that increase of CT-P13 SC dose to 240 mg has effect on patients who initially responded but then lost response.

Moreover, as discussed in Response to Question 35, the efficacy of patients who met loss of response (LoR) criteria and received adjusted dose were compared to the efficacy of patients who met LoR criteria but did  not  receive adjusted  dose  in  the  CT-P13  SC group. The  results showed that greater proportion of patients achieved co-primary and key secondary endpoints when patients who met LoR criteria received adjusted dose of CT-P13 SC 240 mg. Therefore, dose adjustment from CT-P13 SC 120 mg to 240 mg is considered as a rescue therapy for patients who meet LoR criteria.

## 3    Safety Following Dose Adjustment

As  previously  discussed  in  Section  2.7.4.2.1.4.3.2  (SN0264),  no  noticeable  difference  was  observed between the subgroups with dose adjustment and without dose adjustment in the incidence rates of TESAE,  TEAE  leading  to  study  drug  discontinuation  and  TEAESIs  (SIR,  delayed  hypersensitivity, localised ISR, infection, malignancy) during the Maintenance Phase of Study CT-P13 3.8 (Table 2.7.4- 23 [SN0264]).

To  further  examine  safety  profile  of  patients  with  dose  adjustment, the  Applicant  conducted  post- hoc analyses including all safety data up to Week 102 regardless of switching from placebo to CT- P13 SC (120 mg) and dose adjustment from CT-P13 SC 120 mg or Placebo SC to 240 mg (Section 5.3.5.3 Posthoc Table 3.114). The adverse events occurred on or after the first administration of each treatment are included in the corresponding treatment group. As discussed in detail in Response to Question 42, the results showed that there was no significant difference in the number of events by 100 persons year (PY) between each dose of CT-P13 SC 120 mg, 240 mg and placebo. The number of patients with at least 1 TEAE, TESAE, TEAE  leading  to  study  drug  discontinuation  or  TEAESI  with  exposure  adjusted  rate  by  100  PY  were comparable between the groups.

Moreover, considering  that  the  mean  and  median  duration  of  treatment  for  patients  who  received CTP13 SC 240 mg are 58.9 weeks and 68.1 weeks, respectively, and 73 patients received CT-P13 SC  240 mg as maintenance treatment for at least 44 weeks in Study CT-P13 3.8, the post-hoc analysis result sufficiently  represents  long-term  safety  profile  of  CT-P13  SC  240  mg.  Study  drug exposure in Safety Population of Study CT-P13 3.8 is presented in Table 2 (from the response document).

<div style=\"page-break-after: always\"></div>

Table 75. Summary of Study Drug Exposure in Study CT-P13 3.8: Safety Population

|                                           | Placebo (N=105)                           | CT-P13 SC120mg (N=275)                    | CT-P13 SC240mg (N=105)                    |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Duration of Treatment (weeks)             | Duration of Treatment (weeks)             | Duration of Treatment (weeks)             | Duration of Treatment (weeks)             |
| Mean (SD)                                 | 29.9 (15.87)                              | 69.0 (32.98)                              | 58.9 (27.99)                              |
| Median (Min, Max)                         | 35.0 (4, 51)                              | 94.4 (4, 113)                             | 68.1 (5, 96)                              |
| Subjects Treated by Duration of Treatment | Subjects Treated by Duration of Treatment | Subjects Treated by Duration of Treatment | Subjects Treated by Duration of Treatment |
| ≥ 1 dose                                  | 105                                       | 275                                       | 105                                       |
| ≤ 4 weeks                                 | 0                                         | 1                                         | 0                                         |
| > 4 to ≤ 20 weeks                         | 45                                        | 34                                        | 17                                        |
| > 20 to < 44 weeks                        | 17                                        | 30                                        | 15                                        |
| ≥ 44 weeks                                | 43                                        | 210                                       | 73                                        |

Source: Section 5.3.5.3 Post-hoc Table 3.113

Note:  Duration of  treatment  (weeks)  is calculated  as  (the  last  visit  date  -  date of first  administration  of  each treatment  +1)/7.  For  patients with  any  change  in  treatment due  to  entering  extension  phase  or  dose adjustment, the duration of previous treatment is calculated as (date of first administration of later treatment

- date of first administration of each treatment)/7.

N = the number of patients administered at least one dose for each  treatment.

Abbreviation: SD, standard deviation

As presented in Response to Question 46, pooled analyses including all available CT-P13 SC clinical studies were conducted to examine safety profile of CT-P13 SC 240 mg. These results also support that there is no significant difference between the long-term safety profiles of CT-P13 SC 120 mg and CT-P13 SC 240 mg. Also, the result of the analysis comparing the events occurring prior to dose adjustment vs after dose adjustment in both CT-P13 SC and Placebo groups showed that the number  of  adverse  events  did  not significantly increase after dose adjustment in general.

## 4    Conclusion

The efficacy  and  safety  results  from  Study  CT-P13  3.8  support  positive  benefit  and  risk  ratio  for  dose adjustment from CT-P13 SC 120 mg to 240 mg for CD patients with loss of response. The subgroup of patients in CT-P13 SC 120 mg group with dose adjustment showed greater proportions of patients achieving the co-primary and key secondary endpoints compared to the Placebo SC group. In terms of safety, no notable difference was observed between the subgroups with and without dose adjustment in the CT-P13 SC 120 mg group. Also, the proposed dose adjustment would provide another treatment option for patients with  LoR.  Therefore,  based  on  the  benefit-risk  assessment,  the  totality  of  the  CT-P13  SC  programme supports that the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for CD patients who initially showed response but then lost response has favourable benefit-risk ratio.

## Assessment of the MAH's response

Data in Crohn's disease (including data provided in response to other questions)

A total of 41 patients in the CT-P13 SC 120 mg group and 48 patients in the placebo group experienced LoR prior to Week 54. Among these patients, 34/41 (82.9%) in CT-P13 SC 120 mg group and 41/48 (85.4%) in placebo group received adjusted dose while 7 patients in each group remained on the initially assigned treatment.  A few patients received adjusted dose despite not being eligible for the dose adjustment, 5/182 (2.7%) in CT-P13 SC 120 mg group and 4/57 (7.0%) in placebo group. This protocol violation seems to be driven by the clinicians' desire to improve the treatment for poor responders but exposes poor adherence to GCP. However, the frequency of these protocol violations is small enough not to pursue the issue further.

Among the 34 patients with dose adjustment in the CT-P13 SC 120 mg group 17 (50%) patients achieved clinical remission by CDAI and 7 (20.6%) patients achieved endoscopic response at Week 54. On the other

<div style=\"page-break-after: always\"></div>

hand, in the 7 patients who experienced a LoR but did not receive a dose adjustment, regain of clinical remission by CDAI occurred in 1/7 (14.3%) and endoscopic response re-emerged in 3 (42.9%) of these patients on initial active treatment. Regain of response occurred in 21/34 (61.8%) patients with a dose escalation while patients who lost response but remained on active treatment had a renewed response in 2 (28.6%) cases. Spontaneous regain of response and remission was also seen in patients who remained on placebo (3 and 1 patients, respectively).

Although the numbers are small, it can be concluded that spontaneous regain of response is not negligible. However, regain of response according to CDAI is more common and the improvement in absolute CDAI score  is  more  pronounced  in  patients  with  a  dose  adjustment  than  in  those  who  remained  on  initial treatment despite a LoR.

A clear difference between patients who experienced LoR and those who did not is seen in terms of serum drug concentration before LoR. This finding supports the theory of loss of response being associated with suboptimal drug concentrations.

Based on the submitted data, the 240 mg SC dose is overall associated with a closely similar safety profile as the 120 mg SC dose in subjects with CD. There were somewhat more infections with the 240 mg dose (table 8.2.1.2). However, the number of treatment-emergent serious adverse events (TESAE) was similar: 28/275 (10.2%, PY 7.70) during use of CT-P13 120 mg SC and 7/105 (6.7%, PY 5.91) during use of CTP13 240 mg SC. Furthermore, injections-site reactions were more frequent with the higher dose, but this was expected since the 240 mg SC regimen included two injections instead of only one.

The mean and median duration of treatment for patients who received CT-P13 SC 240 mg were 58.9 weeks and 68.1 weeks, respectively, and 73 patients received CT-P13 SC 240 mg as maintenance treatment for at least 44 weeks. Therefore, the post-hoc analysis result is considered to sufficiently represent long-term safety profile of CT-P13 SC 240 mg in subjects with CD.

## Data in Ulcerative colitis

The question on dose escalation in UC is no longer relevant.

## Conclusion

In CD patients, loss of response is associated with lower drug concentrations.

Regain of response according to CDAI is more common and the improvement in absolute CDAI score is more pronounced in patients with a dose adjustment than in those who remained on initial treatment despite a LoR. Although the groups are not comparable, the totality of data is sufficiently compelling in terms of magnitude and consistency to support a dose increase in patients who lost response. A majority of patients in the active treatment arm who received a dose adjustment had a positive outcome 16 weeks after the dose increase.

The long-term safety profile of 240mg SC is sufficiently identified. The 240 mg SC dose is overall associated with a closely similar safety profile as the 120 mg SC dose in subjects with CD.

The major objection is resolved as sufficient data on safety was provided but some other concerns remain before the data presented in the SPC can be approved.

## Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

<div style=\"page-break-after: always\"></div>

## SC induction in UC/CD

## Question 2

The MAH's justifications for the proposed SC induction regimen in treatment of CD and UC are not sufficient (see  section  6.3  of  the  assessment  report).  The  concentration-time  profile  and  exposure  parameters following the SC regimen will not match those following the approved IV regimen. Therefore, efficacy and safety of the proposed SC induction regimen should be demonstrated in a clinical study or, if modelling and simulation approach is utilized, the MAH should A) very robustly demonstrate which exposure parameter(s) and exposure level(s) drive the efficacy and safety of infliximab in induction treatment of moderately to severely  active  Crohn's  disease,  fistulising  active  Crohn's  disease,  and  moderately  to  severely  active ulcerative colitis, and B) demonstrate that these exposure levels will be achieved with the proposed SC induction regimen in all body weight categories. (See also OC / Clinical pharmacology / Population PK model).

## Summary of the MAH's response

The Applicant would like to withdraw the proposed SC induction dosing regimen (240 mg at Week 0 followed by 120 mg at Weeks 1, 2, 3 and 4) followed by SC maintenance treatment (120 mg Q2W) from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to support the SC induction dosing  regimen.  Consequently,  responses  to  Questions  2  and  6-9  are  omitted  in  this  response  to  RSI package.

## Assessment of the MAH's response

The proposed SC induction dosing regimen for CD and UC indications was withdrawn from the grouped variation application procedure.

## Conclusion

Issue resolved as questions related to this variation are no longer relevant.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [ ] No need to update overall conclusion and impact on benefit-risk balance

## Switch from high IV dose to SC dose in CD

## Question 3

The provided data does not justify the proposed amendment which implies that sufficient information on switching from higher than 5 mg/kg IV doses to SC Remsima is available in Crohn's disease. The MAH should either remove the amendment from the SPC, or further justify that the available information is sufficient to support maintenance of the positive benefit-risk balance after a switch in CD patients treated with an approved (as described in section 5.1 of the SPC) high IV dose. The usual rate of relapses in a comparable population could be used as reference. (See also OC)

## Summary of the MAH's response

The Applicant would like to withdraw the proposed switching from high-dose (&gt;5 mg/kg) IV maintenance to SC maintenance treatment from the grouped variation for CD and UC indications. This is mainly due to

<div style=\"page-break-after: always\"></div>

lack of clinical data to support the switching from high-dose (5 mg/kg) IV maintenance to SC maintenance treatment.

Consequently, responses to Questions 3 and 41 are omitted in this response to RSI package.

## Assessment of the MAH's response

The  proposed  switching  from  high-dose  IV  maintenance  to  SC  maintenance  was  withdrawn  from  the grouped variation application procedure.

## Conclusion

Issue resolved as questions related to this variation are no longer relevant.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## 13.2. Other concerns

## Clinical aspects

## Bioanalytics

## Question 4

ADA-method: The partial validation with new SA plates provided by Roche was performed only in healthy human serum. Since the clinical studies are performed with ulcerative colitis and Crohn's disease patients, the Applicant is requested to evaluate matrix interference of corresponding disease serum unless otherwise justified.

## Summary of the MAH's response

Matrix interference in ulcerative colitis and Crohn's disease serum was evaluated as additional method validation. Ten individual pre-dose samples each from Studies CT-P13 3.7 and CT-P13 3.8 were randomly selected and evaluated unspiked and spiked with low and high level of surrogate positive control (HCA233, BioRad®). All the results met the acceptance criteria specified in the method validation plan.

## Assessment of the MAH's response

MAH  performed  matrix  interference  studies  in  ulcerative  colitis  and  Crohn's  disease  serum  as  was requested. The provided data met the acceptance criteria and no matrix interference was observed. This point is considered resolved.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

<div style=\"page-break-after: always\"></div>

## Question 5

Bioanalytical report of CT-P13 plasma concentrations: The Applicant is requested to provide full ISR data once available.

## Summary of the MAH's response

The full incurred sample reanalysis (ISR) for Study CT-P13 3.7 and Study CT-P13 3.8 have been performed and the results are provided in Appendix 16.1.13 of W102 CSR CT-P13 3.7 (ROPH) and Appendix 16.1.13 of W102 CSR CT-P13 3.8 (RNEM), respectively.

## Assessment of the MAH's response

The full ISR data has been provided and is considered acceptable.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Clinical pharmacology

## Question 6

Population PK model: According to Section 5.1.1.1 of the population PK/PD report, PK measurements from 3114 subjects were available for PK model development and after exclusions PK measurements from 2998 subjects  were  included  in  the  population  PK  model  development.  According  to  Table  13  Summary  of continuous covariates and Table 14 Summary of categorical covariates, 3017 subjects were included in the population PK model development. Please clarify the discrepancy. In addition, please provide summary tables of continuous and categorical covariates for the final unblinded dataset.

## Summary of the MAH's response

The Applicant withdrew the proposed SC induction dosing regimen followed by SC maintenance treatment from the grouped variation for CD and UC indications. Consequently, responses to Questions 2 and 6-9 are omitted in this response to RSI package.

## Assessment of the MAH's response

The proposed SC induction dosing regimen for CD and UC indications was withdrawn from the grouped variation application procedure. Questions related to this variation are no longer relevant.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [ ] No need to update overall conclusion and impact on benefit-risk balance

<div style=\"page-break-after: always\"></div>

## Question 7

Population PK model: ADA and NAb were significant covariates in the population PK model. The MAH should confirm that immunogenicity samples (ADA and NAb) from studies CT-P13 1.6, 1.10, 1.11, 3.5, 3.7, and 3.8 were measured using the same methods, or if the methods were not the same that the results of the methods are comparable.

## Summary of the MAH's response

The Applicant withdrew the proposed SC induction dosing regimen followed by SC maintenance treatment from the grouped variation for CD and UC indications. Consequently, responses to Questions 2 and 6-9 are omitted in this response to RSI package.

## Assessment of the MAH's response

The proposed SC induction dosing regimen for CD and UC indications was withdrawn from the grouped variation application procedure. Questions related to this variation are no longer relevant.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 8

Population PK model: The scope of the variation application is to add induction regimen for subcutaneously administered Remsima in treatment of CD and UC, i.e., the MAH proposes a new dosing regimen for the first 6 weeks of treatment. This period is not adequately shown in the presented pcVPC plots. Additional pcVPC plots should be provided for the final updated PK model (run5102) for time periods 6 weeks after the first dose and 6 weeks after the last dose. Binning should be selected carefully to avoid artefacts in the plots. Plots for the whole dataset should be stratified at least by route of administration, SC dose, and immunogenic response (unknown/no/yes). In addition, separate plots should be provided for patients with CD and UC (stratified by route of administration).

## Summary of the MAH's response

The Applicant withdrew the proposed SC induction dosing regimen followed by SC maintenance treatment from the grouped variation for CD and UC indications. Consequently, responses to Questions 2 and 6-9 are omitted in this response to RSI package.

## Assessment of the MAH's response

The proposed SC induction dosing regimen for CD and UC indications was withdrawn from the grouped variation application procedure. Questions related to this variation are no longer relevant.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [ ] No need to update overall conclusion and impact on benefit-risk balance

<div style=\"page-break-after: always\"></div>

## Question 9

Population  PK  model:  The  model  appears  to  have  significant  model  misspecifications  according  to  the pcVPCs stratified by route of administration (Figure 6.2.2.9) which should be addressed.

- a. The median profile for the observed data is not adequately described by the model predictions. Infliximab may have non-linear PK with respect to dose/concentration and/or time (i.e., targetmediated drug disposition) which is not accounted for. The Applicant should address this limitation by exploring model(s) for non-linear PK and update the final model as appropriate.
- b. The variability (i.e., outer percentiles) is over-predicted for the IV route and under-predicted for the SC route, which is problematic considering that the Applicant propose to use the PK model to support a new SC induction regimen. Potential differences in variability between IV and SC is an important aspect for assessing the new SC induction regimen. The SC dosing may display higher variability than IV due to variability in rate and extent of absorption from the subcutaneous injection site. The Applicant should resolve the misspecification in variability, for example by exploring interindividual variability in KA and/or F and update the SC induction regimen predictions.

## Summary of the MAH's response

The Applicant withdrew the proposed SC induction dosing regimen followed by SC maintenance treatment from the grouped variation for CD and UC indications. Consequently, responses to Questions 2 and 6-9 are omitted in this response to RSI package.

## Assessment of the MAH's response

The proposed SC induction dosing regimen for CD and UC indications was withdrawn from the grouped variation application procedure. Questions related to this variation are no longer relevant.

## Conclusion

- [x] Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [ ] No need to update overall conclusion and impact on benefit-risk balance

Efficacy

Study CT-P13 3.7

## Question 10

The protocol assumptions differ to a large degree from what was observed in the study. In the protocol a 45% response rate in the placebo arm was expected whereas the results show a response rate of 20.8%. Furthermore, in the protocol a 15% delta was expected which would have translated into 60% response rate in the active arm. This is also notably lower (43%) though the expected delta was observed. The Applicant should discuss whether the difference in the expected vs observed results is due to low number of true responders or whether the dose escalation/switch to placebo allowed in the protocol, or some other

<div style=\"page-break-after: always\"></div>

reason,  explains  the  difference.  The  response  may  refer  to  the  OC  in  the  efficacy  section  related  to categories for non-responders.

## Summary of the MAH's response

Historical data used for the assumption was ACT1 study (Rutgeerts et al., 2005) and Study CT-P13 1.6 Part 2 (CSR CT-P13 1.6 Part 2). Although there were a few aspects of the two reference studies that did not exactly match Study CT-P13 3.7, those studies were selected due to limitation of available historical data at the time of Study CT-P13 3.7. For assumption, clinical remission rate of CT-P13 SC 120 mg group was assumed by result of CTP13 at Week 30 (64.4%, 38/59) in Study CT-P13 1.6 Part 2 which was most upto-date data at the time of Study CT-P13 3.7 sample size assumption. In Study CT-P13 1.6 Part 2, clinical remission rate of CT-P13 intravenous (IV) group and CT-P13 subcutaneous (SC) group was 58.1% (18/31) and 71.4% (20/28), respectively. Clinical remission rate of Study CT-P13 1.6 Part 2 was based on partial Mayo score among patients who showed clinical response based on partial Mayo score of IV induction (at Week 6) whereas clinical remission rate of Study CT-P13 3.7 was based on modified Mayo score among patients who showed clinical response based on modified Mayo score of IV induction (at Week 10). The modified Mayo score consists of the stool frequency, rectal bleeding and endoscopic subscores, whereas the  partial  Mayo  score  consists  of  the  stool  frequency,  rectal  bleeding  subscore  and  physician's  global assessment (PGA).

Study CT-P13 1.6 Part 2 was an open-label study and only biologic naïve patients were included in this study which could have caused higher clinical remission rate compared to blinded Study CT-P13 3.7 which included patients with previous exposure of biologics or JAK inhibitors. Applying different criteria of clinical remission and eligibility in each study could have had impact on lower clinical remission rate of Study of CT-P13 3.7.

Considering that different criteria of clinical remission and eligibility were applied, clinical remission rate of CT-P13 SC 120 mg group in Study CT-P13 3.7 was estimated as 60% by conservative assumption. For assumption of clinical remission rate of Placebo group, delta was assumed by using ACT1 study, due to lack of historical data of subcutaneous placebo. Though 18% delta was observed in ACT1 study, 15% delta was estimated due to difference in regimen. In ACT1 study, placebo was administered during both induction and maintenance periods while in Study CT-P13 3.7, CT-P13 IV was administered during induction period and placebo was administered during maintenance period. Based on 60% clinical remission rate of CT-P13 SC 120 mg group and 15% delta, 45% clinical remission rate of Placebo group was applied on Study of CTP13 3.7. Though observed clinical remission rate of Placebo SC group (20.8%) in the Study CT-P13 3.7 is lower than expected, it is similar compared to clinical studies of other drugs (Feagan et al., 2013; Sands et al., 2019), where 16%, and 24% of clinical remission rate in Placebo group were observed, respectively.

Additionally, Study CT-P13 3.7 considered patients with dose adjustment as non-responder which could have had impact on lower clinical remission rate for both CT-P13 SC 120 mg group and Placebo group.

The Applicant had limited historical sources with data for CT-P13 SC and Placebo SC at the time of study protocol development, thus the Applicant inevitably chose ACT1 and Study CT-P13 1.6 Part 2 for sample size assumption despite the differences described above.

## Assessment of the MAH's response

The MAH argues that limited data was available at the time of study planning. This argument cannot be fully supported as treatment of this indication with the same MoA has been established for a long time.

As the MAH states, it appears that the lower absolute number of responders could be linked to the fact that

<div style=\"page-break-after: always\"></div>

patients whose dose was escalated were automatically counted as non-responders. This further confirms the  impression  that  the  impact  of  dose  escalation  in  both  active  and  placebo  groups  on  the  overall robustness of the results was not adequately considered at the planning stage of the study. This impacts the robustness of the results at Week 54.

## Conclusion

Issue not pursued further.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 11

One analysis was included in the SAP to assess dose escalation: In addition, for the descriptive comparison of the treatment effect between patients with and without dose adjustment to CT-P13 SC 240 mg prior to Week 54 within CT-P13 SC treatment group, the primary endpoint was summarized by patients with and without dose adjustment in CT-P13 SC treatment group using frequency table without the statistical test. In this analysis, remitter was determined as per remission criteria regardless of dose adjustment. This analysis  is,  however,  not  included  in  the  submitted  dossier  which  is  rather  surprising  considering  the intended changes to the SmPC. This analysis should be provided.

## Summary of the MAH's response

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently, responses to Questions 11-15, 18-22 and 24 are omitted in this response to RSI package.

## Assessment of the MAH's response

The requested analysis was not provided. The results are covered by other questions and, hence, these tables do not need to be provided.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 12

The Applicant is requested to provide a Figure of Patient Disposition which outlines for how many patients the dose was escalated at/after week 22.

## Summary of the MAH's response

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for

<div style=\"page-break-after: always\"></div>

UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently, responses to Questions 11-15, 18-22 and 24 are omitted in this response to RSI package.

## Assessment of the MAH's response

The requested Figure of Patient Disposition was not provided. Although the proposal for dose escalation was dropped for UC indication, the figure would have been relevant for assessment of the week 54 outcome. However, as only W22 data will be acceptable in the SPC, the issue is not pursued further.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 13

It  should be clarified how patients with progressive disease, who discontinued the study, differed from patients who received a dose increase. If possible, the differentiation should be displayed in the flow chart Figure of Patient Disposition.

## Summary of the MAH's response

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently,  responses  to  Questions  11-15,  18-22  and  24  are  omitted  in  this  response  to  RSI package.

## Assessment of the MAH's response

The proposed dose escalation in UC patients with loss of response was withdrawn from the grouped variation application procedure. Questions related to this variation are no longer relevant.

## Conclusion

Issue resolved

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 14

Baseline  characteristics  should  be  tabulated  for  patients  who  required/received  dose  escalation  and compared to those who did not.

<div style=\"page-break-after: always\"></div>

## Summary of the MAH's response

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently, responses to Questions 11-15, 18-22 and 24 are omitted in this response to RSI package.

## Assessment of the MAH's response

The proposed dose escalation in UC patients with loss of response was withdrawn from the grouped variation application procedure. Questions related to this variation are no longer relevant.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 15

There are no tables depicting the details of the non-responder category at Week 54. The MAH should provide tables outlining the number of patients who were: a) non-responder according to the clinical criteria b) dose was escalated/switch to active c) discontinuation before Week 54 d) missing data e) incomplete data f) any other reason and corresponding combination categories.

## Summary of the MAH's response

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently, responses to Questions 11-15, 18-22 and 24 are omitted in this response to RSI package.

## Assessment of the MAH's response

The  requested  table  was  not  provided.  Although  the  proposal  for  dose  escalation  was  dropped  for  UC indication, data on baseline characteristics for the main subgroups would have been relevant for assessment of the week 54 outcome. However, as only W22 data will be acceptable in the SPC, the issue is not pursued further.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 16

<div style=\"page-break-after: always\"></div>

Male and female patients achieved remission and response at week 54 with equal frequency in the CT-P13 SC 120 mg treatment arm. However, in the placebo arm, women seemed to achieve response almost twice as often as men and the difference between treatment and placebo was not as pronounced. According to corticoid-free remission, there was no clear difference between Remsima and placebo among women (38% of women in the treatment arm and 35% in the placebo arm were remitters at 54 weeks). The MAH should discuss whether this reflects a true gender difference in placebo response or if the different criteria leading to classification as a non-responder (corticosteroid use, dose increase, missing value) could have caused a discrepancy between sexes.

## Summary of the MAH's response

In Study CT-P13 3.7 conducted in patients with ulcerative colitis (UC), there were fewer patients in the Placebo SC group compared to CT-P13 SC group. Small number of patients in the Placebo SC group may have  had  impact  on  the  difference  in  clinical  remission  and  response  rate  between  male  and  female subgroups in the Placebo SC group. Also, patients with dose adjustment prior to Week 54 or patients with incomplete or missing modified Mayo score at Week 54 were considered as nonremitter/ non-responder for the primary and key secondary endpoints. The criteria for classification as a non-remitter/non-responder were the same for all enrolled patients (regardless of treatment or gender), however, more male patients were considered as non-remitter/non-responder. This may have had impact on the difference in clinical remission and response rate between male and female subgroups in the Placebo SC group as more male patients were considered as non-responder due to incomplete or missing modified Mayo score at Week 54 and dose adjustment prior to Week 54.

Total  number  of  patients  randomized  in  CT-P13  SC  group  and  Placebo  SC  group  was  294  and  144, respectively, and the number of patients in Placebo SC group were almost half of CT-P13 SC 120 mg group. Also, the number of male and female patients in the CT-P13 SC group was 163 and 131, respectively, and the number of male and female patients in the placebo SC group was 83 and 61, respectively. Similarly, male and female patients of Placebo SC group was almost a half of CT-P13 SC group. As Placebo SC group had small number of patients, there were limitations for interpreting the results. Small number of patients could have caused impact on the difference in clinical remission and response rate between male and female subgroups in the Placebo SC group.

The number of patients who had dose adjustment prior to Week 54 or with incomplete or missing modified Mayo score at Week 54 in the Placebo SC group was 57/83 (68.7%) in males and 34/61 (55.7%) in females, respectively. In CT-P13 SC 120 mg group, the number of patients who had dose adjustment prior to Week 54 or with incomplete or missing modified Mayo score at Week 54 was 53/163 (32.5%) in males and 39/131 (29.8%) in females, and difference in clinical remission and response rate between male and female was not observed. Dose adjustment and discontinuation from the study in the Placebo SC arm was allowed by investigator's judgement, regardless of treatment or gender. Total of dose adjustment prior to Week 54 and incomplete or missing values per the Statistical Analysis Plan of Study CT-P13 3.7 occurred more in male compared to female patients.

Lower clinical remission and clinical response rates in males compared to females in the Placebo SC group was shown in Table 1 and Table 2. As mentioned by CHMP, there was no clear difference in corticosteroidfree remission at Week 54 between CT-P13 SC 120 mg group and Placebo SC group among female patients (Table  3).  However,  this  result  was  obtained  only  by  chance  due  to  the  small  number  of  patients  are analysed for the corticosteroid-free remission. Only the patients who was treated with oral corticosteroid at baseline were included in the analysis. Also, in corticosteroid-free remission, the difference between the CT-P13 SC group and Placebo SC group in male and female was 26.3 and 4.2, respectively, which is within the difference (95% CI) of 17.3 [3.1, 28.9] between the CT-P13 SC group and Placebo SC group in total all-randomized population (Table 3).

<div style=\"page-break-after: always\"></div>

Although a difference was seen in clinical remission and response rates between the male and female in the Placebo SC group, Applicant believes this was not a true gender difference. It might be a coincidental finding due to small number of patients in Placebo SC group and difference in number of patients classified as non-remitter/non-responder in male and female patients in the Placebo SC group based on the factors mentioned above.

## Assessment of the MAH's response

The Applicant has provided the requested tables. As the difference between male and female is prominent in the placebo group, it is not linked to the MoA of the active treatment. It may not be a full chance finding; however, the difference does not appear to question the efficacy of CP-P13 in male and female patients.

## Conclusion

## Issue resolved

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 17

According to the label, available data suggest that clinical response is usually achieved within 14 weeks in the treatment of UC. This recommendation stems from the initial IV formulation and dosing intervals. The MAH is invited to discuss, whether another time point could be introduced with the current and newly proposed SC regimen.

## Summary of the MAH's response

The Applicant would like to keep the time point for decision on continuation of treatment within 14 weeks of the infliximab treatment for UC.

As  a  biosimilar  to  Remicade,  CT-P13  intravenous  (IV)  is  approved  in  adult  patients  for  treatment  of rheumatoid  arthritis  (RA),  Crohn's  disease  (CD),  ulcerative  colitis  (UC),  ankylosing  spondylitis  (AS), psoriatic arthritis (PsA), and  psoriasis (Ps). After EC  approval of  CT-P13  IV,  a  subcutaneous formulation with the same active pharmaceutical ingredient (API) as CT-P13 IV has been developed (CTP13 SC), and CT-P13 subcutaneous (SC) is also approved for treatment of same indications including UC as CT-P13 IV in line extension EMA/CHMP/548703/2019.

Compared to clinical response rate based on total Mayo score at Week 8 in ACT1 and ACT2 combined study (66.9%),  clinical  response  rate  based  on  total  Mayo  score  at  Week  10  in  intent  to  treat population of Study CT-P13 3.7 (78.1%) showed similar result (Table 4). Considering that Week 8 in ACT1 and ACT2 study and Week 10 in Study CT-P13 3.7 are both the first visit after 3 induction doses, the Applicant believes that it is reasonable to compare Week 8 from ACT 1 and 2 studies and Week 10 from Study CTP13 3.7.

As  mentioned  above,  CT-P13  IV  was  approved  as  biosimilar  to  Remicade  and  Study  CT-P13  1.6 demonstrated clinical  similarity between  CT-P13  IV and  CT-P13  SC.  In  the  Study CT-P13  3.7, clinical response rate after 3 rd  dosing of Infliximab IV 5mg/kg was similar to clinical response rate of ACT1 and ACT2  studies.  Therefore,  the  Applicant  would  like  to  apply  identical  timepoints  to  observe achieved clinical response as the previously submitted label for CT-P13 SC (Table 5).

<div style=\"page-break-after: always\"></div>

Table 76: Currently Approved and Proposed Table from the Label

| Currently Approved                                                                                                                                                                                                                                                                                                     | Proposed                                                                                                                                                                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Available data suggest that the clinical response is usually achieved within 14 weeks of treatment, i.e. 2 intravenous infusions and 4 subcutaneous injections (see section 5.1). Continued therapy should be carefully reconsidered in patients who show Ino evidence of therapeutic benefit within this time period. | Available data suggest that the clinical response is usually achieved within 14 weeks of treatment,  1.0.2 intravene 51 infusions and 4 subcutaneous injections (see section 5.1). Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within this time period. |

## Assessment of the MAH's response

It is acceptable not to change the approved wording.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 18

The MAH should clarify how many patients in each treatment arm were eligible for a dose increase before Week 54 and how many got it. The data should be presented by sex, body weight, disease severity, drug concentration and ADA status. It should also be clarified which weeks the dose increase was initiated at, i.e for how long the patients were exposed to the higher dose.

## Summary of the MAH's response

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently, responses to Questions 11-15, 18-22 and 24 are omitted in this response to RSI package.

## Assessment of the MAH's response

The requested level of detail is no longer needed as the proposal for dose escalation was withdrawn.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 19

The MAH should describe how the disease activity evolved among those who stayed on initial treatment regimen versus those who had a dose escalation. The analysis should be conducted for patients for whom

<div style=\"page-break-after: always\"></div>

dose was escalated/not escalated and patients who were eligible for dose escalation but did not escalate/did escalate. Did regain of response occur in patients who continued on placebo? Spontaneous fluctuation of the disease should be discussed and comparison should be made to patients who did not escalate and to historical controls. The MAH should provide spaghetti plots (overlay and individual) where time point of dose escalation is standardized in the middle of the graph and 4 visits before and after dose escalation are included.

## Summary of the MAH's response

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently, responses to Questions 11-15, 18-22 and 24 are omitted in this response to RSI package.

## Assessment of the MAH's response

The requested level of detail is no longer needed as the proposal for dose escalation was withdrawn.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 20

The MAH claims that for patients who adjusted the dose, the reduction in the efficacy scores was observed from their following scheduled visit after the first dose adjustment. Appropriate data should be provided to support this claim.

## Summary of the MAH's response

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently, responses to Questions 11-15, 18-22 and 24 are omitted in this response to RSI package.

## Assessment of the MAH's response

The requested level of detail is no longer needed as the proposal for dose escalation was withdrawn.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

<div style=\"page-break-after: always\"></div>

## Question 21

Did the groups (i.e., patients for whom dose was escalated/not escalated and patients who were eligible for dose escalation but did not escalate/did escalate) differ in terms of compliance with the protocol or other parameters which could describe their well-being in addition to the primary endpoint?

## Summary of the MAH's response

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently, responses to Questions 11-15, 18-22 and 24 are omitted in this response to RSI package.

## Assessment of the MAH's response

The requested level of detail is no longer needed as the proposal for dose escalation was withdrawn.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 22

Did loss of response or regain of response correlate with PK and/or ADA titres? Did the subjects needing dose escalation have lower concentrations of CT-P13 during the induction treatment (placebo group) and during induction and maintenance treatment (CT-P13 group)? Did the subjects who regained response have higher concentrations of CT-P13 compared to those who did not? Was the need for dose escalation or failure to  regain  response  associated  with  high  ADA  titres?  Were  high  ADA  titres  associated  with  low  drug concentrations?

## Summary of the MAH's response

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently, responses to Questions 11-15, 18-22 and 24 are omitted in this response to RSI package.

## Assessment of the MAH's response

The proposal for dose escalation was withdrawn and the question is no longer relevant for dose escalation. However, the data could influence a previously approved paragraph on immunogenicity in SPC section 4.8. As a clear correlation between loss of response and ADA titre was seen in CD, it is expected that ADA significantly influences also the efficacy in UC. The paragraph on immunogenicity in SPC section 4.8 needs to  be  justified  or  amended  taking  into  account  the  new  available  data  from  study  3.7.  The  correlation

<div style=\"page-break-after: always\"></div>

between loss of response and ADA status, median ADA titres and drug concentrations should be presented for both indications in tables where subgroups 1 and 3 are pooled and compared to subgroups 2 and 4, as defined in responses to Q 34.

## Conclusion

Issue not resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 23

An analysis according to principal stratum estimand should be provided.

## Summary of the MAH's response

As per the Agency's request, for the assessment of treatment effects within principal stratum composed by the  target  population  where  the  intercurrent  event  would  not  occur,  the  analysis  of  primary  and  key secondary endpoints was conducted excluding patients who experienced dose adjustment prior to Week 54 (81 and 70 patients with dose adjustment in CT-P13 SC 120 mg and Placebo SC groups, respectively), where the dose adjustment was considered as the only intercurrent event in Study CT-P13 3.7 (Table 6).

The proportion of patients who achieved primary and key secondary endpoints was numerically higher in the CT-P13 SC 120 mg group than in the Placebo SC group. Regarding corticosteroid-free remission, no notable difference was seen between treatment groups. However, there is a limitation in interpreting results due  to  small  sample  size  of  patients  with  oral  corticosteroid  at  baseline  among  patients  who  did  not experience  dose  adjustment  prior  to  Week  54.  Additionally,  despite  the  small  number  of  patients,  the difference (5.6%) in corticosteroid-free remission between treatment groups in the target population (which is  a  subset  of  All-randomized  population)  falls  within  the  95%  CI  (3.1%,  28.9%)  of  the  difference  in corticosteroid-free remission between treatment groups in the All-randomized population (W54 CSR CTP13 3.7 Sections 11.4.1.1 and 11.4.1.2 [SN0264]).

In  conclusion,  the  results  for  the  primary  and  key  secondary  endpoints  according  to  principal  stratum estimand  showed  a  consistent  trend  with  the  findings  from  the  main  analysis  in  the  All-randomized population.

<div style=\"page-break-after: always\"></div>

Table 77 Proportion of Patients Achieving Primary and Key Secondary Endpoints (principal stratum estimand): All-Randomized Population

|                                                  | CT-P13 SC 120 mg (N=294)   | Placebo (N=144)   | Difference (95% CI)1   |   P-value2 |
|--------------------------------------------------|----------------------------|-------------------|------------------------|------------|
| Clinicalremission atWeek54                       | 127/213 (59.6%)            | 30/74 (40.5%)     | 17.1 (3.7, 29.4)       |     0.0094 |
| ClinicalresponseatWeek54                         | 158/213 (74.2%)            | 45/74 (60.8%)     | 11.1 (-1.1, 23.8)      |     0.0673 |
| Endoscopic-histologicmucosal improvementatWeek54 | 105/213 (49.3%)            | 24/74 (32.4%)     | 15.0 (1.8, 26.9)       |     0.0216 |
| Corticosteroid-freeremission at Week54           | 44/77 (57.1%)              | 11/23 (47.8%)     | 5.6 (-16.9, 27.1)      |     0.6289 |

Sources:Section5.3.5.3.Post-hocTables2.227,2.228,2.229and2.230

Note:Analysis is stratifiedbyUseof treatmentwithoralcorticosteroids atWeek O(usedornotused)and remissionatWeek54,percentagesarecalculatedusingthenumberofpatientswithoutdoseadjustmentto CT-P13SC240mgpriortoWeek54asthedenominator.

Clinical remission is defined asmodified Mayoscore with a stool frequencysubscore of 0or1,rectalbleeding subscoreofo,andendoscopicsubscoreof0or1.

30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0or 1 point.

Endoscopic-histologicmucosalimprovementisdefinedasanabsoluteendoscopicsubscoreof0or1pointfrom accompanying laminal propria neutrophils and neutrophils in epithelium subscore of O point.

Corticosteroid-free remission is defined as being in clinical remissionby modified Mayo score in addition to not requiringanytreatmentwithcorticosteroidfor atleast8weeks atWeek54,amongthepatientswhoused oralcorticosteroidsatbaseline.AnalysisisstratifiedbyUseoftreatmentwithoralcorticosteroidsatWeek0 (used or not used)and Clinical remission at Week 1o (remitter or non-remitter by modified Mayo score). Percentagesarecalculatedbyusingthenumberofpatientswhousedoralcorticosteroidsatbaselinewithout doseadjustmenttoCT-P13SC 240mgprior toWeek54asthedenominator.

2 The nominal p-value from stratified CMH test is presented in descriptive purpose.

1 The difference of proportions between two treatment groups estimated using CMH (Cochran-MantelHaenszel)weights, and the 95%stratified Newcombe CI with CMH weights are presented.

## Assessment of the MAH's response

It appears that Table 6 in MAH´s response is basically just an analysis restricted to patients with no dose escalation. This does not correspond to principal stratum estimand. The results are challenging to interpret because the groups are not comparable. However, the results do demonstrate the large overall impact of dose escalation on week 54 results and how the clinical response/remission data is actually largely replaced by whether dose was escalated/patients in the placebo arm switched to active treatment.

## Conclusion

Issue not pursued further.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 24

The MAH should discuss how the fact that patients and investigators were effectively unblinded at the time of dose escalation, impacts the results.

## Summary of the MAH's response

<div style=\"page-break-after: always\"></div>

The Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for UC patients with loss of response from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to statistically support the proposed dose adjustment for UC indication.

Consequently, responses to Questions 11-15, 18-22 and 24 are omitted in this response to RSI package.

## Assessment of the MAH's response

The requested discussion was not provided. Although the proposal for dose escalation was dropped for UC indication,  the  question  on  blinding  would  have  been  relevant  for  assessment  of  the  week  54  primary outcome. However, as only W22 data will be acceptable in the SPC, the issue is not pursued further.

## Conclusion

Issue not pursued further.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Study CT-P13 3.8

## Question 25

The proposed update of section 4.2 for Remsima SC includes a harmonisation of posologies between active Crohn's disease and fistulising active Crohn's disease but many patients with active fistulising CD were excluded from the study. Taking into account the exclusion criteria, the MAH should discuss how well the current study results and resulting amendments to the SPC are applicable to patients with active fistulising CD.

## Summary of the MAH's response

Fistula  is  one  of  the  complications  in  patients  with  Crohn's  disease  (CD),  with  approximately  one third of CD patients experiencing fistulas during their disease course (Schari et al .,  2017). TNF α signalling  is known to be involved in mucosal damage as well as ulcer and fistula development through stimulation of  macrophages,  neutrophils  and  myofibroblasts,  ultimately  leading  to  tissue damage, remodeling and secondary effects on tissue damage (Di Sabatino et al ., 2007). Therefore, infliximab is effective for both fistulising CD (fCD) and CD through its mechanism of inhibiting TNF α signalling. Infliximab was approved with the same dose for both indications.

CT-P13  subcutaneous  (SC)  has  the  same  active  pharmaceutical  ingredient  (infliximab)  as  CT-P13 intravenous (IV) and the totality of evidence from a number of studies including Studies CT-P13 1.6, CTP13 3.7 and CT-P13 3.8 demonstrates that CT-P13 SC is as effective as CT-P13 IV as maintenance treatment.

Suggested  therapeutic  threshold of infliximab for  IBD  treatment  is  determined  to be 5 μ g/mL according  to  the  guideline  on  therapeutic  drug  monitoring  in  inflammatory  bowel  disease  (IBD) (Feuerstein et al ., 2017). The optimal trough level of infliximab in patient with perianal fCD also identified as &gt;7.1 μ g/mL for both fistula healing and closure (Plevris et  al .,  2020). In Study CT-P13 3.8,  trough concentration range of CT-P13 SC was shown from 13.3 to 14.8 μ g/mL in patients with CD. The proposed dosing regimens of CT-P13 SC for fCD, which is the same as for CD, are expected to achieve and maintain the therapeutic thresholds at least one year.

<div style=\"page-break-after: always\"></div>

Considering the mechanism of action and the therapeutic threshold of both fCD and CD, CT-P13 SC is expected to be effective in both fCD and  CD. Therefore, the posology of CT-P13 SC approved for IBD indication is applicable for patients with fCD.

## Assessment of the MAH's response

No harmonisation of posologies between active Crohn's disease and fistulising active Crohn's disease is proposed anymore. Therefore, the question is no longer relevant.

The newly included possibility to use a 3 IV induction regimen in addition to the 2 IV induction regimen is a minor amendment for which the small differences in the indications are not relevant. Therefore, the 3 IV regimen can be applied also to the fCD although such patients were not included in the clinical study.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 26

In the protocol, a 2% response rate in placebo has been assumed for endoscopic response at Week 54. In the end 17.9% response rate was observed. The difference between the assumed (basically no responders) and observed (a meaningful proportion of responders) cannot be neglected because it reflects that either the study population or the behavior of the endpoint (potentially including data analysis), or something else, is not as expected. The MAH should elaborate on the potential root cause(s) for this finding.

## Summary of the MAH's response

Since there was no historical data from infliximab for the endoscopic response at Week 54, historical data from study conducted with adalimumab was used for examination of the statistical power (Feagan et al ., 2018) and the following limitations described below could have caused the difference between the assumed and observed response rate in Placebo SC group.

While only patients who had clinical response (by CDAI-100) to induction therapy was randomized and included  in  the  analysis  in  Study  CT-P13  3.8,  all  randomized  patients  were  involved  in  the  analysis regardless  of  patient's  clinical  response  to  the  adalimumab  induction  therapy  in  the  historical  study  of adalimumab (Rutgeerts et al ., 2012). Given that the long-term efficacy of anti-TNF alpha treatment is not expected for patients who had not initial clinical response, those randomized patients who had no initial response may have affected the result in the low response rate of placebo group in the historical study of adalimumab.

According to the definition of endoscopic response in Study CT-P13 3.8, patients who had 50% reduction from baseline in SES-CD were classified as a responder. However, a patient with the same degree of SESCD reduction who would have been classified as responder in Study CT-P13 3.8 was classified as nonresponder in the historical adalimumab study because the endoscopic response was defined as more than 50% reduction from baseline in SES-CD. In other words, the endoscopic response standard for historical adalimumab study was slightly more conservative than Study CT- P13 3.8, thus, this difference in the endpoint definition may have had impact and led to lower assumed response rate for Placebo SC group in the study protocol as it was based on the historical adalimumab study.

<div style=\"page-break-after: always\"></div>

Additionally, the literature reports that use of non-biologic agents such as MTX, AZA in CD studies also led to some degree of endoscopic response. For instance, in systematic review (Picco et al. , 2019), rates of endoscopic  response  in  non-biologic  treated  patients  could  range  between  8-30%.  Therefore,  some concomitant  immunomodulatory  therapies  also  contribute  to  the  response  rates.  However,  the  use  of concomitant immunomodulatory therapy was balanced between treatment groups in Study CT-P13 3.8. The treatment effect for SES-CD response between CT-P13 SC and placebo was 34.6 at Week 54 and was statistically and clinically meaningful supporting the superiority of the CT-P13 SC.

## Assessment of the MAH's response

The MAH argues that the difference stems from the fact that at the planning stage the MAH had used an adalimumab study as reference which included responders and non-responders in the analysis.

## Conclusion

The issue is not pursued further.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 27

One analysis was included in the SAP to assess dose escalation: In addition, for the descriptive comparison of the treatment effect between patients with and without dose adjustment to CT-P13 SC 240 mg prior to Week 54 within CT-P13 SC treatment group, the primary endpoint was summarized by patients with and without dose adjustment in CT-P13 SC treatment group using frequency table without the statistical test. In this analysis, remitter was determined as per remission criteria regardless of dose adjustment. This analysis  is,  however,  not  included  in  the  submitted  dossier  which  is  rather  surprising  considering  the intended changes to the SmPC. This analysis should be provided.

## Summary of the MAH's response

The Applicant would like to clarify that results for the questioned analysis included in the statistical analysis plan (SAP) for dose escalation assessment was submitted in the following parts of the dossier:

1. W54 CSR CT-P13 3.8 Post-text Tables 14.2.1.1Z and 14.2.1.2Z [SN0264]
2. W54 CSR CT-P13 3.8 Sections 11.4.1.1.1.2 and 11.4.1.1.2.2 [SN0264]
3. CTD Module 2.7.3 Section 4.3 [SN0264]

Analyses on the co-primary endpoints (clinical remission based on CDAI score and endoscopic response based on central SES-CD score at Week 54) were summarized for patients with or without dose adjustment in CT-P13 SC 120 mg treatment group using frequency table without statistical test. For these analyses on the  treatment  effect  in  patients  with  dose  adjustment,  remitter/responder  was  determined  as  per remission/response  criteria  regardless  of  dose  adjustment.  The  results  table  for  these  analyses  in  Allrandomized  Population  were  presented  in  CSR  CT-P13  3.8  Post-text  Tables  14.2.1.1Z  and  14.2.1.2Z, respectively, as included in the SAP.

## Assessment of the MAH's response

The analysis provided is extremely simplistic considering the fundamental impact of dose escalation to the

<div style=\"page-break-after: always\"></div>

results at Week 54. It does show that in the active arm there were 39 patients whose dose was escalated and 21 of them where responders at week 54. Of note, in the primary analysis, all 39 were counted as nonresponders although 5 of the patients never lost response but received a dose increase anyway.

## Conclusion

Issue not pursued further.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 28

The Applicant is requested to provide a Figure of Patient Disposition which outlines for how many patients the dose was escalated at/after week 22.

## Summary of the MAH's response

In Study CT-P13 3.8, dose adjustment to CT-P13 SC 240 mg was allowed from Week 22 through Week 102 when the patient met loss of response criteria defined in the protocol. In the Maintenance Phase, dose was adjusted at least once for a total of 93 (27.1%) patients (44 [19.0%] and 49 [43.8%] patients in the CTP13 SC 120 mg and Placebo groups, respectively) in all-randomised population. In the Extension Phase, a total of 12 (3.5%) patients (9 [3.9%] and 3 [2.7%] patients in the CT-P13 SC 120 mg and Placebo groups, respectively) had dose adjustment at least once for the first time in all-randomised population. In the whole Treatment Period up to Week 102, dose was adjusted at least once for a total of 105 (30.6%) patients (53 [22.9%] and 52 [46.4%] patients in the CT-P13 SC 120 mg and Placebo groups, respectively).

The number of dose adjusted patients for the safety population is reported in the W54 and Final clinical study reports (CSRs). In the Maintenance Phase, dose was adjusted at least once for a total of 93 (27.1%) patients (45 [18.9%] and 48 [45.7%] patients in the CT-P13 SC 120 mg and Placebo groups, respectively) in safety population. In the whole Treatment Period up to Week 102, dose was adjusted at least once for a total of 105 (30.6%) patients (54 [22.7%] and 51 [48.6%] patients in the CT-P13 SC 120 mg and Placebo groups, respectively) in safety population.

As per request, the Applicant has identified the distribution of patients with dose adjustment at/after Week 22 in all-randomised population, and a flow-chart outlining the number and proportion of patients with dose adjustment at/after Week 22 is provided in Figure 1.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Sources:FinalCSR CT-P13 3.8Post-text Table 14.1.1 and Section5.3.5.3 Post-hoc Table 2.238

Abbreviation: SC, subcutaneous

Figure 37: Flow Chart of Patient Disposition of Study CT-P13 3.8: All-randomised Population

## Assessment of the MAH's response

The number of patients with dose adjustment has been presented as requested. The numbers do not fully comply with the response to 27 and it would have been appreciated is this would have been proactively discussed.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 29

It  should  be  clarified  how  patients  with  progressive  disease  who  discontinued  the  study  differed  from patients who received a dose increase. If possible, the differentiation should be displayed in the flow chart Figure of Patient Disposition.

## Summary of the MAH's response

According to the protocol of Study CT-P13 3.8, dose adjustment was provided to patients who met the loss

<div style=\"page-break-after: always\"></div>

of response (LoR) criteria from Week 22. The protocol specified the definition of LoR as an increase in Crohn's disease activity index (CDAI) of ≥100 points from the Week 10 CDAI score with a total score ≥220. Disease progression was decided by the investigator if the disease had worsened continuously or if the patient was considered to lack the benefit of study continuation. Dose adjustment and disease progression had different indicators and were independently decided. In other words, the patient could be discontinued by disease progression even after receiving an adjusted dose.

As requested, the Applicant provides the flow chart of patient disposition regarding discontinuation for allrandomised population (Figure 2).

In all-randomised population, 8 patients discontinued before Week 22 in CT-P13 SC 120 mg group. A total of 39 patients in CT-P13 SC 120 mg group had received adjusted dose before Week 54 visit. Among patients who discontinued on or after Week 22, 10 patients discontinued (7 patients by disease progression as primary reason) after dose adjustment and 17 patients discontinued (2 patients by disease progression as primary reason) without dose adjustment.

In placebo group, 6 patients discontinued before Week 22. A total of 45 patients had received adjusted dose before Week 54 visit. Among patients who discontinued on or after Week 22, 7 patients discontinued (2 patients by disease progression as primary reason) after dose adjustment and 12 patients discontinued (3 patients by disease progression as primary reason) without dose adjustment.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note: The number of patients who discontinued during the maintenance phase was counted up to the Week 54

visit.

Source:Section5.3.5.3Post-hocTable3.117

Abbreviations:PD, progressive disease; SC, subcutaneous.

Figure 38: Flow Chart of Patient Disposition of Study CT-P13 3.8: All-randomised Population

## Assessment of the MAH's response

The MAH has explained that dose adjustment and disease progression had different indicators and were independently decided. It is still not entirely clear why some patients with disease progression were not offered a dose escalation but were discontinued instead. However, as this was the case only for 2 patients in each treatment arm, it has no impact on final conclusions and the issue will not be pursued further.

The flow chart provided in Q28 shows that 44 patients received dose adjustment while the flow chart provided in Q29 shows 39 patients receiving dose adjustment. The difference should be clarified.

## Conclusion

Issue not resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 30

There is a discrepancy in the reported number of patients analysed. It is stated that 11 patients with major protocol  deviation  were  excluded  from  the  PP  population,  only  one  of  whom  was  in  the  CT-P13  arm.

<div style=\"page-break-after: always\"></div>

However, in Table 10-2 of the CSR (Table 7.2.3.1 of the AR) it is stated that 7 major protocol deviations occurred in the CT-P13 arm and 4 in the placebo arm. The numbers should be clarified and aligned.

## Summary of the MAH's response

The discrepancy as noted by the Agency is caused by the different definition of population analysis in Study CT-P13 3.8.

The all-randomized population was analysed according to the planned treatment group (i.e, randomized treatment group) which was assigned at Week 10 randomly, while safety and per- protocol (PP) population were analysed according to the actual treatment group. The actual treatment group was assigned according to their treatment actually administered during the double-blind maintenance phase, even if there was a discrepancy between the treatment actually administered and the randomized group. If there was a patient with such a discrepancy, the patient receiving at least one dose of CT-P13 SC prior to initiation of dose adjustment during the double-blind maintenance phase was treated as CT-P13 SC 120 mg group. All other patients were treated as placebo group as per statistical analysis plan (SAP) Study CT-P13 3.8 Section 5.4, and as reported in CSR Study CT-P13 3.8 Section 9.7.1.2 Population of analysis. Therefore, the number of patients  reported  in  each  treatment  group  was  different  between  all-randomized  population  based  on randomized treatment group (CT-P13 SC 120 mg group: 231 patients; Placebo group: 112 patients) and safety population based on actual treatment group (CT-P13 SC 120 mg group: 238 patients; Placebo group: 105 patients) even if the total number of patients was the same in both analysis populations.

A total of 11 patients were counted as major protocol deviation in Table 10-2 (Major Protocol Deviations) from the CT-P13 3.8 CSR, and 7 and 4 patients were classified as CT-P13 SC 120 mg group and placebo group based on the 'all-randomized population', respectively. However, based on the safety population (actual treatment group which was the same analysis criteria of PP population), 8 and 3 patients were classified as CT-P13 SC 120 mg group and placebo group since one patient in placebo group based on allrandomized population received at least one dose of CT-P13 SC during the maintenance phase. This means the actual treatment group for this patient was CT-P13 SC 120 mg group.

The applicant would like to stress that the number of patients excluded from each treatment group in PP population should be compared with safety population not with the all-randomized population. Since the PP population was based on actual treatment group like safety population, 238 patients would be included in CT-P13 SC 120 mg group in PP population if there was no major protocol deviation. However, the number of patients with major protocol deviation in CT-P13 SC 120 mg group based on actual treatment group was 8 (Table 7). Given that 8 of 238 patients in CT-P13 SC 120 mg group are required to be excluded from the PP population, the number of patients in CT-P13 SC 120 mg group in PP population should be 230. As a result, the results in Table 11-1 Population of analysis from the CSR of Study CT-P13 3.8 are correct.

## Assessment of the MAH's response

The discrepancies have been clarified and a table with more detailed descriptions of the major protocol deviations was provided in the response document.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

<div style=\"page-break-after: always\"></div>

## Question 31

Baseline  characteristics  should  be  tabulated  for  patients  who  required/received  dose  escalation  and compared to those who did not.

## Summary of the MAH's response

As  per  request,  baseline  characteristics  of  patients  in  Study  CT-P13  3.8  by  dose  adjustment  status  is presented  below  in  Table  8.  In  Study  CT-P13  3.8,  there  was  no  meaningful  difference  between  the subgroups of patients who required or received dose adjustment compared to those who did not, in terms of baseline characteristics.

Table 78 (Truncated for brevity): Baseline Characteristics by Dose Adjustment Status in Study CT-P13 3.8: All-randomised Population

|                                                                  | With Dose Adjustment 1   | With Dose Adjustment 1   | Not Required / Not Dose Adjusted   | Not Required / Not Dose Adjusted   |
|------------------------------------------------------------------|--------------------------|--------------------------|------------------------------------|------------------------------------|
|                                                                  | CT-P13 SC 120 mg (N'=39) | Placebo (N'=45)          | CT-P13 SC 120 mg (N'=177)          | Placebo (N'=53)                    |
| Screening BMI (kg/m 2 )                                          |                          |                          |                                    |                                    |
| n                                                                | 39                       | 45                       | 177                                | 53                                 |
| Mean (SD)                                                        | 24.410 (5.0903)          | 22.475 (4.7291)          | 23.073 (4.2419)                    | 22.732 (4.1938)                    |
| Median (min, max)                                                | 24.050 (16.95, 34.54)    | 21.460 (15.93, 34.72)    | 22.480 (14.2, 34.61)               | 22.210 (16.04, 33.75)              |
| Previous exposure to biologic agent and/or JAK inhibitors, n (%) |                          |                          |                                    |                                    |
| Used                                                             | 3 (7.7%)                 | 5 (11.1%)                | 19 (10.7%)                         | 3 (5.7%)                           |
| Not used                                                         | 36 (92.3%)               | 40 (88.9%)               | 158 (89.3%)                        | 50 (94.3%)                         |
| Use of Treatment with oral corticosteroids at Week 0, n (%)      |                          |                          |                                    |                                    |
| Used                                                             | 22 (56.4%)               | 22 (48.9%)               | 69 (39.0%)                         | 17 (32.1%)                         |
| Not used                                                         | 17 (43.6%)               | 23 (51.1%)               | 108 (61.0%)                        | 36 (67.9%)                         |

1 With Dose Adjustment Group includes subgroup of patients regardless of whether the LoR criteria are met.

## Assessment of the MAH's response

The only baseline characteristic where some difference was seen between the subgroups of patients who received dose adjustment compared to those who did not was the use of oral corticosteroids at baseline. Among patients who received a dose escalation the use of oral corticosteroids was more frequent at baseline compared to those who did not require a dose increase. This difference was seen in both treatment groups and could possibly reflect a more severe form of disease among those who lost response.

The basis for assessment of the efficacy of an escalated dose would have been comparison between the outcome following dose escalation versus no dose escalation in patients who lost response. Therefore, baseline characteristics should have been provided for all subgroups 1-4 as defined in Q 34. However, as no randomisation occurred, the groups are not comparable in any case. Some unknown factors lead to different decisions regarding dose escalation among patients who lost response but these factors and their impact on the primary outcome cannot be reliably assessed. Therefore, this issue is not pursued further.

## Conclusion

Issue not pursued further.

<div style=\"page-break-after: always\"></div>

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 32

There are no tables depicting the details of the non-responder category at Week 54. The MAH should provide tables outlining the number of patients who were: a) non-responder according to the clinical criteria b) dose was escalated/switch to active c) discontinuation before Week 54 d) missing data e) incomplete data f) any other reason and corresponding combination categories.

## Summary of the MAH's response

In Protocol Study CT-P13 3.8, non-remitter or non-responder were defined as below.

For the efficacy endpoints related remission or response, the following patients were considered as nonremitter or non-responder:

- Patients who did not met th e remission or response criteria
- Patients with missing or incomplete data for the evaluation of each endpoint at their scheduled visit of interest, even after applying the data handling rule
- Patients with dose adjustment to CT-P13 SC 240 mg prior to their scheduled visit of interest

As requested by the Agency, the Applicant analysed the non-remitter or non-responder at Week 54 with detailed reasons. Patients with two or more reasons for being considered as non-remitter/non- responder are included in one of the reasons in following order; c) discontinuation before Week 54 - b) dose escalation or switch to CT-P13 SC from placebo - e) incomplete data - d) missing data - a) nonremitter/non-responder according to the criteria - f) any other reason.

Incomplete data and missing data were categorized by following rules. Incomplete data is the case when data was collected in CDAI diary but there were invalid data for more than 4 days (or at least 1 day at screening) or when at least 1 component of CDAI score is missing. Missing data is the case when data was collected as 'No' in CRF, thus the evaluation was not conducted.

Since the patients who had dose adjustment prior to Week 54 were considered as non-remitter or nonresponder at Week 54 in the analysis of co-primary endpoints and key secondary endpoints, patients who were considered as non-remitter or non-responder at Week 54 are summarised for co-primary endpoints and key secondary endpoints. The results are presented in Table 9 for co-primary endpoints and Table 10 for key secondary endpoints.

The most frequent reason for being considered as non-remitter or non-responder in co-primary endpoints analysis for each endpoint were 'Dose escalation or switch to CT-P13 SC from placebo' and 'Non-responder according to the clinical criteria' for clinical remission (based on CDAI) and endoscopic response (based on SES-CD [Central]), respectively. The proportion of patients who were non-remitter or non-responder due to 'Dose escalation or switch to CT-P13 SC from placebo' was higher in placebo group, which led to much higher proportion of non-remitter/non-responder in placebo group. This result also suggests that patients in the placebo group had higher chance of loss of response and dose escalation as a result of receiving placebo instead of CT-P13 SC. Similar results were observed for key secondary endpoints.

<div style=\"page-break-after: always\"></div>

Table 79: Number of Patients who were Non-remitter/Non-responder for Co-primary Endpoints at Week 54 in Study CT-P13 3.8: All-randomised Population

| Endpoint Non-remitter/non-responder Reasonfornon-remitter/non-responder   | CT-P13 SC (N=231)   | Placebo (N=112)   | Total (N=343)   |
|---------------------------------------------------------------------------|---------------------|-------------------|-----------------|
| ClinicalRemission(BasedonCDAI)1                                           | 144 (62.3%)         | 36 (32.1%)        | 180 (52.5%)     |
| Non-remitter                                                              | 87 (36.7%)          | 76 (67.9%)        | 163 (47.5%)     |
| DiscontinuationbeforeWeek54                                               | 34 (14.7%)          | 21 (18.8%)        | 55 (16.0%)      |
| DoseescalationorswitchtoCT-P13SCfromplacebo                               | 29 (12.6%)          | 40 (35.7%)        | 69 (20.1%)      |
| Incomplete data                                                           | 0                   | 0                 | 0               |
| Missing data                                                              | 0                   | 0                 | 0               |
| Non-remitteraccordingtotheclinicalcriteria                                | 24 (10.4%)          | 15 (13.4%)        | 39 (11.4%)      |
| EndoscopicResponse(Based on SES-CD[Central])2                             | 118 (51.1%)         | 20 (17.9%)        | 138 (40.2%)     |
| Non-responder                                                             | 113 (48.9%)         | 92 (82.1%)        | 205 (59.8%)     |
| DiscontinuationbeforeWeek54                                               | 34 (14.7%)          | 21 (18.8%)        | 55 (16.0%)      |
| DoseescalationorswitchtoCT-P13SCfromplacebo                               | 29 (12.6%)          | 40 (35.7%)        | 69 (20.1%)      |
| Incomplete data                                                           | 0                   | 0                 | 0               |
| Missing data                                                              | 7 (3.0%)            | 3 (2.7%)          | 10 (2.9%)       |
| Non-responder according to the clinical criteria                          | 43 (18.6%)          | 28 (25%)          | 71 (20.7%)      |

Note:Apatient withtwo or morereasons for non-responder/non-remitter is included inone of thereasonsinfollowing order;c)discontinuationbeforeWeek54-b)dose escalationorswitchtoCT-P13SCfromplacebo-e)incompletedata-d)missingdata-a)non-remitter/non-responderaccordingtothecriteria-f)anyotherreason.There werenocasesdueto'anyotherreason.'

2 Endoscopic response is defined as a 50% decrease in SES-CD score from the baseline value.

1ClinicalremissionisdefinedasanabsoluteCDAIscoreoflessthan150points.

Abbreviations:CDAI,Crohn'sdiseaseactivityindex;SES-CD.simplifiedendoscopicactivityscoreforCrohn'sdisease

## Assessment of the MAH's response

As expected, the proportion of patients who were non-remitter or non-responder due to 'Dose escalation or switch to CT-P13 SC from placebo' was higher in the placebo group. The difference in proportion of remitters/responders at week 54 is mainly driven by the automatic classification as a non-remitter in case of a dose escalation. While it is not known how many of the patients who received a dose escalation could have been responders at week 54 despite the loss of response at or after week 22, some indication of the possibility of renewed response is seen in the answer to Q35: In both treatment arms, there were 7 patients who met the loss of response criteria but did not receive a dose adjustment. Of these patients, one patient in each group (14.3%) was in clinical remission at week 54. Hence, the ability to regain response is possible but not frequent.

Overall, it is clearly visible that the non-remmitter and non-responser categories consist mainly of other categories than no clinical response. The impact of intercurrent events on the overall results is large. In the active arm the most frequent ICEs are discontinuation and dose escalation (14.7% and 12.6%). In the placebo group, the most common ICE is dose escalation (36%) followed by discontinuation (19%), that is, more than half of the patients in the placebo group had an ICE before reaching the timepoint of the primary analysis. Hence, the inclusion of possibility for dose escalation in the protocol, does not allow for accurate assessment of the primary endpoint of interest. Afterall, this was a placebo controlled study because there is the possibility to maintain a response without any treatment after induction until week 54 and responderstatus can also fluctuate over time.

Nevertheless, the difference in proportion of remitters is considered clinically meaningful and the magnitude of  the  difference  sufficiently  large  such  that  the  results  can  be  overall  concluded  to  be  relevant  to  be included in Section 5.1. However, in the SPC, the MAH should include information that dose escalated patients were non-responders. See annotated SPC.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

<div style=\"page-break-after: always\"></div>

## Question 33

According to the current label, available data suggest that clinical response is usually achieved within 6 weeks in the treatment of CD and 14 weeks in the treatment of fistulising CD. With the current variation, the MAH proposes to change the timing for decision on continuation of treatment to 10 weeks for both CD and fistulising CD. Since patients with active fistulising CD were excluded, Study CT-P13 3.8 cannot directly support this change for all fistulising CD. Furthermore, no discussion on this aspect of the amended wording was provided in the dossier. The MAH should provide scientific justification for the newly proposed time frame for decision making in both CD and fistulising CD. It should also be noted that decision after 6 weeks of treatment is still recommended with IV Remsima in CD and that this wording for IV is bound by the originator wording.

## Summary of the MAH's response

The  Applicant  would  like  to  keep  the  timepoint  for  the  decision  on  the  continuation  of  infliximab treatment for CD within 6 weeks.

The  clinical  response  rates  of  CT-P13  IV  at  Week  6  in  Study  CT-P13  3.8  were  as  high  as  clinical response rates of Infliximab historical Study (i.e., SONIC Study; Colombel et al , 2010) and the results are provided in Table 11.

Table 80: Proportion  of  Patients  Achieving  CDAI-70  Response  and  CDAI-100 Response  Based  on  CDAI  in  Study  CT-P13  3.9  and  SONIC  (Infliximab historical)

| Study                      | CT-P13 3.8              | SONIC                    | SONIC                               |
|----------------------------|-------------------------|--------------------------|-------------------------------------|
| Dosage                     | CT-P13 IV 5mg/kg        | IFX 5mg/kg (Monotherapy) | IFX 5mg/kg + AZA (Combined therapy) |
|                            | Number (%o) of patients | Number (%o) of patients  | Number (%o) of patients             |
| CDAI-70 response at Week 6 | 308/396 (77.8)          | 109/169 (64.5)           | 125/169 (74.0)                      |
| CDAI-100 response atWeek 6 | 271/396 (68.4)          | 92/169 (54.4)            | 107/169 (63.3)                      |

Source:Section5.3.5.3Posthoctable2.221,SupplementtoColombeletal.2010.

Note: Percentages are calculated by using the total number of patients in the ITT Population as the denominator and the total numberof responders asnumerators inStudyCT-P133.8.

Abbreviations: AZA, azathioprine; CDAI, crohn's disease activity index; IFX, infliximab; IV, intravenous.

As  mentioned  above,  CT-P13  IV  was  approved  as  biosimilar  to  Remicade  and  Study  CT-P13  1.6 demonstrated clinical  similarity between  CT-P13  IV and  CT-P13  SC.  In  the  Study CT-P13  3.8, clinical response  rate  at  Week  6  was  similar  to  the  clinical  response  rate  of  SONIC  study.  Therefore,  the Applicant  would  like  to  apply  identical  timepoints  to  observe  achieved  clinical  response  as  the previously submitted label for CT-P13 SC (Table 12).

## Assessment of the MAH's response

Only the timepoint related to the CD indication was discussed in the response. Based on the presented results it is acceptable to maintain the 6 weeks for CD. No new data on fistulising CD has been presented and therefore it is endorsed to keep the approved wording, i.e 14 weeks before decision on continuation.

## Conclusion

<div style=\"page-break-after: always\"></div>

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 34

The MAH should clarify how many patients in each treatment arm were eligible for a dose increase before Week 54 and how many got it. The data should be presented by sex, body weight, disease severity, drug concentration and ADA status. It should also be clarified which weeks the dose increase was initiated at, i.e for how long the patients were exposed to the higher dose.

## Summary of the MAH's response

In Study CT-P13 3.8, dose adjustment to CT-P13 SC 240 mg was allowed from Week 22 when the patient met loss of response (LoR) criteria defined in the protocol. The LoR was defined as an increase in  Crohn's disease activity index (CDAI) of ≥ 100 points from the Week 10 CDAI score with a total score ≥ 220.

Of 343 patients for all-randomised population, 328 (95.6%) patients who had CDAI score on or after Week 22  visit  including  Unscheduled  and  End  of  study  visit  are  categorised  into  4  subgroups according to LoR and dose adjustment from Week 22 prior to Week 54; patients with dose adjustment  meeting  LoR (subgroup  1),  patients  with  dose  adjustment  not  meeting  LoR  (subgroup  2),  patients  without  dose adjustment meeting LoR (subgroup 3), patients without dose adjustment not meeting LoR (subgroup 4).

The number of patients in each subgroup and summary of sex, body weight, disease severity, pre- dose serum  concentration  and  anti-drug  antibody  (ADA)  status  according  to  4  subgroups  are provided in Table 13.

A total of 41 patients in CT-P13 SC 120 mg group and 48 patients in placebo group experienced LoR (subgroups 1 and 3). Among these patients, 34/41 (82.9%) in CT-P13 SC 120 mg group and 41/48 (85.4%) in placebo group received adjusted dose (subgroup 1). In contrast, 182 patients in CT-P13 SC 120 mg group and 57 patients in placebo group did not meet LoR criteria (subgroups 2 and 4). Among these patients, 5/182 (2.7%) in CT-P13 SC 120 mg group and 4/57 (7.0%) in placebo group received adjusted dose but were not eligible for the dose adjustment (subgroup 2).

In  both  CT-P13  SC  120  mg  group  and  placebo  group,  sex,  and  body  weight  show  no  notable differences  among  the  subgroups.  Disease  severity  with  mean  CDAI  score  collected  at  specific timepoint for each subgroup (at dose adjustment visit for subgroups 1 and 2, at first occurrence of LoR for subgroup 3, and at Week 22 visit for subgroup 4) are similarly highest in subgroups 1 and 3, followed by subgroup 2, and lowest in subgroup 4. This trend is similar between CT-P13 SC 120 mg group and placebo group. The mean pre-dose serum concentration analysed in subgroup 1 (at dose adjustment visit) of  CT-P13  SC  120  mg  group  shows  the  lowest,  followed  by  subgroup  3  (at  first occurrence of LoR), subgroup 2 (at dose adjustment visit) and subgroup 4 (at Week 22 visit) in CT- P13 SC 120 mg group. The patients who experienced LoR (subgroups 1 and 3) show higher disease severity and lower pre-dose serum concentration compared to the patients who did not experience LoR  and  not  received  adjusted dose  (subgroup  4)  in  CT-P13  SC  120  mg  group.  In  addition,  the patients who received adjusted dose without LoR (subgroup 2) also show higher disease severity and  lower  pre-dose  serum  concentration compared to the patients of subgroup 4 in CT-P13 SC 120 mg group. However, these results should be interpreted  taking  into  account  the  number  of  patients  in  subgroups  2  and  3.  Since  the  serum concentrations in placebo group shown in Table 13 were collected during maintenance phase, when placebo

<div style=\"page-break-after: always\"></div>

group received placebo SC, interpretation by subgroups would be unnecessary. The serum concentrations by  subgroups  of  placebo  group  are  analysed  for Induction  Phase  treating  CT-P13  IV  in  Response  to Question 38. There was no notable difference of ADA positive rate across the subgroups.

The visit for first dose adjustment before Week 54 visit and duration of dose adjustment for subgroups 1 and 2 are summarised in Table 14. In subgroup analysis, the visit of the most patients received their first dose adjustment at Week 22 visit, when the dose adjustment was first allowed. No meaningful trend was observed in mean durations of exposure to adjusted dose in subgroups of CT-P13 SC 120 mg group and placebo  group;  20.1  weeks  and  28.0  for  subgroup  1,  31.0  weeks  and  27.1  weeks  for  subgroup  2, respectively.

Table 81: Summary of Demographics, CDAI score, Pre-dose Serum Concentration, ADA  Status  by  Dose  Adjustment  Status  in  Study  CT-P13  3.8:  Allrandomised Population

|                                 |           | CT-P13SC (N=223)   | CT-P13SC (N=223)   | CT-P13SC (N=223)   | CT-P13SC (N=223)      | Placebo (N=105)     | Placebo (N=105)   | Placebo (N=105)   | Placebo (N=105)   |
|---------------------------------|-----------|--------------------|--------------------|--------------------|-----------------------|---------------------|-------------------|-------------------|-------------------|
|                                 |           | subgroup1 (N'=34)  | subgroup2 (N'=5)   | subgroup3 (N'=7)   | subgroup 4 (N' = 177) | subgroup 1 (N'= 41) | subgroup2 (N'=4)  | subgroup3 (N'=7)  | subgroup4 (N'=53) |
| Gender                          |           |                    |                    |                    |                       |                     |                   |                   |                   |
| male                            | n (%)     | 20 (58.8)          | 3 (60)             | 2 (28.6)           | 105 (59.3)            | 26 (63.4)           | 1 (25)            | 4 (57.1)          | 34 (64.2)         |
| female                          | (%) u     | 14 (41.2)          | 2 (40)             | 5 (71.4)           | 72 (40.7)             | 15 (36.6)           | 3 (75)            | 3 (42.9)          | 19 (35.8)         |
| Screening weight(kg)            | mean (SD) | 71.71 (20.767)     | 69.94 (21.003)     | 60.34 (11.327)     | 68.57 (14.526)        | 68.90 (16.480)      | 66.83 (20.371)    | 71.17 (17.862)    | 66.88 (13.721)    |
| CDAIscore                       | mean (SD) | 283.47 (68.404)    | 194.66 (58.432)    | 293.51 (60.668)    | 77.74 (60.017)        | 295.64 (53.045)     | 152.35 (57.310)   | 301.57 (80.402)   | 78.11 (56.805)    |
| Change from baseline, CDAIscore | mean (SD) | -32.71 (61.995)    | -151.60 (54.567)   | -46.90 (86.438)    | -231.02 (80.718)      | -19.22 (62.997)     | -118.05 (51.631)  | -16.79 (121.254)  | -222.95 (69.885)  |
| Serum concentration (mg/mL)     | mean (SD) | 8547.0 (8436.42)   | 13260.0 (7983.92)  | 12235.7 (8142.46)  | 15509.1 (8725.68)     | 696.9 (2177.42)     | 143.3 (59.45)     | 100.0 (0.00)      | 385.9 (698.93)    |
| ADA status                      |           |                    |                    |                    |                       |                     |                   |                   |                   |
| positive                        | (%) u     | 20 (58.8)          | 4 (80)             | 4 (57.1)           | 79 (44.6)             | 28 (68.3)           | 3 (75)            | 5 (71.4)          | 38 (71.7)         |
| negative                        | (%)u      | 14 (41.2)          | 1 (20)             | 3 (42.9)           | 98 (55.4)             | 13 (31.7)           | 1 (25)            | 2 (28.6)          | 15 (28.3)         |

Source:Section5.3.5.3Post-hocTable1.171

Note:Lossof response(LoR)is defined asfollowing:an increase inCDAIof&gt;=100pointsfrom theWeek 10CDAI score with a total score&gt;=220.Thepatientswhohave at least one CDAIresult on or after Week 22 including Unscheduled and EOSvisit are categorised according toLoR and dose adjustment from Week 22 prior to Week 54.Percentages arecalculatedusingthenumberofpatientsineachsubgroupasdenominator.Whentheresultforcorrespondingvisitwasmissing,thelatestresultbeforethevisitwasused instead.

4subgroupswerecategorisedamongthepatientswhohadCDAIscoreonorafterWeek22visitincludingUnscheduledandEndofstudyvisit;patientswithdoseadjustment meetingLoR(subgroup 1),patients with dose adjustment not meeting LoR(subgroup 2),patients without dose adjustment meeting LoR(subgroup 3),patients without dose adjustmentnotmeetingLoR(subgroup4).CDAIscore,pre-doseserumconcentrationandADAstatusincludedatathatwerecollectedatdoseadjustmentforsubgroups1&amp;2, collected atfirstoccurrenceof LoRforsubgroup3,andcollected atWeek22forsubgroup4.

N':thenumberofpatientsinthesubgroup

Abbreviations:ADA,anti-drug antibody;CDAI, Crohn's disease activity index;LoR,Loss of response; SC,subcutaneous; SD, standard deviation.

## Assessment of the MAH's response

A total of 41 patients (18%) in the CT-P13 SC 120 mg group and 48 patients (46%) in the placebo group experienced LoR (subgroups 1 and 3) by week 54. Among these patients, 34/41 (82.9%) in CT-P13 SC 120 mg group and 41/48 (85.4%) in placebo group received adjusted dose (subgroup 1).

In the CT-P13 SC 120 mg group, those who experienced LoR were more often ADA positive compared to those who maintained response. Referring to the answer to Q31, patients who experienced LoR may have had a more treatment resistant form of CD at baseline since the use of oral corticosteroids was more frequent among those who received a dose escalation at baseline compared to those who did not require a dose increase. However, patients who received dose escalation are not the same as the LoR group as patients who received dose escalation also included patients without a loss of response by prespecified criteria.

Loss of response was obviously accompanied by high CDAI scores but also patients who did not meet the criteria for LoR but received a dose increase anyway had markedly higher CDAI scores than those who continued on the previous dose. The decision to increase the dose for these patients is a protocol violation which seems to have been driven by the clinicians' desire to improve the treatment for poor responders,

<div style=\"page-break-after: always\"></div>

but it exposes poor adherence to GCP. Such violations occurred in 9/328 patients (2.7%). The frequency is small enough not to pursue the issue further.

Patients who had a LoR but did not receive a dose adjustment were more often female but did not seem to differ from those who did receive a dose adjustment in any of the other reported aspects. However, as no randomisation occurred and the decision to increase the dose was based on un documented factors, the groups (subgroups 1 and 3) are not comparable.

A clear difference between patients who experienced LoR and those who did not is seen in terms of serum drug concentration at loss of response. This finding supports the theory of loss of response being associated with suboptimal drug concentrations.

Most patients received their first dose adjustment at Week 22 visit, when the dose adjustment was first allowed.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 35

The MAH should describe how the disease activity evolved among those who stayed on initial treatment regimen versus those who had a dose escalation. The analysis should be conducted for patients for whom dose was escalated/not escalated and patients who were eligible for dose escalation but did not escalate/did escalate. Did regain of response occur in patients who continued on placebo? Spontaneous fluctuation of the disease should be discussed and comparison should be made to patients who did not escalate and to historical controls. The MAH should provide spaghetti plots (overlay and individual) where time point of dose escalation is standardized in the middle of the graph and 4 visits before and after dose escalation are included.

## Summary of the MAH's response

For the assessment of disease activity, mean actual Crohn's disease activity index (CDAI) score at newly defined baseline (hereafter referred to as the 'baseline') and Week 54 were evaluated. The baseline was newly defined as the visit of dose adjustment for subgroups 1 and 2, visit of occurrence of LoR from Week 22 for subgroup 3 and Week 22 for subgroup 4, respectively.

Although the small number of people in subgroup 3 should be interpreted with caution, the dose adjustment might induce higher improvement in disease activity than spontaneous recovery. (Table 15)

<div style=\"page-break-after: always\"></div>

Table 82: CDAI Score for Patients by Dose Adjustment Status in Study CT-P13 3.8: All-randomised Population

|                            |            | CT-P13SC (N=223)   | CT-P13SC (N=223)   | CT-P13SC (N=223)   | CT-P13SC (N=223)      | Placebo (N=105)    | Placebo (N=105)    | Placebo (N=105)    | Placebo (N=105)    |
|----------------------------|------------|--------------------|--------------------|--------------------|-----------------------|--------------------|--------------------|--------------------|--------------------|
| CDAI score                 | CDAI score | subgroup 1 (N'=34) | subgroup 2 (N'= 5) | subgroup 3 (N'=7)  | subgroup 4 (N' = 177) | subgroup 1 (N'=41) | subgroup 2 (N' =4) | subgroup3 (N' = 7) | subgroup 4 (N'=53) |
|                            | n          | 34                 | 5                  | 7                  | 177                   | 41                 | 4                  | 7                  | 53                 |
|                            | mean (SD)  | 283.47 (68.404)    | 194.66 (58.432)    | 293.51 (60.668)    | 77.74 (60.017)        | 295.64 (53.045)    | 152.35 (57.310)    | 301.57 (80.402)    | 78.11 (56.805)     |
|                            | n          | 24                 | 5                  | 4                  | 164                   | 36                 | 3                  | 5                  | 46                 |
|                            | mean (SD)  | 105.77 (77.704)    | 94.42 (107.064)    | 258.23 (136.908)   | 77.63 (70.374)        | 98.91 (70.199)     | 81.40 (70.520)     | 227.68 (176.350)   | 102.42 (94.688)    |
| Week54 baseline Changefrom | n          | 24                 | 5                  | 4                  | 164                   | 36                 | 3                  | 5                  | 46                 |
| Week54 baseline Changefrom | mean (SD)  | -163.93 (74.396)   | -100.24 (131.430)  | -31.35 (117.949)   | 1.18 (61.615)         | -193.58 (89.517)   | -98.47 (52.017)    | -57.98 (210.789)   | 27.33 (101.950)    |

Source:Section5.3.5.3Post-hocTable2.223

Note:Lossof response(LoR)is defined asfollowing:anincrease inCDAIof&gt;=100pointsfrom theWeek10CDAIscore withatotalscore&gt;=220.Thepatientswhohave atleast

Four subgroups;patients withdoseadjustment meetingLoR(subgroup1),patients withdose adjustment notmeetingLoR(subgroup2),patients without doseadjustment meetingLoR(subgroup3),patientswithoutdoseadjustmentnot meetingLoR(subgroup4).Whentheresultfor correspondingvisitwasmissing,thelatestresultbeforethe visit was used instead for all subgroups.

Baselineforeachsubgroupwasdefinedasfollowing:

- With/without LoR andWithDose Adjustment (subgroup 1 and 2)-Visit of Dose adjustment
- WithLoRandWithoutDoseAdjustment(subgroup3)-Visitoffirstoccurrenceof LoRfromWeek22
- WithoutLoRandWithoutDoseAdjustment(subgroup4)-Week22

N':the number of patients in the subgroup

Abbreviations:CDAI,Crohn'sdiseaseactivityindex;SC,subcutaneous;SD,standard deviation.

There were no available historical data for the comparison for spontaneous fluctuation of the disease activity score (before/after meeting LoR criteria) depending on the dose adjustment status. However, the Applicant found the same trend with Study CT-P13 3.8 in Remicade historical data (D'Haens G et al., 2018 and Katz L et al., 2012) that doubling the infliximab IV dose (5 mg/kg every 8 weeks  10 mg/kg every 8 weeks) for patients who had LoR would induce regain clinical response, although it is inappropriate to directly compare the efficacy results of dose adjustment due to the difference of study design.

In the CT-P13 SC 120 mg group, most of co-primary/key secondary endpoints results were higher in patients with dose  adjustment  (subgroup  1  and  2)  than patients  without  dose adjustment  meeting LoR criteria (subgroup 3), except for endoscopic response and endoscopic remission at Week 54. (Table 16)

Table 83: Proportions of Patients Achieving Co-primary and Key Secondary Endpoints by Dose Adjustment Status: All-randomised Population

|                                              | CT-P13SC (N=223)   | CT-P13SC (N=223)   | CT-P13SC (N=223)   | CT-P13SC (N=223)   | Placebo (N=105)   | Placebo (N=105)   | Placebo (N=105)    | Placebo (N=105)   |
|----------------------------------------------|--------------------|--------------------|--------------------|--------------------|-------------------|-------------------|--------------------|-------------------|
|                                              | subgroup1 (N'=34)  | subgroup2 (N' = 5) | subgroup3 (N'=7)   | subgroup4 (N'=177) | subgroup1 (N'=41) | subgroup2 (N'=4)  | subgroup3 (N' = 7) | subgroup4 (N'=53) |
| Co-primaryendpoints                          |                    |                    |                    |                    |                   |                   |                    |                   |
| ClinicalRemission(BasedonCDAI) atWeek54      | 17 (50%)           | 4 (80%)            | 1 (14.3%)          | 143 (80.8%)        | 27 (65.9%)        | 3 (75%)           | 1 (14.3%)          | 35 (66.0%)        |
| EndoscopicResponse atWeek54                  | 7 (20.6%)          | 4 (80%)            | 3 (42.9%)          | 115 (65.0%)        | 24 (58.5%)        | 1 (25%)           | 3 (42.9%)          | 17 (32.1%)        |
| Keysecondaryendpoints                        |                    |                    |                    |                    |                   |                   |                    |                   |
| Regainedclinicalresponse(CDAI- 100) atWeek54 | 21 (61.8%)         | 3 (60%)            | 2 (28.6%)          | 150 (84.7%)        | 31 (75.6%)        | 3 (75%)           | 3 (42.9%)          | 40 (75.5%)        |
| Clinicalremission(BasedonAP/SF) atWeek54     | 17 (50%)           | 3 (60%)            | 1 (14.3%)          | 130 (73.4%)        | 29 (70.7%)        | 3 (75%)           | 1 (14.3%)          | 34 (64.2%)        |
| Endoscopicremission atWeek54                 | 3 (8.8%)           | 2 (40%)            | 2 (28.6%)          | 78 (44.1%)         | 13 (31.7%)        | 1 (25%)           | 2 (28.6%)          | 10 (18.9%)        |
| Corticosteroid-freeremission atWeek54        | 5/17 (29.4%)       | 2/5 (40%)          | 0/5                | 40/69 (58.0%)      | 11/19 (57.9%)     | 1/3 (33.3%)       | 0/2                | 10/17 (58.8%)     |

An analysis of overlay and individual spaghetti plots of CDAI score at the time of dose adjustment and 4 visits before and after dose adjustment for subgroup 1 and 2 for CT-P13 SC and placebo groups are provided in Figure 3. Overall, the CDAI scores of patients with dose adjustment showed decreasing trend compared to the visit of the dose adjustment in both subgroup 1 and 2 in the CT-P13 SC group. Similar trend of results was observed in the placebo group as well.

<div style=\"page-break-after: always\"></div>

Figure 39: CDAI Score versus Time by Dose Adjustment Status

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source: Section 5.3.5.3 Post-hoc Figure 2.051

Note: LoR is defined as following: an increase in CDAI of &gt;=100 points from the Week 10 CDAI score with a total score &gt;=220. The patients who have at least one CDAI result on or after Week 22 including Unscheduled and EOS visit are categorised according to LoR and dose adjustment from Week 22 prior to Week 54. Two subgroups; patients with dose adjustment meeting LoR (subgroup 1), patients with dose adjustment not meeting LoR (subgroup 2). Two CDAI results prior to dose adjustment and 2 results after dose adjustment excluding EOS are displayed for each patient. The CDAI result at the time of the dose adjustment is the result right before the dose adjustment according to protocol.

Abbreviations: CDAI, Crohn's disease activity index; DA, dose adjustment; LoR, loss of response; SC, subcutaneous.

## Assessment of the MAH's response

Among the 34 patients with dose adjustment in the CT-P13 SC 120 mg group 17 (50%) patients achieved clinical remission by CDAI and 7 (20.6%) patients achieved endoscopic response at Week 54. On the other hand, in the 7 patients who experienced a LoR but did not receive a dose adjustment, regain of clinical remission by CDAI occurred in 1/7 (14.3%) and endoscopic response re-emerged in 3 (42.9%) of these patients on initial active treatment. Regain of response occurred in 21/34 (61.8%) patients with a dose

<div style=\"page-break-after: always\"></div>

escalation while patients who lost response but remained on active treatment had a renewed response in 2 (28.6%) cases. Spontaneous regain of response and remission was also seen in patients who remained on placebo (3 and 1 patients, respectively).

Although the numbers are small, it can be concluded that spontaneous regain of response is not negligible. However, regain of response according to CDAI is more common and the improvement in absolute CDAI score  is  more  pronounced  in  patients  with  a  dose  adjustment  than  in  those  who  remained  on  initial treatment despite a LoR. There is no clear difference between dose adjusted LoR and dose maintained LoR patients in terms of endoscopic response but the number of patients who regain endoscopic response after LoR is small and does not permit conclusions.

Based on the provided spaghetti plots, the loss of response was usually not seen at the previous visit before DA (usually week 14). Improvement in CDAI scores was usually seen 8 weeks after DA and was usually maintained for the next 8 weeks. Some patients did not respond at all to the DA and some lost response again after a brief improvement but overall, a majority of patients in the active treatment arm who received a DA had a positive outcome 16 weeks after DA.

## Conclusion

Although  spontaneous  regain  of  response  does  occur,  regain  of  response  is  more  common  and  the improvement in absolute CDAI score seems to be more pronounced in patients with a dose adjustment than in those who remained on initial treatment despite a LoR. A majority of patients in the active treatment arm who received a dose adjustment had a positive outcome 16 weeks after the dose increase.

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 36

The MAH claims that for patients who adjusted the dose, the reduction in the efficacy scores was observed from their following scheduled visit after the first dose adjustment. Appropriate data should be provided to support this claim.

## Summary of the MAH's response

Overlay and individual spaghetti plots of CDAI score before and after dose adjustment for patients with dose adjustment are provided in Question 35. Overall, the CDAI scores of patients with dose adjustment generally decreased after the dose adjustment.

For assessment of change in scores for patients with dose adjustment, mean actual CDAI or SES-CD score of patients who had efficacy measurements at both first dose adjustment visit (just before first adjusted dose treatment) and Week 54 was evaluated. Compared to the first dose adjustment visits, patients with dose adjustment from CT-P13 SC 120 mg to CT-P13 SC 240 mg had almost a half reduction in mean CDAI score at Week 54, and approximately 20% reduction in mean SES-CD score after dose adjustment.

<div style=\"page-break-after: always\"></div>

Table 84:  Change in Mean CDAI and SES-CD Score for Patients with Dose Adjustment in CTP13 SC 120 mg Group in Study CT-P13 3.8: All-randomised Population

| Endpoint   | First visit of dose adjustment (just before first adjusted dose treatment)   | Week 54   | Mean Change   | p-value 1   |
|------------|------------------------------------------------------------------------------|-----------|---------------|-------------|
| CDAI       | 256.37                                                                       | 105.43    | -150.94       | <0.0001     |
|            | (n=28)                                                                       | (n=28)    |               |             |
| SES-CD     | 7.8                                                                          | 6.5       | -1.3          | 0.1237      |
|            | (n=16)                                                                       | (n=16)    |               |             |

Sources: Section 5.3.5.3 Post-hoc Tables 2.123 and 2.124 [SN0264]

Note:  The  patients  with  dose  adjustment  before  Week  54  who  had  efficacy  measurements  at  both  dose adjustment visit and Week 54 are included in this summary. For the first visit of dose adjustment, the CDAI and SES-CD scores are measured just before the first dose adjustment.

1   P-value  for  difference  in  the  mean  of  actual  value  between  dose  adjustment  visit  and  Week  54  visit  within treatment group was obtained by paired t-test.

Abbreviations: CDAI, Crohn's disease activity index; SES-CD, simplified endoscopic activity score for Crohn's

Change in disease activity scores for patients by dose adjustment status were summarised in Question 35.

The time to achieve clinical response and clinical remission is provided in Table 19.

Table 85: Time to Achieve Clinical Remission/Clinical Response after Dose Adjustment: AllRandomised Population

|                                           |           | CT-P13 SC 120mg (N=231)   |
|-------------------------------------------|-----------|---------------------------|
| Time to achieve clinical remission (days) | n         | 27                        |
|                                           | Mean (SD) | 74.7 (34.73)              |
| Time to achieve clinical response (days)  | n         | 26                        |
|                                           | Mean (SD) | 65.2 (29.92)              |

## Assessment of the MAH's response

Based on the plots provided in Q 35 it is agreed that CDAI scores of patients with dose adjustment generally decreased after the dose adjustment and the change was usually seen at the first scheduled visit after the dose adjustment.

## Conclusion

Issue resolved

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

<div style=\"page-break-after: always\"></div>

## Question 37

Did the groups (i.e., patients for whom dose was escalated/not escalated and patients who were eligible for dose escalation but did not escalate/did escalate) differ in terms of compliance with the protocol or other parameters which could describe their well-being in addition to the primary endpoint?

## Summary of the MAH's response

Table 86: Major Protocol Deviation by Dose Adjustment Status in Study CT-P13 3.8: All-randomised Population

<!-- image -->

|                                                           | CT-P13SC 120mg (N=231)   | Placebo (N=112)      |
|-----------------------------------------------------------|--------------------------|----------------------|
|                                                           | Number(%o)ofpatients     | Number(%o)ofpatients |
| Major protocol deviation                                  | 7/231 (3.0%)             | 4/112 (3.6%)         |
| Patients with dose adjustment meeting LoR (Subgroup 1)    | 0/34 (0%)                | 1/41 (2.4%)          |
| Patientswithdoseadjustmentnot meeting LoR (Subgroup 2)    | 1/5 (20%)                | 0/4 (0%)             |
| Patientswithoutdoseadjustment meeting LoR(Subgroup3)      | 0/7 (0%)                 | 0/7 (0%)             |
| Patientswithoutdoseadjustmentnot meeting LoR (Subgroup 4) | 6/177 (3.4%)             | 3/53 (5.7%)          |

Source: Section 5.3.5.3 Post-hoc Table 3.118

Note: A patient was not summarised in this table, since he was excluded from all populations due to significant GCP noncompliance of the 3001 site. LoR is defined as following: an increase in CDAI of ≥ 100 points from the Week 10 CDAI score with a total score ≥ 220. The patients who have at least one CDAI result on or after Week 22 including Unscheduled and EOS visit are categorised according to LoR and dose adjustment from Week 22 prior to Week 54. Four subgroups; patients with dose adjustment meeting LoR (subgroup 1), patients with dose adjustment not meeting LoR (subgroup 2), patients  without  dose  adjustment  meeting  LoR  (subgroup  3),  patients  without  dose  adjustment  not  meeting  LoR (subgroup 4).

Percentages are calculated using the number of patients in each subgroup as denominator.

Abbreviations: CDAI, Crohn's disease activity index; EOS, end of study; LoR, loss of response; SC, subcutaneous.

Table 87: Number of Patients who Achieved Clinical Remission by PGS at Week 54 by  Dose Adjustment Status in Study CT-P13 3.8: All-randomised Population

<!-- image -->

|                                                            | CT-P13 SC 120 mg (N=231)   | Placebo (N=112)      |
|------------------------------------------------------------|----------------------------|----------------------|
|                                                            | Number(%o)ofpatients       | Number(%o)ofpatients |
| Patientswithdoseadjustmentmeeting LoR (Subgroup 1)         | 16/34 (47.1%)              | 32/41 (78.0%)        |
| Patients with dose adjustment not meeting LoR (Subgroup 2) | 3/5 (60%)                  | 2/4 (50%)            |
| Patients without dose adjustment meeting LoR(Subgroup3)    | 1/7 (14.3%)                | 3/7 (42.9%)          |
| Patientswithoutdoseadjustmentnot meeting LoR (Subgroup 4)  | 138/177 (78.0%)            | 37/53 (69.8%)        |

## Assessment of the MAH's response

There was no relation between dose adjustment status and protocol compliance or patient's well-being.

<div style=\"page-break-after: always\"></div>

## Conclusion

Issue resolved

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 38

Did loss of response or regain of response correlate with PK and/or ADA titres? Did the subjects needing dose escalation have lower concentrations of CT-P13 during the induction treatment (placebo group) and during induction and maintenance treatment (CT-P13 group)? Did the subjects who regained response have higher concentrations of CT-P13 compared to those who did not? Was the need for dose escalation or failure to  regain  response  associated  with  high  ADA  titres?  Were  high  ADA  titres  associated  with  low  drug concentrations?

## Summary of the MAH's response

Loss of Response and PK (Pre-dose Serum Concentration) and/or Immunogenicity (ADA Titer)

As  requested  by  the  agency,  post-hoc  analysis  was  performed  to  see  the  correlation  between  loss  of response (LoR) and PK level by analysing the pre-dose concentration of infliximab at major timepoints by dose  adjustment  status  (Table  88).  Data  for  induction  phase  were  collected  at  Week  10.  Data  for maintenance phase were collected at dose adjustment for subgroup 1&amp;2, were collected at first occurrence of LoR for subgroup 3, and were collected at Week 22 for subgroup 4.

Table 88: Pre-dose Serum Concentration at Major Timepoints by Dose Adjustment status

|                  |             | CT-P13SC (N=223)    | CT-P13SC (N=223)    | CT-P13SC (N=223)    | CT-P13SC (N=223)      | Placebo (N=105)    | Placebo (N=105)   | Placebo (N=105)   | Placebo (N=105)   |
|------------------|-------------|---------------------|---------------------|---------------------|-----------------------|--------------------|-------------------|-------------------|-------------------|
|                  |             | subgroup1 (N'=34)   | subgroup2 (N'=5)    | subgroup3 (N'=7)    | subgroup4 (N'=177)    | subgroup1 (N'= 41) | subgroup2 (N'=4)  | subgroup3 (N'= 7) | subgroup4 (N'=53) |
|                  | n           | 34                  | 5                   | 6                   | 174                   | 41                 | 4                 | 7                 | 52                |
| Inductionphase   | Mean (SD)   | 10796.2 (5673.33)   | 10522.8 (7141.18)   | 9064.0 (6837.88)    | 13074.6 (7623.11)     | 13794.7 (8094.16)  | 11282.5 (6676.81) | 13608.6 (4686.06) | 15532.5 (8543.96) |
| Maintenancephase | n Mean (SD) | 34 8547.0 (8436.42) | 5 13260.0 (7983.92) | 7 12235.7 (8142.46) | 177 15509.1 (8725.68) |                    |                   |                   |                   |

Source:Section5.3.5.3Post-hocTable1.175

Note:All concentrations(ng/mL)BLQafterstudydrugexposurearesetequaltoLLoQ.Pre-doseconcentrations(ng/mL) areincludedin thissummary.LoRis definedasfollowing: anincreaseinCDAIof&gt;=100pointsfromtheWeek10CDAIscorewithatotalscore&gt;=220.ThepatientswhohaveatleastoneCDAIresultonorafterWeek22including UnscheduledandEoSvisitarecategorisedaccordingtoLoRanddoseadjustmentfromWeek22priortoWeek54.Foursubgroups;patientswithdoseadjustmentmeetingLoR (subgroup1),patientswithdoseadjustmentnotmeetingLoR(subgroup2),patientswithoutdoseadjustmentmeetingLoR(subgroup3),patientswithoutdoseadjustmentnot meetingLoR(subgroup4).WhentheresultforcorrespondingvisitinMaintenancePhasewasmissing,thelatestresultbeforethevisitwasusedinstead.Dataforinduction phasewerecollectedatWeek10.Dataformaintenancephasewerecollectedatdoseadjustmentforsubgroup1&amp;2,werecollectedatfirstoccurrenceof LoRforsubgroup3, andwerecollectedatWeek22forsubgroup4.

N':thenumber ofpatientsinthesubgroup

Abbreviations:BLQ,belowthelowerlimitofquantification;CDAI,Crohn'sdiseaseactivityindex;LLoQ,lowerlimitof quantification;LoR，lossofresponse;SC,subcutaneous; SD,standarddeviation.

Table 89: ADA Titer at Major Timepoint by Dose Adjustment Status

|                  |      | CT-P13SC (N=223)   | CT-P13SC (N=223)   | CT-P13SC (N=223)   | CT-P13SC (N=223)   | Placebo (N=105)   | Placebo (N=105)   | Placebo (N=105)   | Placebo (N=105)   |
|------------------|------|--------------------|--------------------|--------------------|--------------------|-------------------|-------------------|-------------------|-------------------|
|                  |      | subgroup1 (N'=34)  | subgroup2 (N'=5)   | subgroup3 (N'=7)   | subgroup4 (N'=177) | subgroup1 (N'=41) | subgroup2 (N'= 4) | subgroup3 (N'= 7) | subgroup4 (N'=53) |
|                  | n    | 21                 | 4                  | 5                  | 80                 | 28                | 3                 | 5                 | 38                |
| Maintenancephase | Mean | 2553.0             | 1323.0             | 441.0              | 695.6              | 294.0             | 231.0             | 138.6             | 363.6             |
| Maintenancephase | (SD) | (9949.98)          | (2520.00)          | (707.17)           | (2500.15)          | (433.40)          | (290.98)          | (69.01)           | (878.21)          |

Source:Section5.3.5.3Post-hocTable1.176

Clinical Response Regain and PK (Pre-dose Serum Concentration) and/or Immunogenicity (ADA Titer)

<div style=\"page-break-after: always\"></div>

In CT-P13 SC 120 mg group, the mean pre-dose concentration of patients who regained CDAI-100 response (at Week 54) was higher than patients who did not regained CDAI-100 response (at Week 54) at both dose adjustment visit and Week 54 visit. But the increase of mean pre-dose concentration from initiation of dose adjustment to Week 54 was much higher in patients who regained CDAI-100 response (at Week 54) than in patients who did not regain CDAI-100 response (at Week 54).

In  both  treatment  groups,  higher  increase  of  mean/median  PK  level  has  been  shown  for  patients  who regained clinical response than in patients who did not regain clinical response.

Table 90: Pre-dose Concentration (ng/mL) by Clinical Response Regain

|                        |             | CT-P13 SC 120 mg (N=231)   | CT-P13 SC 120 mg (N=231)       | Placebo (N=112)            | Placebo (N=112)                |
|------------------------|-------------|----------------------------|--------------------------------|----------------------------|--------------------------------|
|                        |             | Regained CDAI-100 response | Not regained CDAI-100 response | Regained CDAI-100 response | Not regained CDAI-100 response |
| At Doseadjustmentvisit | n Mean      | 24 11590.4                 | 15 5248.5                      | 34 222.0                   | 11 1963.5                      |
| At Week54visit         | n Mean (SD) | 24 21951.7 (14692.14)      | 13 12224.6 (15944.66)          | 34 28993.2 (16721.02)      | 10 12499.5 (13174.55)          |

Source:Section5.3.5.3Post-hocTable1.173

Note: Only patients having dose adjustment prior to Week 54 are summarised. The latest result before initiationof doseadjustmentwasusedforDose Adjustment Visit.Missing data at Week 54 wascarried forward from the last non-missing value after initiation of dose adjustment.

All concentrations (ng/mL) BLQ after study drug exposure are set equal to LLoQ. Pre-dose concentrations (ng/mL) are included in this summary.

Abbreviations: BLQ, below the lower limit of quantification; CDAI, Crohn's disease activity index; LLoQ, lower

The post-hoc analysis was performed to see the correlation between ADA titer and the regain of response by analysing the ADA titer by the clinical response regain for patients with dose adjustment (Table 25).

The mean ADA titer was increased from initiation of dose adjustment visit to Week 54 visit for patients who regained CDAI-100 response at Week 54 in both treatment groups.

For patient who did not regain CDAI-100 response, mean ADA titer was decreased from initiation of dose adjustment visit to Week 54 visit in CT-P13 120 mg group. However, in Placebo group, mean ADA titer was increased from initiation of dose adjustment visit to Week 54 visit.

There was no consistent trend between clinical response regain and ADA titer. However, it is important to interpret the findings based on ADA titer and clinical response regain with caution due to the limited number of patients in each group.

<div style=\"page-break-after: always\"></div>

Table 91: ADA Titer by Clinical Response Regain

<!-- image -->

|                                    |             | CT-P13 SC 120 mg (N=231)   | CT-P13 SC 120 mg (N=231)       | Placebo (N=112)            | Placebo (N=112)                |
|------------------------------------|-------------|----------------------------|--------------------------------|----------------------------|--------------------------------|
|                                    |             | Regained CDAI-100 response | Not regained CDAI-100 response | Regained CDAI-100 response | Not regained CDAI-100 response |
| ADA titer at Dose adjustment visit | n Mean (SD) | 14 3411.0 (12237.77)       | 11 1013.7 (1478.41)            | 23 251.1 (369.61)          | 8 393.8 (551.02)               |
| ADA titer atWeek54 visit           | n Mean (SD) | 15 9493.4 (35492.43)       | 11 868.6 (810.24)              | 17 436.1 (1209.45)         | 7 7425.0 (17077.20)            |

Source:Section5.3.5.3Post-hocTable1.174

Note: Only patients having dose adjustment prior to Week 54 are summarised. The latest post-treatment result before initiation of dose adjustment was used for Dose Adjustment Visit. Missing data at Week 54 was carried forward from the last non-missing value after initiation of dose adjustment.

Abbreviations: CDAI, Crohn's disease activity index; SC, subcutaneous; SD, standard deviation.

PK (Pre-dose Serum Concentration) and Immunogenicity (ADA Titer)

Box plot of pre-dose concentration by visit-based ADA titer quartile (Table 26) is provided in Figure 4. As shown in Figure 4, there was a trend for pre-dose concentration to decrease as ADA titer increases in the CT-P13 SC 120 mg group.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source:Section5.3.5.3Post-hocFigure1.017

Note: All below the lower limit of quantifications after study drug exposure were set to Lower Limit of Quantification (LLoQ). The patients who have ADA result and pre-dose concentration are categorised by ADA titer quartile at each visit in the Pharmacokinetic population. For patients with dose adjustment, data collected before initiation of dose adjustment are included in this figure.

The 25th and 50th percentiles are the same at Week 22, and the 50th and 75th percentiles are the same at Week 38.

Abbreviations: ACE, affinity capture elution; ADA, anti-drug antibody; ECL, electrochemiluminescence; MSD, Meso Scale Discovery; SC, subcutaneous.

## Figure 40: Box plot of Pre-dose Concentration by Visit-based ADA Titer Quartile

## Assessment of the MAH's response

Patients who never lost response had slightly higher drug concentrations after the induction phase at week 10 compared to those who lost response. A slight difference in the same direction was seen even among those who continued on placebo. Based on the numerical values, higher concentrations after induction might be correlated with a better maintenance of response but the groups are still fairly comparable at week 10 in terms of PK.

Samples collected at LoR, or at week 22 if no LoR occurred, indicate a correlation between LoR and lower drug concentrations. For proper statistical comparison of drug concentrations, subgroups 1 and 3 should have been pooled and compared to the pooled subgroups 2 and 4. Patients with dose adjustment despite not meeting LoR criteria (subgroup 2) had lower drug concentrations compared to subgroup 4 at both induction  phase  and  maintenance  phase.  These  patients  also  had  higher  (worse)  CDAI  scores.  Since subgroup 2 only includes 5 patients and these patients were not treated according to protocol, the results of subgroup 2 are difficult to interpret.

The MAH has presented a table comparing drug concentrations among dose adjusted responders at week 54 to dose adjusted non-responders at week 54. According to table 24 drug concentrations are higher among responders. However, since the table compares all dose adjusted patients and not only those who had a loss of response, the term 'regained response' is not accurate, and the results do not answer the original question. To enable meaningful assessment of the correlation between regain of response and drug concentrations the MAH should have present a table including only LoR patients.

Mean ADA titres were substantially higher among patients who lost response compared to those who did not. Again, pooled results of subgroups 1 and 3 should have been compared to pooled results of subgroups 2  and  4  but  the  presented  numbers  indicate  correlation  between  high  ADA  titres  and  LoR.  Table  25, depicting ADA titres in relation to regain of response does not enable meaningful interpretation for two

<div style=\"page-break-after: always\"></div>

reasons. Patients with and without LoR were pooled together and patients without any ADA seem to have been excluded. While it seems that loss of response could be due to a more pronounced development of ADAs and lower drug concentrations as a result, it is still unclear whether failure to regain response is correlated with high ADA titres.

From the box plot it is evident that higher ADA titres have a higher impact on drug concentrations. But it is not known how a dose increase affects the development of ADA. Some studies have shown that higher drug concentrations might counteract the development of ADAs but it is not known whether this is true for patients who have already developed high titres of ADA. While increasing the dose may be a solution to LoR in the short term, it is not known whether or how fast the development of new ADAs will neutralise the potential benefit of such a dose adjustment. Moreover, as loss of response frequently results from high ADA titres and decreased drug concentrations, the drug concentrations are not expected to be doubled after a dose increase among patients who lost response.

## Conclusion

PK analysis by subgroups indicate a correlation between lower drug concentrations and LoR. This association does not seem to be entirely driven by any imbalance in concentrations at baseline (after induction). It seems that loss of response is often due to a more pronounced development of ADAs (higher titres) and lower drug concentrations as a result.

It is still unclear how drug concentrations developed among those with a dose increase and for how long patients with high ADA titres at dose adjustment could maintain a potential benefit from a higher dose. However, as these are not an issues which could affect the wording in SPC, they will not be pursued further.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 39

An analysis according to principal stratum estimand should be provided.

## Summary of the MAH's response

An analysis according to principal stratum estimand should be provided.

## Summary of the MAH's response

As per Agency's request, for the assessment of treatment effects within principal stratum composed by the target  population  where  the  intercurrent  event  would  not  occur,  the  analysis  of  co-primary  and  key secondary endpoints was conducted excluding patients who experienced dose adjustment prior to Week 54 (39 and 35 patients with dose adjustment in CT-P13 SC 120 mg and Placebo SC groups, respectively), where the dose adjustment was considered as the only intercurrent event in Study CT-P13 3.8 (Table 27).

The proportion of patients who achieved co-primary and key secondary endpoints was numerically higher in the CT-P13 SC 120 mg group than in the Placebo SC group. Regarding corticosteroid-free remission at Week 54, no notable difference was seen between treatment groups. However, there is a limitation in interpreting results due to small sample size of patients with oral corticosteroid at baseline among patients who  did  not  experience  dose  adjustment  prior  to  Week  54.  Additionally,  despite  the  small  number  of

<div style=\"page-break-after: always\"></div>

patients, the difference (6.3%) in corticosteroid-free remission at Week 54 between treatment groups in the  target  population  (which  is  a  subset  of  All-randomized  population)  falls  within  the  95%  CI  (1.1%, 32.5%) of the difference in corticosteroid-free remission at Week 54 between treatment groups in the Allrandomized population (W54 CSR CT-P13 3.8 Sections 11.4.1.1 and 11.4.1.2 [SN0264]).

In conclusion, the results for the co-primary and key secondary endpoints according to principal stratum estimand  showed  a  consistent  trend  with  the  findings  from  the  main  analysis  in  the  All-  randomized population.

Table 92: Proportion of Patients Achieving Co-primary and Key Secondary Endpoints (Principal Stratum Estimand): All-Randomized Population

|                                                 | CT-P13 SC 120 mg (N=231)   | Placebo (N=112)   | Difference (95% CI)1   | P-value2   |
|-------------------------------------------------|----------------------------|-------------------|------------------------|------------|
| Clinical remission atWeek54                     | 144/192 (75%)              | 36/67 (53.7%)     | 23.3 (10.1, 36.4)      | 0.0002     |
| Endoscopicresponse atWeek54                     | 118/192 (61.5%)            | 20/67 (29.9%)     | 33.3 (19.4, 45.1)      | <.0001     |
| CDAI-100responseatWeek54                        | 152/192 (79.2%)            | 43/67 (64.2%)     | 17.0 (4.8, 30.0)       | 0.0041     |
| Clinical remission based on AP and SF at Week54 | 131/192 (68.2%)            | 35/67 (52.2%)     | 17.4 (3.9, 30.8)       | 0.0074     |
| EndoscopicRemissionatWeek54                     | 80/192 (41.7%)             | 12/67 (17.9%)     | 24.7 (11.7, 35.1)      | 0.0003     |
| Corticosteroid-freeremission atWeek54           | 40/77 (51.9%)              | 10/22 (45.5%)     | 6.3 (-16.3,28.2)       | 0.5784     |

Source:Section5.3.5.3.Post-hocTables2.231,2.232,2.233,2.234.2.235and2.236

Note: Analysis is stratified by Previous exposure to biologic agents and/or JAK inhibitors (used or not used), Use oftreatmentwithoralcorticosteroidsatWeek0(usedornotused)andClinicalremissionatWeek1o(remitter or non-remitter by CDAI score). Except corticosteroid-free remission at Week 54, percentages are calculated using the number of patients without dose adjustment to CT-P13 SC 240 mg prior to Week 54 as the denominator.

Clinical remission is defined as an absolute CDAI score of less than 150 points.

Endoscopic response is defined as a 5o% decrease in SEs-CD score from the baseline value.

CDAI-100 response is defined as a decrease in CDAI score of 1o0 points or more from the baseline value. Clinical remission is defined as an average worst daily abdominal pain (AP) score of ≤1 (using 4-point scale) and an average daily loose/watery stool frequency (SF)score of ≤3(of Type 6 or Type 7 onBSFS) with no worsening in either average score compared with the baseline value.

EndoscopicremissionisdefinedasanabsoluteSES-CDscoreof≤4andatleast2-pointreductionfromthe baselinevaluewithnoSegmentsub-scoreof&gt;1.

Corticosteroid-freeremissionatWeek54isdefinedasbeinginclinicalremission(byanabsoluteCDAIscoreof &lt;150)in additiontonotreceivingcorticosteroidsfor atleast8weeksprior toWeek54,among thepatientswho usedoralcorticosteroidsatBaseline.Percentagesarecalculatedbyusingthenumberofpatientswhousedoral corticosteroids at baseline without dose adjustment to CT-P13 SC 240 mg prior toWeek 54 as the denominator. 1 The difference of proportions between two treatment groups estimated using CMH (Cochran-Mantel-Haenszel) weights, and the 95% stratified Newcombe CI with CMH weights are presented.

2 The nominal p-value from stratified CMH test is presented in descriptive purpose.

## Assessment of the MAH's response

The Question was for a principal stratum estimand and the MAH has just provided a table within the principal stratum which is not what was requested.

Overall, the results for the co-primary and key secondary endpoints in patients without dose escalation were in line with the findings from the main analysis. Corticosteroid-free remission was only calculated among the patients who used oral corticosteroids at baseline. The study protocol is not crystal clear on this point,  but  it  seems  that  corticosteroids  as  rescue  medication  were  only  allowed  for  patients  with

<div style=\"page-break-after: always\"></div>

corticosteroid use at baseline. Therefore, corticoid free remission is not comparable to other endpoints as the analysed population is completely different.

## Conclusion

Issue not pursued further.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 40

The MAH should discuss how the fact that patients and investigators were effectively unblinded at the time of dose escalation, impacts the results.

## Summary of the MAH's response

In Study CT-P13 3.8, dose escalation was permitted when a patient met the defined loss of response criteria outlined in the study protocol ( Section 5.2 Treatment Administered of the protocol). Since Study CT-P13 3.8 was double blind study, the blinding for the study group assignment for

Maintenance Phase were remained until Final CSR (for Week 102 results) was generated ( Section

5.6 Blinding of the protocol). During dose escalation, a patient received a double injection of active study drug  (CT-P13  SC),  regardless  of  which  arm  the  patient  was  assigned  before  the  dose  escalation.  This process ensured that neither the patient nor the investigator was aware of the patient's initial study arm assignment, thus preserving blinding throughout the study.

While patients and investigators were aware of the administration of active drug (CT-P13 SC 240mg) during dose escalation, potentially impacting patient-self reported outcomes, CELLTRION points that the influence on the efficacy of CT-P13 240 mg administration, treated as an open-label intervention, was very limited. The assessment of efficacy was supported by objective measures such as the CDAI score, encompassing parameters like the number of liquid stools, hematocrit results, disease complications of Crohn's disease (CD), and the SES-CD, which is scored based on colonic conditions using objective standards (Vuitton et al. ,  2016).  In  addition,  there  were  no  notable  differences  in  safety  between  the  CT-P13  SC  120  mg administration and CT-P13 SC 240 mg administration as CELLTRION reported in Response to Question 46.

In  light  of  these  considerations,  CELLTRION  asserts  that  the  dose  escalation  did  not  impact  the  study procedure or results in terms of study blindness.

## Assessment of the MAH's response

While some of the components of the CDAI score can be considered objective, others are not (e.g. average abdominal pain rating, general well being). Furthermore, the real problematic issue is that because dose escalation was allowed, it was possible to knowingly switch a placebo patient to active treatment. Indeed, the results at Week 54 are a combination of the actual, intended primary endpoint and the number of patients with dose escalation/switch to active treatment which makes the results difficult to interpret.

Nevertheless, the difference in proportion of remitters is considered clinically meaningful and the magnitude of  the  difference  sufficiently  large  such  that  the  results  can  be  overall  concluded  to  be  relevant  to  be included in Section 5.1 even if there was some bias involved.

<div style=\"page-break-after: always\"></div>

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## REMSWITCH study

## Question 41

Other indications than RA and CD have not been mentioned in the SPC 4.2 paragraph on switching from high dose IV. While it is understood by the regulator that this paragraph only mentions the indications where higher IV doses are approved (as described in SPC 5.1), it is considered confusing for non-regulators. As  the  data  on  switching  is  still  considered  insufficient  for  all  indications,  it  is  proposed  to  delete  any reference to indications and to amend the paragraph, as follows:

There  is  insufficient  information  regarding  switching  to  the  subcutaneous  formulation  of  Remsima  in patients who received the intravenous infusions of infliximab in doses higher than the initial maintenance dose (see section 5.1).

## Summary of the MAH's response

The Applicant would like to withdraw the proposed switching from high-dose (&gt;5 mg/kg) IV maintenance to SC maintenance treatment from the grouped variation for CD and UC indications. This is mainly due to lack of clinical data to support the switching from high-dose (5 mg/kg) IV maintenance to SC maintenance treatment.  Thus,  the  Applicant  has  reverted  the  paragraph  about  switching  from  IV  formulation  to  SC formulation to the previous paragraph as follows:

There is insufficient information regarding the switching of patients who received the intravenous infusions of infliximab higher than 3 mg/kg for rheumatoid arthritis or 5 mg/kg for Crohn's disease every 8 weeks to the subcutaneous formulation of Remsima.

Consequently, responses to Questions 3 and 41 are omitted in this response to RSI package.

## Assessment of the MAH's response

The Applicant did not address the request to amend the wording of the paragraph on switching from high dose IV to SC. However, the issue is not pursued further as the variation was withdrawn.

## Conclusion

Issue resolved

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Safety

## Question 42

<div style=\"page-break-after: always\"></div>

The MAH has not described in detail the populations for the comparison between placebo and CT-P13 SC and between the 120 mg and 240 mg doses and how exposure time for each dose was accounted for in the analyses. Therefore, the currently submitted safety data is not considered robust. The MAH informs that for the active arm group with dose adjustment, all data were collected regardless of dose adjustment for CT-P13 SC 120 mg group and for the placebo arm, data collected before initiation of dose adjustment to 240 mg were included in both phase 3 studies. Are the data from subjects who were switched from placebo to active treatment with 240 dose omitted? If so, analyses should be repeated with all subjects using 240 mg dose included, also those from the comparator arm. Are the data for subjects with dose escalation only from the period when the patient used that dose or from the entire study duration? How was different duration of use of different doses addressed in the analyses? The data on dose escalation should be analysed also separately for subjects with UC and CD for confirmation of safety in each indication.

## Summary of the MAH's response

As described in Section 2.7.4.1.1.2.1.2 (SN0264) Data Presentation for Adverse Events, for patients with dose adjustment from Studies CT-P13 3.7 and CT-P13 3.8, all data collected regardless of dose adjustment for the CT-P13 SC 120 mg group and data collected before initiation of dose adjustment for the Placebo group were included in the summary tables, which was considered as a conservative approach for the comparison of safety profile between the patients exposed to CT-P13 SC and placebo.

Thus, treatment-emergent adverse events (TEAEs) that occurred after dose adjustment (i.e., TEAEs that occurred after administration of CT-P13 SC 240 mg) in the Placebo group were omitted from the summary tables as the purpose of these tables were to compare the safety profile of CT-P13 SC and Placebo.

For  the  analysis  of  dose  adjustment  in  Study  CT-P13  3.8  (Section  2.7.4.2.1.4.3.2  [SN0264]),  the comparison of safety profile was made within the CT-P13 SC 120 mg group between patients with dose adjustment (from CT-P13 SC 120 mg to 240 mg dose) and patients without dose adjustment (maintained CT-P13 SC 120 mg dose). The data for both subgroups were from the entire duration of the Maintenance Phase.

Per the comment from CHMP, the safety data are re-analysed to include the data of all patients exposed to study treatment (Placebo, CT-P13 SC 120 mg or CT-P13 SC 240 mg), regardless of treatment phase and treatment group. The re-analysis includes the Extension Phase and data collected after dose adjustment from patients in the Placebo arm. All reported TEAEs have been categorised into following subgroups based on the actual treatment the patients received (i.e., Safety Population):

- Placebo: Events reported on or after the date of Week 10 study drug administration and before dose adjustment to CT-P13 SC 240 mg or switch to CT-P13 SC 120 mg at Week 56 in the Placebo group
- CT-P13 SC 120 mg: Events reported on or after the date of Week 10 study drug administration and before dose adjustment to CT-P13 SC 240 mg in the CT-P13 SC 120 mg group and events reported after switch to CT-P13 SC 120 mg at Week 56 and before dose adjustment to CT-P13 SC 240 mg in the Placebo group

CT-P13 SC 240 mg: Events reported after dose adjustment from CT-P13 SC 120 mg to 240 mg in the CTP13 SC 120 mg arm and placebo to CT-P13 SC 240 mg in the Placebo group

Also, to take into account the different duration of use for each treatment (Placebo, CT-P13 SC 120 mg and CT-P13 SC 240 mg), the incidence rates per 100 Person Year (PY) is calculated by multiplying a hundred to the number of patients divided by total person year, which is sum of study duration of each patient. Person year for each treatment and patient is calculated as follows:

- (Last Visit Date - Date of First Administration Date of Each Treatment + 1)/365.25

<div style=\"page-break-after: always\"></div>

For patients with any change in treatment due to entering the Extension Phase or dose adjustment, the duration of previous treatment is calculated as follows:

- (Date of First Administration of Later Treatment -Date of First Administration of Each Treatment)/365.25

The analysis is performed only for patients with Crohn's disease (CD) as the Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for patients with ulcerative colitis (UC).

Comparative  safety  analyses  were  performed  for  the  following  events  that  were  reported  during  the Maintenance and Extension Phase of Study CT-P13 3.8: TEAEs, treatment-emergent serious adverse events (TESAEs), TEAEs leading to study drug discontinuation and TEAEs of special interest (TEAESIs) with each TEAESI category analysed separately. The events that occurred on or after the first administration of each treatment are included in each treatment group. The number of patients with at least 1 TEAE, TESAE, TEAE leading to study drug discontinuation or TEAESI with exposure adjusted rate by 100 PY are presented in Table 1 below by subgroups of CT-P13 SC 120 mg, CT-P13 SC 240 mg and Placebo.

The number of patients reported with localised ISR by 100 PY was higher for CT-P13 SC 240 mg (6.75) compared to Placebo (1.66) and CT-P13 SC 120 mg (4.95); however, this was expected given that patients with dose adjustment to CT-P13 SC 240 mg were given 2 injections instead of 1. Also, localised ISRs reported in patients exposed to CT-P13 SC 240 mg were grade 1 or 2 in severity and majority of the events were resolved within the same day of onset without requiring treatment (Final CSR CT-P13 3.8 Listing 16.2.7.6).

The number of patients reported with infection by 100 PY was also higher for CT-P13 SC 240 mg (33.74) compared to Placebo (31.55) and CT-P13 SC 120 mg (28.88). However, most events were grade 1 or 2 infections which were unrelated to the study drug and the number of patients reported with study drugrelated infection by 100 PY for CT-P13 SC 240 mg (4.22) was lower than Placebo (9.96) or similar to CTP13 SC 120 mg (4.40). Also, there was no notable difference in the number of patients with TESAE of infection by 100 PY between the 3 subgroups (1.66 for Placebo, 3.30 for CT-P13 SC 120 mg, 2.53 for CTP13 SC 240 mg) (Section 5.3.5.3 Post-hoc Table 3.122)

Overall, the results showed that there was no significant difference in the number of events by 100 PY between each dose of 120 mg and 240 mg and placebo, supporting that no safety risk is expected from the higher dose of CT-P13 SC 240 mg.

## Table 93: Summary of Safety by the Dosage of Study Drug in Study CT-P13 3.8 (Maintenance Phase + Extension Phase): Safety Population

<div style=\"page-break-after: always\"></div>

Source:Section5.3.5.3Post-hocTable3.114

|                                           | Placebo (N=105, PY=60.22)               | CT-P13 SC 120 mg (N=275,PY=363.58)      | CT-P13 SC 240 mg (N=105, PY=118.54)     |
|-------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                           | Number(%o,10oPY)ofPatientswith≥ 1 Event | Number(%o,10oPY)ofPatientswith≥ 1 Event | Number(%o,10oPY)ofPatientswith≥ 1 Event |
| TEAE                                      | 64 (61.0%, 106.27)                      | 202 (73.5%,55.56)                       | 67 (63.8%, 56.52)                       |
| TESAE                                     | 8 (7.6%, 13.28)                         | 28 (10.2%,7.70)                         | 7 (6.7%, 5.91)                          |
| TEAE Leading to Study DrugDiscontinuation | 5 (4.8%, 8.30)                          | 14 (5.1%, 3.85)                         | 5 (4.8%, 4.22)                          |
| SIR                                       | 1 (1.0%,1.66)                           | 3 (1.1%,0.83)                           | 0                                       |
| DelayedHypersensitivity                   | 0                                       | 0                                       | 0                                       |
| Localised ISR                             | 1 (1.0%, 1.66)                          | 18 (6.5%, 4.95)                         | 8 (7.6%, 6.75)                          |
| Infection                                 | 19 (18.1%, 31.55)                       | 105 (38.2%,28.88)                       | 40 (38.1%, 33.74)                       |
| Malignancy                                | 1 (1.0%, 1.66)                          | 0                                       | 0                                       |

emergent adverse event; TESAE, treatment-emergent serious adverse event

Moreover, considering that the mean and median duration of treatment for patients who received CT-P13 SC 240 mg are 58.9 weeks and 68.1 weeks, respectively, and 73 patients received CT-P13 SC 240 mg as maintenance treatment for at least 44 weeks (Section 5.3.5.3 Post-hoc Table 3.113), the post-hoc analysis result sufficiently represents long-term safety profile of CT-P13 SC 240 mg.

Also per the comment from CHMP, the pooled analysis of the CT-P13 SC 120 mg dose and 240 mg dose for all approved indications of SC administered Remsima and analysis comparing TEAEs occurring prior to dose adjustment (CT-P13 SC 120 mg) vs after dose adjustment (from CT-P13 SC 120 mg to 240 mg) within the CT-P13 SC group and TEAEs occurring prior to dose adjustment (Placebo) vs after dose adjustment (from Placebo to CT-P13 SC 240 mg) within the Placebo group are provided in Response to Question 46.

## Assessment of the MAH's response

The Applicant withdraws the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for patients with ulcerative colitis (UC). Hence, the requested additional analyses were performed by the Applicant only for patients with Crohn's disease (CD), comparing the safety profile of the 120 mg SC and 240 mg SC doses of  CT-P13 and placebo.

The re-analyses performed by the Applicant include the data of all patients exposed to study treatment (Placebo, CT-P13 SC 120 mg or CT-P13 SC 240 mg) in Study CT-P13 3.8, regardless of treatment phase and treatment group.

The number of patients reported with localised ISR by 100 PY was higher for CT-P13 SC 240 mg (6.75) than CT-P13 SC 120 mg (4.95) (for Placebo 1.66). However, it is agreed with the Applicant that this was expected as patients with dose adjustment to CT-P13 SC 240 mg were given two injections instead of one.

The number of patients reported with infection by 100 PY was also higher for CT-P13 SC 240 mg (33.74) compared to Placebo (31.55) and CT-P13 SC 120 mg (28.88) in Study CT-P13 3.8. It is noteworthy that in all groups, the TEAE classified as Infection were as often classified to be unrelated as related to treatment (Table 3.1.2.2, CTD Module 5, Section 5.3.5.3 copied below). The number of patients by 100 PY with TEAE classified as unrelated was also higher in subjects administered CT-P13 SC 240 mg (33.74) than 120 mg (26.95) or placebo (26.75); hence, assessment of relatedness has obviously not been accurate.

There was no notable difference in the number of patients with TESAE of infection by 100 PY between the 3 subgroups, but the actual numbers of subjects are too low for firm conclusions (table 1 of the response and table 3.1.2.2 below).

<div style=\"page-break-after: always\"></div>

Table 94 Summary of Infection by the Dosage of Study Drug/ Safety Population

| Number(%,10oPY)ofPatientsWith at Least OneEvent   | Placebo (N=105,PY=60.22)   | SC120mg (N=275,PY=363.58)   | SC240mg (N=105,PY=118.54)   |
|---------------------------------------------------|----------------------------|-----------------------------|-----------------------------|
| TEAE classified asInfection                       | 19 (18.1%, 31.55)          | 105 (38.2%,28.88)           | 40 (38.1%,33.74)            |
| Related                                           | 6 (5.7%, 9.96)             | 16 (5.8%, 4.40)             | 5 (4.8%,4.22)               |
| Grade 1                                           | 4 (3.8%, 6.64)             | 5 (1.8%,1.38)               | 2 (1.9%, 1.69)              |
| Grade 2                                           | 2 (1.9%,3.32)              | 10 (3.6%, 2.75)             | 3 (2.9%,2.53)               |
| Grade 3                                           | 0                          | 1 (0.4%, 0.28)              | 0                           |
| Unrelated                                         | 16 (15.2%,26.57)           | 98 (35.6%,26.95)            | 40 (38.1%,33.74)            |
| Grade 1                                           | 6 (5.7%, 9.96)             | 39 (14.2%,10.73)            | 24 (22.9%,20.25)            |
| Grade 2                                           | 7 (6.7%, 11.62)            | 49 (17.8%, 13.48)           | 13 (12.4%, 10.97)           |
| Grade 3                                           | 2 (1.9%,3.32)              | 9 (3.3%, 2.48)              | 1 (1.0%,0.84)               |
| Grade 4                                           | 1 (1.0%,1.66)              | 1 (0.4%, 0.28)              | 2 (1.9%, 1.69)              |
| TESAEclassified asInfection                       | 1 (1.0%,1.66)              | 12 (4.4%, 3.30)             | 3 (2.9%,2.53)               |
| Related                                           | 0                          | 1 (0.4%, 0.28)              | 0                           |
| Grade 3                                           | 0                          | 1 (0.4%, 0.28)              | 0                           |
| Unrelated                                         | 1 (1.0%,1.66)              | 11 (4%, 3.03)               | 3 (2.9%, 2.53)              |
| Grade 2                                           | 0                          | 3 (1.1%,0.83)               | 0                           |
| Grade 3                                           | 0                          | 7 (2.5%,1.93)               | 1 (1.0%, 0.84)              |
| Grade 4                                           | 1 (1.0%,1.66)              | 1 (0.4%, 0.28)              | 2 (1.9%, 1.69)              |

Note: At each level of summarization, patients are counted once using the most severe event if they reported one or more events. The event is considered to be related if the relationship is defined as 'Possible', 'Probable', 'Definite'. The intensity is defined as Grade 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Life-threatening, 5 = Death.

The adverse events occurred on or after the first administration of each treatment are included in each treatment group. The number of patients per 100 PY is presented along with percentages in parentheses. The person year for each patient is calculated as the (last visit date - date of first administration of each treatment +1)/365.25. For patients with any change in treatment due to entering extension phase or dose adjustment, the duration of previous treatment is calculated as (date of first administration of later treatment - date of first administration of each treatment)/365.25.

N= The number of patients administered at least one dose for each treatment, PY= Person Year.

As a conclusion, in Study CT-P13 3.8, the incidence of TEAE classified as infection was slightly higher per PY with the 240 mg SC dose than with placebo or the 120 mg SC dose, but the difference was small. All TEAE were markedly more frequent in the placebo group vs. both active groups, raising the question if a great part of reported TEAEs represented symptoms of the disease. Nevertheless, the data support the MAH's claim that there was no significant difference in the number of events by 100 PY between each dose of 120 mg and 240 mg.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 43

For both pivotal trials, discrepant numbers are given in the figures and tables on disposition of patients vs. the summary tables on subjects discontinuing treatment due to adverse events during the induction and maintenance  phases  of  the  studies.  The  Applicant  is  requested  to  clarify  the  root  cause  of  these discrepancies and to confirm numbers of subjects who discontinued treatment due to adverse events during the induction and maintenance phases of studies CT-P13 37 and CT-P13 38. Details of TEAEs leading to discontinuation should be reported separately for the induction and maintenance periods of both studies.

## Summary of the MAH's response

The MAH clarifies that the discrepant numbers between the patient disposition summary and the summary of treatment-emergent adverse event (TEAE) leading to study drug discontinuation were mainly due to the different source of data and analysis method according to Statistical Analysis Plan (SAP) of both pivotal studies.

<div style=\"page-break-after: always\"></div>

Summaries of patient discontinuation in the Induction and Maintenance Phases of Studies CT-P13 3.7 and CT-P13  3.8  are  provided  in  Table  2,  Table  3,  Table  4  and  Table  5  of  the  MAH's  response  document, respectively, and the reasons for discrepancy are provided in each section. The information is not copied here for brevity.

## Assessment of the MAH's response

Sufficient clarifications were received for the discrepancies noted  between the disposition figures and tables vs. summary tables on subjects discontinuing treatment due to AEs.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 44

It is noteworthy that even in the placebo arms, 15.0 % and 14.3 % of subjects in studies CT-P13 3.7 and CT-P13 3.8, respectively, experienced TEAEs that were considered to be related to study drug. Hence, the observed TEAEs obviously overlap with symptoms of the medical conditions of the subjects; or the TEAEs in the placebo arm may have occurred after switch from placebo to active treatment with the 240 mg dose. The MAH should clarify if the TEAEs related to study drug occurred in the placebo group during placebo treatment or during active treatment with CT-P13 after dose adjustment.

## Summary of the MAH's response

For both Study CT-P13 3.7 and Study CT-P13 3.8, only data collected before initiation of dose adjustment for Placebo SC group were included in Treatment-Emergent Adverse Event (TEAE) summary tables as per Statistical Analysis Plan (SAP) of Study CT-P13 3.7 and SAP of Study CT-P13 3.8. Thus, the study drugrelated TEAEs reported in 15.0% and 14.3% of subjects in Studies CT-P13 3.7 and CT-P13 3.8, respectively, were not reported after dose adjustment to the 240 mg dose. Since both studies were double-blind during the maintenance period, the investigators reported relatedness of TEAE in the blind state. Most of the TEAEs were considered by the investigator as possibly related to study drug, by the definition suggesting that treatment with the study drug caused or contributed to the AE, i.e., the event follows a reasonable temporal sequence from the time of study drug administration or follows a known response pattern to the study drug but could also have been produced by other factors.

## Assessment of the MAH's response

The MAH has sufficiently clarified the issue.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 45

<div style=\"page-break-after: always\"></div>

The MAH should clarify for both pivotal studies the numbers of the adverse reactions which occurred more frequently in active than placebo arms but are nevertheless not proposed to be included in the SmPC. The MAH should discuss the potential relatedness of these ADRs with the medication and justify for each adverse reaction why they are not proposed to be included in the SmPC or alternatively, add them in the proposed SmPC. If the ADRs seen with the SC treatment have not occurred with the IV treatment and are added in the tabulated list in Section 4.8, they should be marked with an asterisk referring to a clarifying footnote.

## Summary of the MAH's response

The adverse reactions listed in Table 1 - Adverse reactions in clinical studies and from post-marketing experience of intravenous infliximab in section 4.8 of the SmPC were initially proposed as identical as those in the SmPC of original medication of infliximab.

To identify and evaluate adverse events that were more prevalent than placebo, aiming to determine if their addition to the SmPC is warranted, CELLTRION has listed the TEAEs reported for at least 1% of patients in the CT-P13 SC 120 mg group and at a higher rate than the Placebo SC group (Table 6). This table was analysed  from  pooled  studies  (Study  CT-P13  3.7  and  Study  CT-P13  3.8)  in  accordance  with  the  EMA Guideline on SmPC. This guideline emphasizes that the frequency of adverse reactions should be derived from pooled placebo-controlled studies, as outlined in Revision 2, 2009.

TEAEs reported for less than 1% of patients in the CT-P13 SC 120 mg group were intentionally excluded from the table due to their low reported rate, deemed insufficient to consider potential relatedness to subcutaneously administered Remsima.

Data in Table 6 from pooled studies include adverse events that occurred prior to dose adjustment from CT-P13 SC 120 mg or placebo to CT-P13 SC 240 mg during the Maintenance Phase. This approach ensures a  direct  comparison  of  the  safety  profile  between  the  two  groups  while  excluding  the  impact  of  dose adjustment.

Among TEAEs listed in Table 6, five TEAEs by preferred term (PT) (thrombocytosis, large intestine polyp, Blood creatine phosphokinase increased, arthritis and haematuria) were identified as not being listed in Section 4.8 of the SmPC. However, after thorough assessment on causal relationship between the medicinal product and the adverse events, it was deemed unnecessary to add them to the SmPC. Those TEAEs are presented  along  with  justifications  regarding  their  potential  relatedness  with  the  medication.  Overall, CELLTRION asserts the rationale for maintaining the list of AEs in Section 4.8 of the SmPC based on these justifications.

<div style=\"page-break-after: always\"></div>

Table 95: TEAEs Reported for at Least 1% of Patients in the CT-P13 SC Treatment Arm and at Higher Rate than the Placebo Group (Study CT-P13 3.7+3.8)

| System Organ Class                                   | CT-P13 SC120 mg (N=534)                              | Placebo SC                                           | Justification                                                                                                                                                                                                                                                              |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Preferred Term (N=245)                               | Preferred Term (N=245)                               | Preferred Term (N=245)                               | Preferred Term (N=245)                                                                                                                                                                                                                                                     |
| Leukopenla                                           | 8 (1.5%)                                             | 1 (0.4%)                                             | Listed in the tabulated list in Sectlon 4.8 of SmPC as Common adverse event and the frequency or severity of the reaction was not changed.                                                                                                                                 |
| Neutropenia                                          | 10 (1.9%)                                            | 2(0.8%)                                              | Lated In the tabulated lst In Section 4.8 of SmPC es Common adverse event end the frequency or severity of the reaction was not changed.                                                                                                                                   |
| Thrombocytosis                                       | 9 (1.7%)                                             | 4 (1.6%)                                             | All cases wene considered unrelated to the study drug by the investigator and occurred in both CT-P13 SC 120 mg end Placebo SC groups at  simllar rate.Thus,thrombocytosis s not proposed to be added in the tabulated lst in Section 4.8 of SmPC.                         |
| Gastrolntestinal disorders                           | Gastrolntestinal disorders                           | Gastrolntestinal disorders                           | Gastrolntestinal disorders                                                                                                                                                                                                                                                 |
| Abdominall pain upper                                | 9 (1.7%)                                             | 1 (0.4%)                                             | Listed in the tabulated list in Section 4.8 of SmPC as Very common adverse event of                                                                                                                                                                                        |
| Diarrhoea                                            | 13 (2.4%)                                            | 3 (1.2%)                                             | Llsted In the tabulated list in Section 4.8 of SmPC as Common adverse event and the frequency or severity of the reaction was not changed.                                                                                                                                 |
| Large intestine polyp                                | 6[1.1%)                                              | 1(0.4%)                                              | All cases wene considered unrelated to the study drug by the investigator. Most of the cas oecurred in UC（ForUC,5[1.7%]and 1 [0.7%]patlent In CT-P13 SC 120mg nd added in the tabulated list in Section 4.8 of SmPC.                                                       |
| Nausea                                               | (%61]01                                              | 3(1.2%)                                              | Listed in the tabulated list in Section 4.b of SmPC as Very Common adverte event ang                                                                                                                                                                                       |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions                                                                                                                                                                                                                       |
| Injection site reaction                              | 21 (3.96)                                            | 4 (1.6%)                                             | Listed in the tabulated list in Section 4.8 of SmPC as Common adverse ewent and the frequency or severity of the reoction was not changed.                                                                                                                                 |
| Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                                                                                                                                                                                                                                                |
| COVID-19                                             | 49 (9.2%)                                            |                                                      | Updated in the tabulated list in Section 4.8 of SmPC es Very Common edverse event of Viral infection (eg. influenza, herpes virus infection]                                                                                                                               |
| Herpes zoster                                        | 6[1.1%]                                              | 2(0.8%)                                              | Contidered tobe lted in the tabulated Est in Section 4.8 of SmPC as Very Common adverse event of Virallinfection (e.g. influenza, herpes virus infection) and the frequency or semerity of the reection was not chenged.                                                   |
| Oral herpes                                          | 10 (1.9%)                                            | 1(0.4%)                                              | Considered to be listed in the tabulabed list in Section 4.8 of SmPC as Very Common adverse event of Viral infection (e.g.Influenza, herpes virus lnfection） and the frequency or senerity of the reaction was not changed.                                                |
| Pharyngitis                                          | 10 (1.9%)                                            | 0                                                    | adverse event of Viral infection （e.g.influenza, herpes virus Infection)and the frequency or severity of the reaction was not changed.                                                                                                                                     |
| Urinary tract infection                              | 13 (2.4%)                                            | 4[1.6%)                                              | Listed in the tebuleted list in Section 4.0 of SmPC as Common adverse event and the frequency or severity of the reaction was not changed.                                                                                                                                 |
| Injury.poisoning and procedural complications        | Injury.poisoning and procedural complications        | Injury.poisoning and procedural complications        | Injury.poisoning and procedural complications                                                                                                                                                                                                                              |
| Injection related reaction                           | 12 (2.2%)                                            | 5 (2.0%)                                             | Injection related reaction ls systemlc Injection reaction caused by subcutaneous treatment which is identical to Infusion related reaction by lntravenous treatment. Thus, it is considered to be listed in the tabulated list In Section 4.8 of SmPC es Very Common       |
| was not changed. Investigations                      | was not changed. Investigations                      | was not changed. Investigations                      | was not changed. Investigations                                                                                                                                                                                                                                            |
| Alanine aminotransferase increased                   | 18 (3.4%)                                            | 3(1.2%)                                              | Considered to be listed in the tabuleted list in Section 4.o of SmPC as Common adverse event of transaminases increased and the frequency or severity of the reaction was not changed.                                                                                     |
| Aspartate aminotransferase increased                 | 0（1.5%）                                              | 2[0.8%]                                              | Considered to be listed in the tabulated list in Section 4.8 of SmPC as Common adverse event of transaminases increased and the frequency or severity of the reaction was not changed.                                                                                     |
| Blood creatine phosphokinase increased               | 16 (3.0%)                                            | 7 (2.9%)                                             | The events occurred in both CT-P13 SC 120 mg and Placebo SC greups at a similar rate. Thus,blood creatine phosphokinase Increated ls not proposed to be added in the tabuleted st in Section 4.8 of SmPC.                                                                  |
| Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders                                                                                                                                                                                                                            |
| Arthralgla                                           | 21 (3.9%)                                            | 5 (2.0%)                                             | Listed in the tabuleted list in Section 4.8 of SmPC as Common adverse event and the frequency or severity of the reaction wes not changed.                                                                                                                                 |
| Arthritis                                            | 6 (1.1%)                                             |                                                      | The events were reported only in the CT-P13 SC 120 mg group:however,all cass were rate of 1.1%. Thus, arthritis ls not proposed to be added In the tebullated list In Section moA  podu pue oyeu  Aq nup Apns u  pun pupu? 4.0 of SmPC                                     |
| Beck pain                                            | 6(1.1%)                                              | 1 (0.4%)                                             | Lsted in the tabulated lst In Section 4. of SmPC as Common adverse event and th frequency or severity of the reaction was not changed.                                                                                                                                     |
| Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                                                                                                                                                                                                                                                   |
| Dizziness                                            | 10 (1.9%)                                            | 1 (0.4%)                                             | Listed in the tebueted Bst in Section 4.8 of SmPCes Common adverse event and the frequency or severity of the reaction was not changed.                                                                                                                                    |
| Headache                                             | 33 (6.2%)                                            | 12 (4.9%)                                            | Listed in the tabulated list in Section 4.8 of SmPC as Very Common advense event and                                                                                                                                                                                       |
| Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                                                                                                                                                                                                                                                |
| Haematuria                                           | 9 (1.7%)                                             | 2(0.8%）                                              | Acases were considered unrelated to the study drug by the investigator and the Placebo SC group. Thus,heematuri is not proposed to be added in the tabulated list in reported rete was only 0.9% higher ln the CT-P13 SC 120 mg group compared to the Section 4.0 of SmPc. |
| Skin and subcutaneous tissue disorder                | Skin and subcutaneous tissue disorder                | Skin and subcutaneous tissue disorder                | Skin and subcutaneous tissue disorder                                                                                                                                                                                                                                      |
| Rash                                                 | 7 (1.3%)                                             | 3 (1.2%)                                             | Listed In the tabuleted list In Section 4.8 of SmPC as Common adverse event and the freguency or severity of the neaction was not changed.                                                                                                                                 |
| Vascular disorders                                   | Vascular disorders                                   | Vascular disorders                                   | Vascular disorders                                                                                                                                                                                                                                                         |
| Hypertension                                         | 14 (2.6%)                                            | 2（0.8%）                                              | Listed In the tabulated list in Section 4.8 of SmPC as Common adverse event and the frequency or severity of the neaction was not changed.                                                                                                                                 |

Note: At each level of summarisation, patients are counted once if they reported one or more events

<div style=\"page-break-after: always\"></div>

## Assessment of the MAH's response

The submitted information from pooled placebo-controlled studies on TEAEs reported for at least 1% of patients in the CT-P13 SC 120 mg group and at a higher rate than the Placebo SC group is considered sufficient. The MAH has adequately justified for each observed TEAE the inclusion or omission of that AE from the table in Section 4.8 of the SmPC. Based on these data, no change is warranted on the table except for  Covid-19, which was added in the updated tabulated list in Section 4.8 of SmPC as Very Common adverse event of Viral infection.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 46

The MAH is requested to submit safety analyses for the integrated data for SC administered Remsima in all approved indications separately 1) for subjects who were administered the 120 mg SC dose and 2) for subjects who were administered the 240 mg SC dose in studies CT-P13 3.7 (UC), CT-P13 3.8 (CD),  CTP13 3.5 Part 1 and Part 2 (rheumatoid arthritis, RA) and CT-P13 1.6 Part 1 and Part 2 (UC and CD); and 3) pooled together for both SC doses. Adverse events occurring prior to dose escalation from 120 mg SC to 240 mg SC vs. after dose escalation should be compared, with adjustment for duration of exposure to each dose. The same analysis is requested to be conducted for the patients who originally were administered placebo and were switched to the 240 mg SC dose. The analyses should be performed separately for both of the currently assessed phase 3 studies and for the pooled safety population from all patient trials listed above. The MAH should propose an update to the Product Information based on the results of the analyses described above.

## Summary of the MAH's response

Per the comment from CHMP, the pooled analysis of the CT-P13 SC 120 mg and 240 mg doses for all approved indications of SC administered Remsima has been conducted and includes the following final data from each study:

- Study 1.6 Part 1 (CD): CT-P13 SC 120 mg group and CT-P13 SC 240 mg group from Week 6
- Study 1.6 Part 2 (CD/UC): CT-P13 SC 120/240 mg group from Week 6 and CT-P13 IV 5 mg/kg group from Week 30
- Study 3.5 Part 1 (RA): CT-P13 SC 120 mg group from Week 6
- Study 3.5 Part 2 (RA): CT-P13 SC 120 mg group from Week 6 and CT-P13 IV 3 mg/kg group from Week 30
- Study CT-P13 3.7 (UC): CT-P13 SC 120 mg group from Week 10 and Placebo group from Week 56 or after dose adjustment
- Study CT-P13 3.8 (CD): CT-P13 SC 120 mg group from Week 10 and Placebo group from Week 56 or after dose adjustment

Comparative safety analyses were performed for the events that occurred on or after the first administration of each treatment of CT-P13 SC 120 mg or 240 mg. The number of patients with at least 1 treatmentemergent adverse event  (TEAE),  treatment-emergent  serious  adverse  event  (TESAE),  TEAE  leading  to study drug discontinuation or treatment-emergent adverse event of special interest (TEAESI) with exposure adjusted rate by 100 PY are presented in Table 7 by subgroups of CT-P13 SC 120 mg, CT-P13 SC 240 mg

<div style=\"page-break-after: always\"></div>

and CT-P13 SC Total. The results showed that there was no significant difference in the number of events by 100 PY between each dose of CT-P13 SC 120 mg and 240 mg from the pooled analysis, indicating that the safety profile of higher dose of CT-P13 SC 240 mg is comparable to the approved dose of 120 mg for SC administered Remsima.

Table 96: Summary of Safety by the Dosage of Study Drug in All CT-P13 SC Studies: Safety Population

|                                         | CT-P13 SC 120 mg (N=1056, PY=1106.05)         | CT-P13 SC 240 mg (N=342,PY=344.24)            | Total (N=1230,PY=1450.30)                     |
|-----------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                         | Number (%o, 10oPY) of Patients with ≥ 1 Event | Number (%o, 10oPY) of Patients with ≥ 1 Event | Number (%o, 10oPY) of Patients with ≥ 1 Event |
| TEAE                                    | 674 (63.8%, 60.94)                            | 232 (67.8%, 67.39)                            | 835 (67.9%, 57.57)                            |
| TESAE                                   | 71 (6.7%, 6.42)                               | 29 (8.5%, 8.42)                               | 99 (8.0%, 6.83)                               |
| TEAELeadingtoStudy Drug Discontinuation | 40 (3.8%, 3.62)                               | 17 (5.0%, 4.94)                               | 57 (4.6%, 3.93)                               |
| SIR                                     | 22 (2.1%, 1.99)                               | 8 (2.3%, 2.32)                                | 30 (2.4%, 2.07)                               |
| Delayed Hypersensitivity                | 7 (0.7%, 0.63)                                | 3 (0.9%, 0.87)                                | 10 (0.8%,0.69)                                |
| LocalisedISR                            | 99 (9.4%, 8.95)                               | 20 (5.8%, 5.81)                               | 119 (9.7%, 8.21)                              |
| Infection                               | 327 (31.0%, 29.56)                            | 117 (34.2%, 33.99)                            | 427 (34.7%, 29.44)                            |
| Malignancy                              | 2 (0.2%, 0.18)                                | 3 (0.9%, 0.87)                                | 5 (0.4%, 0.34)                                |

Abbreviations: ISR, injection site reaction; PY, person year; SIR, systemic injection reaction; TEAE, treatment emergent adverse event; TESAE, treatment-emergent serious adverse event

Per the additional comment from CHMP, analysis comparing the events occurring prior to dose adjustment (CT-P13 SC 120 mg) vs after dose adjustment (from CT-P13 SC 120 mg to 240 mg) within the CT-P13 SC group and TEAEs occurring prior to dose adjustment (Placebo) vs after dose adjustment (from Placebo to CT-P13 SC 240 mg) within the Placebo group are provided in Table 8 for Study CT-P13 3.8 and Table 9 for the pooled population. As the Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for patients with ulcerative colitis (UC), the analysis on dose adjustment for the Phase 3 study is performed only for the safety data from Study CT-P13 3.8. For the pooled population, only Studies CT-P13 3.7, CT-P13 3.8 and CT-P13 1.6 Part 2 are included as these are the only studies that allowed dose adjustment to CT-P13 SC 240 mg.

Table 97: Summary of Safety by the Dose Adjustment in Study CT-P13 3.8: Safety Population

<!-- image -->

|                                          | CT-P13 SC 120 mg (N=54, PY=30.82)           | CT-P13 SC 240 mg (from Sc 120 mg) (N=54,PY=52.58)   | Placebo (N=50, PY=17.83)                    | CT-P13 SC 240 mg (from Placebo) (N=50, PY=65.11)   |
|------------------------------------------|---------------------------------------------|-----------------------------------------------------|---------------------------------------------|----------------------------------------------------|
|                                          | Number(%o, 1ooPY)of Patients with ≥ 1 Event | Number(%o, 1ooPY)of Patients with ≥ 1 Event         | Number(%o, 1ooPY)of Patients with ≥ 1 Event | Number(%o, 1ooPY)of Patients with ≥ 1 Event        |
| TEAE                                     | 33 (61.1%, 107.07)                          | 34 (63.0%, 64.66)                                   | 27 (54%, 151.42)                            | 32 (64%, 49.14)                                    |
| TESAE                                    | 2 (3.7%, 6.49)                              | 4 (7.4%, 7.61)                                      | 1 (2%, 5.61)                                | 3 (6%, 4.61)                                       |
| TEAELeadingto Study Drug Discontinuation | N/A1                                        | 3 (5.6%, 5.71)                                      | N/A1                                        | 2 (4%, 3.07)                                       |
| SIR 1 (1.9%, 3.24)                       |                                             | 0                                                   | 1 (2%, 5.61)                                | 0                                                  |
| Delayed Hypersensitivity                 | 0                                           | 0                                                   | 0                                           | 0                                                  |
| Localised ISR                            | 2 (3.7%, 6.49)                              | 4 (7.4%, 7.61)                                      | 0                                           | 4 (8%, 6.14)                                       |
| Infection                                | 15 (27.8%, 48.67)                           | 21 (38.9%, 39.94)                                   | 5 (10%, 28.04)                              | 19 (38%, 29.18)                                    |
| Malignancy                               | 0                                           | 0                                                   | 0                                           | 0                                                  |

Note: Excluding TEAEs reported from patients in the Placebo group who switched from Placebo to CT-P13 SC 120 mg at Week 56 then underwent dose adjustment from CT-P13 SC 120 mg to 240 mg during the Extension Phase. 1 Marked as N/A since TEAE leading to study drug discontinuation can only be reported once for each patient.

<div style=\"page-break-after: always\"></div>

Abbreviations: ISR, injection site reaction; PY, person year; SIR, systemic injection reaction; TEAE, treatment emergent adverse event; TESAE, treatment-emergent serious adverse event

Table 98: Summary of Safety by the Dose Adjustment in Studies CT-P13 3.7, CT-P13 3.8 and CT-P13 1.6 Part 2: Safety Population

|                                            | CT-P13 3.7+CT-P133.8+CT-P13 1.6 Part 2        | CT-P13 3.7+CT-P133.8+CT-P13 1.6 Part 2               | CT-P133.7+CT-P133.8                           | CT-P133.7+CT-P133.8                                |
|--------------------------------------------|-----------------------------------------------|------------------------------------------------------|-----------------------------------------------|----------------------------------------------------|
|                                            | CT-P13 SC 120 mg (N=159, PY=74.69)            | CT-P13 SC 240 mg (from Sc 120 mg) (N=159, PY=153.98) | Placebo (N=126, PY=43.53)                     | CT-P13 SC 240 mg (from Placebo) (N=126, PY=153.13) |
|                                            | Number (%o, 1ooPY) of Patients with ≥ 1 Event | Number (%o, 1ooPY) of Patients with ≥ 1 Event        | Number (%o, 1ooPY) of Patients with ≥ 1 Event | Number (%o, 1ooPY) of Patients with ≥ 1 Event      |
| TEAE                                       | 93 (58.5%, 124.51)                            | 107 (67.3%, 69.49)                                   | 67 (53.2%,153.93)                             | 92 (73.0%, 60.08)                                  |
| TESAE                                      | 6 (3.8%, 8.03)                                | 14 (8.8%, 9.09)                                      | 2 (1.6%, 4.59)                                | 10 (7.9%, 6.53)                                    |
| TEAE Leading to Study Drug Discontinuation | N/A1                                          | 8 (5.0%, 5.20)                                       | N/A1                                          | 8 (6.3%, 5.22)                                     |
| SIR                                        | 3 (1.9%, 4.02)                                | 4 (2.5%,2.60)                                        | 3 (2.4%, 6.89)                                | 3 (2.4%, 1.96)                                     |
| Delayed Hypersensitivity                   | 0                                             | 1 (0.6%, 0.65)                                       | 0                                             | 0                                                  |
| Localised ISR                              | 8 (5.0%,10.71)                                | 8 (5.0%, 5.20)                                       | 1 (0.8%, 2.30)                                | 8 (6.3%, 5.22)                                     |
| Infection                                  | 34 (21.4%, 45.52)                             | 51 (32.1%, 33.12)                                    | 21 (16.7%, 48.25)                             | 50 (39.7%, 32.65)                                  |
| Malignancy                                 | 0                                             | 1 (0.6%, 0.65)                                       | 0                                             | 2 (1.6%, 1.31)                                     |

Note: Excluding TEAEs reported from patients in the Placebo group who switched from Placebo to CT-P13 SC 120 mg at Week 56 then underwent dose adjustment from CT-P13 SC 120 mg to 240 mg during the Extension Phase.

1 Marked as N/A since TEAE leading to study drug discontinuation can only be reported once for each patient. Abbreviations: ISR, injection site reaction; PY, person year; SIR, systemic injection reaction; TEAE, treatment emergent adverse event; TESAE, treatment-emergent serious adverse event

Other than TEAE leading to study drug discontinuation, the results showed that the number of patients with at least 1 TEAE, TESAE or TEAESI with exposure adjusted rate by 100 PY was not significantly increased after  dose  adjustment to CT-P13 SC 240 mg for both patients switching from CT-P13 SC 120 mg and placebo.

In both Table 8 and Table 9, TEAE leading to study drug discontinuation appears to occur only after each patient started receiving CT-P13 SC 240 mg, but the comparison between before and after dose adjustment cannot be since each patient can be reported only once with TEAE leading to study drug discontinuation. Also, patients who discontinued from the study while receiving CT-P13 SC 120 mg or placebo did not have the chance for dose adjustment to receive CT-P13 SC 240 mg.

When compared by study treatment, the number of patients reported with TEAE leading to study drug discontinuation by 100 PY was slightly higher for the CT-P13 SC 240 mg group (4.94) compared to the CTP13 SC 120 mg group (3.62) (Table 7) and similar trend was shown in the analysis for Study CT-P13 3.8 as the number of patients reported with TEAE leading to study drug discontinuation by 100 PY was 8.30, 3.85 and 4.22 for Placebo, CT-P13 SC 120 mg and CT-P13 SC 240 mg subgroups, respectively (Table 1 of Response to Question 42).

As all analyses provided in this response showed that the safety profile of higher dose of CT-P13 SC 240 mg is comparable to the approved dose of CT-P13 SC 120 mg, no proposal is made for an update to the Product Information.

<div style=\"page-break-after: always\"></div>

## Assessment of the MAH's response

The MAH has submitted the requested analyses: except for that the analysis on dose adjustment for the Phase 3 study was performed only for the safety data from Study CT-P13 3.8, since the MAH would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for patients with ulcerative colitis (UC),

In the pooled analysis of all CT-P13 SC studies, there were slightly more TEAE, TESAE, TEAE leading to study drug discontinuation, SIR, delayed hypersensitivity and infections with the 240 mg SC dose than the 120 mg SC dose (Table 7). Regarding malignancy, there were only 2/1056 cases (0.2%, 0.18 100 PY) in the 120 mg SC group and 3/342 cases (0.9%, 0.87 100 PY) in the 240 mg SC group, so interpretation of the difference in incidence of malignancy is futile.

In study CT-P13 3.8, interestingly, there were markedly more TEAE with placebo (54%, 151.42/100 PY)) and CT-P13 120 mg SC (61.1%, 107.07/100 PY) than in subjects with dose escalation from 120 mg to 240 mg  SC  (63.0%,  64.66/100  PY)  or  subjects  with  dose  escalation  from  placebo  to  240  mg  SC  (64%, 49.14/100 PY) (Table 8).

Only studies CT-P13 3.7, CT-P13 3.8 and CT-P13 1.6 Part 2 were included in the pooled analysis, as these are the only studies that allowed dose adjustment to CT-P13 SC 240 mg. In this analysis (table 9) that includes subjects with both CD and UC (from studies CT-P13 3.7, CT-P13 3.8 and CT-P13 1.6), there were also markedly more TEAE in the placebo and CT-P13 120 mg SC groups than in the CT-P13 240 mg SC groups (escalated from 120 mg SC or placebo). However, the incidence of TESAE was larger in the 240 mg SC group escalated from 120 mg SC than in subjects continuing with 120 mg SC and also larger in the 240mg SC group escalated from placebo than in the placebo group. Notably, also infections occurred less often during treatment with CT-P13 240 mg SC (39.7%, 32.65/100 PY when escalation from 120 mg and 39.7%, 32.65/100 PY) than during treatment with CT-P13 120 mg SC (21.4%, 45.54/100 PY) or placebo (16.7 %, 48.25/100 PY).

Overall, the results do not indicate that the safety profile of the 240 mg SC dose would relevantly differ from the safety profile of 120 mg SC of CT-P 13.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 47

COVID-19 should be added in the examples of infections mentioned in parentheses in the table of ADRs in Section 4.8 of the SmPC, together with influenza and herpes virus infection, with an asterisk referring to a footnote describing that these ADRs were seen with the SC administered Remsima.

## Summary of the MAH's response

As requested, the Applicant has added COVID-19 as an example of viral infections with the suggested footnote to the table of ADRs in Section 4.8 of SmPC.

## Assessment of the MAH's response

Issue resolved.

<div style=\"page-break-after: always\"></div>

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 48

From tables included in the document 'Post-hoc Analyses' (Module 5.3.5.3) it is understood that there were 534 subjects in the pooled analysis for assessment of safety of the doses of 120 mg SC and 240 mg SC, of whom 137 with dose adjustment and 397 without dose adjustment. The MAH is however requested to further clarify the patient populations used for investigating effects of dose escalation in the pooled data set and in the separate analyses of both phase 3 trials. The MAH informs that for the active arm group with dose adjustment, all data were collected regardless of dose adjustment for CT-P13 SC 120 mg group; and for the placebo arm, data collected before initiation of dose adjustment to 240 mg were included. The MAH should clarify if the data from subjects who were switched from placebo to active treatment with 240 dose were omitted? If so, analyses should be repeated with all subjects using 240 mg dose included, also those from the comparator arm. Are the data for subjects with dose escalation only from the period when the patient used that dose or from the entire study duration? The MAH is requested to clarify how different durations of use of different doses were addressed in the analyses?

## Summary of the MAH's response

As discussed in Response to Question 42, the comparison of safety profile between patients with dose adjustment (from CT-P13 SC 120 mg to 240 mg dose) and patients without dose adjustment (maintained CT-P13  SC  120  mg  dose)  was  made  within  the  CT-P13  SC  group  of  Study  CT-P13  3.8  (Section 2.7.4.2.1.4.3.2 [SN0264]). The data for both subgroups were from the entire duration of the Maintenance Phase.

By including the Extension Phase and data collected after dose adjustment from patients in the Placebo arm and calculating the incidence rates per 100 Person Year (PY), the re-analysis of the safety data include the  data  of  all  patients  regardless  of  treatment  phase  and  treatment  group  and  take  into  account  the different duration of each treatment. The results are provided in Response to Question 42 and Response to Question 46.

## Assessment of the MAH's response

The submitted analyses are assessed in context of questions 42 and 46. The provided analyses on incidence of AEs during use of either 120 mg Sc, 240 mg SC or placebo per patient year are considered adequate.

Issue resolved.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

<div style=\"page-break-after: always\"></div>

## Question 49

The data on dose escalation should be analysed also separately for subjects with UC and CD for confirmation of safety in each indication.

## Summary of the MAH's response

As the Applicant would like to withdraw the proposed dose adjustment from CT-P13 SC 120 mg to 240 mg for patients with ulcerative colitis (UC), the analysis on dose adjustment is performed only for patients with Crohn's disease (CD). The analysis comparing events occurring prior to dose adjustment (CT-P13 SC 120 mg) vs after dose adjustment (from CT-P13 SC 120 mg to 240 mg) within the CT-P13 SC group and TEAEs occurring prior to dose adjustment (Placebo) vs after dose adjustment (from Placebo to CT-P13 SC 240 mg) within the Placebo group are provided in Table 8 of Response to Question 46.

## Assessment of the MAH's response

See assessment of question 46. Issue resolved.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 50

The MAH should also confirm that once the dose was adjusted for a patient, the dose was 240 mg for the rest of the duration of the trial. The numbers of subjects with dose escalation appear to be lower at some visits than the previous visit: was this due to drop-outs or were there subjects who returned to previous dose after having had dose adjustment earlier?

## Summary of the MAH's response

Among patients with dose adjustment in Study CT-P13 3.8 (both CT-P13  SC 120 mg and Placebo  SC groups), no patients have returned to their previous dose by the decision of the investigator to decrease the dose. The number of patients with dose adjustment appeared to be lower at some visits than the previous visit due to dropouts, dose skip and dosing error (e.g. human error) (CSR CT-P13 3.8 (Week 54) Section 12.1 [SN0264]). The dosing errors were corrected in the subsequent study visit. In all, a total of 93 patients received at least one adjusted dose for the safety population during the Maintenance Phase on or after Week 22 and until Week 54. Among them, 9 patients started the adjusted dose at Week 54, 67 patients maintained the adjusted dose at Week 54 and 17 patients were early terminated before the Week 54 administration.

## Assessment of the MAH's response

The requested clarifications were received and are sufficient. Issue resolved.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

<div style=\"page-break-after: always\"></div>

No need to update overall conclusion and impact on benefit-risk balance

## Question 51

Since the elderly more often suffer from multiple background diseases and are more prone to infections (e.g., herpes zoster and severe influenza or COVID-19), the MAH is requested to submit data on exposure to the 240 mg dose in subjects aged 65 years and above, and if such subjects exist, safety data in these subjects. The MAH should discuss the safety of the 240 mg dosage in the elderly and if any changes to Product Information are needed regarding use of the higher dose in the elderly.

## Summary of the MAH's response

In Study CT-P13 3.8 (Crohn's disease), two patients aged above 65 years received the adjusted dose of CT-P13 SC 240 mg during Treatment Period.

A patient in the CT-P13 SC 120 mg group received the adjusted dose of CT-P13 SC 240 mg from Week 22 until study discontinuation at Week 32. The patient was not reported with any treatment-emergent adverse events (TEAEs) during study participation.

A patient in the Placebo group received the adjusted dose of CT-P13 SC 240 mg from Week 22 until study completion at Week 102. The patient's TEAEs reported during the study treatment period (up to Week 102) are presented in Table 10. The patient was reported with 2 TEAEs of infection and 1 TEAE of blood creatine phosphokinase increased after dose adjustment.

Both events of infection (respiratory tract infection viral and latent tuberculosis) were expected adverse reactions  based  on  the  product  information  of  Infliximab.  In  addition,  both  events  were  considered unrelated to study drug by the decision of the investigator. Treatment-emergent adverse event of blood creatine phosphokinase increased was reported as possibly related to study drug after dose adjustment. However, TEAE was reported as grade 1 in intensity and recovered with no action taken.

To summarize, no new safety risk was observed from both elderly patients exposed to the dose of CT-P13 SC 240 mg.

Table 99: Treatment-Emergent Adverse Events of A Patient in Treatment Period of Study CTP13 3.8

| Phase                               | PT                                      | sOC                         | Grade   | Causality   | Action Taken     | Outcome                     |
|-------------------------------------|-----------------------------------------|-----------------------------|---------|-------------|------------------|-----------------------------|
| Induction (21 days after Week 2)    | Abdominal distension                    | Gastrointestinal disorders  | Grade 1 | possible    | Dose not changed | Recovered/ resolved         |
| Maintenance (2 days after Week 18)  | Crohn's disease                         | Gastrointestinal disorders  | Grade 2 | unrelated   | Dose not changed | Recovered/ resolved         |
| Maintenance (12 days after Week 26) | Respiratory tract infection viral*      | Infections and infestations | Grade 2 | unrelated   | Drug interrupted | Recovered/ resolved         |
| Extension (on Week 70)              | Latent tuberculosis*                    | Infections and infestations | Grade 1 | unrelated   | Drug interrupted | Not recovered/ not resolved |
| Extension (on Week 94)              | Blood creatine phosphokinase increased* | Investigations              | Grade 1 | possible    | Dose not changed | Recovered/ resolved         |

*TEAEs occurred after dose adjustment Abbreviations: PT, preferred term; SOC, system organ class; TEAE, treatment-emergent adverse event

<div style=\"page-break-after: always\"></div>

## Assessment of the MAH's response

It is agreed that no new safety risk was observed from two elderly patients exposed to the dose of CT-P13 SC 240 mg. One of the two subjects aged &gt;65 years experienced infections (respiratory track infection and latent  tuberculosis)  and  one  did  not.  For  comparison,  in  the  entire  study  population,  the  incidence  of infections during treatment with the 240 mg SC dose was 21/54 (38.9%, 39.94/100 PY) in subjects who escalated from 120 mg SC, and 19/50 (38%, 29.18/100 PY) in subjects who escalated from placebo (table 8 of the response document, see assessment of Question 46). It is known from previous scientific data that the elderly are more at risk of serious infections during infliximab treatment; but there exists no definitive information if the risk is associated with the level of infliximab. Since the increased risk of infections is already covered in the SmPC Sections 4.4 and 4.8, it is agreed that no amendment is warranted in Section 4.2, which refers to Sections 4.4 and 4.8 regarding this risk in the elderly.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## 14. 2 nd  request for supplementary information

## 14.1. Major objections

None

## 14.2. Other concerns

## Clinical aspects

## Efficacy

Please see Section 15 for 2 nd  round RSI questions and assessment.

## 15. Assessment of the responses to the 2 nd  request for supplementary information

## 15.1. Major objections

None.

<div style=\"page-break-after: always\"></div>

## 15.2. Other concerns

## Clinical aspects

## Efficacy

## UC - Study CT-P13 3.7

## Question 1

The possibility to adjust the dose before W54/switch to active treatment is significantly intertwined in the primary endpoints as only patients who did not adjust the dose had a possibility to be responders at week 54. However, mentioning the possibility to increase the dose from the currently approved 120mg SC to 240mg in the SmPC would be promoting an off-label posology, which is not acceptable.

The MAH should discuss whether the results of the primary endpoint at 54 can be clinically interpreted and considered  methodologically  robust,  enough  to  be  included  in  the  SmPC  5.1,  without  mentioning  the possibility of dose escalation.

The following data are required, even though the possibility for dose escalation is no longer sought:

- a. The  MAH  should  provide  a  patient  disposition  flow  chart  where  discontinuations  and  dose escalations are clearly outlined up to week 54 (corresponding to Figure 2 in Question 29 in the previous responses).
- b. The MAH should provide tables outlining the number of patients who were: a) non-responder according to the clinical criteria b) dose was escalated/switch to active c) discontinuation before Week 54 d) missing data e) incomplete data f) any other reason and corresponding combination categories.
- c. The intercurrent event of loss of response was handled differently for different patients and this flaw in the study design could skew the results of the primary outcome. Therefore, it is of interest how many patients had loss of response, how many of them received an escalated dose and how many patients regained response with and without dose escalation. The MAH should provide  a  table  describing  the  primary  and  key  secondary  endpoints  by  treatment  and subgroup:  patients with  dose  adjustment  meeting  LoR  (subgroup  1),  patients  with  dose adjustment  not  meeting  LoR  (subgroup  2),  patients without dose  adjustment meeting LoR (subgroup 3), patients without dose adjustment not meeting LoR (subgroup 4) (corresponding to Table 16 in the response to the previous Q 35).
- d. The  MAH  should  also  provide  spaghetti  plots  of  actual  values  of  the  modified  Mayo  score (overlay and individual) where the time point of dose escalation is standardized in the middle of the graph and 2 visits before and 3 visits after dose escalation are included.

The MAH could also make a proposal for how to include the W22 results in the SmPC and how to refer to the endpoints at W22 as these are not prespecified primary endpoints and not type I error controlled.

<div style=\"page-break-after: always\"></div>

To enable assessment of the whole study the above requested tables should be provided even if the MAH might propose not to include any data from study 3.7 into the SPC or if only W22 data are included.

## Summary of the MAH's response

Patients who participated in Study CT-P13 3.7 were eligible to receive adjusted dose from Week 22 if they met the loss of response (LoR) criteria according to Study CT-P13 3.7 Protocol Section 5.2 Treatments Administered. These were patients who experienced secondary loss of response (in other words,  treatment failure) and were therefore expected to stop receiving the study drug and be withdrawn from the study to  initiate  new  treatment.  However,  the  option  for  dose  adjustment  was given for those patients who experienced LoR, in order to provide an alternative treatment option as rescue therapy in considering the ethical aspect of the study.

To  demonstrate  superiority  of  CT-P13  SC  120  mg  treatment  over  Placebo,  the  primary  and  the  key secondary endpoints were only compared between dosing of CT-P13 SC 120 mg and dosing of Placebo, excluding the effect of CT-P13 SC 240 mg treatment. Patients who received adjusted dose were considered as  not  achieving  primary  and  key  secondary  endpoints  based  on  pre-defined  data  analysis  rules,  as specified in the statistical analysis plan (SAP). Therefore, the treatment effect of CT-P13  SC  240 mg was not accounted for in the results of the primary and the key secondary endpoints. CELLTRION therefore wishes to maintain the W54 results from the UC study.

While the Agency's concern regarding the possibility of off-label treatment is acknowledged, the use of CTP13 SC 240 mg in ulcerative colitis is not mentioned in the SPC. Therefore, with the current context there is no possibility to promote an off-label posology by mentioning dose adjustment to CT-P13 SC 240 mg.

In addition, Applicant presents pos-hoc analysis data requested by Agency as below.

## a. Patient disposition flow chart where discontinuations and dose escalations are clearly outlined up to week 54.

Applicant provides the flow chart of patient disposition regarding discontinuation for all-randomized population as Figure 1.

<div style=\"page-break-after: always\"></div>

Figure 41: Flow chart of Patient Disposition of Study CT-P13 3.7: All-Randomized Population

<!-- image -->

In CT-P13 SC 120 mg group, 19 (6.5%) patients discontinued the study before Week 22. A total of 81 (27.6%)  patients  in  CT-P13  SC  120 mg  group  received  adjusted  dose  before  Week 54  visit. Among patients who discontinued on or after Week 22, 25 (8.5%) patients discontinued after dose adjustment and 10 (3.4%) patients discontinued without dose adjustment.

In Placebo group, 5 (3.5%) patients discontinued the study before Week  22, and a total of 70 (48.6%) patients received adjusted dose before Week 54. Among patients who discontinued the study on or after Week 22, 19 (13.2%) patients discontinued after dose adjustment and 7 (4.9%) patients discontinued without dose adjustment.

b. Tables outlining the number of patients who were: a) non-responder according to the clinical criteria b) dose was escalated/switch to active c) discontinuation before Week 54 d) missing data e) incomplete data f) any other reason and corresponding combination categories.

As requested, the requested table including the number of patients that correspond to those criteria for the primary and the key secondary endpoints is presented below.

<div style=\"page-break-after: always\"></div>

Table 100: Number of Patients who were Non-remitter/Non-responder for Primary and  Key  Secondary  Endpoints  at  Week  54  in  Study  CT-P13  3.7:  Allrandomized Population

| Endpoint Reasonfornon-remitter/non-responder     | CT-P13SC (N=294)   | Placebo (N=144)   | Total (N=438)   |
|--------------------------------------------------|--------------------|-------------------|-----------------|
| ClinicalRemission                                |                    |                   |                 |
| DiscontinuationbeforeWeek54                      | 48 (16.3%)         | 24 (16.7%)        | 72 (16.4%)      |
| DoseescalationorswitchtoCT-P13SCfromplacebo      | 61 (20.7%)         | 58 (40.3%)        | 119 (27.2%)     |
| Incompletedata                                   | 11 (3.7%)          | 9 (6.3%)          | 20 (4.6%)       |
| Missing data                                     | 0                  | 0                 | 0               |
| Non-remitter accordingtotheclinicalcriteria      | 47 (16.0%)         | 23 (16.0%)        | 70 (16.0%)      |
| ClinicalResponse2                                |                    |                   |                 |
| DiscontinuationbeforeWeek54                      | 48 (16.3%)         | 24 (16.7%)        | 72 (16.4%)      |
| DoseescalationorswitchtoCT-P13SCfromplacebo      | 61 (20.7%)         | 58 (40.3%)        | 119 (27.2%)     |
| Incomplete data                                  | 11 (3.7%)          | 9 (6.3%)          | 20 (4.6%)       |
| Missing data                                     | 0                  | 0                 | 0               |
| Non-responder according to theclinical criteria  | 16 (5.4%)          | 8 (5.6%)          | 24 (5.5%)       |
| Endoscopic-histologicMucosal Improvement3        |                    |                   |                 |
| DiscontinuationbeforeWeek54                      | 48 (16.3%)         | 24 (16.7%)        | 72 (16.4%)      |
| DoseescalationorswitchtoCT-Pi3SCfromplacebo      | 61 (20.7%)         | 58 (40.3%)        | 119 (27.2%)     |
| Incompletedata                                   | 8 (2.7%)           | 2 (1.4%)          | 10 (2.3%)       |
| Missing data                                     | 9 (3.1%)           | 7 (4.9%)          | 16 (3.7%)       |
| Non-responder according to the clinical criteria | 63 (21.4%)         | 29 (20.1%)        | 92 (21.0%)      |
| Corticosteroid-freeRemission*                    |                    |                   |                 |
| DiscontinuationbeforeWeek54                      | 21/120 (17.5%)     | 13/61 (21.3%)     | 34/181 (18.8%)  |
| DoseescalationorswitchtoCT-P13SCfromplacebo      | 32/120 (26.7%)     | 29/61 (47.5%)     | 61/181 (33.7%)  |
| Incomplete data                                  | 3/120 (2.5%)       | 2/61 (3.3%)       | 5/181 (2.8%)    |
| Missing data                                     | 0/120              | 0/61              | 0/181           |
| Non-remitteraccordingtotheclinicalcriteria       | 20/120 (16.7%)     | 6/61 (9.8%)       | 26/181 (14.4%)  |

Source:Section5.3.5.3Post-hocTable2.285

Note:Apatientwith two or morereasons for non-responder/non-remitter is included in one of the reasons infollowing order;c)discontinuationbeforeWeek54-b)dose escalationorswitchtoCT-P13SCfromplacebo-e)incompletedata-d)missingdata-a)non-remitter/non-responderaccordingtothecriteria-f)anyotherreason.There werenocasesdueto'anyotherreason.

2 Clinical response is defined as a decrease in modified Mayo score from baseline of at least 2 points and at least 30%,with an accompanying decrease in the rectal bleeding subscore of at least 1point or an absolute rectal bleeding subscore of 0 or1 point.

1 Clinicalremissionisdefined asmodifiedMayoscorewithastoolfrequencysubscoreof0or1,rectal bleedingsubscoreof O, andendoscopicsubscoreof 0or1.

3 Endoscopic-histologic mucosal improvement is defined as an absolute endoscopic subscore of 0 or 1 point from modified Mayo score and an absolute Robarts Histopathology Index(RHI) score of 3pointsorlesswith an accompanyinglaminalproprianeutrophils andneutrophils inepitheliumsubscore of 0point.

4 Corticosteroid-free remission is defined as being in clinical remission by modified Mayo score in addition to not requiring any treatment with corticosteroid for at least 8 weeks at Week54,among thepatientswhousedoralcorticosteroids atbaseline.

c. Table describing the primary and key secondary endpoints by treatment and subgroup: patients with dose adjustment meeting LoR (subgroup 1), patients with dose adjustment not meeting LoR (subgroup 2),  patients  without  dose  adjustment meeting LoR (subgroup 3), patients without dose adjustment not meeting LoR (subgroup 4).

In Study CT P13 3.7, dose adjustment to CT P13 SC 240 mg was allowed from Week 22 when the patient met LoR criteria defined in the protocol. The LoR was defined as an increase in modified Mayo score (mMS) of ≥ 2 points and ≥ 30% from the Week 10 mMS with actual value of ≥ 5 points, and endoscopic subscore of ≥ 2 points.

Patients in Study CT-P13 3.7 were divided into four subgroups for CT-P13 SC 120 mg and placebo groups to evaluate the impact of meeting LoR criteria and dose adjustment.

Analysis results for  the primary/key secondary endpoints for patients by dose adjustment  status in allrandomised population are provided in Table 2. Primary endpoints include clinical remission at Week  54. Key-secondary endpoints include clinical response at Week 54, endoscopic-histologic  mucosal improvement and corticosteroid-free remission at Week 54.

As shown in Table 2, as number of patients without dose adjustment meeting LoR criteria was very small and  patients  with  dose  adjustment  were  considered  as  non-remitter/non-responder,  the Applicant believes that efficacy result of Week 54 is not impacted by the handling of the intercurrent event of Loss of Response.

<div style=\"page-break-after: always\"></div>

Table 101: Number  of  Patients  who  achieved  efficacy  endpoints  (Primary/Keysecondary) at Week 54 by dose adjustment status

|                                                    | CT-P13 SC (N=294)    | CT-P13 SC (N=294)   | CT-P13 SC (N=294)   | CT-P13 SC (N=294)     | Placebo (N=144)      | Placebo (N=144)     | Placebo (N=144)    | Placebo (N=144)     |
|----------------------------------------------------|----------------------|---------------------|---------------------|-----------------------|----------------------|---------------------|--------------------|---------------------|
|                                                    | subgroup 1 (N' = 48) | subgroup2 (N' = 29) | subgroup3 (N' = 5)  | subgroup 4 (N' = 187) | subgroup 1 (N' = 46) | subgroup2 (N' = 21) | subgroup3 (N' = 3) | subgroup4 (N' = 64) |
| Primaryendpoints                                   |                      |                     |                     |                       |                      |                     |                    |                     |
| ClinicalRemissionatWeek54                          | 10 (20.8%)           | 10 (34.5%)          | 0                   | 127 (67.9%)           | 13 (28.3%)           | 11 (52.4%)          | 0                  | 30 (46.9%)          |
| Keysecondaryendpoints                              |                      |                     |                     |                       |                      |                     |                    |                     |
| ClinicalresponseatWeek54                           | 20 (41.7%)           | 20 (69.0%)          | 2 (40%)             | 156 (83.4%)           | 25 (54.3%)           | 16 (76.2%)          | 0                  | 45 (70.3%)          |
| Endoscopic-histologic mucosal improvement atWeek54 | 9 (18.8%)            | 9 (31.0%)           | 0                   | 105 (56.1%)           | 12 (26.1%)           | 11 (52.4%)          | 0                  | 23 (35.9%)          |
| Corticosteroid-freeremissionat Week54              | 7/21 (33.3%)         | 6/18 (33.3%)        | 0/0                 | 44/70 (62.9%)         | 6/26 (23.1%)         | 4/11 (36.4%)        | 0/1                | 11/19 (57.9%)       |

Source:Section5.3.5.3Post-hocTable2.286

thenumberofpatientswhousedoral corticosteroidsatBaselineineachsubgroupasthedenominator.

Note: LoR is defined as following: an increase in modified Mayo score ≥ 2 points and ≥ 30% from the Week 10 modified Mayo score with actual value of ≥ 5 points, and endoscopic subscoreof ≥2points.Thepatientswhohave at least one mMSresult on or afterWeek22includingUnscheduledandEoSvisit are categorizedaccording toLoRanddose adjustment from Week 22 prior to Week54.Four subgroups; patients with dose adjustment meeting LoR(subgroup 1),patients with dose adjustment not meeting LoR(subgroup 2)，patientswithout doseadjustment meetingLoR(subgroup3),patientswithout doseadjustmentnotmeetingLoR(subgroup4).Exceptcorticosteroid-freeremissionatWeek 54,percentagesarecalculatedusing thenumberofpatientsineachsubgroupasdenominator.Forcorticosteroid-freeremission at Week54,percentagesarecalculatedby using

[1]ClinicalremissionisdefinedasmodifiedMayoscorewithastool frequencysubscoreof 0or1,rectalbleedingsubscoreof 0,andendoscopicsubscoreof 0or1.

[3] Endoscopic-histologic mucosal improvement is defined as an absolute endoscopic subscore of 0 or 1 point from modified Mayo score and an absolute Robarts Histopathology Index(RHI) scoreof 3pointsorlesswith an accompanyinglaminalpropria neutrophilsandneutrophilsinepitheliumsubscoreof 0point.

[2] Clinical response is defined as a decrease in modified Mayo score from baseline of at least 2 points and at least 30%, with an accompanying decrease in the rectal bleeding subscoreof atleast1pointoranabsoluterectalbleedingsubscoreof0or1point.

[4]Corticosteroid-free remission is defined as being in clinical remissionby modifiedMayo score in addition to not requiring any treatment withcorticosteroid for at least 8weeks at Week54,among thepatientswho used oral corticosteroids atbaseline. Abbreviations:LoR,loss of response;mMS，modifiedmayo score;N',numberof patients inthe subgroup;RHI,robartshistopathologyindex;SC,subcutaneous.

d.  Spaghetti plots of actual values of the modified Mayo score (overlay and individual) where the time point of dose escalation is standardized in the middle of the graph and 2 visits before and 3 visits after dose escalation are included.

Applicant provides overlay and individual spaghetti plots of partial Mayo score at 2 visits before (including the time of dose adjustment) and 3 visits after dose adjustment for patients with dose adjustment meeting Lose of response (subgroup 1) and patients with dose adjustment not meeting loss of response (subgroup 2) for CT-P13 SC group (Figure 2). While the modified Mayo score is assessed only at three time points (Weeks 10, 22, and 54), the partial Mayo score is assessed at seven time points (Weeks 10, 14, 22, 30, 38, 46, and 54) in the maintenance phase per protocol and a spaghetti plot was generated based on the partial Mayo score. Dose adjustments were allowed based on loss of response criteria starting at week 22, the condition of '2 visits before and 3 visits after dose escalation' could not be satisfied if calculated with modified Mayo score due to not enough visits, partial Mayo score was substituted to create a spaghetti plot.

Overall, partial Mayo scores in 1 st  after dose adjustment visit were decreased after dose adjustment compared  to  dose  adjustment  visit.  In  the  long  term  (2 nd and  3 rd after  dose  adjustment),  the decreased partial Mayo scores were further reduced or maintained compared to the dose adjustment visit, with a few outliers in both subgroups 1 and 2 in the CT-P13 SC group.

<div style=\"page-break-after: always\"></div>

Figure 42: Partial Mayo Score versus Time by Dose Adjustment Status

<!-- image -->

## Assessment of the MAH's response

The Applicant has provided the requested tables and figures

The numbers in the flow chart and in table 1 and 2 do not add up. According to the Flow chart 81 and 70 patients in SC 120 and placebo groups, respectively received a dose escalation. According to Table 2 the numbers seem to be 77 and 67 and in Table 1 the numbers are 61 and 58. This discrepancy might be due to missing efficacy data or different classification of patients who increased the dose on W54. However, as these discrepancies do not affect the final conclusions or the SPC, the issue will not be pursued further.

The efficacy results in table 2 and the spaghetti plots illustrate that there is no apparent benefit to be gained from a dose escalation from 120mg to 240mg Remsima in UC patients. Although a decrease on Partial Mayo score is seen immediately after the dose escalation, the improvement does not last rendering it clinically insignificant.  The  initial  improvement  also  needs  to  be  interpreted  with  caution  as  subjective  symptom assessment after an open label dose adjustment is prone to bias due to expectations and the results are also prone to regression to the mean. Therefore, the decision to withdraw the application for dose escalation

<div style=\"page-break-after: always\"></div>

is endorsed.

The Applicant proposes to maintain the W54 results of the UC study 3.7 in the SPC section 5.1 but it is apparent  that  the  Applicant  did  not  grasp  the  problem  concerning  the  study  design  leading  to  biased outcome.

According to study protocol, patients were offered a dose escalation if they met LoR criteria after week 22. However, based on the provided results, 29/294 patients in the infliximab group and 21/144 in the placebo group were switched to 240 mg Remsima despite not meeting LoR criteria. Hence, a total of 35% (50/144) of all patients who received a dose adjustment did not meet LoR criteria. No special criteria for these dose escalation decisions were prespecified or explained post hoc. Some patients with LoR were immediately established as being treatment failures, while others, were considered non-responders only if they remained non-responders also at week 54. The criteria for continuing on randomized treatment despite LoR were never defined in the protocol.

The Applicant believes that efficacy results of Week 54 are not impacted by the handling of the intercurrent event of Loss of Response. Patients without dose adjustment despite meeting LoR criteria were few (5 and 3 in SC 120 and placebo groups, respectively). Therefore, it is agreed that these particular patients are not expected to have a meaningful impact on the final outcome even though they were included as potential responders at week 54. (None of these patients were remitters/responders at W 54.)

However, handling of the LoR event was different for different patients. The different handling was not according to protocol, not randomised and not free from bias. Ultimately, 10% of all patients in the SC 120mg group and 15% in the placebo group were classified as non-remitter/non-responder only due to dose escalation, not due to per protocol LoR. As 35% of all patients who received a dose adjustment did not meet LoR criteria, classifying patients with dose escalation as non-responders as if they were all patients who lost response after W22 is simply not reflecting reality.

Out of all non-responders at W54, only 5.5% were classified as non-responders based on clinical criteria, with no difference between treatment groups, while the rest of the non-responders were due to intercurrent events, mainly dose adjustment, which did not equal LoR.

As all patients randomised are included in the primary endpoint, all the aforementioned issues have a direct impact on the results of the primary endpoint.

As understood by the assessor, the intention of the study protocol was to reflect a treatment policy situation where a patient  in  case  of  loss  of  response  could  either  be  taken  off  the  randomised  treatment  (incl. placebo)  and  switched  to  alternative/rescue  therapy  or  continue  in  hope  of  better  days  to  come.  This approach likely reflects the real-world situation and could have been an acceptable approach. The decision to continue with a double dose was in effect handled as a switch to rescue therapy. Handling a switch to rescue therapy as a treatment failure is in line with the EMA guideline on the development of new medicinal products for the treatment of Crohn's Disease. However, in this particular study where the investigators knew  that  patients  could  be  assigned  to  placebo  although  the  efficacy  of  the  active  treatment  as maintenance therapy is already established, the psychological incentive to start rescue therapy may have been higher than usual.

Some patients were apparently not considered to benefit from the treatment by the treating physician despite not meeting clinical LoR criteria. These patients were also 'put on rescue therapy'. In study 3.7 such  physician  decisions  were  abundant  (35%  of  all  dose  escalations)  and  done  off  protocol,  without prespecified criteria or any post hoc explanation. Therefore, the outcome does not reflect the prespecified primary  endpoint,  as  the  protocol  defined  all  dose  escalations  to  be  consequences  of  LoR  and  dose

<div style=\"page-break-after: always\"></div>

escalations by physicians' decision (other than LoR) were not specified in the protocol as appropriate reason to start 'rescue therapy' nor an intercurrent event. In the protocol, 'Patient develops signs of disease progression in the investigator's judgement' was a reason for withdrawal, but these patients were not recorded as withdrawals.

The reason for the high number of this type of protocol violations may be related to the definition of LoR. In the protocol, the LoR criteria were based on modified Mayo score (including the endoscopic subscore): 'an increase in modified Mayo score of ≥ 2 points and ≥ 30% from the Week 10 modified Mayo score with actual value of ≥ 5 points, and endoscopic subscore of ≥ 2 points.' However, the modified Mayo score was only recorded at weeks 10, 22 and 54. Hence, according to protocol it was not even possible to detect a LoR between W22 and 54. Therefore, if not done on W22, the decisions to escalate the dose were probably based on partial Mayo score (excluding the endoscopic subscore), which was recorded at every visit. The problem is that a patient who meets the hitherto undefined criteria for LoR by partial Mayo, would not necessarily be a non-responder according to the modified Mayo, which defines the primary endpoint.

To conclude, the off-label dose escalation after W22 meaningfully affects the interpretation of the results at W54 and the true impact of Remsima SC maintenance regiment cannot be estimated based on the results of this study. 35% of the dose escalations were not according to protocol, which introduces a major bias and puts the whole planning and conduct of the study into question. Therefore, the W54 results from study 3.7 are invalid for inclusion in the SPC.

While there is no doubt that Remsima SC is in fact more effective than placebo in the treatment of UC, the magnitude of the difference  cannot  be  accurately  estimated  based  on  the  results  of  this  trial.  The  UC indication is already granted and is not put into question but no new useful information for the prescriber has been presented with this application.

Of  note,  the  same  flaw  in  study  design  was  present  in  study  3.8  in  CD  patients,  including  suboptimal definition of non-remitter/non-responder and unclear criteria and some non-compliance with the protocol regarding dose escalation. However, the number of patients receiving dose escalation despite not meeting LoR criteria was small and the overall data were more robust. Hence, inclusion of study 3.8 results in SPC 5.1 is considered acceptable.

## Conclusion

Issue not resolved.

The results from study 3.7 are invalid for inclusion in the SPC.  The follow-up question is upgraded to a MO.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## CD - Study CT-P13 3.8

## Question 2

The flow chart provided in response to Q28 shows that 44 patients received dose adjustment, while the flow chart provided in response to Q29 shows 39 patients receiving dose adjustment. The difference should be clarified.

<div style=\"page-break-after: always\"></div>

## Summary of the MAH's response

Response to Question 28 provided flow chart providing how many patients had received adjusted dose in all randomized population throughout the whole study duration including Maintenance (from Week 10 to Week 54) and Extension phase (from Week 56 to Week 102). The number of patients received dose adjustment during Maintenance phase on or after Week 22 until Week 54 was 44 in CT-P13 SC 120 mg group and 49 in Placebo group.

However, in Response to Question 29, 39 patients in CT-P13 SC 120 mg group and 45 patients in Placebo group who had received adjusted dose before Week 54 visit were reported. As mentioned in Response to Question 50, the number of patients who started the adjusted dose at Week 54 was 9. These  patients  (5 patients  in  CT-P13  SC  120  mg  group  and  4  patients  in  Placebo  group)  were excluded in Response to Question 29.

## Assessment of the MAH's response

The discrepancy in numbers has been explained.

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

SPC

## Question 3

In section 5.1 the following paragraph is included for both CD and UC:

… the impact of use of immunosuppressant (azathioprine, 6-mercaptopurine and methotrexate) on efficacy was evaluated. There was no significant difference between patients with and without immunosuppressants in the primary and the key secondary efficacy endpoints.

No  data  were  provided  to  justify  the  statements.  The  statements  should  be  removed  or  appropriately justified for both indications.

## Summary of the MAH's response

Per the comment from CHMP, an additional post-hoc analysis was performed to evaluate the impact of the use of immunosuppressant (azathioprine, 6-mercatopurine and methotrexate) on efficacy as presented in Table 1, Table 2.

As  shown  in  Table  1,  Table  2  there  was  no  significant  difference  between  patients  with  and  without immunosuppressants  in  the  (co-)primary  and  the  key  secondary  efficacy  endpoints  for  both  studies (Studies CT-P13 3.7 [UC] and CT-P13 3.8 [CD]).

The difference in the proportion of patients achieving corticosteroid-free remission at week 54 in the CTP13 SC arm appears to be relatively greater than other endpoints for both Studies CT-P13

<div style=\"page-break-after: always\"></div>

3.7  and  CT-P13  3.8.  However,  the  proportion  of  patients  achieving  corticosteroid-free  remission  was calculated using the number of patients who received corticosteroid at baseline as a denominator, the results  should  therefore  be  interpreted  with  caution  considering  the  small  number  of  patients  actually included in the calculation.

Therefore, based on the results of the post-hoc analysis presented in Table 1, Table 2 CELLTRION wishes to maintain the statement in section 5.1 of the SmPC.

Table 102: Summary of the impact of use of immunosuppressant (azathioprine, 6mercaptopurine and methotrexate) on the primary and key secondary endpoints in study CT-P13 3.7

|                                                                                   | CT-P13 SC 120 mg (N=294)           | CT-P13 SC 120 mg (N=294)               | CT-P13 SC 120 mg (N=294)   | CT-P13 SC 120 mg (N=294)   | Placebo (N=144)                    | Placebo (N=144)                        | Placebo (N=144)      | Placebo (N=144)   |
|-----------------------------------------------------------------------------------|------------------------------------|----------------------------------------|----------------------------|----------------------------|------------------------------------|----------------------------------------|----------------------|-------------------|
|                                                                                   | Patients with AZA/6MP/ (N'=65) XIW | Patients AZA/6MP/ (N'=229) without MTX | Difference (95% CI)1       | P-value2                   | Patients with AZA/6MP/ (N'=32) XIW | Patients AZA/6MP/ (N'=112) without MTX | (95% CI)1 Difference | P-value2          |
| Proportion ofPatients Achieving Clinical RemissionatWeek54                        | 32 (49.2%)                         | 95 (41.5%)                             | 5.3 (-8.3, 18.9)           | 0.4119                     | 7 (21.9%)                          | 23 (20.5%)                             | 1.5 (-12.6, 19.8)    | 0.8535            |
| ProportionofPatients Achieving Clinical ResponseatWeek54                          | 34 (52.3%)                         | 124 (54.1%)                            | -3.6 (-17.3, 9.9)          | 0.5760                     | 10 (31.3%)                         | 35 (31.3%)                             | 1.5 (-15.3, 20.8)    | 0.8682            |
| ProportionofPatients AchievingEndoscopic- histologicMucosal Improvement at Week54 | 27 (41.5%)                         | 78 (34.1%)                             | 4.6 (-8.4, 18.2)           | 0.4763                     | 8 (25%)                            | 16 (14.3%)                             | 9.8 (-4.7, 27.8)     | 0.2106            |
| Proportion of Patients Achieving Corticosteroid-free Remission atWeek 543         | 12/26 (46.2%)                      | 32/94 (34.0%)                          | 13.0 (-7.3, 33.4)          | 0.1966                     | 3/16 (18.8%)                       | 8/45 (17.8%)                           | 1.6 (-17.5, 27.4)    | 0.8906            |

Source:Section5.3.5.3Post-hocTables2.275-2.278

N'=numberofpatientswith/withoutAZA/6MP/MTXatBaseline

Note:Analysis is stratified byPrevious exposure tobiologic agent and/orJAKinhibitors(used or notused), Useof treatment with oral corticosteroids at WeekO(used or notused) and Clinical remission at Week10(remitteror non-remitterby modifiedMayoscore[Study3.7]).Patients withdose adjustmenttoCT-P13SC 240mgpriortoWeek54 are considered asnon-remitter/non-responder.

1 The difference of proportionsbetweenpatientswith/without AZA/6MP/MTXestimated using CMH weights, and the 95%stratified Newcombe CI withCMH weights arepresented.

3 The proportion of patients achieving corticosteroid-free remission was calculated using the number of patients who received corticosteroid at baseline as a denominator, the resultsshouldthereforebeinterpretedwithcautionconsideringthesmallnumberofpatientsactuallyincludedinthecalculation.

2 The nominal p-value from stratified CMH test is presented in descriptive purpose.

<div style=\"page-break-after: always\"></div>

Table 103: Summary  of  the  impact  of  use  of  immusuppressant  (azathioprine,  6mercaptopurine and methotrexate) on the co-primary and key secondary endpoints in study CT-P13 3.8

|                                                                                           | CT-P13SC120mg (N=231)              | CT-P13SC120mg (N=231)                  | CT-P13SC120mg (N=231)   | CT-P13SC120mg (N=231)   | Placebo (N=112)                   | Placebo (N=112)                       | Placebo (N=112)      | Placebo (N=112)   |
|-------------------------------------------------------------------------------------------|------------------------------------|----------------------------------------|-------------------------|-------------------------|-----------------------------------|---------------------------------------|----------------------|-------------------|
|                                                                                           | Patients with AZA/6MP/ MTX (N'=71) | Patients without AZA/6MP/ MTX (N'=160) | Difference (95% CI)1    | P-value2                | Patientswith AZA/6MP/ MTX (N'=40) | Patients without AZA/6MP/ MTX (N'=72) | Difference (95% CI)1 | P-value2          |
| Proportion of Patients Achieving Clinical Remission(based on CDAI)atWeek54                | 47 (66.2%)                         | 97 (60.6%)                             | -2.5 (-16.4, 10.8)      | 0.7194                  | 16 (40%)                          | 20 (27.8%)                            | 11.1 (-7.0, 29.3)    | 0.2380            |
| Proportion ofPatients AchievingEndoscopic Response (Based on SES-CD[Central])at Week54    | 37 (52.1%)                         | 81 (50.6%)                             | -0.5 (-14.7, 13.6)      | 0.9492                  | 10 (25%)                          | 10 (13.9%)                            | 9.8 (-5.3, 26.8)     | 0.2082            |
| Proportion of Patients Achieving CDAI-100 Response atWeek54                               | 49 (69.0%)                         | 103 (64.4%)                            | -2.0 (-15.8, 10.9)      | 0.7686                  | 18 (45%)                          | 25 (34.7%)                            | 9.0 (-9.7, 27.5)     | 0.3592            |
| Proportion of Patients Achieving Clinical Remission(Basedon AP and SF) at Week54          | 42 (59.2%)                         | 89 (55.6%)                             | -4.1 (-18.2, 9.7)       | 0.5647                  | 16 (40%)                          | 19 (26.4%)                            | 12.3 (-5.9, 30.4)    | 0.1872            |
| Proportion ofPatients Achieving Endoscopic Remission(Based on SES-CD [Central]) at Week54 | 25 (35.2%)                         | 55 (34.4%)                             | -1.4 (-14.7, 12.7)      | 0.8439                  | 7 (17.5%)                         | 5 (6.9%)                              | 9.6 (-3.6, 25.3)     | 0.1318            |
| Proportion ofPatients Achieving Corticosteroid-free Remission(Basedon CDAI)atWeek543      | 13/23 (56.5%)                      | 27/76 (35.5%)                          | 8.2 (-14.7, 30.9)       | 0.4875                  | 4/12 (33.3%)                      | 5/32 (15.6%)                          | 18.3 (-7.5, 45.1)    | 0.1820            |

Note: Analysis is stratified by Previous exposure to biologic agent and/or JAK inhibitors (used or not used), Use of treatment with oral corticosteroids at Week 0 (used or not used) and Clinical remission at Week 10(remitter or non-remitter by CDAI score[Study3.8]).Patients with dose adjustment toCT-P13SC 240mg prior toWeek54 are considered as non-remitter/non-responder.

Source:Section5.3.5.3Post-hocTables2.279-2.284

## Assessment of the MAH's response

No significant difference in primary and key secondary outcome  was seen between patients with or without immunosuppressant treatment (azathioprine, 6-mercatopurine and methotrexate). The SPC paragraph may remain in the section about Crohn's but not in the UC section as the whole UC section should be deleted (see MO).

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 4

In section 5.1 for CD the MAH should add an explanation that patients with dose escalation were considered non-responders. This could be in the form of a suffix to the results table.

## Summary of the MAH's response

Per EMA's comment, suffix has been added in the results table of Section 5.1 to explain that patients with dose escalation were considered non-responders.

<div style=\"page-break-after: always\"></div>

## Assessment of the MAH's response

The following sentence was added as a suffix to the results table: 'Patients with dose adjustment prior to Week 54 were considered non-responders/non-remitters.' An alternative wording is still requested to add more clarity.

## Conclusion

Issue partly resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## Question 5

In section 4.8 the MAH should propose a revision of the paragraph on immunogenicity. ADA status and especially high ADA titres had a clear association with drug concentrations and loss of response in study 3.8. This should be reflected in the SPC as the current text is misleading. To properly justify the amended text, which is also referring to UC patients, the correlation between loss of response and ADA status, median ADA titres and drug concentrations should be presented for both indications in tables where subgroups 1 and 3 are pooled and compared to subgroups 2 and 4, as defined in responses to Q 34.

## Summary of the MAH's response

Per the comment from CHMP, an additional post-hoc analysis was performed to explore the correlation between loss of response and ADA status, median ADA titres and drug concentrations for both indications in Studies CT-P13 3.7 and CT-P13 3.8.

As shown in Table 3, in study CT-P13 3.7, and in Table 4 in study CT-P13 3.8, the proportion of ADA positive patients was slightly higher in the patients with loss of response (subgroup 1+3 pooled) compared to the patients without dose adjustment and not meeting loss of response (subgroup 4). The proportion of ADA positive  patients  was  higher  in  the  patients  with  dose  adjustment  and  not  meeting  loss  of  response (subgroup 2), but since the number of patients included in subgroup 2 is limited, the result of subgroup 2 was not considered when interpretating the overall trend. However, the association between ADA titre and loss of response was seen in the CT-P13 SC treatment arm as the median ADA titre was higher in patients with loss of response (subgroup 1+3 pooled) compared to patients without loss of response. Lastly, the correlation between drug concentrations and loss of response was evaluated, and relatively lower drug concentration was observed in patients with loss of response (subgroup 1+3 pooled) compared to patients without loss of response (subgroup 2 and subgroup 4).

In addition, further analyses conducted with integrated safety data from studies CT-P13 3.7 and CT-P13 3.8 in the CT-P13 SC treatment arm in a post-hoc manner to assess potential impact of ADA on safety suggests that the incidence of infection, malignancy and immune-mediated AEs, TEAE and TESAE by ADA titre quartile showed no apparent correlation between ADA titre and AE incidences. The data is presented in Table 5 and Table 6.

Therefore, the paragraph on immunogenicity in section 4.8 is revised to indicate the impact of ADA on efficacy, while the text on safety profile remains unamended.

<div style=\"page-break-after: always\"></div>

## Assessment of the MAH's response

The proposed wording is acceptable with a small editorial amendment. The word 'slight' should be deleted as it is too vague.

## Conclusion

Issue resolved.

- [ ] Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## 16. 3 rd  request for supplementary information

## 16.1. Major objections

## Clinical aspects/SPC

1. Study  3.7  in  UC  patients  does  not  provide  methodologically  robust  and  clinically  significant information for the prescriber. The study was not conducted according to protocol. The number and nature  of  the  protocol  violations  are  such  that  the  W54  results  do  not  provide  a  meaningful interpretation.  Further,  it  would  not  be  possible  to  describe  the  study  appropriately  without mentioning the possibility to increase the dose from the currently approved 120mg SC to 240mg, which would be promoting an off-label posology. Hence the description of the study should be removed from SPC 5.1.

## 16.2. Other concerns

## Clinical aspects/SPC

2. Including  p-values  in  the  table  describing  efficacy  results  from  study  3.8  in  CD  patients  is  not acceptable. The results are merely descriptive as the interpretation of the outcome is hampered by the study design.
3. Please see attached product information for additional minor amendments.

## 17. Assessment of the responses to the 3 rd  request for supplementary information

## 17.1. Major obections

## Question 1

Study 3.7 in UC patients does not provide methodologically robust and clinically significant information for the prescriber. The study was not conducted according to protocol. The number and nature of the protocol

<div style=\"page-break-after: always\"></div>

violations are such that the W54 results do not provide a meaningful interpretation. Further, it would not be possible to describe the study appropriately without mentioning the possibility to increase the dose from the currently approved 120mg SC to 240mg, which would be promoting an off-label posology. Hence the description of the study should be removed from SPC 5.1.

## Summary of the MAH's response

The  Applicant  acknowledges  that  in  Study  CT-P13  3.7,  some  patients  who  did  not  meet  the  loss  of response  (LoR)  criteria  underwent  a  dose  adjustment.  Thus,  the  applicant  proposes  to  show  key efficacy results at Week 22, as per the recommendation received from the CHMP in the 2nd RSI, which weren't  influenced  by  dose  adjustment  design.  The  key  efficacy  results  at  Week 22  are presented in Table 1, demonstrating significant findings with all p-values still below 0.05.

Table 104      Proportion of patients achieving primary and key secondary endpoints at Week 22: all-randomized population

|                                                      | CT-P13 SC 120 mg (N=294)   | Placebo Sc (N=144)   | Difference (95% CI)1   |   P-value2 |
|------------------------------------------------------|----------------------------|----------------------|------------------------|------------|
| Clinical Remission at Week 22                        | 128 (43.5%)                | 41 (28.5%)           | 13.8 (4.1, 22.7)       |     0.0025 |
| Clinical Response at Week 22                         | 187 (63.6%)                | 64 (44.4%)           | 18.3 (8.4, 27.9)       |     0.0002 |
| Endoscopic-histologic Mucosal Improvement at Week 22 | 105 (35.7%)                | 36 (25%)             | 9.5 (0.2, 18.0)        |     0.0343 |

Source: CSR CT-P13 3.7 Post-text Tables 14.2.3.1, 14.2.3.4 and 14.2.3.5.

Abbreviations: CI, confidence interval; CMH, Cochran-Mantel-Haenszel; SC, subcutaneous.

Clinical remission is defined as modified Mayo score with a stool frequency subscore of 0 or 1, rectal bleeding subscore of 0, and endoscopic subscore of 0 or 1.

Clinical response is defined as a decrease in modified Mayo score from baseline of at least 2 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1 point.

Endoscopic-histologic mucosal improvement is defined as an absolute endoscopic subscore of 0 or 1 point from modified  Mayo  score  and  an  absolute  Robarts  Histopathology  Index  (RHI)  score  of  3  points  or  less  with  an accompanying laminal propria neutrophils and neutrophils in epithelium subscore of 0 point.

The Applicant has updated Section 5.1 of the SmPC with the Week 22 results presented above.

As an alternative, considering the CHMP's opinion, a post-hoc analysis excluding patients who did not meet the LoR criteria but received a dose adjustment was conducted.

## Assessment of the MAH's response

The Week 22 endpoints were not pre-specified in the protocol and SAP. Generally, post-hoc analyses are included in SmPC 5.1. only in exceptional situations. Furthermore, as previously discussed, it has become apparent during the assessment that the overall study conduct and the concordance of the protocol and planned  statistical  analyses  are  not  considered  to  produce  reliable  and  robust  results.  For  all  the aforementioned reasons, the Week 22 results are not considered adequate for inclusion in the SmPC.

The alternative approach proposed by the MAH to exclude patients who did not meet the LoR criteria but received  a  dose  adjustment,  and  to  present  W54  data  from  this  subpopulation  is  not  acceptable.  This

approach would also be presenting post-hoc data. Moreover, W54 data could not be presented without mentioning the possibility to dose adjust, which would be promoting off-label dosing.

## Conclusion

Issue not resolved. A major objection remains.

- [x] Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [ ] No need to update overall conclusion and impact on benefit-risk balance

## 17.2. Other concerns

## Question 2

Including p-values in the table describing efficacy results from study 3.8 in CD patients is not acceptable. The results are merely descriptive as the interpretation of the outcome is hampered by the study design.

## Summary of the MAH's response

Agency's comment to exclude the p-values in the table is acceptable. The p-value is therefore deleted from the table.

## Assessment of the MAH's response

P-values were removed from the table.

## Conclusion

Issue resolved.

- [ ] Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [x] No need to update overall conclusion and impact on benefit-risk balance

## Question 3

Please see attached product information for additional minor amendments.

## Summary of the MAH's response

The minor amendments suggested by the Agency are acceptable. Please see the product information for applicant's response to Agency's suggestions for minor amendments.

## Assessment of the MAH's response

Suggested amendments have been implemented.

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## Conclusion

Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

No need to update overall conclusion and impact on benefit-risk balance

## 18. 4 th  request for supplementary information

## 18.1. Major objections

## Clinical aspects/SPC

1. Study  3.7  in  UC  patients  does  not  provide  methodologically  robust  and  clinically  significant information for the prescriber. The study was not conducted according to protocol. The number and nature  of  the  protocol  violations  are  such  that  the  W54  results  do  not  provide  a  meaningful interpretation.  Further,  it  would  not  be  possible  to  describe  the  study  appropriately  without mentioning the possibility to increase the dose from the currently approved 120mg SC to 240mg, which would be promoting an off-label posology.

The Week 22 endpoints were not pre -specified in the protocol and SAP. Generally, post -hoc analyses are included in SmPC 5.1. only in exceptional situations. In this case, there is no clinical necessity to include the data.

Furthermore, it has become apparent during the assessment that the overall study conduct and the concordance of the protocol and planned statistical analyses are not considered to produce reliable and  robust  results.  For  all  the  aforementioned  reasons,  the Week 22 results  are  not  considered adequate for inclusion in the SmPC. Hence the description of the study should be removed from SPC 5.1.

## 19. Assessment of the early responses to the 4 th  request for supplementary information

## 19.1. Major Objections

## Question 1

Study 3.7 in UC patients does not provide methodologically robust and clinically significant information for the prescriber. The study was not conducted according to protocol. The number and nature of the protocol violations are such that the W54 results do not provide a meaningful interpretation. Further, it would not be possible to describe the study appropriately without mentioning the possibility to increase the dose from the currently approved 120mg SC to 240mg, which would be promoting an off-label posology.

The Week 22 endpoints were not pre-specified in the protocol and SAP. Generally, post-hoc analyses are included in SmPC 5.1. only in exceptional situations. In this case, there is no clinical necessity to include the data.

<div style=\"page-break-after: always\"></div>

Furthermore,  it  has  become  apparent  during  the  assessment  that  the  overall  study  conduct  and  the concordance of the protocol and planned statistical analyses are not considered to produce reliable and robust results. For all the aforementioned reasons, the Week 22 results are not considered adequate for inclusion in the SmPC. Hence the description of the study should be removed from SPC 5.1.

## Summary of the MAH's response

The MAH agreed to delete the proposed text.

## Assessment of the MAH's response

Study 3.7 is no longer described in the SPC section 5.1.

## Conclusion

## Issue resolved.

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [ ] No need to update overall conclusion and impact on benefit-risk balance

## 20. Attachments

1. Product Information (changes highlighted) as adopted by the CHMP on 30 May 2024